# ESC Guidelines: Ventricular Arrhythmias SCD (2022)

**Source**: `2022_Ventricular_Arrhythmias_SCD.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 130

---

## Table of Contents

- [2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death](#2022-esc-guidelines-for-the-management-of-patients) *(p. 1)*
  - [Abbreviations and acronyms](#abbreviations-and-acronyms) *(p. 6)*
  - [1. Preamble](#1-preamble) *(p. 7)*
  - [2. Introduction](#2-introduction) *(p. 9)*
    - [2.1. What is new](#21-what-is-new) *(p. 9)*
  - [3. Definitions](#3-definitions) *(p. 15)*
    - [3.1. Ventricular arrhythmia subtypes](#31-ventricular-arrhythmia-subtypes) *(p. 15)*
    - [3.2. Sudden cardiac death](#32-sudden-cardiac-death) *(p. 15)*
    - [3.3. Syncope](#33-syncope) *(p. 15)*
    - [3.4. Specialized centres](#34-specialized-centres) *(p. 15)*
    - [3.5. Genetics](#35-genetics) *(p. 15)*
  - [4. Epidemiology of sudden cardiac death, public awareness, and risk stratification](#4-epidemiology-of-sudden-cardiac-death,-public-awa) *(p. 15)*
    - [4.1. Incidence of sudden cardiac death](#41-incidence-of-sudden-cardiac-death) *(p. 15)*
    - [4.2. Causes of sudden cardiac death in different age groups](#42-causes-of-sudden-cardiac-death-in-different-age) *(p. 16)*
    - [4.3. Population vs. individual risk prediction](#43-population-vs-individual-risk-prediction) *(p. 16)*
    - [4.4. Risk calculators for sudden cardiac death and review of the methodology](#44-risk-calculators-for-sudden-cardiac-death-and-r) *(p. 16)*
    - [4.5. Awareness and intervention: public basic life support, and access to automated external defibrillators](#45-awareness-and-intervention:-public-basic-life-s) *(p. 16)*
  - [5. Evaluation and treatment. General aspects](#5-evaluation-and-treatment-general-aspects) *(p. 18)*
    - [5.1. Diagnostic tools](#51-diagnostic-tools) *(p. 18)*
      - [5.1.1. History and physical examination](#511-history-and-physical-examination) *(p. 18)*
      - [5.1.2. Laboratory testing](#512-laboratory-testing) *(p. 18)*
      - [5.1.3. Non-invasive and invasive tests](#513-non-invasive-and-invasive-tests) *(p. 18)*
        - [5.1.3.1. Electrocardiogram and ambulatory electrocardiographic monitoring2](#5131-electrocardiogram-and-ambulatory-electrocardi) *(p. 18)*
        - [5.1.3.2. Signal-averaged electrocardiogram](#5132-signal-averaged-electrocardiogram) *(p. 18)*
        - [5.1.3.3. Exercise testing](#5133-exercise-testing) *(p. 18)*
        - [5.1.3.4. Imaging](#5134-imaging) *(p. 18)*
        - [5.1.3.5. Provocative diagnostic tests](#5135-provocative-diagnostic-tests) *(p. 19)*
        - [5.1.3.6. Electrophysiological study](#5136-electrophysiological-study) *(p. 19)*
      - [5.1.4. Genetic testing](#514-genetic-testing) *(p. 19)*
    - [5.2. Diagnostic evaluation at first presentation with ventricular arrhythmia in patients without known cardiac disease](#52-diagnostic-evaluation-at-first-presentation-wit) *(p. 22)*
      - [5.2.1. Scenario 1: Incidental finding of a non-sustained ventricular tachycardia](#521-scenario-1:-incidental-finding-of-a-non-sustai) *(p. 22)*
      - [5.2.2. Scenario 2: First presentation of sustained monomorphic ventricular tachycardia](#522-scenario-2:-first-presentation-of-sustained-mo) *(p. 22)*
      - [5.2.3. Scenario 3: Sudden cardiac arrest survivor](#523-scenario-3:-sudden-cardiac-arrest-survivor) *(p. 24)*
      - [5.2.4. Scenario 4: Sudden death victim](#524-scenario-4:-sudden-death-victim) *(p. 27)*
      - [5.2.5. Scenario 5: Relatives of sudden arrhythmic death syndrome decedents](#525-scenario-5:-relatives-of-sudden-arrhythmic-dea) *(p. 28)*
  - [6. Therapies for ventricular arrhythmias. General aspects](#6-therapies-for-ventricular-arrhythmias-general-as) *(p. 31)*
    - [6.1. Acute management](#61-acute-management) *(p. 31)*
      - [6.1.1. Treatment of reversible causes](#611-treatment-of-reversible-causes) *(p. 31)*
      - [6.1.2. Acute management of sustained monomorphic ventricular tachycardia](#612-acute-management-of-sustained-monomorphic-vent) *(p. 33)*
      - [6.1.3. Management of electrical storm and incessant ventricular tachycardia](#613-management-of-electrical-storm-and-incessant-v) *(p. 34)*
    - [6.2. Long-term management](#62-long-term-management) *(p. 38)*
      - [6.2.1. Pharmacotherapy](#621-pharmacotherapy) *(p. 38)*
      - [6.2.2. Device therapy](#622-device-therapy) *(p. 42)*
        - [6.2.2.1. Implantable cardioverter defibrillator](#6221-implantable-cardioverter-defibrillator) *(p. 42)*
        - [6.2.2.2. Adding cardiac resynchronization therapy2](#6222-adding-cardiac-resynchronization-therapy2) *(p. 44)*
        - [6.2.2.3. Wearable cardioverter defibrillator](#6223-wearable-cardioverter-defibrillator) *(p. 44)*
      - [6.2.3. Special aspects of device therapy](#623-special-aspects-of-device-therapy) *(p. 45)*
        - [6.2.3.1. Optimization of device programming](#6231-optimization-of-device-programming) *(p. 45)*
        - [6.2.3.2. Concomitant treatment to avoid inappropriate implantable cardioverter defibrillator therapy](#6232-concomitant-treatment-to-avoid-inappropriate-) *(p. 45)*
        - [6.2.3.3. Psychosocial impact of implantable cardioverter defibrillator treatment](#6233-psychosocial-impact-of-implantable-cardiovert) *(p. 46)*
        - [6.2.3.4. Patients with left ventricular assist devices](#6234-patients-with-left-ventricular-assist-devices) *(p. 46)*
        - [6.2.3.5. Complications of devices](#6235-complications-of-devices) *(p. 46)*
        - [6.2.3.6. End-of-life issues](#6236-end-of-life-issues) *(p. 47)*
      - [6.2.4. Interventional therapy](#624-interventional-therapy) *(p. 47)*
        - [6.2.4.1. Catheter ablation](#6241-catheter-ablation) *(p. 47)*
          - [6.2.4.1.1. Patients with structural heart disease](#62411-patients-with-structural-heart-disease) *(p. 47)*
          - [6.2.4.1.2. Patients without apparent structural heart disease](#62412-patients-without-apparent-structural-heart-d) *(p. 48)*
        - [6.2.4.2. Autonomic modulation](#6242-autonomic-modulation) *(p. 48)*
  - [7. Diagnostic evaluation, management, and risk stratification according to clinical presentation and known (likely) disease](#7-diagnostic-evaluation,-management,-and-risk-stra) *(p. 48)*
    - [7.1. Specific structural heart diseases](#71-specific-structural-heart-diseases) *(p. 48)*
      - [7.1.1. Coronary artery disease](#711-coronary-artery-disease) *(p. 48)*
        - [7.1.1.1. Acute coronary syndromes and vasospasm](#7111-acute-coronary-syndromes-and-vasospasm) *(p. 48)*
          - [7.1.1.1.1. Acute coronary syndromes](#71111-acute-coronary-syndromes) *(p. 48)*
          - [7.1.1.1.2. Vasospasm](#71112-vasospasm) *(p. 49)*
        - [7.1.1.2. Early after myocardial infarction](#7112-early-after-myocardial-infarction) *(p. 50)*
        - [7.1.1.3. Chronic coronary artery disease](#7113-chronic-coronary-artery-disease) *(p. 50)*
          - [7.1.1.3.1. Primary prevention of sudden cardiac death in patients with reduced ejection fraction](#71131-primary-prevention-of-sudden-cardiac-death-i) *(p. 50)*
          - [7.1.1.3.2. Primary prevention of sudden cardiac death in patients with preserved or mildly reduced ejection fraction](#71132-primary-prevention-of-sudden-cardiac-death-i) *(p. 51)*
          - [7.1.1.3.3. Secondary prevention of sudden cardiac death](#71133-secondary-prevention-of-sudden-cardiac-death) *(p. 51)*
          - [7.1.1.3.4. Management of patients with haemodynamically tolerated ventricular tachycardia and preserved and mildly reduced ejection fraction](#71134-management-of-patients-with-haemodynamically) *(p. 52)*
          - [7.1.1.3.5. Management of recurrent ventricular tachycardia in implantable cardioverter defibrillator carriers](#71135-management-of-recurrent-ventricular-tachycar) *(p. 53)*
        - [7.1.1.4. Coronary anomalies](#7114-coronary-anomalies) *(p. 53)*
      - [7.1.2. Idiopathic premature ventricular complexes/ventricular tachycardia and premature ventricular complex-induced cardiomyopathy](#712-idiopathic-premature-ventricular-complexes/ven) *(p. 54)*
        - [7.1.2.1. Idiopathic premature ventricular complexes/ventricular tachycardia](#7121-idiopathic-premature-ventricular-complexes/ve) *(p. 54)*
        - [7.1.2.2. Premature ventricular complex-induced/-aggravated cardiomyopathy](#7122-premature-ventricular-complex-induced/-aggrav) *(p. 56)*
      - [7.1.3. Cardiomyopathies](#713-cardiomyopathies) *(p. 58)*
        - [7.1.3.1. Dilated cardiomyopathy and hypokinetic non-dilated cardiomyopathy](#7131-dilated-cardiomyopathy-and-hypokinetic-non-di) *(p. 58)*
          - [7.1.3.1.1. Diagnostic evaluation and risk stratification](#71311-diagnostic-evaluation-and-risk-stratificatio) *(p. 58)*
          - [7.1.3.1.2. Primary prevention of sudden cardiac death](#71312-primary-prevention-of-sudden-cardiac-death) *(p. 59)*
          - [7.1.3.1.3. Secondary prevention of sudden cardiac death and management of ventricular arrhythmias](#71313-secondary-prevention-of-sudden-cardiac-death) *(p. 61)*
        - [7.1.3.2. Arrhythmogenic right ventricular cardiomyopathy](#7132-arrhythmogenic-right-ventricular-cardiomyopat) *(p. 62)*
          - [7.1.3.2.1. Risk stratification](#71321-risk-stratification) *(p. 62)*
          - [7.1.3.2.2. Treatment](#71322-treatment) *(p. 64)*
        - [7.1.3.3. Hypertrophic cardiomyopathy](#7133-hypertrophic-cardiomyopathy) *(p. 64)*
          - [7.1.3.3.1. Risk stratification and primary prevention of sudden cardiac death](#71331-risk-stratification-and-primary-prevention-o) *(p. 65)*
          - [7.1.3.3.2. Treatment to prevent ventricular arrhythmia recurrence](#71332-treatment-to-prevent-ventricular-arrhythmia-) *(p. 66)*
        - [7.1.3.4. Left ventricular non-compaction](#7134-left-ventricular-non-compaction) *(p. 67)*
        - [7.1.3.5. Restrictive cardiomyopathy](#7135-restrictive-cardiomyopathy) *(p. 67)*
        - [7.1.3.6. Neuromuscular disorders](#7136-neuromuscular-disorders) *(p. 67)*
      - [7.1.4. Inflammatory cardiac diseases](#714-inflammatory-cardiac-diseases) *(p. 70)*
        - [7.1.4.1. Myocarditis](#7141-myocarditis) *(p. 70)*
        - [7.1.4.2. Cardiac sarcoidosis](#7142-cardiac-sarcoidosis) *(p. 71)*
        - [7.1.4.3. Chagas’ cardiomyopathy](#7143-chagas’-cardiomyopathy) *(p. 72)*
      - [7.1.5. Valvular heart disease](#715-valvular-heart-disease) *(p. 74)*
      - [7.1.6. Congenital heart disease](#716-congenital-heart-disease) *(p. 75)*
    - [7.2. Primary electrical disease](#72-primary-electrical-disease) *(p. 77)*
      - [7.2.1. Idiopathic ventricular fibrillation](#721-idiopathic-ventricular-fibrillation) *(p. 77)*
      - [7.2.2. Long QT syndrome (including acquired long QT syndrome)](#722-long-qt-syndrome-(including-acquired-long-qt-s) *(p. 78)*
      - [7.2.3. Andersen–Tawil syndrome Type 1](#723-andersen–tawil-syndrome-type-1) *(p. 83)*
      - [7.2.4. Brugada syndrome](#724-brugada-syndrome) *(p. 83)*
      - [7.2.5. Early repolarization syndromes](#725-early-repolarization-syndromes) *(p. 85)*
      - [7.2.6. Catecholaminergic polymorphic ventricular tachycardia](#726-catecholaminergic-polymorphic-ventricular-tach) *(p. 88)*
      - [7.2.7. Short QT syndrome](#727-short-qt-syndrome) *(p. 90)*
  - [8. Special aspects in selected populations](#8-special-aspects-in-selected-populations) *(p. 92)*
    - [8.1. Pregnant patients and peri-partum cardiomyopathy](#81-pregnant-patients-and-peri-partum-cardiomyopath) *(p. 92)*
      - [8.1.1. Electrocardioversion and implantable cardioverter defibrillator therapy in pregnancy](#811-electrocardioversion-and-implantable-cardiover) *(p. 92)*
      - [8.1.2. Pharmacological treatment](#812-pharmacological-treatment) *(p. 92)*
      - [8.1.3. Catheter ablation](#813-catheter-ablation) *(p. 92)*
    - [8.2. Heart transplantation](#82-heart-transplantation) *(p. 93)*
    - [8.3. Sudden cardiac death in athletes](#83-sudden-cardiac-death-in-athletes) *(p. 93)*
    - [8.4. Wolff–Parkinson–White syndrome](#84-wolff–parkinson–white-syndrome) *(p. 94)*
    - [8.5. Prevention of sudden cardiac death in the elderly](#85-prevention-of-sudden-cardiac-death-in-the-elder) *(p. 94)*
  - [9. Key messages](#9-key-messages) *(p. 94)*
    - [9.1. General aspects](#91-general-aspects) *(p. 94)*
    - [9.2. Structural heart disease](#92-structural-heart-disease) *(p. 94)*
    - [9.3. Primary electrical disease](#93-primary-electrical-disease) *(p. 95)*
  - [10. Gaps in evidence](#10-gaps-in-evidence) *(p. 95)*
    - [10.1. General aspects](#101-general-aspects) *(p. 95)*
    - [10.2. Structural heart disease—general](#102-structural-heart-disease—general) *(p. 95)*
    - [10.3. Idiopathic premature ventricular complexes/ventricular tachycardia](#103-idiopathic-premature-ventricular-complexes/ven) *(p. 95)*
    - [10.4. Coronary artery disease](#104-coronary-artery-disease) *(p. 95)*
    - [10.5. Cardiomyopathies](#105-cardiomyopathies) *(p. 95)*
    - [10.6. Valvular heart disease](#106-valvular-heart-disease) *(p. 95)*
    - [10.7. Congenital heart disease](#107-congenital-heart-disease) *(p. 95)*
    - [10.8. Primary electrical disease](#108-primary-electrical-disease) *(p. 95)*
  - [11. ‘What to do’ and ‘what not to do’ messages from the Guidelines](#11-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 96)*
  - [12. Quality indicators](#12-quality-indicators) *(p. 103)*
  - [13. Supplementary data](#13-supplementary-data) *(p. 103)*
  - [14. Data availability statement](#14-data-availability-statement) *(p. 103)*
  - [15. Author information](#15-author-information) *(p. 103)*
  - [Appendix](#appendix) *(p. 104)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC)
Endorsed by the Association for European Paediatric and
Congenital Cardiology (AEPC)
Authors/Task Force Members: Katja Zeppenfeld*† (Chairperson) (Netherlands),
Jacob Tfelt-Hansen
*† (Chairperson) (Denmark), Marta de Riva** (Task Force
Coordinator) (Netherlands), Bo Gregers Winkel** (Task Force Coordinator)
(Denmark), Elijah R. Behr (United Kingdom), Nico A. Blom1 (Netherlands),
Philippe Charron (France), Domenico Corrado (Italy), Nikolaos Dagres
(Germany), Christian de Chillou (France), Lars Eckardt (Germany), Tim Friede
(Germany), Kristina H. Haugaa (Norway), Mélèze Hocini (France), Pier
D. Lambiase (United Kingdom), Eloi Marijon (France), Jose L. Merino (Spain),
Petr Peichl (Czech Republic), Silvia G. Priori (Italy), Tobias Reichlin (Switzerland),
Jeanette Schulz-Menger (Germany), Christian Sticherling (Switzerland),
Stylianos Tzeis (Greece), Axel Verstrael (Belgium), Maurizio Volterrani (Italy),
and ESC Scientiﬁc Document Group
*Corresponding authors: Katja Zeppenfeld, Department of Cardiology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, Netherlands. Tel +31 715262020, E-mail:
K.Zeppenfeld@LUMC.nl
Jacob Tfelt-Hansen, The Department of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark. Tel +45 61360399,
E-mail: jacob.tfelt@regionh.dk
†The two chairpersons contributed equally to the document and are joint corresponding authors.
**The two task force Coordinators contributed equally to the document.
Author/task force Member afﬁliations are listed in Author information.
1Representing the Association for European Paediatric and Congenital Cardiology (AEPC).
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular
Imaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Working Groups: Cardiac Cellular Electrophysiology, Myocardial and Pericardial Diseases.
Patient Forum
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University
Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (Journals.Permissions@oup.com).
https://doi.org/10.1093/eurheartj/ehac262
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document-Reviewers: Maja Cikes (CPG Review Coordinator) (Croatia), Paulus Kirchhof (CPG Review
Coordinator) (Germany), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Elena Arbelo (Spain),
Fernando Arribas (Spain), Riccardo Asteggiano (Italy), Cristina Basso (Italy), Axel Bauer (Austria),
Emanuele Bertaglia (Italy), Tor Biering-Sørensen (Denmark), Carina Blomström-Lundqvist (Sweden),
Michael A. Borger (Germany), Jelena Čelutkienė (Lithuania), Bernard Cosyns (Belgium), Volkmar Falk
(Germany), Laurent Fauchier (France), Bulent Gorenek (Turkey), Sigrun Halvorsen (Norway), Robert Hatala
(Slovakia), Hein Heidbuchel (Belgium), Stefan Kaab (Germany), Aleksandra Konradi (Russian Federation),
Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf Landmesser (Germany),
Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Lars H. Lund (Sweden),
Andreas Metzner (Germany), Richard Mindham (United Kingdom), Jens Cosedis Nielsen (Denmark),
Tone M. Norekvål (Norway), Monica Patten (Germany), Eva Prescott (Denmark), Amina Rakisheva
(Kazakhstan), Carol Ann Remme (Netherlands), Ivo Roca-Luque (Spain), Andrea Sarkozy (Belgium),
Daniel Scherr (Austria), Marta Sitges (Spain), Rhian M. Touyz (Canada/United Kingdom), Nicolas Van Mieghem
(Netherlands), Vedran Velagic (Croatia), Sami Viskin (Israel), and Paul G. A. Volders (Netherlands)
All experts involved in the development of these guidelines have submitted declarations of interest. These have been compiled in a report and published in a supplementary document simultaneously to the guidelines. The report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary data that includes background information and detailed discussion of the data that have provided the basis of the guidelines.
Click here to access the corresponding ESC CardioMed chapters.
Keywords
Guidelines • Anti-arrhythmic drugs • Cardiac magnetic resonance • Cardiomyopathies • Catheter ablation •
Chronic coronary artery disease • Genetic testing • Implantable cardioverter deﬁbrillator • Premature ventricular complex • Primary electrical disease • Recommendations • Risk calculator • Risk stratiﬁcation • Sudden cardiac death • Sudden death • Ventricular arrhythmia • Ventricular ﬁbrillation • Ventricular tachycardia
Table of contents
1. Preamble ........................................................................................................
4003
2. Introduction .................................................................................................
4005
2.1. What is new ........................................................................................ 4005
3. Deﬁnitions .....................................................................................................
4011
3.1. Ventricular arrhythmia subtypes ................................................ 4011
3.2. Sudden cardiac death ....................................................................... 4011
3.3. Syncope ................................................................................................. 4011
3.4. Specialized centres ............................................................................ 4011
3.5. Genetics ................................................................................................. 4011
4. Epidemiology of sudden cardiac death, public awareness, and risk stratiﬁcation ..............................................................................................
4011
4.1. Incidence of sudden cardiac death ............................................. 4011
4.2. Causes of sudden cardiac death in different age groups . 4012
4.3. Population vs. individual risk prediction .................................. 4012
4.4. Risk calculators for sudden cardiac death and review of the methodology ................................................................................................ 4012
4.5. Awareness and intervention: public basic life support, and access to automated external deﬁbrillators ................................... 4012
5. Evaluation and treatment. General aspects ....................................
4014
5.1. Diagnostic tools ................................................................................. 4014
5.1.1. History and physical examination ......................................
4014
5.1.2. Laboratory testing ....................................................................
4014
5.1.3. Non-invasive and invasive tests ..........................................
4014
5.1.3.1. Electrocardiogram and ambulatory electrocardiographic monitoring ................................................ 4014
5.1.3.2. Signal-averaged electrocardiogram ............................ 4014
5.1.3.3. Exercise testing .................................................................. 4014
5.1.3.4. Imaging ................................................................................... 4014
5.1.3.5. Provocative diagnostic tests ......................................... 4015
5.1.3.6. Electrophysiological study ............................................. 4015
Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the
ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
© The European Society of Cardiology 2022. All rights reserved. For permissions please e-mail: Journals.Permissions@oup.com


<!-- PAGE 3 -->

### Page 3

5.1.4. Genetic testing ...........................................................................
4015
5.2. Diagnostic evaluation at ﬁrst presentation with ventricular arrhythmia in patients without known cardiac disease .................................................................................................... 4018
5.2.1. Scenario 1: Incidental ﬁnding of a non-sustained ventricular tachycardia ........................................................................
4018
5.2.2. Scenario 2: First presentation of sustained monomorphic ventricular tachycardia .........................................
4018
5.2.3. Scenario 3: Sudden cardiac arrest survivor ...................
4020
5.2.4. Scenario 4: Sudden death victim ........................................
4023
5.2.5. Scenario 5: Relatives of sudden arrhythmic death syndrome decedents ...........................................................................
4024
6. Therapies for ventricular arrhythmias. General aspects ...........
4027
6.1. Acute management .......................................................................... 4027
6.1.1. Treatment of reversible causes ..........................................
4027
6.1.2. Acute management of sustained monomorphic ventricular tachycardia ........................................................................
4029
6.1.3. Management of electrical storm and incessant ventricular tachycardia ........................................................................
4030
6.2. Long-term management ................................................................. 4034
6.2.1. Pharmacotherapy ......................................................................
4034
6.2.2. Device therapy ...........................................................................
4038
6.2.2.1. Implantable cardioverter deﬁbrillator ....................... 4038
6.2.2.2. Adding cardiac resynchronization therapy ............. 4040
6.2.2.3. Wearable cardioverter deﬁbrillator .......................... 4040
6.2.3. Special aspects of device therapy ......................................
4041
6.2.3.1. Optimization of device programming ...................... 4041
6.2.3.2. Concomitant treatment to avoid inappropriate implantable cardioverter deﬁbrillator therapy ..................... 4041
6.2.3.3. Psychosocial impact of implantable cardioverter deﬁbrillator treatment .................................................................... 4042
6.2.3.4. Patients with left ventricular assist devices ............ 4042
6.2.3.5. Complications of devices ............................................... 4042
6.2.3.6. End-of-life issues ................................................................ 4043
6.2.4. Interventional therapy ............................................................
4043
6.2.4.1. Catheter ablation .............................................................. 4043
6.2.4.1.1. Patients with structural heart disease ............. 4043
6.2.4.1.2. Patients without apparent structural heart disease ............................................................................................... 4044
6.2.4.2. Autonomic modulation .................................................. 4044
7. Diagnostic evaluation, management, and risk stratiﬁcation according to clinical presentation and known (likely)
disease ..................................................................................................................
4044
7.1. Speciﬁc structural heart diseases ................................................ 4044
7.1.1. Coronary artery disease ........................................................
4044
7.1.1.1. Acute coronary syndromes and vasospasm .......... 4044
7.1.1.1.1. Acute coronary syndromes ................................. 4044
7.1.1.1.2. Vasospasm ................................................................... 4045
7.1.1.2. Early after myocardial infarction ................................. 4046
7.1.1.3. Chronic coronary artery disease ................................ 4046
7.1.1.3.1. Primary prevention of sudden cardiac death in patients with reduced ejection fraction ............................. 4046
7.1.1.3.2. Primary prevention of sudden cardiac death in patients with preserved or mildly reduced ejection fraction ............................................................................................. 4047
7.1.1.3.3. Secondary prevention of sudden cardiac death .................................................................................................. 4047
7.1.1.3.4. Management of patients with haemodynamically tolerated ventricular tachycardia and preserved and mildly reduced ejection fraction ............. 4048
7.1.1.3.5. Management of recurrent ventricular tachycardia in implantable cardioverter deﬁbrillator carriers .............................................................................................. 4049
7.1.1.4. Coronary anomalies ......................................................... 4049
7.1.2. Idiopathic premature ventricular complexes/
ventricular tachycardia and premature ventricular complexinduced cardiomyopathy ...................................................................
4050
7.1.2.1. Idiopathic premature ventricular complexes/
ventricular tachycardia .................................................................... 4050
7.1.2.2. Premature ventricular complex-induced/-
aggravated cardiomyopathy .......................................................... 4052
7.1.3. Cardiomyopathies ....................................................................
4054
7.1.3.1. Dilated cardiomyopathy and hypokinetic nondilated cardiomyopathy .................................................................. 4054
7.1.3.1.1. Diagnostic evaluation and risk stratiﬁcation .. 4054
7.1.3.1.2. Primary prevention of sudden cardiac death
4055
7.1.3.1.3. Secondary prevention of sudden cardiac death and management of ventricular arrhythmias ................... 4057
7.1.3.2. Arrhythmogenic right ventricular cardiomyopathy ................................................................................. 4058
7.1.3.2.1. Risk stratiﬁcation ....................................................... 4058
7.1.3.2.2. Treatment .................................................................... 4060
7.1.3.3. Hypertrophic cardiomyopathy .................................... 4060
7.1.3.3.1. Risk stratiﬁcation and primary prevention of sudden cardiac death .................................................................. 4061
7.1.3.3.2. Treatment to prevent ventricular arrhythmia recurrence ....................................................................................... 4062
7.1.3.4. Left ventricular non-compaction ................................ 4063
7.1.3.5. Restrictive cardiomyopathy .......................................... 4063
7.1.3.6. Neuromuscular disorders ............................................. 4063
7.1.4. Inﬂammatory cardiac diseases .............................................
4066
7.1.4.1. Myocarditis ........................................................................... 4066
7.1.4.2. Cardiac sarcoidosis ........................................................... 4067
7.1.4.3. Chagas’ cardiomyopathy ................................................ 4068
7.1.5. Valvular heart disease .............................................................
4070
7.1.6. Congenital heart disease ........................................................
4071
7.2. Primary electrical disease ............................................................... 4073
7.2.1. Idiopathic ventricular ﬁbrillation .........................................
4073
7.2.2. Long QT syndrome (including acquired long QT
syndrome) ................................................................................................
4074
7.2.3. Andersen–Tawil syndrome Type 1 ..................................
4079
7.2.4. Brugada syndrome ...................................................................
4079
7.2.5. Early repolarization syndromes ..........................................
4081
7.2.6. Catecholaminergic polymorphic ventricular tachycardia ...............................................................................................
4084
7.2.7. Short QT syndrome ................................................................
4086
8. Special aspects in selected populations ............................................
4088
8.1. Pregnant patients and peri-partum cardiomyopathy ......... 4088
8.1.1. Electrocardioversion and implantable cardioverter deﬁbrillator therapy in pregnancy ..................................................
4088
8.1.2. Pharmacological treatment ...................................................
4088
8.1.3. Catheter ablation ......................................................................
4088
8.2. Heart transplantation ...................................................................... 4089
8.3. Sudden cardiac death in athletes ................................................ 4089
ESC Guidelines
3999


<!-- PAGE 4 -->

### Page 4

8.4. Wolff–Parkinson–White syndrome .......................................... 4090
8.5. Prevention of sudden cardiac death in the elderly ............. 4090
9. Key messages ...............................................................................................
4090
9.1. General aspects .................................................................................. 4090
9.2. Structural heart disease .................................................................. 4090
9.3. Primary electrical disease ............................................................... 4091
10. Gaps in evidence ......................................................................................
4091
10.1. General aspects ............................................................................... 4091
10.2. Structural heart disease—general ........................................... 4091
10.3. Idiopathic premature ventricular complexes/ventricular tachycardia .................................................................................................... 4091
10.4. Coronary artery disease .............................................................. 4091
10.5. Cardiomyopathies .......................................................................... 4091
10.6. Valvular heart disease ................................................................... 4091
10.7. Congenital heart disease .............................................................. 4091
10.8. Primary electrical disease ............................................................ 4091
11. ‘What to do’ and ‘what not to do’ messages from the
Guidelines ...........................................................................................................
4092
12. Quality indicators ....................................................................................
4099
13. Supplementary data ................................................................................
4099
14. Data availability statement ...................................................................
4099
15. Author information ................................................................................
4099
16. Appendix .....................................................................................................
4100
4101
Tables of Recommendations
Recommendation Table 1 — Recommendations for public basic life support and access to automated external deﬁbrillators ............................................................................................ 4014
Recommendation Table 2 — Recommendations for genetic testing ...................................................................................................................
4018
Recommendation Table 3 — Recommendations for evaluation of patients presenting with newly documented ventricular arrhythmia ..........................................................................................................
4018
Recommendation Table 4 — Recommendations for evaluation of patients presenting with a ﬁrst episode of sustained monomorphic ventricular tachycardia ...................................................
4020
Recommendation Table 5 — Recommendations for evaluation of sudden cardiac arrest survivors ................................................................
4022
Recommendation Table 6 — Recommendations for evaluation of sudden death victims .....................................................................................
4023
Recommendation Table 7 — Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents ........
4027
Recommendation Table 8 — Recommendations for treatment of reversible conditions ......................................................................................
4029
Recommendation Table 9 — Recommendations for the acute management of sustained ventricular tachycardia and electrical storm ....................................................................................................................
4033
Recommendation Table 10 — Recommendations for treatment with heart failure medication .....................................................................
4034
Recommendation Table 11 — Recommendations for implantable cardioverter deﬁbrillator implantation (general aspects) ..............
4040
Recommendation Table 12 — Recommendations for secondary prevention of sudden cardiac death .......................................................
4040
Recommendation Table 13 — Recommendations for subcutaneous implantable cardioverter deﬁbrillator .......................
4040
Recommendation Table 14 — Recommendations for adding cardiac resynchronization therapy to implantable cardioverter deﬁbrillator ........................................................................................................
4040
Recommendation Table 15 — Recommendations for wearable cardioverter deﬁbrillator ..............................................................................
4040
Recommendation Table 16 — Recommendations for optimization of device programming .....................................................
4041
Recommendation Table 17 — Recommendations for concomitant treatment to avoid inappropriate implantable cardioverter deﬁbrillator therapy ............................................................
4042
Recommendation Table 18 — Recommendations for psychosocial management after implantable cardioverter deﬁbrillator implantation .............................................................................
4042
Recommendation Table 19 — Recommendations for implantable cardioverter deﬁbrillator implantation in left ventricular assist device recipients ..............................................................................................
4042
Recommendation Table 20 — Recommendations for prevention of implantable cardioverter deﬁbrillator complications .................
4043
Recommendation Table 21 — Recommendations for end-of-life issues in implantable cardioverter deﬁbrillator carriers .................
4043
Recommendation Table 22 — Recommendations for treatment of ventricular arrhythmias in acute coronary syndrome and vasospasm ..........................................................................................................
4046
Recommendation Table 23 — Recommendations for risk stratiﬁcation and treatment of ventricular arrhythmias early after myocardial infarction .....................................................................................
4046
Recommendation Table 24 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in chronic coronary artery disease .........
4047
Recommendation Table 25 — Recommendations for sudden cardiac death prevention in patients with coronary anomalies .......
4050
Recommendation Table 26 — Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia ..........................................................
4052
Recommendation Table 27 — Recommendations for the management of patients with premature ventricular complex-induced or premature ventricular complex-aggravated cardiomyopathy ............................................................................................................. 4053
Recommendation Table 28 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/
hypokinetic non-dilated cardiomyopathy ......................................
4057
Recommendation Table 29 — Recommendations for diagnostic,
risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy ........................................................................
4060
Recommendation Table 30 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in hypertropic cardiomyopathy ...............
4062
Recommendation Table 31 — Recommendations for implantable cardioverter deﬁbrillator implantation in left ventricular non-compaction ..............................................................................................
4063
Recommendation Table 32 — Recommendations for implantable cardioverter deﬁbrillator implantation in patients with cardiac amyloidosis .........................................................................................................
4063
Recommendation Table 33 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in neuromuscular diseases .........................
4065


<!-- PAGE 5 -->

### Page 5

Recommendation Table 34 — Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in myocarditis ..........................................................................
4066
Recommendation Table 35 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in cardiac sarcoidosis ....................................
4067
Recommendation Table 36 — Recommendations for the treatment of ventricular arrhythmias in Chagas’
cardiomyopathy ....................................................................................... 4070
Recommendation Table 37 — Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in valvular heart disease ......................................................
4070
Recommendation Table 38 — Recommendations for risk stratiﬁcation and primary prevention of sudden cardiac death in congenital heart disease ...............................................................................
4072
Recommendation Table 39 — Recommendations for secondary prevention of sudden cardiac death and treatment of ventricular arrhythmia in congenital heart disease ..................................................
4072
Recommendation Table 40 — Recommendations for the management of patients with idiopathic ventricular ﬁbrillation ..
4073
Recommendation Table 41 — Recommendations for the management of patients with long QT syndrome ...........................
4077
Recommendation Table 42 — Recommendations for management of patients with Andersen–Tawil syndrome ...........
4079
Recommendation Table 43 — Recommendations for management of patients with Brugada syndrome ............................
4080
Recommendation Table 44 — Recommendations for the management of patients with early repolarization pattern/
syndrome ............................................................................................................
4083
Recommendation Table 45 — Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia ..................................................................................
4086
Recommendation Table 46 — Recommendations for the management of patients with short QT syndrome .........................
4087
Recommendation Table 47 — Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy ..............................................
4088
Recommendation Table 48 — Recommendations for the prevention of sudden cardiac death before and after heart transplantation .................................................................................................
4089
Recommendation Table 49 — Recommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes
4089
Recommendation Table 50 — Recommendations for implantable cardioverter deﬁbrillator implantation in the elderly ......................
4090
List of tables
Table 1 Classes of recommendations ....................................................
4003
Table 2 Levels of evidence ..........................................................................
4004
Table 3 New sections and concepts ......................................................
4005
Table 4 New recommendations in 2022 .............................................
4005
Table 5 Changes in recommendations since 2015 ...........................
4010
Table 6 Intravenous provocative diagnostic tests .............................
4016
Table 7 Genetic tests and suggested work-up of probands and relatives with primary electrical diseases ..............................................
4017
Table 8 Anti-arrhythmic drugs (acute and chronic treatment) ..
4035
Table 9 Summary of the recommendations for the treatment of patients with frequent idiopathic premature ventricular complexes/ventricular tachycardia or premature ventricular complex-induced cardiomyopathy ..........................................................
4051
Table 10 Modiﬁed long QT syndrome diagnostic score ...................... 4076
List of ﬁgures
Figure 1 Central ﬁgure ..................................................................................
4013
Figure 2 Algorithm for the evaluation of patients presenting with an incidental ﬁnding of non-sustained ventricular tachycardia ....
4019
Figure 4 Algorithm for the evaluation of patients presenting with a
ﬁrst sustained monomorphic ventricular tachycardia episode ....
4021
Figure 3 Typical idiopathic ventricular tachycardia morphologies
4020
Figure 5 Bundle branch re-entrant ventricular tachycardia ..........
4022
Figure 6 Part One. Algorithm for the evaluation of sudden cardiac arrest survivors ................................................................................................
4024
Figure 6 Part Two. Algorithm for the evaluation of sudden cardiac arrest survivors ................................................................................................
4025
Figure 7 Algorithm for the evaluation of sudden death victims .
4026
Figure 8 Algorithm for the evaluation of relatives of unexplained sudden death decedents ..............................................................................
4028
Figure 9 Algorithm for the acute management of regular wide
QRS complex tachycardia ...........................................................................
4029
Figure 10 Repetitive runs of ventricular tachycardia interrupted by occasional sinus beats .............................................................................
4030
Figure 11 Part One. Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges ......................................................................................................... 4031
Figure 11 Part Two.Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges ................................................................................................... 4032
Figure 11 Part Three. Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges ...........................................................................................................
4033
Figure 12 Algorithm for evaluation before initiation and follow-up of patients requiring sodium channel blocking agents ....................
4038
Figure 13 Algorithm for evaluation before initiation and follow-up of patients requiring drugs associated with QT prolongation ....
4039
Figure 14 Algorithm for the prevention and management of ventricular arrhythmias in ST-elevation myocardial infarction .........
4045
Figure 15 Algorithm for risk stratiﬁcation and primary prevention of sudden cardiac death in patients with chronic coronary artery disease and reduced ejection fraction ....................................................
4048
Figure 16 Algorithm for the management of sustained monomorphic ventricular tachycardia in patients with chronic coronary artery disease ................................................................................
4049
Figure 17 Algorithm for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia and non-apparent structural heart disease .................
4051
Figure 18 Algorithm for the management of patients with premature ventricular complex-induced/-aggravated cardiomyopathy ...............................................................................................
4053
Figure 19 Algorithm for risk stratiﬁcation and primary prevention of sudden cardiac death in patients with dilated cardiomyopathy/
hypokinetic non-dilated cardiomyopathy .............................................
4001


<!-- PAGE 6 -->

### Page 6

Figure 20 Typical features of dilated cardiomyopathy associated with lamin A/C gene mutation with ventricular arrhythmias ......
4056
Figure 21 Typical features of arrhythmogenic right ventricular cardiomyopathy associated with ventricular arrhythmias ................................................................................................ 4059
Figure 22 Typical features of hypertrophic cardiomyopathy associated with sustained monomorphic ventricular tachycardia ................................................................................................. 4061
Figure 23 Algorithm for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in myotonic dystrophy .......................................................................................................................... 4064
Figure 24 Algorithm for sudden cardiac death prevention and treatment of ventricular arrhythmia in patients with cardiac sarcoidosis ..........................................................................................................
4068
Figure 25 Typical features of cardiac sarcoidosis associated with sustained monomorphic ventricular tachycardia ..............................
4069
Figure 26 Algorithm for the management of sustained ventricular arrhythmia in patients with congenital heart disease ......................
4071
Figure 27 Algorithm for the management of patients with idiopathic ventricular ﬁbrillation ...............................................................
4074
Figure 28 Idiopathic ventricular ﬁbrillation triggered by short-coupled premature ventricular complexes .............................
4075
Figure 29 Long QT syndrome electrocardiograms and torsade-de-pointes ventricular tachycardia .........................................
4076
Figure 30 Brisk standing electrocardiogram changes and T wave alternans in Long QT syndrome patients .............................................
4077
Figure 31 Algorithm for the management of patients with long
QT syndrome ...................................................................................................
4078
Figure 32 Typical examples of (A) Brugada type 1
electrocardiogram, and (B) early repolarization pattern electrocardiogram ...........................................................................................
4080
Figure 33 Part One. Algorithm for the management of patients with Brugada pattern electrocardiogram .............................................
4082
Figure 33 Part Two. Algorithm for the management of patients with Brugada pattern electrocardiogram .............................................
4083
Figure 34 Management of patients with early repolarization pattern/syndrome ...........................................................................................
4084
Figure 35 Management of patients with catecholaminergic polymorphic ventricular tachycardia ......................................................
4085
Figure 36 Exercise test of a patient with catecholaminergic polymorphic ventricular tachycardia ......................................................
4086
Figure 37 Short QT syndrome .................................................................
4087
Abbreviations and acronyms
AAD
Anti-arrhythmic drug
ACE-I
Angiotensin-converting enzyme inhibitor
ACS
Acute coronary syndrome
AED
Automated external deﬁbrillator
AF
Atrial ﬁbrillation
AH
Atrial–His interval
ALS
Advanced life support
ARB
Angiotensin receptor blocker
ARNI
Angiotensin receptor neprilysin inhibitor
ARVC
Arrhythmogenic right ventricular cardiomyopathy
ATP
Anti-tachycardia pacing
AV
Atrioventricular
AVRT
AV re-entry tachycardia
BBR-VT
Bundle branch re-entrant ventricular tachycardia
BrS
Brugada syndrome
CA
Cardiac arrest cAMP
Cyclic adenosine monophosphate
CAD
Coronary artery disease
CAG
Coronary angiogram
CCB
Calcium channel blocker
CHD
Congenital heart disease
CIED
Cardiac implantable electronic devices
CMR
Cardiac magnetic resonance
CPR
Cardiopulmonary resuscitation
CPVT
Catecholaminergic polymorphic ventricular tachycardia
CRT
Cardiac resynchronization therapy
CT/CTA
Computed tomography/Computed tomography angiography
DCM
Dilated cardiomyopathy
DNA
Deoxyribonucleic acid
ECG
Electrocardiogram
EF
Ejection fraction
ERP
Early repolarization pattern
ERS
Early repolarization syndrome
FBI
Fast, broad, irregular
HCM
Hypertrophic cardiomyopathy
HFrEF
Heart failure with reduced ejection fraction
HNDCM
Hypokinetic non-dilated cardiomyopathy
HTX
Heart transplantation
HV
His–ventricular interval
ICD
Implantable cardioverter deﬁbrillator
ILR
Implantable loop recorder
IVF
Idiopathic ventricular ﬁbrillation
LBBB
Left bundle branch block
LCSD
Left cardiac sympathetic denervation
LGE
Late gadolinium enhancement
LMNA
Lamin A/C
LQTS
Long QT syndrome
LV
Left ventricular
LVAD
Left ventricular assist device
LVEF
Left ventricular ejection fraction
LVH
Left ventricular hypertrophy
LVNC
Left ventricular non-compaction
LVOT
Left ventricle outﬂow tract
MI
Myocardial infarction
MRA
Mineralocorticoid receptor antagonist
MVP
Mitral valve prolapse
MVT
Monomorphic ventricular tachycardia
NSVT
Non-sustained ventricular tachycardia
NYHA
New York Heart Association
OHCA
Out-of-hospital cardiac arrest
OMT
Optimal medical treatment
PCI
Percutaneous coronary intervention
PCR
Polymerase chain reaction
PES
Programmed electrical stimulation
PET-CT
Positron emission tomography computed tomography
PPCM
Peri-partum cardiomyopathy
PVC
Premature ventricular complex
PVT
Polymorphic ventricular tachycardia
QI
Quality indicators
RBBB
Right bundle branch block


<!-- PAGE 7 -->

### Page 7

RCM
Restrictive cardiomyopathy
RCT
Randomized control trial
RV
Right ventricular
RVOT
Right ventricle outﬂow tract
SADS
Sudden arrhythmic death syndrome
SaECG
Signal-averaged ECG
SCA
Sudden cardiac arrest
SCD
Sudden cardiac death
SD
Sudden death
SGLT2
Sodium–glucose co-transporter 2
SHD
Structural heart disease
S-ICD
Subcutaneous implantable cardioverter deﬁbrillator
SMVT
Sustained monomorphic ventricular tachycardia
SPTV
Sustained polymorphic ventricular tachycardia
SQTS
Short QT syndrome
STEMI
ST elevation myocardial infarction
SVT
Supraventricular tachycardia
TAVI
Transcatheter aortic valve implantation
TdP
Torsades de pointes
TOF
Tetralogy of Fallot
VA
Ventricular arrhythmia
VF
Ventricular ﬁbrillation
VT
Ventricular tachycardia
WCD
Wearable cardioverter deﬁbrillator
WPW
Wolff–Parkinson–White
1. Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition.
Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, guidelines are not a substitute for the patient’s relationship with their practitioner. The ﬁnal decisions concerning an individual patient must be made by the responsible health professional(s), based on what they consider to be the most appropriate in the circumstances. These decisions are made in consultation with the patient and caregiver as appropriate.
Guidelines are intended for use by health professionals. To ensure that all users have access to the most recent recommendations, the
ESC makes its guidelines freely available. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
A great number of guidelines have been issued in recent years by the ESC. Because of their impact on clinical practice, quality criteria for the development of guidelines have been established to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website
(https://www.escardio.org/Guidelines). The ESC Guidelines represent the ofﬁcial position of the ESC on a given topic and are regularly updated.
In addition to the publication of Clinical Practice Guidelines, the
ESC carries out the EURObservational Research Programme of international registries of cardiovascular diseases and interventions that are essential to assess diagnostic/therapeutic processes, use of resources, and adherence to guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on high-quality data collected during routine clinical practice.
Furthermore, the ESC develops sets of quality indicators (QIs),
which are tools to evaluate the level of implementation of the guidelines and may be used by the ESC, hospitals, healthcare providers,
and professionals to measure clinical practice, and in educational
Table 1
Classes of recommendations
©ESC 2022
Classes of recommendations
Class I 
Evide beneficial, useful, effective.
effcacy of the given treatment or procedure.
nce and/or general agreement that a given treatment or procedure is
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given tr useful/effective, and in some cases eatment or procedure is not may be harmful. 
Is not recommended
Class IIb established by evidence/opinion.
May be considered
Class IIa
W
favour of usefulness/effcacy.
eight of 
Usefulness/efficacy is less well evidence/opinion is in
Should be considered
Class II 
© ESC 2022
ESC Guidelines
4003


<!-- PAGE 8 -->

### Page 8

programmes, alongside the key messages from the guidelines, to improve quality of care and clinical outcomes.
The Members of this task force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. The selection procedure aimed to ensure that there is a representative mix of members predominantly from across the whole of the ESC region and from relevant ESC Subspecialty
Communities. Consideration was given to diversity and inclusion,
notably with respect to gender and country of origin. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk–beneﬁt ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and scored according to predeﬁned scales, as outlined below. The task force followed the ESC voting procedures.
All recommendations subject to a vote achieved at least 75% among voting members.
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conﬂicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (http://www.escardio.org/
Guidelines) and have been compiled in a report and published in a supplementary document simultaneously to the guidelines.
This process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arise during the writing period were notiﬁed to the ESC
and updated. The task force received its entire ﬁnancial support from the ESC without any involvement from the healthcare industry.
The ESC CPG Committee supervises and coordinates the preparation of new guidelines. The Committee is also responsible for the approval process of these guidelines. The ESC Guidelines undergo extensive review by the CPG Committee and external experts, including a mix of members from across the whole of the ESC region and from relevant ESC Subspecialty Communities and National
Cardiac Societies. After appropriate revisions, the guidelines are signed off by all the experts involved in the task force. The ﬁnalized document is signed off by the CPG Committee for publication in the
The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recommendations, including condensed pocket guideline versions,
summary slides, summary cards for non-specialists, and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access the full-text version of the guidelines, which is freely available via the ESC website and the European Heart
Journal. The National Cardiac Societies of the ESC are encouraged to endorse, adopt, translate, and implement all ESC Guidelines.
Implementation programmes are needed because it has been shown that the outcome of disease may be favourably inﬂuenced by the thorough application of clinical recommendations.
Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive,
diagnostic, or therapeutic medical strategies. However, the ESC
Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient‘s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and, where appropriate, to respect the ethical rules of their profession.
Off-label use of medication may be presented in this guideline if sufﬁcient level of evidence shows that it can be considered medically appropriate to a given condition and if patients could beneﬁt from the recommended therapy. However, the ﬁnal decisions concerning an individual patient must be made by the responsible health professional giving special consideration to:
(1) the speciﬁc situation of the patient. In this respect, it is speciﬁed that, unless otherwise provided for by national regulations, offTable 2
Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2022


<!-- PAGE 9 -->

### Page 9

label use of medication should be limited to situations where it is in the patient’s interest to do so, with regard to the quality,
safety, and efﬁcacy of care, and only after the patient has been informed and has provided consent;
(2) country-speciﬁc health regulations, indications by governmental drug regulatory agencies, and the ethical rules to which health professionals are subject, where applicable.
2. Introduction
This document presents an update of the 2015 ESC Guidelines for the management of patients with ventricular arrhythmias (VA)
and the prevention of sudden cardiac death (SCD). New insights into the epidemiology of SCD, new evidence on genetics, imaging,
and clinical ﬁndings for risk stratiﬁcation for VA and SCD, and advances in diagnostic evaluation and therapeutic strategies made this revision necessary. The committee was composed of 25 members including 23 expert physicians, one methodologist, and one patient representative. Experts were selected to cover all areas of VA and
SCD as well as subspecialties of cardiology with the assistance of related ESC working groups.
All 25 members of the task force committee approved the guideline recommendations after an anonymous voting process.
Ninety-nine peer reviewers reviewed the document. A systematic literature survey was conducted, after instructions by the methodologist in the group, that led to the incorporation of 1155 references,
of which 485 were selected to support the recommendations and further speciﬁed in the table of evidence (Supplementary data).
2.1. What is new
The diagnostic and management parts of the guidelines have been adapted to facilitate their use in everyday clinical decision-making.
The ﬁrst general part has new sections on diagnostic evaluation,
including pharmacologic provocative tests, genetic testing, and a systematic work-up of probands and relatives with primary electrical diseases. Comprehensive ﬂowcharts and recommendations for the diagnostic evaluation at ﬁrst presentation with a VA of patients without a previously known cardiac disease are provided for ﬁve frequently encountered clinical scenarios. Practical recommendations for optimization of implantable cardioverter deﬁbrillator (ICD) programming and algorithms for management of patients experiencing regular wide complex tachycardia and electrical storm are presented
(Table 3).
Table 3
New sections and concepts
New sections and concepts
Section
Provocative diagnostic tests
5.1.3.5
Genetic testing
5.1.4
Diagnostic evaluation at ﬁrst presentation with VA in patients without known cardiac disease
5.2
Management of patients with electrical storm
6.1.3
Special aspects of device therapy
6.2.3
© ESC 2022
Table 4
New recommendations in 2022
Recommendations
Class
Public basic life support and access to AEDs
It is recommended that public-access deﬁbrillation be available at sites where cardiac arrest is more likely to occur.a
I
Prompt CPR by bystanders is recommended at OHCA.
I
It is recommended to promote community training in basic life support to increase bystander CPR rate and AED use.
I
Mobile phone-based alerting of basic life support-trained bystander volunteers to assist nearby OHCA victims should be considered.
IIa
Treatment of VA. General aspects
DC cardioversion is recommended as the ﬁrst-line treatment for patients presenting with tolerated SMVT provided that the anaesthetic/sedation risk is low.
I
Optimal medical treatment including ACE-I/ARB/ARNIs,
MRAs, beta-blockers, and SGLT2 inhibitors is indicated in all heart failure patients with reduced EF.
I
Implantation of a cardioverter deﬁbrillator is only recommended in patients who have an expectation of good-quality survival .1 year.
I
In patients presenting with a haemodynamically tolerated
SMVT and known or suspected SHD, intravenous procainamide should be considered.
IIa
In patients presenting with a haemodynamically tolerated
SMVT in the absence of an established diagnosis, intravenous amiodarone may be considered.
IIb
In patients with SMVT or SPVT/VF triggered by a PVC with similar morphology and an indication for ICD, catheter ablation may be considered when an ICD is not available,
contraindicated for concurrent medical reasons, or declined by the patient.
IIb
The WCD may be considered in the early phase after MI in selected patients.
IIb
Coronary artery disease
In patients with CAD and recurrent, symptomatic SMVT, or
ICD shocks for SMVT despite chronic amiodarone therapy,
catheter ablation is recommended in preference to escalating
AAD therapy.
I
Cardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test after surgery in patients with anomalous aortic origin of a coronary artery with a history of aborted CA.
I
In SCA survivors with coronary artery spasm, implantation of an ICD should be considered.
IIa
ICD therapy should be considered in patients with CAD,
NYHA class I, and LVEF ≤30% despite ≥3 months of OMT.
IIa
ICD implantation should be considered in patients with CAD,
LVEF ≤40% despite ≥3 months of OMT and NSVT, if they are inducible for SMVT by PES.
IIa
Continued
ESC Guidelines
4005


<!-- PAGE 10 -->

### Page 10

In patients with CAD and haemodynamically well-tolerated
SMVT and LVEF ≥40%, catheter ablation in experienced centres should be considered as an alternative to ICD therapy,
provided that established endpoints have been reached.b
IIa
Catheter ablation should be considered in patients with CAD
and recurrent, symptomatic SMVT, or ICD shocks for SMVT
despite beta-blocker or sotalol treatment.
IIa
Idiopathic PVC/VT and PVC-induced cardiomyopathy
Catheter ablation as ﬁrst-line treatment is recommended for symptomatic idiopathic VT/PVCs from the RVOT or the left fascicles.
I
Beta-blockers or non-dihydropyridine CCBs are indicated in symptomatic patients with idiopathic VT/PVCs from an origin other than the RVOT or the left fascicles.
I
In patients with PVCs/VT and a presentation not typical for an idiopathic origin,c CMR should be considered, despite a normal echocardiogram.
IIa
Beta-blockers, non-dihydropyridine CCBs or ﬂecainide should be considered when catheter ablation is not available, not desired, or is particularly risky in symptomatic patients with idiopathic VT/PVCs from the RVOT or the left fascicles.
IIa
Catheter ablation or ﬂecainide should be considered in symptomatic patients with idiopathic VT/PVCs from an origin other than the RVOT or the left fascicles.
IIa
In patients with an unexplained reduced EF and a PVC burden of at least 10%, PVC-induced cardiomyopathy should be considered.
IIa
In patients with suspected PVC-induced cardiomyopathy, CMR
should be considered.
IIa
In non-responders to CRT with frequent, predominately monomorphic PVCs limiting optimal biventricular pacing despite pharmacological therapy, catheter ablation or AADs should be considered.
IIa
Catheter ablation may be considered for idiopathic VT/PVCs in asymptomatic patients with repeatedly more than 20% of
PVCs per day at follow-up.
IIb
Amiodarone as a ﬁrst-line treatment is not recommended in patients with idiopathic VTs/PVCs.
III
DCM/HNDCM
Genetic testing (including at least LMNA, PLN, RBM20, and
FLNC genes) is recommended in patients with DCM/HNDCM
and AV conduction delay at ,50 years, or who have a family history of DCM/HNDCM or SCD in a ﬁrst-degree relative (at age ,50 years).
I
In a ﬁrst-degree relative of a DCM/HNDCM patient, an ECG,
and an echocardiogram are recommended if:
• the index patient was diagnosed ,50 years of age or has clinical features suggestive of an inherited cause, or
• there is a family history of DCM/HNDCM, or premature unexpected SD.
I
CMR with LGE should be considered in DCM/HNDCM
patients for assessing the aetiology and the risk of VA/SCD.
IIa
Continued
Genetic testing (including at least LMNA, PLN, RBM20, and
FLNC genes) should be considered for risk stratiﬁcation in patients with apparently sporadic DCM/HNDCM, who present at young age or with signs suspicious for an inherited aetiology.
IIa
ICD implantation should be considered in DCM/HNDCM
patients with an LVEF ,50% and ≥2 risk factors (syncope, LGE
on CMR, inducible SMVT at PES, pathogenic mutations in
LMNA, PLN, FLNC, and RBM20 genes).
IIa
ICD implantation should be considered in patients with DCM/
HNDCM and haemodynamically tolerated SMVT.
IIa
In a ﬁrst-degree relative of a patient with apparently sporadic
DCM/HNDCM, an ECG, and an echocardiogram may be considered.
IIb
Participation in high-intensity exercise including competitive sports is not recommended for individuals with DCM/
HNDCM and a LMNA mutation.
III
ARVC
In patients with suspected ARVC, CMR is recommended.
I
In patients with a suspected or deﬁnite diagnosis of ARVC,
genetic counselling and testing are recommended.
I
ICD implantation should be considered in symptomaticd patients with deﬁnite ARVC, moderate right or left ventricular dysfunction, and either NSVT or inducibility of SMVT at PES.
IIa
In ARVC patients with indication for ICDs, a device with the capability of ATP programming for SMVT up to high rates should be considered.
IIa
Avoidance of high-intensitye exercise may be considered in carriers of ARVC-related pathogenic mutations and no phenotype.
IIb
Beta-blocker therapy may be considered in all patients with a deﬁnite diagnosis of ARVC.
IIb
In patients with ARVC and symptoms highly suspicious for VA,
PES may be considered for risk stratiﬁcation.
IIb
HCM
CMR with LGE is recommended in HCM patients for diagnostic work-up.
I
Genetic counselling and testing are recommended in HCM
patients.
I
In a ﬁrst-degree relative of a patient with HCM, ECG, and echocardiogram are recommended.
I
ICD implantation should be considered in HCM patients aged
16 years or more with an intermediate 5-year risk of SCD (≥4
to ,6%)f, and with (a) signiﬁcant LGE at CMR (usually ≥15% of
LV mass); or (b) LVEF ,50%; or (c) abnormal blood pressure response during exercise testg; or (d) LV apical aneurysm; or
(e) presence of sarcomeric pathogenic mutation.
IIa
In children ,16 years of age with HCM and an estimated
5-year risk of SD ≥6% (based on HCM Risk-Kids scoreh), ICD
implantation should be considered.
IIa
In patients with HCM presenting with haemodynamically tolerated SMVT, ICD implantation should be considered.
IIa
Continued


<!-- PAGE 11 -->

### Page 11

In patients with HCM and recurrent, symptomatic VA, or recurrent symptomatic ICD therapy, AAD treatment should be considered.
IIa
Participation in high-intensity exercise may be considered for asymptomatic adult HCM patients without risk markers.
IIb
ICD implantation may be considered in HCM patients aged 16
years or more with a low estimated 5-year risk of SCD (,4%),f and with (a) signiﬁcant LGE at CMR (usually ≥15% of LV mass);
or (b) LVEF , 50%; or (c) LV apical aneurysm.
IIb
Catheter ablation in specialized centres may be considered in selected patients with HCM and recurrent, symptomatic
SMVT, or ICD shocks for SMVT, in whom AADs are ineffective, contraindicated, or not tolerated.
IIb
LVNC and RCM
In patients with an LVNC cardiomyopathy phenotype based on
CMR or echocardiography, implantation of an ICD for primary prevention of SCD should be considered to follow DCM/
HNDCM recommendations.
IIa
An ICD should be considered in patients with light-chain amyloidosis or transthyretin-associated cardiac amyloidosis and haemodynamically not-tolerated VT.
IIa
Neuromuscular diseases
Invasive electrophysiological evaluation is recommended in patients with myotonic dystrophy and palpitations or syncope suggestive of VA or surviving a CA.
I
ICD implantation is recommended in patients with myotonic dystrophy and SMVT or aborted CA not caused by BBR-VT.
I
Invasive electrophysiological evaluation should be considered in patients with myotonic dystrophy and a sudden increase in the PR interval or QRS duration.
IIa
Invasive electrophysiological evaluation should be considered in patients with myotonic dystrophy and a PR interval ≥240 ms or QRS duration ≥120 ms or who are older than 40 years and have supraventricular arrhythmias, or who are older than 40
years and have signiﬁcant LGE on CMR
IIa
In myotonic dystrophy patients without AV conduction delay and a syncope highly suspicious for VA, ICD implantation should be considered.
IIa
In myotonic dystrophy patients with palpitations highly suspicious for VA and induction of a non-BBR-VT, ICD
implantation should be considered.
IIa
In patients with limb-girdle type 1B or Emery–Dreifuss muscular dystrophies and indication for pacing, ICD
implantation should be considered.
IIa
Implantation of an ICD may be considered in patients with
Duchenne/Becker muscular dystrophy and signiﬁcant LGE at
CMR.
IIb
Implantation of an ICD over a permanent pacemaker may be considered in myotonic dystrophy patients with additional risk factorsi for VA and SCD.
IIb
In patients with myotonic dystrophy, serial electrophysiological evaluation of AV conduction and arrhythmia induction is not recommended without arrhythmia suspicion or progression of
ECG conduction disorders.
III
Continued
Inﬂammatory diseases
In patients with haemodynamically not-tolerated sustained VT
or VF during the acute phase of myocarditis, ICD implantation before hospital discharge should be considered.
IIa
In post-myocarditis patients with recurrent, symptomatic VT,
AAD treatment should be considered.
IIa
Catheter ablation, performed in specialized centres, should be considered in post-myocarditis patients with recurrent,
symptomatic SMVT, or ICD shocks for SMVT in whom AADs are ineffective, not tolerated, or not desired.
IIa
In patients with haemodynamically tolerated SMVT occurring in the chronic phase of myocarditis, ICD implantation should be considered.
IIa
In patients with cardiac sarcoidosis who have an LVEF .35%
but signiﬁcant LGE at CMR after resolution of acute inﬂammation, ICD implantation should be considered.
IIa
In patients with cardiac sarcoidosis who have an LVEF 35–50%
and minor LGE at CMR, after resolution of acute inﬂammation,
PES for risk stratiﬁcation should be considered.
IIa
In patients with cardiac sarcoidosis, LVEF 35–50%, and inducible SMVT at PES, ICD implantation should be considered.
IIa
In patients with cardiac sarcoidosis and recurrent, symptomatic
VA, AAD treatment should be considered.
IIa
Amiodarone should be considered to reduce arrhythmia burden in patients with Chagas’ cardiomyopathy who present with symptomatic PVCs or VT.
IIa
In patients with Chagas’ cardiomyopathy and recurrent,
symptomatic SMVT, or ICD shocks for SMVT in whom AADs are ineffective, contraindicated, or not tolerated, catheter ablation in specialized centres should be considered.
IIa
In patients with haemodynamically well-tolerated SMVT
occurring in the chronic phase of myocarditis, preserved LV
function and a limited scar amenable to ablation, catheter ablation may be considered as an alternative to ICD therapy,
after discussion with the patient and provided that established endpoints have been reached.b
IIb
Catheter ablation, in specialized centres, may be considered in cardiac sarcoidosis ICD recipients with recurrent, symptomatic
SMVT, or ICD shocks for SMVT, in whom AADs are ineffective, contraindicated, or not tolerated.
IIb
Congenital heart disease
In patients with CHD presenting with sustained VAs,
evaluation for residual lesions or new structural abnormalities is recommended.
I
In selected patients with CHD (including atrial bafﬂe repair for transposition of the great arteries, Fontan operation, and
Ebstein anomaly) presenting with CA, evaluation and treatment of SVT with rapid ventricular conduction should be considered.
IIa
In patients with repaired TOF undergoing surgical or transcutaneous pulmonary valve replacement, pre-operative catheter mapping and transection of VT-related anatomical isthmuses before or during the intervention may be considered.
IIb
Continued
ESC Guidelines
4007


<!-- PAGE 12 -->

### Page 12

In patients with repaired TOF with a preserved biventricular function and symptomatic SMVT, catheter ablation or concomitant surgical ablation performed in specialized centres may be considered as an alternative to ICD therapy.
IIb
Idiopathic VF
It is recommended that idiopathic VF is diagnosed in a SCA
survivor, preferably with documentation of VF, after exclusion of an underlying structural, channelopathic, metabolic, or toxicological aetiology.
I
Isoproterenol infusion, verapamil, or quinidine for acute treatment of an electrical storm or recurrent ICD discharges should be considered in idiopathic VF.
IIa
Quinidine should be considered for chronic therapy to suppress an electrical storm or recurrent ICD discharges in idiopathic VF.
IIa
Clinical testing (history, ECG, and high precordial lead ECG,
exercise test, echocardiogram) of ﬁrst-degree family members of idiopathic VF patients may be considered.
IIb
In idiopathic VF patients, genetic testing of genes related to channelopathy and cardiomyopathy may be considered.
IIb
Long QT syndrome
In patients with clinically diagnosed LQTS, genetic testing, and genetic counselling are recommended.
I
Beta-blockers, ideally non-selective beta-blockers (nadolol or propranolol), are recommended in LQTS patients with documented QT interval prolongation, to reduce risk of arrhythmic events.
I
Mexiletine is indicated in LQT3 patients with a prolonged QT
interval.
I
In LQTS, it should be considered to calculate the arrhythmic risk before initiation of therapy based on the genotype and the duration of QTc interval.
IIa
ICD implantation may be considered in asymptomatic LQTS
patients with high-risk proﬁle (according to the 1-2-3 LQTS
Risk calculator) in addition to genotype-speciﬁc medical therapies (mexiletine in LQT3 patients).
IIb
Routine diagnostic testing with epinephrine challenge is not recommended in LQTS.
III
Andersen–Tawil syndrome
Genetic testing is recommended in patients with suspected
Andersen–Tawil syndrome.
I
ICD implantation is recommended in patients with Andersen–
Tawil syndrome after aborted CA or not-tolerated sustained
VT.
I
Andersen–Tawil syndrome should be considered in patients without SHD who present with at least two of the following:
• Prominent U waves with or without prolongation of the QT
interval
• Bidirectional and/or polymorphic PVCs/VT
• Dysmorphic features
• Periodic paralysis
• KCNJ2 pathogenic loss of function mutation.
IIa
Continued
Beta-blockers and/or ﬂecainide with or without acetazolamide should be considered in patients with Andersen–Tawil syndrome to treat VA.
IIa
An ILR should be considered in patients with Andersen–Tawil syndrome and unexplained syncope.
IIa
ICD implantation may be considered in patients with
Andersen–Tawil syndrome who have a history of unexplained syncope or suffer from tolerated sustained VT.
IIb
Brugada syndrome
Genetic testing for SCN5A gene is recommended for probands with BrS.
I
BrS should be considered in patients with no other heart disease and induced type 1 Brugada pattern who have at least one of the following:
• Arrhythmic syncope or nocturnal agonal respiration
• A family history of BrS
• A family history of SD (,45 years old) with a negative autopsy and circumstance suspicious for BrS.
IIa
Implantation of a loop recorder should be considered in BrS
patients with an unexplained syncope.
IIa
BrS may be considered as a diagnosis in patients with no other heart disease who exhibit an induced type 1 Brugada ECG.
IIb
PES may be considered in asymptomatic patients with a spontaneous type I BrS ECG.
IIb
Sodium channel blocker test is not recommended in patients with a prior type I Brugada pattern.
III
Catheter ablation in asymptomatic BrS patients is not recommended.
III
Early repolarization syndrome
It is recommended that the ERP is diagnosed as J-point elevation of ≥1 mm in two adjacent inferior and/or lateral ECG leads.
I
It is recommended that the ERS is diagnosed in a patient resuscitated from unexplained VF/PVT in the presence of ERP.
I
ICD implantation is recommended in patients with a diagnosis of ERS who have survived a CA.
I
In a SCD victim with a negative autopsy and medical chart review, and an ante-mortem ECG demonstrating the ERP, the diagnosis of ERS should be considered.
IIa
First-degree relatives of ERS patients should be considered for clinical evaluation for ERP with additional high-risk features.j
IIa
ILR should be considered in individuals with ERP and at least one risk featurek or arrhythmic syncope.
IIa
Isoproterenol infusion should be considered for ERS patients with electrical storm.
IIa
Quinidine in addition to an ICD should be considered for recurrent VF in ERS patients.
IIa
PVC ablation should be considered in ERS patients with recurrent VF episodes triggered by a similar PVC
non-responsive to medical treatment.
IIa
Genetic testing in ERS patients may be considered.
IIb
ICD implantation or quinidine may be considered in individuals with ERP and arrhythmic syncope and additional risk features.k
IIb
Continued


<!-- PAGE 13 -->

### Page 13

The second part of the guidelines is structured according to disease-speciﬁc management, providing a link to the updated
ESC CardioMed chapter for additional content. Risk stratiﬁcation, SCD prevention, treatment of VA, and management of family members are addressed in a systematic fashion. Indications for cardiac magnetic resonance (CMR) imaging, genetic testing,
and updated indications for catheter ablation of ventricular arrhythmias are presented. Flowcharts summarizing the workﬂow for diagnostic and treatment are provided for the disease entities.
The colour-coding of the ﬂowcharts reﬂects the class of recommendation according to this guideline and other ESC Guidelines.1–3
ICD implantation or quinidine may be considered in asymptomatic individuals who demonstrate a high-risk ERPj in the presence of a family history of unexplained juvenile SD.
IIb
Clinical evaluation is not recommended routinely in asymptomatic subjects with ERP.
III
ICD implantation is not recommended in asymptomatic patients with an isolated ERP.
III
CPVT
Genetic testing and genetic counselling are indicated in patients with clinical suspicion or clinical diagnosis of CPVT.
I
Beta-blockers, ideally non-selective (nadolol or propranolol)
are recommended in all patients with a clinical diagnosis of CPVT.
I
Epinephrine or isoproterenol challenge may be considered for the diagnosis of CPVT when an exercise test is not possible.
IIb
Short QT syndrome
Genetic testing is indicated in patients diagnosed with SQTS.
I
SQTS should be considered in the presence of a QTc
≤320 ms.
IIa
SQTS should be considered in the presence of a QTc ≥320 ms and ≤360 ms and arrhythmic syncope.
IIa
ILR should be considered in young SQTS patients.
IIa
ICD implantation should be considered in SQTS patients with arrhythmic syncope.
IIa
SQTS may be considered in the presence of a
QTc ≥320 ms and ≤360 ms and a family history of SD
at age ,40 years.
IIb
Quinidine may be considered in (a) SQTS patients who qualify for an ICD but present a contraindication to the ICD or refuse it, and (b) asymptomatic SQTS patients and a family history of
SCD.
IIb
Isoproterenol may be considered in SQTS patients with an electrical storm.
IIb
Selected populations
It is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current guidelines for sports eligibility.
I
Continuation of beta-blockers should be considered during pregnancy in women with ARVC.
IIa
Oral metoprolol, propranolol, or verapamil should be considered for long-term management of idiopathic sustained
VT during pregnancy.
IIa
Catheter ablation using non-ﬂuoroscopic mapping systems should be considered, preferably after the ﬁrst trimester, in women with highly symptomatic recurrent SMVT refractory or who are intolerant to AADs.
IIa
Continued
In selected transplanted patients with cardiac allograft vasculopathy or treated rejection, ICD implantation may be considered.
IIb
In elderly patients in whom a beneﬁt from the deﬁbrillator is not expected due to the patient’s age and comorbidities,
omission of ICD implantation for primary prevention may be considered.
IIb
© ESC 2022
AAD, anti-arrhythmic drug; ACE-Is, angiotensin-converting enzyme inhibitors; AED,
automated external deﬁbrillator; ARBs, angiotensin receptor blockers; ARNIs,
angiotensin receptor neprilysin inhibitors; ARVC, arrhythmogenic right ventricular cardiomyopathy; ATP, anti-tachycardia pacing; AV, atrioventricular; BBR-VT, bundle branch re-entry; BrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization therapy; DC,
direct current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection fraction; ERP, early repolarization pattern; ERS, early repolarization syndrome; HCM,
hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy;
ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; LGE, late gadolinium enhancement; LMNA, lamin A/C; LQTS, long QT syndrome; LV, left ventricular;
LVEF,
left ventricular ejection fraction;
LVNC,
left ventricular non-compaction;
MI,
myocardial infarction;
MRAs, mineralocorticoid receptor antagonists; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart
Association; OHCA, out-of-hospital cardiac arrest; OMT, optimal medical therapy;
PES, programmed electrical stimulation; PVC, premature ventricular complex; RCM,
restrictive cardiomyopathy; RVOT, right ventricular outﬂow tract; SCA, sudden cardiac arrest;
SCD,
sudden cardiac death;
SD,
sudden death;
SGLT2,
sodium–glucose co-transporter 2; SHD, structural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SPVT, sustained polymorphic ventricular tachycardia; SQTS, short QT syndrome; SVT, supraventricular tachycardia; TOF,
tetralogy of Fallot; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT,
ventricular tachycardia; WCD, wearable cardioverter deﬁbrillator.
aShopping malls, stadiums, public transport stations, casinos.
bVT non-inducibility and elimination of electrograms consistent with conduction delay.
cIncluding but not limited to older age, right bundle branch block (RBBB) morphology,
SMVT consistent with re-entry.
dPresyncope or palpitations suggestive of VA.
eThe 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease.4
fBased on the HCM Risk SCD: https://doc2do.com/hcm/webHCM.html gDeﬁned as a failure to increase systolic pressure by at least 20 mmHg from rest to peak exercise, or a fall of .20 mmHg from peak pressure.
hBased on the HCM Kid Risk score: https://hcmriskkids.org iFactors favouring ICD implantation: Age,5,6,11 CTG expansion,6–9,13,16 SD or family history of SD,5 ECG conduction abnormalities,16 PR prolongation,13 LBBB,5 atrial arrhythmias,6,16
non-sustained VT,5 LV dysfunction,17 structural abnormalities in CMR.14,15,18
jERP high risk features: J waves . 2 mm, dynamic changes in J point and ST morphology.
kHigh-risk ERP: family history of unexplained SD ,40 years, family history of ERS.
ESC Guidelines
4009


<!-- PAGE 14 -->

### Page 14

Another novel concept of this document is the table of evidence
(see Supplementary data). The trials and studies that have been selected to support a recommendation are systematically described in the table of evidence after careful review of the available data and the applied methodology, prioritizing papers published after 2015. Recommendations with level of evidence C that are not accompanied by a reference are supported by this panel of experts. To assist physicians in their daily clinical practice, diagnostic and therapeutic procedures with promising usefulness, typically classiﬁed as class IIb, but for which evidence is limited and difﬁcult to collect in the near future, the related recommendations are not only described in the narratives but are listed in the table of recommendation.
Table 5
Changes in recommendations since 2015
Class
2015
2022
Coronary artery disease
In patients with syncope and previous STEMI, PES is indicated when syncope remains unexplained after non-invasive evaluation.
IIa
I
Intravenous amiodarone treatment should be considered for patients with recurrent PVT/VF
during the acute phase of ACS.
I
IIa
In patients with CAD eligible for ICD implantation,
catheter ablation may be considered just before (or immediately after) ICD implantation to decrease subsequent VT burden and ICD shocks.
IIa
IIb
PVC-induced cardiomyopathy
In patients with a cardiomyopathy suspected to be caused by frequent and predominately monomorphic
PVCs, catheter ablation is recommended.
IIa
I
DCM/HNDCM
ICD implantation should be considered in patients with DCM/HNDCM, symptomatic heart failure
(NYHA class II–III) and LVEF ≤35% after ≥3 months of OMT.
I
IIa
Catheter ablation in specialized centres should be considered in patients with DCM/HNDCM and recurrent, symptomatic SMVT, or ICD shocks for
SMVT, in whom AADs are ineffective,
contraindicated, or not tolerated.
IIb
IIa
ARVC
ICD implantation should be considered in patients with deﬁnite ARVC and an arrhythmic syncope.
IIb
IIa
ICD implantation should be considered in patients with deﬁnite ARVC and severe RV or LV systolic dysfunction.
IIb
IIa
Inﬂammatory diseases
In patients with haemodynamically not-tolerated
SMVT occurring in the chronic phase of myocarditis,
ICD implantation is recommended.
IIa
I
ICD implantation is recommended in patients with cardiac sarcoidosis who have an LVEF ≤35%.
IIb
I
ICD implantation is recommended in patients with cardiac sarcoidosis who (1) have documented sustained VT, or (2) aborted CA.
IIb
I
In patients with cardiac sarcoidosis who have an indication for permanent cardiac pacing related to high-degree AV block, ICD implantation should be considered, regardless of LVEF.
IIb
IIa
In patients with Chagas’ cardiomyopathy and symptomatic VT in whom AADs (amiodarone and beta-blockers) are ineffective or not tolerated, ICD
implantation may be considered.
IIa
IIb
Continued
CHD
In patients after repair of TOF without arrhythmia symptoms, but with a combination of other risk factors,a electrophysiologic evaluation, including PES,
may be considered.
IIa
IIb
In patients with CHD and recurrent, symptomatic
SMVT, or ICD shocks for SMVT not manageable by medical therapy or ICD reprogramming, catheter ablation performed in specialized centres should be considered.
I
IIa
Primary electrical disease and selected populations
ICD implantation is recommended in patients with
LQTS who are symptomaticb while receiving beta-blockers and genotype-speciﬁc therapies.
IIa
I
ICD implantation should be considered in patients with CPVT who experience arrhythmic syncope and/
or documented bidirectional/PVT while on the highest tolerated beta-blocker dose and on ﬂecainide.
I
IIa
Pre-participation cardiovascular evaluation of competitive athletes should be considered.
I
IIa
Catheter ablation of triggering PVCs and/or RVOT
epicardial substrate should be considered in BrS
patients with recurrent appropriate ICD shocks refractory to drug therapy.
IIb
IIa
LCSD should be considered in patients with diagnosis of CPVT when the combination of beta-blockers and
ﬂecainide at therapeutic dosage are either not effective, not tolerated, or contraindicated.
IIb
IIa
© ESC 2022
AAD, anti-arrhythmic drug; ACS, acute coronary syndrome; ARVC, arrhythmogenic right ventricular cardiomyopathy; AV, atrioventricular; BrS, Brugada syndrome; CA,
cardiac arrest; CAD, coronary artery disease; CHD, congenital heart disease; CPVT,
catecholaminergic polymorphic ventricular tachycardia;
DCM,
dilated cardiomyopathy;
HNDCM,
hypokinetic non-dilated cardiomyopathy;
ICD,
implantable cardioverter deﬁbrillator; LCSD, left cardiac sympathetic denervation;
LQTS, long QT syndrome; LV, left ventricle; LVEF, left ventricular ejection fraction;
NYHA, New York Heart Association; OMT, optimal medical treatment; PES,
programmed electrical stimulation; PVC, premature ventricular complex; PVT,
polymorphic ventricular tachycardia; RV, right ventricle; RVOT, right ventricular outﬂow tract; SMVT, sustained monomorphic ventricular tachycardia; STEMI, ST
elevation myocardial infarction; TdP, torsade de pointes; TOF, tetralogy of Fallot; VF,
ventricular ﬁbrillation; VT, ventricular tachycardia.
aOther risk factors include moderate RV or LV dysfunction, extensive RV scarring on
CMR, QRS duration ≥180 ms, and severe QRS fragmentation.
bArrhythmic syncope or haemodynamically not-tolerated VA.


<!-- PAGE 15 -->

### Page 15

### 3 Deﬁnitions

3.1. Ventricular arrhythmia subtypes
Premature ventricular complex (PVC): Premature occurrence of an abnormal QRS complex (duration typically ≥120 ms, corresponding
T-wave typically broad and in the opposite direction of the major
QRS deﬂection, no preceding P-wave).
Unifocal or monomorphic PVCs: PVCs with a single QRS morphology.
Multifocal, multiform, or polymorphic PVCs: PVCs with different QRS
morphologies.
Short-coupled PVC: A PVC that interrupts the T-wave of the preceding conducted beat.
Ventricular tachycardia (VT): ≥3 consecutive beats with a rate
.100 b.p.m. originating from the ventricles, independent from atrial and atrioventricular (AV) nodal conduction.
Non-sustained ventricular tachycardia (NSVT): Run of consecutive ventricular beats persisting for 3 beats to 30 s.
Monomorphic ventricular tachycardia (MVT): Same QRS morphology from beat to beat.
Polymorphic ventricular tachycardia (PVT): Continually changing QRS
morphology.
Sustained monomorphic/polymorphic ventricular tachycardia (SMVT/
SPVT): Continuous VT for at least 30 s, or which requires an intervention for termination.
Bidirectional ventricular tachycardia: Beat to beat alternation of the frontal QRS axis (e.g. in catecholaminergic polymorphic ventricular tachycardia
[CPVT],
Andersen–Tawil,
digoxin toxicity,
acute myocarditis).
Torsades de pointes ventricular tachycardia (TdP): Subtype of a polymorphic VT in the context of QT prolongation with continually changing QRS complexes that appear to spiral around the baseline of the electrocardiogram (ECG) lead in a sinusoidal pattern.
Ventricular ﬁbrillation (VF): A chaotic rhythm with undulations that are irregular in timing and morphology, without discrete QRS complexes on the surface ECG.
Electrical storm: VA that occurs 3 or more times within 24 h (separated by at least 5 min), each requiring termination by an intervention.
Incessant VT: Continuous sustained VT that recurs promptly despite repeated intervention for termination over several hours.
3.2. Sudden cardiac death
Sudden cardiac arrest (SCA): Sudden cessation of normal cardiac activity with haemodynamic collapse.
Sudden cardiac death (SCD): Sudden natural death presumed to be of cardiac cause that occurs within 1 h of onset of symptoms in witnessed cases, and within 24 h of last being seen alive when it is unwitnessed. SCD in autopsied cases is deﬁned as the natural unexpected death of unknown or cardiac cause.
Sudden unexplained death: Unexplained sudden death occurring in an individual older than 1 year.
Sudden infant death syndrome (SIDS): Unexplained sudden death occurring in an individual younger than 1 year with negative pathological and toxicological assessment and negative forensic examination of the circumstances of death.
Sudden arrhythmic death syndrome (SADS): Unexplained sudden death occurring in an individual older than 1 year with negative pathological and toxicological assessment. Note: Synonymous with
‘autopsy-negative sudden unexplained death’.
3.3. Syncope
Unexplained syncope: Transient loss of consciousness due to cerebral hypoperfusion, characterized by a rapid onset, short duration, and spontaneous complete recovery, but unexplained after conventional workup. Work-up and differential diagnosis are provided in the 2018
ESC Guidelines for the diagnosis and management of syncope.1
Arrhythmic syncope: as above, but highly suspicious for intermittent bradycardia, rapid supraventricular tachycardia (SVT), or VA.
3.4. Specialized centres
Multidisciplinary teams: A multidisciplinary team across specialties is characterized by open communication, positive management and leadership,
appropriate resources,
and a
mix of skills.
Decision-making should be shared in the team.
Specialized centre for catheter ablation of VA: Patient and procedural complexity vary widely. Some patients require a more experienced operator and a centre with more capabilities, which is more likely in patients with a non-ischaemic aetiology. A specialized centre has at least one operator with appropriate experience in interventions that may be required for a successful procedure (e.g. percutaneous epicardial access). The centre performs catheter ablation of VT in structural heart disease (SHD) on a regular basis. In addition, the centre has the required resources to manage medical conditions, comorbidities, and potential complications in patients undergoing complex VA ablation; this includes interventional cardiology expertise, acute placement of mechanical circulatory assist devices, and cardiothoracic surgical back-up. Considering the variable availability across European countries, it is preferable to treat complex patients in the most experienced centre within reasonable distance.
3.5. Genetics
Pathogenic variant and likely pathogenic variant: The American College of Medical Genetics has provided a framework for the interpretation of disease causation by genetic variants standardized into classes. The genetic variants most likely to cause an associated disease are termed
V, ‘pathogenic’, and IV, ‘likely pathogenic’.
Mutation: This term is used in this document to mean a Class IV or
V variant.
Variant of uncertain signiﬁcance: A change in a gene’s deoxyribonucleic acid (DNA) sequence that has an unknown effect on a person’s health.
4. Epidemiology of sudden cardiac death, public awareness, and risk stratiﬁcation
4.1. Incidence of sudden cardiac death
SCD accounts for approximately 50% of all cardiovascular deaths,
with up to 50% being the ﬁrst manifestation of cardiac disease.19–24
Ideally, cases suspicious of SCD should be identiﬁed from multiple
ESC Guidelines
4011


<!-- PAGE 16 -->

### Page 16

sources and undergo autopsy, which is required to reliably exclude non-cardiac causes of sudden death (SD).
The incidence of SCD increases markedly with age. With a very low incidence during infancy and childhood (1 per 100 000 personyears),25–27 the incidence is approximately 50 per 100 000 personyears in middle-aged individuals (in the ﬁfth to sixth decades of life).28–30 In the eighth decade of life, it reaches an annual incidence of at least 200 per 100 000 person-years.20 At any age, males have higher SCD rates compared with females, even after adjustment for risk factors of coronary artery disease (CAD).24,31–33 Ethnic background also seems to have large effects.34,35 It is estimated that 10–20% of all deaths in Europe are SCD.36,37 Approximately
300 000 people in Europe have out-of-hospital cardiac arrest
(OHCA) treated by emergency medical systems every year.38,39
In the Western world, the epidemiology of SCD is closely related to CAD, which is responsible for up to 75–80% of SCD cases.40
While the prevalence of CAD has not decreased, there has been a signiﬁcant decline in mortality due to CAD. Reports show that the incidence of SCD is declining,40–42 but the risk of SCD as a proportion of the overall cardiovascular deaths may have increased.43,44
Although regular physical activity beneﬁts cardiovascular health,
sport, particularly when practiced vigorously, has been shown to be associated with SCD during or shortly after exercise in selected populations.45–51 Reports have suggested that the majority of sportsrelated SCD occurs in a recreational52,53 rather than competitive setting, especially among middle-aged male participants, suggesting that CAD is the most common underlying cause.46,54,55
4.2. Causes of sudden cardiac death in different age groups
Cardiac diseases associated with SCD vary depending on the individual’s age. In the young there is a predominance of primary electric diseases and cardiomyopathies, as well as myocarditis, and coronary anomalies.25,27,56–61 However, half of SCD cases during the fourth decade are related to CAD, especially acute coronary syndrome
(ACS).62,63
In older populations, chronic structural diseases predominate
(CAD either through acute coronary events or chronic coronary stenoses, valvular heart diseases, and heart failure), while potentially inherited electrical diseases or structural non-ischaemic diseases may cause more than 50% of SCD in individuals under the age of 50
years.27
Age distribution at presentation with ventricular arrhythmias and sudden cardiac death, dominant arrhythmia subtypes, triggers, genetic factors, and gender associated with increased risk for ventricular arrhythmias in selected primary electrical and structural heart diseases are presented in Figure 1.
4.3. Population vs. individual risk prediction
In the general population (individuals without known heart disease),
the most effective approach for preventing SCD resides in quantiﬁcation of the individual risk of developing CAD based on risk score charts.64,65 Several studies have provided evidence that there is a genetic predisposition to die suddenly during acute ischaemia.66–70
The goal would be to identify the relatively small, high-risk subgroups from the general population at risk of SCD as their ﬁrst cardiac event.
Models for novel SCD risk stratiﬁcation in the general population have recently been proposed.71–73 There are no clear data supporting the beneﬁt of mass screening programs in the general population for preventing SCD.74–76
For decades, investigators have envisioned a broad range of ‘indicators’ for SCD, especially occurring in the setting of CAD. Several non-invasive markers of risk have been proposed (including late potentials, heart rate variability, periodic repolarization dynamics, and baroreﬂex sensitivity).77 Despite the promising outcomes of initial studies, however, these ‘predictors’ have not yet inﬂuenced clinical practice. Left ventricular ejection fraction (LVEF) is only used, often in combination with New York Heart Association (NYHA) class, for primary prevention indication of an ICD in the setting of chronic
CAD and dilated cardiomyopathy (DCM). Risk stratiﬁcation schemes and calculators have been developed for inheritable arrhythmogenic diseases, such as hypertrophic cardiomyopathy (HCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and lamin A/C
(LMNA) cardiomyopathy.78–82
What is considered low, intermediate, or high risk will depend on the type of event (e.g. fatal or not) and the risk of an event in the background population. For instance, mortality depends on age,
sex, and other risk factors including comorbidities. The situation is further complicated when considering a speciﬁc type of death, e.g.
SCD. Then non-SCD deaths are competing events (or competing risks) to SCD in the sense that their occurrence prevents the observation of SCD, and may make interventions to prevent SCD, such as an ICD, of limited beneﬁt.
4.4. Risk calculators for sudden cardiac death and review of the methodology
A number of risk calculators for SCD have been proposed for adult and paediatric populations.80,81,83–85 The ﬁeld of prediction modelling has evolved over the past decades, establishing standards for the development, validation (internal and external), and reporting of prediction models in SCD.86,87 In addition to discrimination measures such as the c-index, measures of calibration such as the calibration slope have recently received more attention because it is not only important to distinguish patients with higher risks from those with lower risks but also to obtain a robust quantiﬁcation of the risk itself from the risk calculators.88 Typical shortcomings in the development and validation of risk calculators include, but are not limited to, the use of historic samples not representative of contemporary patient cohorts, missing values, composite outcomes with composite events of different clinical importance, lack of external validation, and missing calibration. In this document different cut-off for 5 years risk of
SCD/VA is used for indication of ICD. Each cut-off was chosen by the original authors and the task force group considering the competing risk, the outcome measured (SCD vs VA) and the robustness of each risk calculator.
4.5. Awareness and intervention: public basic life support, and access to automated external deﬁbrillators
Survival rate remains strikingly low after OHCA,89–95 although major regional disparities have been described.96 Early implementation of


<!-- PAGE 17 -->

### Page 17

resuscitative interventions, especially prior to emergency medical system arrival, has been identiﬁed as key elements to improve survival.95,97 Bystander cardiopulmonary resuscitation (CPR) and use of public automated external deﬁbrillators (AEDs) have demonstrated improvement of neurological and functional outcome as well as survival of OHCA patients. Data support the need for increased availability of public access deﬁbrillators and community training in basic life support,89–95 preferably initiated in childhood and repetitive.98–100 Finally, dispatch of basic life support-trained volunteers, through speciﬁc mobile apps networks, has been shown to increase the rate of bystander-initiated CPR, and as a result, greatly reduces the resuscitation-free interval and improves the outcome of
Genetic risks and triggers for VA/SCD
CPVT
LQT
BrS
ACS
Sarcoid
HCM
DCM
ARVC
rTOF
chronic
CAD
Age at 
VA/SCD
Dominant subtype of VA (%)
10
20
30
40
50
60
70
80
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
PVT
MVT
P
M
0
50
100
Figure 1 Central ﬁgure. Genetic risk for VA/SCD, typical triggers for VA/SCD, age at presentation with VA/SCD, sex predominance, and typical VA
(PVT/VF vs. MVT) in different diseases associated with VA/SCD. ACS, acute coronary syndrome; ARVC, arrhythmogenic right ventricular cardiomyopathy; BrS, Brugada syndrome; CAD, coronary artery disease; CPVT, catecholaminergic polymorphic ventricular tachycardia; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LQT, long QT syndrome; MVT, monomorphic ventricular tachycardia; PVT, polymorphic ventricular tachycardia; rTOF, repaired tetralogy of Fallot; SCD, sudden cardiac death; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation.
ESC Guidelines
4013


<!-- PAGE 18 -->

### Page 18

OHCA victims.101–103 Education of public ofﬁcials and community members regarding the importance of increasing rates of bystander
CPR and promoting the use of early deﬁbrillation by lay and professional rescuers is critical to increasing survival rates.
5. Evaluation and treatment.
General aspects
5.1. Diagnostic tools
5.1.1. History and physical examination
History should focus on ‘red ﬂags’, including features of arrhythmic syncope, e.g. absence of vagal prodrome, and family history of premature or SCD including, e.g. drowning or car accident in long QT
syndrome (LQTS), and CPVT.1,106 Subtle features to suggest inherited causes include a family history of epilepsy, sudden infant death syndrome, deafness (LQTS), heart failure, or pacemaker implantation at ,50 years old. Features of diseases related to pro-arrhythmic conditions include mid-systolic click in mitral valve prolapse (MVP) and outﬂow tract murmurs with Valsalva in HCM. Speciﬁc skin features may be relevant, e.g. Lupus pernio, erythema nodosum in sarcoidosis,
angiokeratoma in Fabry’s disease, xanthelasma/xanthoma, and palmoplantar keratosis in ARVC.
5.1.2. Laboratory testing
Natriuretic peptides (b-type-natriuretic peptide, or N-terminal pro-b-type-natriuretic peptide) may have a role in the identiﬁcation of individuals at increased risk of SCD in the general population107,108
or in patients with CAD.109 There is not sufﬁcient evidence to use b-type-natriuretic peptide as a method to select the need for an
ICD.110,111
5.1.3. Non-invasive and invasive tests
5.1.3.1. Electrocardiogram and ambulatory electrocardiographic monitoring2
The 12-lead ECG is an important tool for the diagnosis of underlying disease, for risk stratiﬁcation in selected populations, and for the diagnosis of the VA subtype, if captured. Documentation of arrhythmias related to symptoms is clinically pivotal but may be challenging with sporadic events. The type of ECG-monitoring device and the recording time should therefore match the frequency of clinical events.
Monitoring over a period of 24–48 h (typically ‘Holter recording’) is appropriate for daily arrhythmias,112 while intermittent monitoring over a longer period, with patient-activated ECG recorders (or mobile-health/smartphones), should be preferred for infrequent events.113 Implantable loop recorders (ILR) can be useful in diagnosing arrhythmias in patients with potentially life-threatening symptoms, such as unexplained syncope.114
5.1.3.2. Signal-averaged electrocardiogram
Signal-averaged electrocardiogram (SaECG) can detect very low amplitude signals (‘late potentials’) in the terminal QRS segment115
using three time-domain measurements: QRS duration, low-amplitude
(,40 µV) signal duration and root mean square voltage of terminal
40 ms QRS.112 Abnormalities in the SaECG can also be assessed by frequency-domain analysis.112 SaECG can contribute to the diagnosis of ARVC.116
5.1.3.3. Exercise testing
Exercise testing is useful for the diagnosis and for evaluating response to therapy in patients with suspected/proven adrenergic-dependent rhythm disturbances, such as exercise-induced idiopathic MVT, PVT,
or bidirectional VT in CPVT.117,118 The 4-minute recovery QTc after exercise testing can contribute to the diagnosis LQTS.119
5.1.3.4. Imaging
Imaging is crucial to assess cardiac function and detect cardiomyopathies (
ESC CardioMed chapter 10).120 A negative imaging study supports primary electrical disease in a patient with VA.
Echocardiography is a readily available and ﬁrst-line diagnostic and risk stratiﬁcation tool for valve diseases, CAD and DCM, HCM, ARVC,121
and left ventricular non-compaction (LVNC). Echocardiographic strainrate imaging allows differentiation between active and passive movement of myocardial segments and early detection of myocardial dysfunction. Wall motion abnormalities can indicate previous infarcts,
cardiomyopathies, or inﬂammatory disease. Global longitudinal strain is a robust measure of left ventricular (LV) function and can detect subtle changes in LV function while LVEF is still preserved.122 Strain imaging can assess mechanical dispersion reﬂecting inhomogeneous contraction that could be associated with increased risk of VA.122–125
CMR currently provides the most accurate and reproducible measurement of atrial, biventricular global and regional systolic function,
and can detect myocardial oedema, ﬁbrosis, inﬁltration, and
Recommendation Table 1 — Recommendations for public basic life support and access to automated external deﬁbrillators
Recommendations
Classa
Levelb
It is recommended that public access deﬁbrillation be available at sites where cardiac arrest is more likely to occur.c,90–92
I
B
Prompt CPR by bystanders is recommended at
OHCA.93–95
I
B
It is recommended to promote community training in basic life support to increase bystander
CPR rate and AED use.93,97,104
I
B
Mobile phone-based alerting of basic life support-trained bystander volunteers to assist nearby OHCA victims should be considered.101–103,105
IIa
B
© ESC 2022
AED, automated external deﬁbrillator; CPR, cardiopulmonary resuscitation; OHCA,
out-of-hospital cardiac arrest.
aClass of recommendation.
bLevel of evidence.
cShopping centres, stadiums, public transport stations, casinos.


<!-- PAGE 19 -->

### Page 19

perfusion defects (
ESC CardioMed chapter 11.4).126 CMR is more sensitive than echocardiography to diagnose ARVC,127 is diagnostic in LVNC, and can detect apical aneurysms in HCM. Fibrosis detection by late gadolinium enhancement (LGE) contributes to
VA risk stratiﬁcation in HCM,128 DCM,129 and potentially in mitral valve prolapse arrhythmic syndrome.130,131 Novel myocardial mapping techniques can detect diffuse ﬁbrosis and can suggest the aetiology of left ventricular hypertrophy (LVH) for speciﬁc therapy guiding, e.g. Fabry disease and amyloidosis. The prognostic value remains to be evaluated.
Cardiac imaging by computed tomography (CT) has the advantage of a high spatial resolution (
ESC CardioMed chapter 12.1).132
ECG synchronization, additional breath-hold sequences, and betablocker to lower the heart rate improve the quality. Radiation exposure is in the range of an invasive coronary angiogram
(CAG). Coronary computed tomography angiography (CTA) is the preferred method to rule out coronary artery stenosis in patients with low probability of CAD.133,134 The quality of almost all image modalities is inﬂuenced by the presence of frequent
PVCs.
5.1.3.5. Provocative diagnostic tests
These are summarized in Table 6. Common tests performed are sodium channel blocker testing for Brugada syndrome (BrS) and adenosine test to exclude latent pre-excitation.135,136 Epinephrine challenge may be useful in CPVT when exercise cannot be performed. Epinephrine test is not recommended for LQTS due to the high false positive rate and utility of exercise testing.137
Coronary vasospasm as a cause of VF in the absence of obstructive coronary diseases/cardiomyopathy can be tested with incremental intracoronary doses of acetylcholine/ergonovine.
5.1.3.6. Electrophysiological study
Electrophysiological studies including measurement of baseline intervals (e.g. atrial–His interval [AH] and His–ventricular interval [HV]),
programmed electrical stimulation (PES), and electroanatomical mapping can be used for diagnostic purposes and to guide therapy.145–150 The yield of PES varies with the underlying cardiac condition and its severity, the presence or absence of spontaneous VT,
concomitant drug therapy, stimulation protocol, and site(s) of stimulation. Typical protocols include stimulation from 2 right ventricular
(RV) sites with 2–3 basic drive cycle lengths, introduction of 3 extrastimuli, and isoprenaline administration.148,151,152
In the current era, PES is mainly employed to conﬁrm the diagnosis of VT and induce mappable VAs with non-inducibility being an ablation endpoint. Patients with heart failure and LVEF ≤35% generally will have an indication for an ICD; therefore, VT/VF induction before implantation is not necessary. In patients with SHD and mildly reduced or preserved LVEF who present with unexplained syncope, induction of SMVT with PES can be helpful to identify the underlying cause and to predict subsequent events.146,153 PVT/VF induction in
SHD is in general considered as a non-speciﬁc ﬁnding.154–156
In primary electrical diseases, PES is not of prognostic value, although there is some evidence to consider its use in BrS.127
Invasive electrophysiological evaluation can have important clinical implications in patients with myotonic dystrophy.157
With advances in high-density mapping, voltage mapping, conduction/repolarisation metrics, and electrogram fractionation can be employed to identify ablation targets,
or to diagnose cardiomyopathic disease. Endocardial mapping may be helpful in the differentiation of ARVC from benign outﬂow tract VT and for targeting biopsy in suspected myocarditis, ARVC, and sarcoidosis cases.158–162
5.1.4. Genetic testing
Massive parallel or next-generation sequencing has led to increasing availability of genetic testing at reduced cost. Most diagnostic cardiac genetic testing employs large gene panels determined by associations with disease generated by prior research, i.e. candidate genes.163
Many previous gene associations have, however, been challenged for their diagnostic utility. Therefore, it is not recommended to include questionable genes in routine diagnostic panels.164–168
Genome-wide association studies have identiﬁed that common genetic variation single nucleotide polymorphisms can cause or modify phenotypes in BrS, LQTS, HCM, and DCM. Polygenic risk scores,
measures derived from the cumulative effects of these single nucleotide polymorphisms, may therefore play a role in diagnosis and prognostication in these conditions in the future.168–173
Sequencing produces digital data that require subsequent bioinformatic analysis, permitting accurate ascertainment of most
DNA alterations affecting the coding frame of each gene.174 The most common ﬁndings are single nucleotide variants causing simple amino acid substitutions (missense), premature terminations, or splicing abnormalities. Insertions and/or deletions are rarer. The clinical importance of most non-coding variants is still to be determined.174,175
A framework for the interpretation of disease causation by genetic variants has standardized adjudication into ﬁve classes: V ‘pathogenic’; IV ‘likely pathogenic’; III ‘variant of uncertain signiﬁcance’; II ‘likely benign’; and I ‘benign’. A combination of evidence is employed: gene–
disease association; presence of a variant in healthy and/or diseased populations; in silico data; in vitro and in vivo functional data; and family segregation data.176
A mutation (Class IV or V variant) can be used immediately either for conﬁrmation of diagnosis in probands (the ﬁrst affected family member), or for initial diagnosis of relatives and may help to guide therapy and/or prognosis. Periodic reassessment of all class IV and
III variants is indicated.176
Pre-implantation genetic testing is an early form of pre-natal genetic diagnosis. Genetic diagnoses of in vitro fertilized embryos are identiﬁed by biopsies, thereby allowing transfer of genetically normal embryos into the uterus. If the technique is available, it is important to provide information to patients with monogenic heart diseases in child-bearing age. The legislation for pre-implantation genetic testing varies in different countries and strategies differ.
Genetic and clinical testing should be undertaken only by multidisciplinary teams including professionals with skills to counsel on the implications and the uncertainty of results and experienced cardiologists able to direct testing to the correct phenotype.135,177–179 A
negative result does not exclude a diagnosis and should not be used for this purpose. A framework for genetic and other clinical diagnostic tests for primary electrical diseases based on evidence where available has been provided in Table 7.
ESC Guidelines
4015


<!-- PAGE 20 -->

### Page 20

Table 6
Intravenous provocative diagnostic tests
Diagnostic test
Indication
Protocols
Dose/infusion rate/duration
Positive test
Contraindications
Criteria to stop test,
counselling and management
Observation times
Location
Ref
Ajmaline
Family history of BrS
or SADS.
Resuscitated CA
without SHD.
1 mg/kg over 5–10 min
(maximum dose
100 mg) or 1 mg/kg at 10 mg/min.
Record in standard and high precordial leads over 30 min.
BrS type 1 ECG.
Type I BrS ECG, HF.
Precaution if evidence of conduction disease (consider temporary pacing wire).
VT/VF, Type 1 BrS ECG,
PVCs, QRS widening
.150%.
If VT/VF, administer iv isoprenaline, iv sodium bicarbonate.
30 min if negative test; 4 h if positive test.
Cath lab or outpatient testing location with full resuscitation equipment.
136,138,139
Flecainide
Same as ajmaline.
2 mg/kg over 10 min
(maximum dose
150 mg).
Record in standard and high precordial leads over 30 min.
Same as ajmaline.
Same as ajmaline.
Same as ajmaline.
4 h if negative test;
24 h if positive test.
Same as ajmaline.
140
Epinephrine
CPVT and resuscitated CA
with or without
SHD when exercise test not feasible.
Family history of
SADS.
Rest 10 min.
Start at 0.025 µg/ kg/
min for 10 min increase sequentially to 0.05, 0.1 and 0.2 µg/
kg/min in 5 min steps.
≥3 beats of PVT
or bidirectional
VT.
QTc prolongation ≥480 ms.
Systolic blood pressure ≥
200 mmHg,
non-sustained VT or PVT,
.10 PVCs /min, T-wave alternans, or patient intolerance.
If symptoms persist after discontinuation, iv metoprolol 2.5–5 mg over 1 min.
30 min.
Same as ajmaline.
141
Acetylcholine
Suspicion of coronary vasospasm.
Intracoronary injection: RCA: 20 and
50 µg. LCA: 20, 50,
and 100 µg over 20 s.
.3-min intervals between injections.
Maximal dose of 50 µg in the RCA and 100 µg in the LCA.
Coronary artery spasm visualized during procedure.
Left main stenosis .50%,
3-vessel disease, 2-vessel disease with total occlusion,
NYHA III/IV HF, renal failure,
severe bronchial asthma.
Temporary wire for back-up pacing.
Risk of cardiogenic shock.
Normal post-procedure observational time.
Cath lab.
142
Continued


<!-- PAGE 21 -->

### Page 21

Table 7
Genetic tests and suggested work-up of probands and relatives with primary electrical diseases
LQTS
BrS
CPVT
Idiopathic VF
ERS
Genetic test
Class Ia
Class I
Class Ia
Class IIb
Class IIb
Proband
Initial clinical test
Cornerstone for diagnosis
ECG
Exercise test
ECG and high precordial lead ECG
Sodium channel blockers provocative testc
Exercise test
See Section 5.2.3, scenario 3
ECG
Other tests/processes
Exclude acquired
LQTS
Exclude phenocopyb
Exclude phenocopyb/SHD
Holter
Echocardiography
Follow-up
1–3 years dependent on level of risk
Relatives
Clinical screening
ECG
Exercise test
(when feasible)
From birth
ECG and high precordial lead ECGs: start at 10 years
Sodium channel blockers provocative testc: start .16
years unless clinically indicated180,181
ECG
Exercise test
From birth
ECG and high precordial lead ECGs
Exercise test
Echocardiogram182
ECG
Echocardiogram
Follow-up
Positive phenotype and/or
Class IV/V variant
1–3 years dependent on level of risk
Negative phenotype and no
Class IV/V variant
Discharge
© ESC 2022
BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; ECG, electrocardiogram; ERS, early repolarization syndrome; LQTS, long QT syndrome; VF, ventricular ﬁbrillation.
aIncluding neonatal genetic testing.
bA phenocopy has characteristics of a genetic disease but is produced environmentally.
cNot in case of a documented type 1 Brugada pattern.
Ergonovine
Same as acetylcholine.
Intracoronary stepwise injection:
RCA (20–60 mg)
LCA (20–60 mg) over a period of 2–5 min.
Same as acetylcholine
Left main stenosis .50%,
3-vessel disease, 2-vessel disease with total occlusion,
NYHA III/V HF, renal failure.
Temporary wire should be placed for back-up pacing.
Risk of cardiogenic shock.
Same as acetylcholine.
Cath lab.
143
Adenosine
Exclude latent pre-excitation.
6, 12, 18 mg boluses up to maximum dose
24 mg or until AV
block or pre-excitation occurs.
Identiﬁcation of accessory pathway.
Asthma, sinus node disease,
allergy to adenosine.
Side effects:
Bronchospasm,
bradycardia, asystole, AF,
seizure. Antagonist:
theophylline.
5 min.
Same as ajmaline.
144
© ESC 2022
AF, atrial ﬁbrillation; AV, atrioventricular; BrS, Brugada syndrome; CA, cardiac arrest; CPVT, catecholaminergic polymorphic ventricular tachycardia; ECG, electrocardiogram; HF, heart failure; LCA, left coronary artery; NYHA, New York Heart
Association; PVCs, premature ventricular complexes; PVT, polymorphic ventricular tachycardia; RCA, right coronary artery; SADS, sudden arrhythmic death syndrome; SHD, structural heart disease; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
ESC Guidelines
4017


<!-- PAGE 22 -->

### Page 22

5.2. Diagnostic evaluation at ﬁrst presentation with ventricular arrhythmia in patients without known cardiac disease
VA and (aborted) SCD are common ﬁrst manifestations of a previously not known cardiac condition. A comprehensive diagnostic evaluation is provided for ﬁve frequently encountered scenarios.
5.2.1. Scenario 1: Incidental ﬁnding of a non-sustained ventricular tachycardia
An algorithm for the evaluation of patients presenting with an incidental ﬁnding of NSVT is presented in Figure 2.
Incidental NSVT is a common ﬁnding during routine cardiological evaluation (e.g. for non-cardiac diseases, pre-initiation of oncological treatments, pre-participation in sports) and monitoring before induction of anaesthesia/sedation for non-cardiac procedures.184
Patients with incidentally found NSVT require further evaluation.
A recent syncope suspicious for cardiac origin is a high-risk symptom and may prompt admission to hospital.1,185 The morphology of
NSVT (polymorphic or monomorphic) is important to assess.
Typical MVT morphologies (Figure 3) can suggest an idiopathic origin with favourable prognosis. In contrast, short-coupled PVC initiating non-sustained PVT or monomorphic NSVT with short cycle length
(usually ,300 ms, average 245 + 28, in one series) may identify patients at higher risk of SCD.186,187 Resting 12-lead ECG is a ﬁrst-line evaluation and may show signs of SHD or primary electrical diseases
(
ESC CardioMed chapter 8.6).188 Echocardiography is the ﬁrstline imaging modality that provides important information about cardiac function and potential SHD (
ESC CardioMed 10.3, 10.10,
10.12).120,189,190 Holter monitoring is useful to assess the frequency of NSVT and related PVCs (
ESC CardioMed chapter 8.9).191 In addition, an at least 3-lead Holter (V1, two inferior leads) may give a
ﬁrst estimate if NSVT/PVC are unifocal or multifocal and of the
NSVT site(s) of origin. The latter is important if the NSVT has not been previously documented on a 12-lead ECG.192
An exercise test can be helpful to capture the 12-lead ECG of
NSVT and to identify exercise-induced arrhythmias. Increasing arrhythmias with exercise, not suggestive of idiopathic origin, should raise suspicion of SHD and may necessitate advice to refrain from physical exercise until diagnosis and initiation of appropriate treatment. Underlying signiﬁcant CAD should be ruled out according to the patient’s pre-test probability.
CMR should be considered when cardiomyopathies or inﬂammatory diseases are suspected on initial evaluation (
ESC
CardioMed chapter 10.4).193 In addition, CMR can identify areas of
ﬁbrosis as substrates of NSVT.129
5.2.2. Scenario 2: First presentation of sustained monomorphic ventricular tachycardia
An algorithm for the evaluation of patients presenting with a ﬁrst
SMVT episode is presented in Figure 4.
The majority of patients presenting with SMVT have underlying SHD. SMVT in SHD is mainly due to scar-related re-entry and only occasionally due to re-entry involving a diseased conduction system or due to focal sources.
Recommendation Table 3 — Recommendations for evaluation of patients presenting with newly documented ventricular arrhythmia
Recommendations
Classa
Levelb
In patients with newly documented VA (frequent
PVCs, NSVT, SMVT), a baseline 12-lead ECG,
recording of the VA on 12-lead ECG, whenever possible, and an echocardiogram are recommended as ﬁrst-line evaluation.
I
C
In patients with newly documented VA (frequent
PVCs, NSVT, SMVT) and suspicion of SHD other than CAD after initial evaluation, a CMR should be considered.194,195
IIa
B
In patients with an incidental ﬁnding of a NSVT,
a ≥24 h Holter ECG should be considered.
IIa
C
© ESC 2022
CAD,
coronary artery disease;
CMR,
cardiac magnetic resonance;
ECG,
electrocardiogram; NSVT, non-sustained ventricular tachycardia, PVCs, premature ventricular contractions;
SHD,
structural heart disease;
SMVT,
sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 2 — Recommendations for genetic testing
Recommendations
Classa
Levelb
Genetic testing is recommended when a condition is diagnosed in a living or deceased individual with a likely genetic basis and a risk of VA and
SCD.56,183
I
B
When a putative causative variant is ﬁrst identiﬁed,
evaluation for pathogenicity is recommended using an internationally accepted framework.176
I
C
When a Class IV or Class V variant has been identiﬁed in a living or deceased individual with a condition that carries a risk of VA and SCD,
genetic testing of ﬁrst-degree and symptomatic relatives and obligate carriers is recommended.
I
C
It is recommended that genetic testing and counselling on its potential consequences should be undertaken by an expert multidisciplinary team.179
I
C
It is recommended that Class III (variants of uncertain signiﬁcance) and Class IV variants should be evaluated for segregation in families where possible, and the variant re-evaluated periodically.
I
C
It is not recommended to undertake genetic testing in index patients with insufﬁcient evidence of a genetic disease.
III
C
© ESC 2022
SCD, sudden cardiac death; VA, ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 23 -->

### Page 23

The diagnosis of the underlying aetiology and identiﬁcation of patients with idiopathic VT is important. Initial evaluation includes a comprehensive clinical and family history, 12-lead
ECG, and echocardiography. Recording of the 12-lead VT ECG
is indicated as it provides important information on the VT
site of origin. Speciﬁc VT morphologies (e.g. right ventricular outﬂow tract [RVOT] or fascicular origin) (Figure 3) in the absence of a family history for cardiomyopathies and without evidence for SHD are suggestive for idiopathic VTs.196 Atypical
ECG morphologies and uncommon clinical presentations should raise suspicions for underlying SHD even if baseline ECG and echocardiogram are normal. In this scenario, additional evaluation with CMR should be considered.194 Bundle branch reentrant ventricular tachycardia (BBR-VT), resembling bundle branch block conﬁguration on the ECG, is a feature of conduction impairment, e.g. in DCM, myotonic dystrophy, and post-cardiac valve surgery (Figure 5).
If initial evaluation raises suspicion of underlying CAD, a CAG can exclude signiﬁcant CAD. If ECG and echocardiography are suggestive for a cardiomyopathy, CMR provides important diagnostic information on scar distribution and tissue characteristics (Section 5.1.3.4).
When non-invasive evaluation is inconclusive, electroanatomical mapping and PES may be considered for the differential diagnosis between idiopathic VT and early ARVC.197 Electroanatomical mappingguided biopsy can be of value to provide a tissue diagnosis for ARVC
and inﬂammatory diseases with a focal distribution (e.g. cardiac sarcoidosis).198,199 In cases of suspected inﬂammatory diseases, positron emission tomography CT (PET-CT), autoimmune serology,
and biopsies of affected tissue are part of the diagnostic evaluation.200,201
N
N
Patient with incidental finding of NSVT
Arrhythmic syncope or fast monomorphic NSVT
or short coupled PVC foll f
owed by polymorphic NSVT
Dischargee
Go to section
Idiopathic PVC/VT
Suggestive of idiopathic origina
NSVT/PVC burden >10%
12-lead ECG
(Class I)
Ambulatory evaluation
Consider admission
Echocardiogram
(Class I)
≥24 h Holter
(Class IIa)
Suggestive of SHDb
Suggestive/Diagnostic of primary electrical diseasec
Further evaluati a on according to most like k ly diagnosis
Go to section
Primary electrical disease
Y
Y
NSVT evaluation
(Cycle length, morpholo
,
gy,y exercise induced)
(Class I)
Personal history
(Cardiovascular r r isk factors,
symptoms, co
,
-morbidities,
medicati a on)
Family history
 (SCD, prima
,
ry electrical disease, ca
,
rdiomyopathy)
Laboratory
(Electrolytes,
(NT-)p
T
roBNP,P TSH/T4)
CMR
(Class IIa)
Exclude
CADd
Figure 2 Algorithm for the evaluation of patients presenting with an incidental ﬁnding of non-sustained ventricular tachycardia. CAD, coronary artery disease; CMR, cardiac magnetic resonance; ECG, electrocardiogram; N, No; NSVT, non-sustained ventricular tachycardia; PVC, premature ventricular complex; SCD, sudden cardiac death; SHD, structural heart disease; Y, Yes. aECG morphology suggestive of RVOT or fascicular origin, negative family history,
normal 12-lead ECG, and echocardiogram. be.g. atrioventricular conduction abnormalities, Q waves, broad QRS complex, ST/T waves deviations, abnormally high or low voltages. Ventricular dysfunction/dilatation/hypertrophy/wall thinning, wall motion abnormalities, multitopic PVCs/NSVTs/increasing ventricular arrhythmia (VA) burden with exercise. ce.g. Brugada pattern, long/short QT, polymorphic/bidirectional VA with exercise. dDiagnostic test to exclude CAD
according to patient proﬁle and symptoms. eConsider re-evaluation in case of new symptoms or changes in patient clinical condition.
ESC Guidelines
4019


<!-- PAGE 24 -->

### Page 24

5.2.3. Scenario 3: Sudden cardiac arrest survivor
An algorithm for the evaluation of sudden cardiac arrest survivors is presented in Figure 6.
Urgent CAG is recommended for patients presenting with ST elevation myocardial infarction (STEMI).203–206 Despite disparate ﬁndings of pooled data analyses,207–211 three randomized controlled trials
(RCTs) have found no signiﬁcant beneﬁt for early CAG in cardiac arrest (CA) without ST-elevation. In case of electrical instability after
CA, suspicious for ongoing ischaemia, this panel found a CAG indicated. Brain and chest CT scan may acutely identify non-cardiac causes of aborted SD,212 as well as blood test results for pertinent toxicological analysis.213–215 Retention and storage of suitable blood samples will allow subsequent diagnostic evaluation, including DNA analysis.213
LV fascicular VT (RBBB- like, superior axis, QRS 130 ms)
RVOT VT (LBBB-like, inferior axis, V4 transition)
Figure 3 Typical idiopathic ventricular tachycardia morphologies. LBBB, left bundle branch block; LV, left ventricle; RBBB, right bundle branch block;
RVOT, right ventricular outﬂow tract; VT, ventricular tachycardia.
Recommendation Table 4 — Recommendations for evaluation of patients presenting with a ﬁrst episode of sustained monomorphic ventricular tachycardia
Recommendations
Classa
Levelb
In patients presenting with a ﬁrst SMVT episode,
electrophysiological study, electroanatomical mapping, and mapping-guided biopsies may be considered for aetiological evaluation.197–199,202
IIb
C
© ESC 2022
SMVT, sustained monomorphic ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 25 -->

### Page 25

Exclude
CADd
CMR
(Class IIa)
Autoimmune serology
Cardiac/tissue biopsy
PET-CT
T
Mapping-guided biopsy
(if regional ventricular involvement)
(Class IIb)
Go to section
Inflammatory cardiac diseases r
Further evaluation according to most like k ly diagnosis
Go to section
ARVC
EP study and RV
R
electro-anatomical mapping
(± mapping-guided biopsy)
(Class IIb)
Suggestive of SHD other than CADc
Suggestive of CADb
Suggestive of idiopathic origina
Suggestive of inflammatory diseaseg
Suggestive of other cardiomyopathyf
Suggestive of ARVC
R
e
Go to section Idiopathic PVC/VT
CAG
CAD
positive negative
No CAD
Go to section CAD
C
N
Y
Patient with first SMVT episode
12-lead ECG
(Class I)
Echocardiogram
(Class I)
VT 12-lead ECG
(Cycle length, morpholo
,
gy,y exercise induced)
(Class I)
Personal history
(Cardiovascular risk factors,
symptoms, co
,
-morbidities,
medicati a on)
Family history
 (SCD, prima
,
ry electrical disease, ca
,
rdiomyopathy)
Laboratory
(Electrolytes,
(NT-)p
T
roBNP,P TSH/T4)
Figure 4 Algorithm for the evaluation of patients presenting with a ﬁrst sustained monomorphic ventricular tachycardia episode. ARVC, arrhythmogenic RV cardiomyopathy; CAD, coronary artery disease; CAG, coronary angiography; CMR, cardiac magnetic resonance; ECG, electrocardiogram; EP,
electrophysiological; LV, left ventricular; N, No; PET-CT, positron emission tomography and computed tomography; PVC, premature ventricular complex; RV, right ventricular; SCD, sudden cardiac death; SHD, structural heart disease; SMVT, sustained monomorphic ventricular tachycardia; VT, ventricular tachycardia; Y, Yes. aECG morphology suggestive of RV outﬂow tract or fascicular origin, negative family history, normal 12-lead ECG, and echocardiogram. be.g. Q waves, QRS fragmentation, ST/T abnormalities, wall motion abnormalities in coronary territories. ce.g. atrioventricular (AV)
conduction abnormalities, Q waves, broad QRS complex, T-wave inversion, abnormally high or low voltages. Ventricular dysfunction/dilatation/hypertrophy/wall thinning/wall motion abnormalities/diffuse hypokinesia. dDiagnostic test to exclude CAD according to patient proﬁle and symptoms.
eAccording to revised task force criteria.116 fe.g. AV conduction abnormalities, abnormally high or low voltages, broad QRS, ST/T wave deviations, LV
dilatation and dysfunction, late gadolinium enhancement with non-ischaemic distribution. ge.g. AV conduction abnormalities, broad QRS, ST/T deviations,
multifocal PVCs, inﬂammatory hyperaemia and oedema, ﬁbrosis, LV and RV systolic dysfunction, pericardial effusion.
ESC Guidelines
4021


<!-- PAGE 26 -->

### Page 26

Any ECG tracing from emergency services, as well as recordings from interrogation of cardiovascular implantable electronic devices
(CIEDs) can also contribute to diagnosis.216–219 The resting 12-lead
ECG (including high precordial lead)220 is fundamental and should be repeated regularly during recovery. Continuous heart rhythm monitoring is recommended until deﬁnite treatment.221,222
Echocardiography may allow early diagnosis to identify any structural abnormality.222,223 Coronary imaging will be important to exclude
CAD, dissection, or anomalies.62,224 Coronary optical coherence tomography and/or intravascular ultrasound may be helpful to characterize stenosis/plaque stability and underlying mechanism of stenosis.225 CMR has repeatedly been shown to provide signiﬁcant incremental diagnostic value, in particular for concealed cardiomyopathy.131,226–228 Primary electrical diseases may be uncovered by provocative manoeuvres such as sodium channel blocker challenge,136,229–231 lying to standing ECGs,232,233 adenosine challenge,144,234
epinephrine challenge,141,152,235–239
ergonovine/
acetylcholine,222,240
mental stress,241,242
and exercise testing.116,117,119,232,243 Electrophysiological study and electroanatomic mapping may be useful to provide patient-speciﬁc insights into the mechanism of CA and to offer therapeutic options in some patients.244–248 Genetic testing may identify a molecular cause of SCA by identifying pathogenic mutations in genes associated with speciﬁc phenotypes.213,249,250
Recommendation Table 5 — Recommendations for evaluation of sudden cardiac arrest survivors
Recommendations
Classa
Levelb
Diagnostic evaluation
The investigation of a SCA survivor without obvious extra-cardiac cause is recommended to be overseen by a multidisciplinary team.177,251–256
I
B
In electrically unstable patients after SCA, with suspicion of ongoing myocardial ischaemia, a coronary angiogram is indicated.
I
C
Continued
ECG during BBR-VT
ECG during sinus rhythm
I
II
III
aVR
aVL
aVF
V1
V4
V5
V6
V2
V3
I
II
III
aVR
aVL
aVF
V1
V4
V5
V6
V2
V3
Figure 5 Bundle branch re-entrant ventricular tachycardia. BBR-VT, bundle branch re-entrant ventricular tachycardia; ECG, electrocardiogram.


<!-- PAGE 27 -->

### Page 27

5.2.4. Scenario 4: Sudden death victim
An algorithm for the evaluation of SD victims is presented in Figure 7.
Potential genetic cardiac disease can be identiﬁed in 25–49% of cases of SCD in the young (,50 years of age). This may also affect relatives of the deceased.25,56,59 To ﬁnd the cause of death, it is important to collect all available data on prior symptoms, comorbidities, and family history.25,56,215,262,263
The main role of autopsy in SD is to establish the cause of death.
An expert cardiac pathologist alters the initial diagnosis in 41% of cases, highlighting the need for expert evaluation.263–265 Inherited cardiac diseases identiﬁed at autopsy include cardiomyopathies
(HCM, DCM, ARVC) and premature CAD.25,27,56,266 A toxicology screen can reveal drug overdose or polypharmacy in 31–56% of young SD cases.267,268 In autopsy-negative cases with negative toxicology, the term sudden arrhythmic death syndrome (SADS) may be applied and primary electrical diseases are potential causes.56,183,223,253 Retaining tissue for DNA extraction is important for post-mortem genetic analysis, where the yield can be as high as one out of three.183,269,270
Clinical evaluation of ﬁrst-degree relatives is important if the cause of death after autopsy is unknown (Section 5.2.5, scenario 5) or suspected to be inherited, with a reported combined diagnostic yield of genetic and clinical evaluation of 18–53%.252,266,271 Post-mortem genetic testing on the deceased, targeted to the cause of death, identiﬁed mutations in around one-third of cases.56,266,269
In SCA survivors, brain/chest CT scan should be considered when patient characteristics, ECG, and echocardiography are not consistent with a cardiac cause.212,257
IIa
C
In SCA survivors, collection of blood samples at presentation is recommended for potential toxicology and genetic testing.56,214
I
B
Retrieval of recordings from CIEDs and wearable monitors is recommended for all SCA
survivors.217,218
I
B
In SCA survivors, repeated 12-lead ECGs during stable rhythm (including high precordial lead
ECG), as well as continuous cardiac monitoring,
are recommended.220,222
I
B
Echocardiography is recommended for evaluation of cardiac structure and function in all SCA survivors.
I
C
Coronary imaging and CMR with LGE are recommended for evaluation of cardiac structure and function in all SCA survivors without a clear underlying cause.62,222,223,226
I
B
Sodium channel blocker test and exercise testing is recommended in SCA survivors without a clear underlying cause.117,222,258–260
I
B
In SCA survivors, ergonovine, acetylcholine, or hyperventilation testing may be considered for the diagnosis of coronary vasospasm.240,261
IIb
B
© ESC 2022
CIEDs, cardiac insertable electronic devices; CMR, cardiac magnetic resonance; CT,
computed tomography; ECG, electrocardiogram; LGE, late gadolinium enhancement;
SCA, sudden cardiac arrest.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 6 — Recommendations for evaluation of sudden death victims
Recommendations
Classa
Levelb
Investigation of unexpected SD, especially in case of suspicion of inherited disease, should be made a public health priority.20,25,56
I
B
In cases of SD, it is recommended to collect a detailed description of circumstances of death,
symptoms prior to death, the family history, and to review prior medical ﬁles.25,56
I
B
A comprehensive autopsy is recommended,
ideally, in all cases of unexpected SD, and always in those ,50 years of age.183,264,265,267,269,270
I
B
In cases of SCD, it is recommended to retain samples suitable for DNA extraction and consult a cardiac pathologist when an inherited cause is suspected or the cause of death unexplained.264,265
I
B
Toxicology screens are recommended in SD cases with uncertain cause of death.267,268
I
B
For SCD where the cause is known or suspected to be heritable, genetic testing targeted to the cause is recommended.56,266,269
I
B
Following SADS, post-mortem genetic testing targeted to primary electrical disease is recommended when the decedent is young (,50)
and/or the circumstances and/or family history support a primary electrical disease.56,183,223
I
B
When an autopsy diagnoses possible heritable cardiac disease, it is recommended to refer
ﬁrst-degree relatives for cardiac assessment in a specialized clinic.271,272
I
B
In non-autopsied cases of SD where inherited cardiac disease is suspected, it is recommended to refer ﬁrst-degree relatives for cardiac assessment in a specialized clinic.223,253,273
I
B
Following SADS, post-mortem genetic testing in the decedent for additional genes may be considered.
IIb
C
Following SADS, hypothesis-free post-mortem genetic testing using exome or genome sequencing is not recommended.274,275
III
B
© ESC 2022
DNA, deoxyribonucleic acid; SADS, sudden arrhythmic death syndrome; SCD, sudden cardiac death; SD, sudden death.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4023


<!-- PAGE 28 -->

### Page 28

5.2.5. Scenario 5: Relatives of sudden arrhythmic death syndrome decedents
An algorithm for the evaluation of relatives of SADS decedents is presented in Figure 8.
Studies evaluating families of SADS decedents have identiﬁed underlying genetic heart disease in relatives that is presumed to be the cause of death in the absence of other
ﬁndings. The overall diagnostic yield ranged from 18 to 53%,
depending on population and clinical investigative protocols.276 Aetiologies included LQTS, BrS, CPVT, and other disorders, such as cardiomyopathy.276 All study protocols relied upon a similar initial approach of evaluating the decedent’s pathological reports, medical history, and circumstances of death, and then offering clinical evaluation to relatives with a minimum of personal history, family history, physical examination,
ECG and exercise test, and echocardiography.223,252,253,277–282
12-lead ECG (Class I)
STEMI
Suspicious for extraca f
rdiac cause
Extracardiac cause identified
Preexcitation or suggestive of primary electrical disease
Non-cardiac
Brain and chest CT scan (Class IIa)
Acute culprit lesion
Further evaluation according to STEMI guidelines
Electrical instability suspicious for on f
going myocardial ischaemia
Urgent CAGa (Class I)
N
N
N
N
N
N
SCA survivor
Y
Y
Y
Y
Y
Preexcited AF
or probable primary electrical diseaseb, c
,
Y
Evaluation of patient characteristics and circumstances of SCA
(Class I)
Echocardiogram
(Class I)
Collect blood sample for t f
oxicology and genetic testing (Class I)
Review/Repeat ECG (Class I)
Figure 6 Part One. Algorithm for the evaluation of sudden cardiac arrest survivors.


<!-- PAGE 29 -->

### Page 29

CAD/coronary anomaly
LGE on CMR
Primary electrical disease
Echocardiogram suggestive of CAD/
cardiomyopathy/valvular heart disease/other SHD
N
Cardiac CT/CAG (if previously not performed)
f
(Class I)
N
High lead and repeated 12-lead ECGs
(Class I)
N
CMR
(Class I)
N
Vasospasm
V
Y
Further evaluation according to most like k ly diagnosis.
If SMVT,T go to scenario 2:
Patient with
P
fif rst
SMVT episoded
CAD/Coronary anomaly
Y
Primary electrical disease
Y
Y
Y
Y
Y
N
Positive
IdiopathicVF
Test
T
for co f
ronary vasospam
(Class IIb)
N
N
Primary electrical disease
N
Suspicion of vasospasme
Exercise test (Class I)
Sodium channel blocker test (Class I)
k
Figure 6 Part Two. Algorithm for the evaluation of sudden cardiac arrest survivors. AF, atrial ﬁbrillation; CAD, coronary artery disease; CAG, coronary angiogram; CMR, cardiac magnetic resonance; CT, computed tomography; ECG, electrocardiogram; LGE, late gadolinium enhancement; N, No;
SCA, sudden cardiac arrest; SHD, structural heart disease; SMVT, sustained monomorphic ventricular tachycardia; STEMI, ST elevation myocardial infarction; VF, ventricular ﬁbrillation; Y, Yes. aThe 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with
ST-segment elevation.3 bRule out SHD according to patient age and characteristics; QT duration needs to be reassessed several days after arrest.
cConsider cardiac CT/CAG depending on patient characteristics and clinical context. dLeft ventricular function on echocardiogram needs to be reassessed several days after arrest to exclude stunning as cause of systolic dysfunction. eIn case of high clinical suspicion (typical symptoms and transient ST elevation during monitoring), it can be considered to test for coronary vasospasm earlier.
ESC Guidelines
4025


<!-- PAGE 30 -->

### Page 30

Sudden death victim
Sav a e tissue for potential genetic testing f
(Class I)
Comprehensive autopsya
(Class I)
Refer first-deg f
ree relatives for ca f
rdiac assessment
(Class I)
Post-mortem genetic testing with genetic counsellingc 
(Class I)
Sav a e blood for potential t f
oxicology testing
(Class I)
Targeted genetic testing
T
(Class I)
Refer first-deg f
ree relatives for ca f
rdiac assessment
(Class I)
To
T xicology testing
(Class I)
Collect detailed description about:
Non-cardiac cause of SD
SCD of non-inherited cause
Cause diagnosed
Negative autopsy
Go to Scenario 5:
Relatives of unexplained SD decedent
SADS decedent age <50 years or circumstances or family history suggestive of heritable disease
SCD of suspected inherited causeb
Cause of death not due to drug overdose
Sudden arrhythmic death syndrome
(SADS)
Drug overdose
(Class I)
Circumstances of death
Symptoms and prior history of deceased
Family history
Figure 7 Algorithm for the evaluation of sudden death victims. SADS, sudden arrhythmic death syndrome; SCD, sudden cardiac death; SD, sudden death. aAutopsy is recommended, ideally in all cases of unexpected SD and always in those under 50 years. Autopsy should include full macroscopic examination and histopathology of all organs. The heart should ideally be examined by an expert cardiac pathologist. Samples suitable for DNA extraction should be retained when inherited causes or unexplained death are suspected. bBased on all circumstances, this includes negative autopsies, autopsies with uncertain ﬁndings, non-ischaemic cardiomyopathies, coronary artery disease where familial hypercholesterolaemia is suspected and thoracic aortic dissections. cAfter informed consent of relatives.


<!-- PAGE 31 -->

### Page 31

Where they diverged was the frequency of usage of additional tests such as high-lead ECGs, Holter monitoring, signal-averaged
ECG, CMR, and provocative testing.135 Sodium channel blocker drug challenge and high-lead ECGs systematically performed in
SADS relatives provided a yield of 28% BrS diagnoses in one study281; however, there are concerns about false positives.139
Furthermore, epinephrine challenge has not been studied systematically in SADS families but, in the opinion of this panel,
may be of utility in CPVT-suspected patients who are unable to exercise.137
Recent data indicated at least a 13% genetic yield in SADS
cases.135,178,183,276,283 Routine follow-up of families without a diagnosis yields little in new diagnoses,284 although children of decedents may be followed for age-penetrant disease until adulthood.181
If an autopsy is ambiguous, or if an autopsy was not undertaken in a young SCD case with family or personal history suspicious for inherited heart disease, then the yield of familial evaluation was similar to that in clear SADS cases.223,253,271
6. Therapies for ventricular arrhythmias. General aspects
6.1. Acute management
6.1.1. Treatment of reversible causes
Reversible causes may account for up to 50% of SCA.285,286 However,
most of the time it is difﬁcult to determine the exact underlying cause of
SCA and whether it is reversible. A comprehensive evaluation of patients with SCA is mandatory if the underlying cardiac disease is unknown or disease progression is suspected (Section 5.2.3, scenario 3).
Electrolyte imbalances, such as hypokalaemia, may trigger VA, and a rapid rise in extracellular potassium may lead to asystole.287–289 Other factors such as bradycardia, ischaemia, coronary spasm, thrombosis, fever,
acute starvation, and dieting may contribute to the occurrence of VA.
290–292 Acute correction of these reversible factors is recommended.
Drug-induced arrhythmias should be suspected in patients being treated with agents known to alter the electrical properties of the heart
(e.g. inducing QRS and/or QT prolongation) or causing electrolyte abnormalities (e.g. thiazide and loop diuretics). When drug-induced arrhythmias are presumed, any offending drug needs to be withdrawn and substances that are known to prolong QT (e.g. sotalol) should be avoided.293,294 Hypomagnesaemia and/or hypokalaemia may be associated with Torsades de pointes (TdP). Intravenous magnesium is an effective therapy for TdP even in the absence of hypomagnesaemia.295
In refractory cases of recurrent TdP in the setting of acquired long QT,
the arrhythmia can be suppressed by increasing the underlying heart rate using isoproterenol (isoprenaline) or transvenous pacing.
Patients who survive SCA in the context of a presumed reversible cause may have a high mortality rate.286 In a recent large observational study296 on survivors of SCA attributed to a reversible and correctable cause, subsequent ICD implantation was associated with lower all-cause mortality except for aborted CA occurring in the presence of acute myocardial infarction (MI). Thus, the need for prophylactic ICD implantation should be considered based on the underlying cardiac disease and an individual evaluation of the future risk of life-threatening VA.
Recommendation Table 7 — Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents
Recommendations
Classa
Levelb
Familial evaluation of SADS decedents is recommended:
• for ﬁrst-degree relatives
• for relatives who must carry a mutation based on analysis of the family history
• for relatives with suspicious symptoms
• when the decedent’s age is ,50 years, or if there is other circumstantial data or family history to suggest heritable disease.223,252,253,277,281
I
B
Familial evaluation of SADS decedents is recommended to include genetic testing when post-mortem genetic testing in a SADS decedent detects a pathogenic mutation.183,253,277,281
I
B
Baseline familial evaluation of SADS decedents is recommended to include taking a medical history and performing physical examination, standard and high precordial lead ECG, echocardiography, and exercise testing.223,252,253,277,281
I
B
In SADS families without a diagnosis after clinical evaluation, follow-up is recommended for children of decedents until they reach adulthood.181,284
I
C
Pharmacological testing with a sodium channel blocker should be considered in relatives of SADS
decedents who are 16 years or older when baseline testing and/or proband ﬁndings increase the suspicion of BrS.277,281
IIa
B
Continued
Ambulatory cardiac rhythm monitoring and CMR
may be considered in relatives of SADS
decedents.223,253,277,281
IIb
C
Pharmacological testing including epinephrine challenge (if exercise testing is impractical) and sodium channel blocker challenge may be considered in ﬁrst-degree relatives of SADS
decedents with normal baseline testing.223,281
IIb
B
In SADS families without a diagnosis after clinical evaluation, follow-up is not recommended for asymptomatic adults who can be discharged with advice to return if they develop symptoms or if the family history changes.181,284
III
C
© ESC 2022
BrS, Brugada syndrome; CMR, cardiac magnetic resonance; ECG, electrocardiogram;
SADS, sudden arrhythmic death syndrome.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4027


<!-- PAGE 32 -->

### Page 32

Diagnosis
N
Diagnosis
N
Diagnosis
N
Relatives of unexplained sudden death decedent
Medical history
Physical examination
Standard and high precordial lead ECG
Echocardiography
Exercise testing
Clinical and/or genetic diagnosis
Manage relatives according to condition
Ambulatory cardiac rhythm monitoring and CMR
(Class IIb)
Follow-up for child f
ren of decedent
Discharge asymptomatic adultsc
(Class I)
Non-autopsied sudden death decedent with young age, fami
,
ly history of
SCD or circumstances suggestive of heritable heart disease
SADS decedent
Genetic testing negative or not performed f
(age <50 years or circumstances or family history suggestive of heritable disease)
SADS decedent
Pathogenic mutation identified
Familial evaluation in first-degree relatives,
or relatives with suspicious symptoms
(Class I)
(Class I)
Y
Y
Y
Familial evaluation in first-degree relatives,
obligate carriers or relatives with suspicious symptoms according to condition
(Class I)
Genetic counselling and cascade testing for 
f relatives
(Class I)
Sodium channel blocker test k
a
(Class IIa)
Epinephrine testb
(Class IIb)
Figure 8 Algorithm for the evaluation of relatives of unexplained sudden death decedents. CMR, cardiac magnetic resonance; ECG, electrocardiogram;
N, No; SADS, sudden arrhythmic death syndrome; SCD, sudden cardiac death; Y, Yes. aOver 16 years old + any suspicions for Brugada syndrome on tests or decedent circumstances of death. bIf exercise is not feasible. cRe-evaluate if change in family history or new symptoms.


<!-- PAGE 33 -->

### Page 33

6.1.2. Acute management of sustained monomorphic ventricular tachycardia
Patients presenting with SMVT should be treated according to symptoms and aetiology (Figure 9). Patients presenting with haemodynamic instability require immediate synchronized cardioversion. If synchronization is not possible, an unsynchronized shock should be used. Cardioversion is not indicated in patients with repetitive
NSVTs (Figure 10). Documentation of any haemodynamically tolerated wide QRS tachycardia on 12-lead ECG is important.
Administration of adenosine300 or vagal manoeuvres with continuous recording of 12-lead ECG should be considered if supraventricular tachycardia (SVT) is likely. Intravenous adenosine may also terminate speciﬁc VT subtypes. Such a response supports cyclic adenosine monophosphate (cAMP)-mediated triggered activity as an underlying
VT mechanism.301 Pre-excited atrial ﬁbrillation (AF) can be recognized by the ‘FBI’ (fast, broad, irregular) ECG pattern. It may mimic
VT, and intravenous administration of drugs that slow AV conduction,
such as adenosine, beta-blockers, and amiodarone, should be avoided.302 Prompt termination of SMVT is recommended even for tolerated SMVT, as rapid haemodynamical deterioration may occur.
Recommendation Table 8 — Recommendations for treatment of reversible conditions
Recommendations
Classa
Levelb
Withdrawal of offending agents is recommended whenever drug-induced VAs are suspected.293,294,297
I
B
Investigation for reversible causes (e.g. electrolyte imbalances, ischaemia, hypoxaemia, fever)c is recommended in patients with VA.292,298
I
C
Despite a possible correctable cause for the presenting VA, the need for ICD implantation should be considered based on an individual evaluation of the risk of subsequent VA/
SCD.286,296,299
IIa
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; SCD, sudden cardiac death; VA, ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
cList not exhaustive.
N
N
N
Acute management of a patient with regular wide QRS complex tachycardia
Cardioversion (Class I)
Procainamide
(Class IIa)
Flecainide
Ajmaline
Sotalol
Amiodaronec
(Class IIb)
Procainamide
(Class IIa)
Amiodarone
(Class IIb)
Verapamil
(Class I)
Cardioversion/defibrillation/ALS
(Class I)
History, physical examination,
12-lead ECG
Known or suspicion of structural heart disease
Adenosine or vagal manoeuvres if SVT likelya
(Class IIa)
Beta-blockers
(Class I)
Anaesthetic risk for cardioversionb
Haemodynamically tolerated
Other type 
or uncertain
Known outflow tractVT
Known 
fascicularVT
Y
N
Anaesthetic risk for cardioversionb
Y
Y
Y
IdiopathicVT
Figure 9 Algorithm for the acute management of regular wide QRS complex tachycardia. ALS, advanced life support; ECG, electrocardiogram; N, No;
SVT, supraventricular tachycardia; VT, ventricular tachycardia; Y, Yes. aBesides SVT, adenosine may also terminate idiopathic VT, which then indicates triggered activity as the mechanism underlying the arrhythmia. bBeneﬁt of cardioversion should be weighed against risks related to anaesthesia/sedation.
cConsidering limited availability of the other anti-arrhythmic drugs.
ESC Guidelines
4029


<!-- PAGE 34 -->

### Page 34

Termination can be achieved with electrical cardioversion, antiarrhythmic medications, or pacing techniques. All anti-arrhythmic drugs (AADs) may lead to hypotension, but the individual risk of anaesthesia/sedation required for cardioversion also needs to be considered. For pharmacological termination of a haemodynamically tolerated VT of unknown aetiology, intravenous procainamide or amiodarone can be used. In the PROCAMIO trial,303 procainamide therapy was associated with a higher proportion of tachycardia termination and fewer major cardiac adverse events than amiodarone. Intravenous procainamide should not be used in patients with severe heart failure, acute MI, and end-stage renal disease.
Administration of other AADs (ajmaline, sotalol, and ﬂecainide)304,305
may be considered in patients without signiﬁcant heart disease, but the risk of adverse events should be carefully weighed. Availability of AADs has to be taken into account, e.g. procainamide is not available in many European countries. In patients with an ICD, manual overdrive pacing may terminate those VTs with a cycle length under the programmed ICD detection rate. In case of a known idiopathic VT
(Figure 4), treatment with beta-blockers (for RVOT VT)306 or verapamil (for fascicular VT)307 is recommended for acute conversion.
Although verapamil may terminate other types of idiopathic VT,307
important adverse effects such as severe hypotension may occur.
If the VT aetiology is uncertain, intravenous administration of verapamil is not recommended.308,309 A comprehensive evaluation of patients presenting with SMVT is mandatory if the underlying cardiac disease is unknown or disease progression is suspected
(Section 5.2.2, scenario 2).
6.1.3. Management of electrical storm and incessant ventricular tachycardia
An electrical storm is common in ICD patients and has been deﬁned as three or more episodes of sustained VA occurring within 24 h,
00:00
mm:ss
00:30
01:00
01:30
02:00
02:30
03:00
03:30
04:00
04:30
05:00
05:30
06:00
06:30
07:00
07:30
08:00
08:30
09:00
Repetitive runs of VT
Figure 10 Repetitive runs of ventricular tachycardia interrupted by occasional sinus beats. VT, ventricular tachycardia.


<!-- PAGE 35 -->

### Page 35

requiring either anti-tachycardia pacing (ATP) or cardioversion/
deﬁbrillation, with each event separated by at least 5 min.310–312
Patients who experience an electrical storm are prone to psychological disorders, heart failure decompensation, and increased mortality.313,314 The severity of an electrical storm can range from recurrent asymptomatic VT episodes terminated by ATP to a lifethreatening electrical instability with VA that recurs frequently after multiple shocks. Frequent ICD shocks can also be inappropriately delivered (Figure 11).
In cases of inappropriate ICD shocks (e.g. due to SVTs or lead defects) or unnecessary ICD therapy (e.g. for NSVT or for repetitive VTs that terminate and restart spontaneously), disabling of ICD therapies is recommended. If an electrophysiology specialist or programmer is not available, the ICD can be disabled by placing a magnet over the device.
Patient with electrical storm or repeated ICD discharges
ALS including external cardioversion/defibrillation
(Class I)
Rhythm assessment/ICD
interrogation
Inappropriate therapy due to AF/SVT/lead oversensing
Recurrent non-sustained
VA episodes
Inappropriate or unnecessary therapies
Electrical storm
Sedation (for comfort)
(Class I)
Assessment of haemodynamic status
N
N
Y
Y
Haemodynamically stable
VA type
Assessment of VA type
STEP 1
STEP 2
STEP 3
ICD
programming optimizationa
(Class I)
Treatment of AF/SVTa
(Class I)
Disable ICD by magnet placement if programmer not available
(Class I)
ICD
programming optimizationa
(Class I)
Disable ICD by magnet placement if programmer not available
(Class I)
PolymorphicVA
MonomorphicVA
Figure 11 Part One. Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges.
ESC Guidelines
4031


<!-- PAGE 36 -->

### Page 36

In case of haemodynamic instability at initial evaluation, institution of advanced life support (ALS) is recommended.315 Reversible conditions contributing to initiation and perpetuation of VA need to be corrected (see Section 6.1.1). Further management depends on the type of VA and the underlying aetiology.312,316 A multifaceted approach is often required for management, consisting of ICD reprogramming when appropriate, AAD therapy, sedation, catheter ablation, autonomic modulation, and mechanical circulatory support.
Elevated sympathetic tone needs to be addressed. For patients with recurrent ICD shocks, sedation is indicated to alleviate psychological distress and decrease pro-arrhythmogenic sympathetic tone.
Initial treatment with beta-blockers, preferably non-selective betablockers like propranolol, which was superior to metoprolol in one study,317 combined with amiodarone318 is most commonly used. In patients with recurrent haemodynamically not-tolerated
VTs resistant to amiodarone,
landiolol
(ultra-short-acting
β1-selective blocker) was found to be effective for arrhythmia suppression in two smaller studies.319,320 Administration of other
AADs such as procainamide,321 lidocaine,322 or quinidine296,297 depends on the speciﬁc situation, type of VA, and underlying aetiology.
When electrical storm remains intractable, with multiple shocks in a few hours, despite available anti-arrhythmic therapies, deep sedation/intubation should be considered, along with mechanical ventilation.325 If beta-blocker treatment is insufﬁcient or not tolerated to decrease sympathetic tone, selected patients may beneﬁt from autonomic modulation, i.e. percutaneous ganglionic stellate blockade,326
thoracic epidural anaesthesia,327
or left cardiac sympathetic denervation.328
The most common arrhythmia underlying electrical storm is
SMVT associated with SHD that is amenable to catheter ablation.313,329 Successful ablation was associated with a signiﬁcant reduction in VT and electrical storm recurrence and improved long-term survival in retrospective analyses.330,331 In patients with incessant slow MVT, catheter ablation is preferred over AAD therapy,
Underlying aetiology
Go to
ﬂowchart
STEMI
(Figure 14)
Treatment according to underlying condition
(Class I)
Polymorphic VA
Acute ischaemia
External precipitating factors
Polymorphic
VA triggered by unifocal
PVC
Acquired long QT
Primary electrical disease
Catheter ablation
(Class IIa)
Catheter ablation
(Class IIa)
Remove precipitating factors
(Class I)
Mg++/K + i.v. 
(Class I)
Mg++/K + i.v. 
(Class I)
Isoproterenol
(Class I)
Isoproterenol
(Class IIa)
Brugada, ERS
Recurrent VA
Idiopathic VF
Long QT, CPVT
Quinidine 
(Class IIa)
Catheter ablation of
PVC triggers
(Class IIa)
Autonomic modulation
(Class IIa)
AAD
according to underlying disease
(Class IIa)
Isoproterenol
(Class IIa)
Beta-blocker
(Class I)
Quinidine 
(Class IIa)
Verapamil
(Class IIa)
Pacing
(Class I)
Pacingd
(Class I)
Quinidineb
(Class IIb)
Deep sedation/ intubation
(Class IIa)
Mechanical circulatory support
(Class IIb)
Figure 11 Part Two.Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges.


<!-- PAGE 37 -->

### Page 37

which may only further slow VT. Catheter ablation should also be considered in patients with recurrent symptomatic episodes of PVT or VF triggered by a similar PVC.221,332–334 Institution of mechanical circulatory support may be considered for haemodynamic stabilization, when conventional therapy fails,
and to provide circulatory support during ablation.335 In a recent meta-analysis336 including 2465 patients, a substantially lower mortality was observed with prophylactic mechanical circulatory support treatment among patients suffering from electrical storm or high-risk PAINESD score.337 In contrast, rescue use of mechanical circulatory support during ablation was associated with a high mortality rate.338 In patients with electrical storm due to recurrent PVT/VF, the underlying aetiology determines further management (Figure 11).
N
Y
VA burdenc
MonomorphicVA
High
Low
ICD programming optimizationa
(Class I)
ICD programming optimizationa
(Class I)
On amiodarone or amiodarone not desirable
Catheter ablation
(Class I)
AAD according to underlying disease and cardiac function
Beta-blocker/sedation
(Class I)
Catheter ablation
(Class I)
Deep sedation/intubation
(Class IIa)
Autonomic modulation
(Class IIb)
Mechanical circulatory support
(Class IIb)
Overdrive pacinge
Amiodarone i.v.
(Class I)
Recurrent VA
Recurrent VA
Figure 11 Part Three. Management of patients with electrical storm or repeated implantable cardioverter deﬁbrillator discharges. AAD, antiarrhythmic drug; AF, atrial ﬁbrillation, ALS, Advanced life support; CPVT, catecholaminergic polymorphic ventricular tachycardia; ERS, early repolarization syndrome; ICD, implantable cardioverter deﬁbrillator; N, No; PVC, premature ventricular complex; STEMI, ST-elevation myocardial infarction; SVT, supraventricular tachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; Y, Yes. aSpecial aspects of device therapy section. bNo data on effect of quinidine on PVC-triggered polymorphic VAs in patients with cardiomyopathies. cHigh VA burden refers to a clinical scenario of very frequent VA episodes requiring ICD shocks, when only short periods of stable rhythm can be achieved. Low VA burden refers to a clinical scenario of repeated ATPs/ICD
shocks followed by stable rhythm. dIf bradycardia or post-extrasystolic pauses facilitate initiation of PVT/VF. eOverdrive pacing (by pacing with a slightly higher rate than the baseline rhythm) can be useful to temporarily suppress slow recurrent/incessant VT.
Recommendation Table 9 — Recommendations for the acute management of sustained ventricular tachycardia and electrical storm
Recommendations
Classa
Levelb
Acute management of sustained VT
DC cardioversion is recommended as the
ﬁrst-line treatment for patients with haemodynamically not-tolerated SMVT.303,339
I
B
DC cardioversion is recommended as the
ﬁrst-line treatment for patients presenting with tolerated SMVT provided that the anaesthetic/
sedation risk is low.
I
C
Continued
ESC Guidelines
4033


<!-- PAGE 38 -->

### Page 38

6.2. Long-term management
6.2.1. Pharmacotherapy
Optimal medical treatment of the underlying cardiac disease, including the maximal tolerated doses of heart failure medication, is mandatory.341
In patients with heart failure with reduced ejection fraction
(HfrEF), the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure recommend angiotensinconverting enzyme inhibitor (ACE-I)/angiotensin receptor blocker
(ARB)/angiotensin receptor neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs), beta-blockers, and sodium–
glucose co-transporter 2 (SGLT2) inhibitors to reduce mortality due to heart failure and SCD.342
AADs have an important role as adjunctive therapy in the management of VA, especially in symptomatic patients (Table 8). Until now,
no AAD except for beta-blockers has demonstrated reduction in allcause mortality. Each drug has a signiﬁcant potential for causing adverse events, including pro-arrhythmia. For example, numerous AADs, as well as a large number of drugs with other therapeutic indications,
can prolong the QT interval (http://www.crediblemeds.org) and provoke TdP, have negative chronotropic effects, may deteriorate heart failure, and cause bradycardia. Several drugs increase the risk of VA in patients with BrS (http://www.brugadadrugs.org).
In patients presenting with a haemodynamically tolerated idiopathic VT, treatment with intravenous beta-blocker (RVOT VT) or verapamil (fascicular VT) is recommended.306,307
I
C
In patients presenting with a regular haemodynamically tolerated wide QRS complex tachycardia suspected for SVT, administration of adenosine or vagal manoeuvres should be considered.300
IIa
C
In patients presenting with a haemodynamically tolerated SMVT and known or suspected SHD,
intravenous procainamide should be considered.303
IIa
B
In patients presenting with a haemodynamically tolerated SMVT in the absence of an established diagnosis, intravenous amiodarone may be considered.303
IIb
B
In patients presenting with a haemodynamically tolerated SMVT in the absence of signiﬁcant SHD,
ﬂecainide, ajmaline, or sotalol may be considered.304,305
IIb
C
Intravenous verapamil is not recommended in broad QRS complex tachycardia of unknown mechanism.308,309
III
B
Management of electrical storm
Mild to moderate sedation is recommended in patients with electrical storm to alleviate psychological distress and reduce sympathetic tone.
I
C
Antiarrhythmic therapy with beta-blockers
(non-selective preferred) in combination with intravenous amiodarone is recommended in patients with SHD and electrical storm unless contraindicated.317,318
I
B
Intravenous magnesium with supplementation of potassium is recommended in patients with
TdP.295
I
C
Isoproterenol or transvenous pacing to increase heart rate is recommended in patients with acquired LQT syndrome and recurrent TdP
despite correction of precipitating conditions and magnesium.
I
C
Catheter ablation is recommended in patients presenting with incessant VT or electrical storm due to SMVT refractory to AADs.330,331
I
B
Deep sedation/intubation should be considered in patients with an intractable electrical storm refractory to drug treatment.325
IIa
C
Catheter ablation should be considered in patients with recurrent episodes of PVT/VF triggered by a similar PVC, non-responsive to medical treatment or coronary revascularization.221,332,333
IIa
C
Quinidine may be considered in patients with
CAD and electrical storm due to recurrent PVT
when other AAD therapy fails.323,324
IIb
C
Continued
Autonomic modulation may be considered in patients with electrical storm refractory to drug treatment and in whom catheter ablation is ineffective or not possible.326,328,340
IIb
C
Institution of mechanical circulatory support may be considered in the management of drug-refractory electrical storm and cardiogenic shock.335
IIb
C
© ESC 2022
AAD, anti-arrhythmic drug; CAD, coronary artery disease; DC, direct current; LQT,
long QT; PVC, premature ventricular complex; PVT, polymorphic VT; RVOT, right ventricular outﬂow tract;
SHD,
structural heart disease;
SMVT,
sustained monomorphic ventricular tachycardia;
SVT,
supraventricular tachycardia;
TdP,
Torsades de pointes; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 10 — Recommendations for treatment with heart failure medication
Recommendations
Classa
Levelb
Optimal medical treatment including ACE-I/ARB/
ARNIs, MRAs, beta-blockers, and SGLT2
inhibitors is indicated in all heart failure patients with reduced EF.343–347
I
A
© ESC 2022
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
ARNIs, angiotensin receptor neprilysin inhibitor; EF, ejection fraction; MRA,
mineralocorticoid receptor antagonists; SGLT2, sodium–glucose co-transporter 2.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 39 -->

### Page 39

Table 8
Anti-arrhythmic drugs (acute and chronic treatment)
Anti-arrhythmic drug
Effects on ECG
Indications
(speciﬁc indication)
Oral dose per day
(i.v. dose)
Side effects
Contraindications,
precautions, other considerations
Amiodarone
Decreases sinus node frequency,
prolongs QT
intervala
PVC, VT, VF
200–400 mg
Loading dose:
600–1200 mg/
24 h 8–10 days.
(Loading dose:
5 mg/kg in
20 min–2 h, 2–3
times in 24 h, then
600–1200 mg/
24 h 8–10 days)
Cardiac:
Bradycardia, TdP
(infrequent)
Extracardiac:
Photosensitivity, corneal deposits, hypothyroidism,
hyperthyroidism,
pulmonary toxicity,
hepatotoxicity,
polyneuropathy, skin discoloration
Precautions:
Sinus node dysfunction,
severe AV conduction disturbances,
hyperthyroidism
Other considerations:
Can be used in patients with heart failure. Increases the risk of myopathy when used with statins
Adenosine
Transitory AV block
Regular wide complex tachycardia of unknown origin
(outﬂow tract
VT)
No oral use
(6–18 mg bolus)
Chest pain, ﬂushing,
bronchoconstriction
Contraindications:
Severe asthma, pre-excited
AF
Other considerations:
Antagonist: theophylline
Ajmaline
Prolongs QRS
duration and QT
intervala
VT
(unmasking BrS
ECG)
No oral use
(1 mg/kg over
5–10 min
(maximum dose
100 mg) or
1 mg/kg at
10 mg/min)
Cardiac:
VF (rare in suspected BrS),
occasional TdP, negative inotrope
Extracardiac:
Cholestatic jaundice,
headache, nausea,
thrombocytopenia
Contraindications:
BrS ECG type I, QT
prolongation
Beta-blocker
Decreases sinus node frequency,
prolongs PR interval,
shortens QT interval
PVC, VT
(LQTS, CPVT)
Various
(various)
Cardiac:
Bradycardia, AV block,
hypotension, negative inotrope
Extracardiac:
Fatigue, bronchospasm,
sexual disturbances,
depression, cold extremities
Contraindications:
Severe sinus node dysfunction, severe AV
conduction disturbances,
decompensated heart failure,
coronary vasospasm, severe asthma, BrS
Landiolol
(Ultra-short acting
β1-selective blocker)
See beta-blocker
VT, electrical storm
No oral use
100 µg/kg bolus in
1 min, infusion
10–40 µg/kg/min
(max 80 µg/kg/
min; max 24 h total dose
57.6 mg/kg/day)
See beta-blocker
Contraindications:
See beta-blocker.
Bradycardia, hypotension
Other considerations:
Limited experience with its use beyond 24 h
Nadolol
(Non-selective
β1β2 blocker)
See beta-blocker
PVC, VT
(LQTS, CPVT)
40–120 mg
See beta-blocker
Contraindications:
See beta-blocker
Other considerations:
Plasma half-life 20–24 h
Propranolol
(Non-selective β1β2
blocker)
See beta-blocker
PVC, VT
(electrical storm,
LQTS, CPVT)
80–320 mg
(160 mg/24 h)
See beta-blocker
Contraindications:
See beta-blocker
Disopyramide
Increases sinus node frequency and prolongs PR interval,
QRS duration, and
QT intervala
PVC, VT
250–750 mg
Cardiac:
Negative inotrope, AV
block, pro-arrhythmia
(MVT, occasional TdP)
Contraindications:
Severe sinus node dysfunction, severe AV
conduction disturbances,
severe intraventricular
Continued
ESC Guidelines
4035


<!-- PAGE 40 -->

### Page 40

Extracardiac:
Anticholinergic effects conduction disturbances,
prior MI, signiﬁcant SHD,
hypotension
Other considerations:
Reduces LV outﬂow tract obstruction and symptoms in
HCM
Flecainide
Prolongs PR interval,
QRS duration, and
QT intervala
PVC, VT
(unmasking BrS
ECGb)
200–400 mg
(1–2 mg/kg over
10 min)
Cardiac:
Pro-arrhythmia (MVT,
occasional TdP), negative inotrope, sinus bradycardia, AV block, 1:1
AV conduction during
ﬂutter
Extracardiac:
Central nervous system effects (e.g. drowsiness,
diplopia, headache)
Contraindications:
Prior MI, signiﬁcant SHD, BrS,
severe sinus node dysfunction, severe AV or intraventricular conduction disturbances, inherited LQTS
(other than LQTS3), severe kidney disease (CrCl
,35 mL/min/1.73 m2)
Other considerations:
Discontinue if QRS widening
.25% or bundle branch block
Isoproterenol
Increases sinus node frequency, shortens
QT interval
(Electrical storm in BrS, idiopathic
VF, and ERS, TdP,
beta-blocker overdose;
acquired LQTS)
No oral use
(0.5–10 µg/min)
Cardiac:
Sinus tachycardia,
vasodilation
Extracardiac:
Headache, sweating,
tremor
Contraindications:
ACS, LQTS
Other considerations:
Short plasma half time
(2 min)
Lidocaine
No signiﬁcant effects
(VT/VF
associated with
ACS)
No oral use
(50–200 mg bolus,
then 2–4 mg/min)
Cardiac:
Sinoatrial arrest
Extracardiac:
Central nervous system effects (e.g. drowsiness,
dizziness)
Precautions:
Reduced dose with reduced liver blood ﬂow (e.g. shock,
β-blockade, severe heart failure)
Other considerations:
More effective with high potassium level. Few haemodynamic side effects
Mexiletine
No signiﬁcant effects
PVC, VT
(LQT3)
600–1200 mg
Loading dose:
400 mg initially followed by
600 mg in the ﬁrst
24 h
Cardiac:
Sinus bradycardia in sinus node dysfunction,
hypotension
Extracardiac:
Central nervous system effects (e.g. tremor,
dysarthria, dizziness),
gastrointestinal complaints
Contraindications:
Sinus node dysfunction,
severe AV conduction disturbances, severe heart failure
Procainamide
Prolongs PR interval,
QRS duration, and
QT intervala
VT
(100 mg bolus,
can be repeated after 5 min if no effect, max 500–
750 mg [max
50 mg/min]. Then,
2–6 mg/min)
Cardiac:
Sinus bradycardia,
hypotension, TdP
Extracardiac:
Rash, myalgia, vasculitis,
systemic lupus,
agranulocytosis
Contraindications:
Severe sinus node dysfunction, severe AV
conduction disturbances,
severe intraventricular conduction disturbances,
severe LV dysfunction hypotension, BrS
Propafenone
Prolongs PR interval,
QRS duration, and
QT intervala
PVC, VT
450–900 mg
Cardiac:
Sinus bradycardia, AV
block, negative inotrope,
pro-arrhythmia (MVT,
occasional TdP)
Extracardiac:
Gastrointestinal disturbances, headache,
dry mouth
Contraindications:
Prior MI, signiﬁcant SHD, BrS,
severe sinus node dysfunction,
severe AV or intraventricular conduction disturbances,
LQTS, signiﬁcant renal or liver disease
Other considerations:
Discontinue if QRS widening
.25% or bundle branch block
Continued


<!-- PAGE 41 -->

### Page 41

Quinidine
Increases sinus node frequency and prolongs PR interval,
QRS duration, and
QT intervala
(VFc, BrS, SQTS)
600–1600 mg
Loading dose:
Start 200 mg every 3 h until effect, max. 3 g in
ﬁrst 24 h
Cardiac:
Hypotension, TdPd
Extracardiac:
Gastrointestinal disturbances, auditory and visual disturbances,
confusion, leukopenia,
haemolytic anaemia,
thrombocytopenia,
anaphylaxis
Contraindications:
Severe sinus node dysfunction, severe AV or intraventricular conduction disturbances, previous MI,
signiﬁcant SHD, hypotension,
LQTS
Ranolazine
Decreases sinus node frequency,
prolongs QT
intervala
VT
(LQTS3)
750–2000 mg
Cardiac:
Sinus bradycardia,
hypotension
Extracardiac:
Dizziness, nausea,
constipation,
gastrointestinal disturbance, headache,
rash
Contraindications:
Severe sinus node dysfunction, severe heart failure, LQTS (other than
LQTS3)
Precautions:
Concomitant treatments associated with QT interval prolongation
Sotalol
Decreases sinus node frequency,
prolongs QT
intervala
VT
160–640 mg
(0.5–1.5 mg/kg in
10 min. If necessary, can be repeated after
6 h)
See beta-blockers, TdPd
(.2% of patients, close monitoring of QT interval and CrCl)
Contraindications:
Severe sinus node dysfunction, severe AV
conduction disturbances,
severe heart failure with reduced LVEF, signiﬁcant
LVH, CrCl ,30 ml/min,
coronary vasospasm, LQTS
Precautions:
Concomitant treatments associated with QT interval prolongation, hypokalaemia
Other considerations:
Potassium channel blocker effects require higher dose than beta-blocker effects
Verapamil
Prolongs PR interval
(LV fascicular tachycardia)
120–480 mg
(5–10 mg in slow bolus. If necessary,
can be repeated in
30 min)
Cardiac:
Sinus bradycardia in sinus node dysfunction, AV
block, negative inotrope,
hypotension
Extracardiac:
Gastrointestinal disturbances, peripheral oedema, ﬂushing
Contraindications:
Heart failure with reduced
LVEF, severe sinus node dysfunction, and severe AV
conduction disturbances, VT
of unknown origin, ACS,
WPW syndrome
Other considerations:
Increase the risk of myopathy when used with statins
© ESC 2022
ACS, acute coronary syndrome; AF, atrial ﬁbrillation; AV, atrioventricular; BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; CrCl, creatinine clearance; ECG, electrocardiogram; ERS, early repolarization syndrome; HCM, hypertrophic cardiomyopathy; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; MI, myocardial infarction; MVT, monomorphic ventricular tachycardia; PVC, premature ventricular complex; SHD, structural heart disease; SQTS, short QT syndrome; TdP, torsades de pointes; VF, ventricular ﬁbrillation; VT, ventricular tachycardia; WPW, Wolff–Parkinson–White.
aPrecaution with concomitant conditions or drugs that prolong QT interval. Should be discontinued if QTc .500 ms. See Figure 13 Algorithm for evaluation before initiation and follow-up of patients requiring drugs associated with QT prolongation.
bIf ajmaline not available.
cSubacute MI, multifocal ectopic Purkinje-related premature contractions, ERS, idiopathic VF.
dProarrhythmic side effects require strong indication in patients without ICD.
ESC Guidelines
4037


<!-- PAGE 42 -->

### Page 42

Modiﬁcation of risk factors, when possible, is important for prevention of pro-arrhythmia. In patients who require a potentially arrhythmiainducing drug, regular ECG and other tests according to the patient’s proﬁle and AAD characteristics are recommended (Figures 12 and 13).
6.2.2. Device therapy
6.2.2.1. Implantable cardioverter deﬁbrillator
ICD is an integral part of treating patients surviving a CA due to a VA
or those deemed to be at high risk thereof. Drawbacks are the high up-front device costs, device-associated complications, and the relatively high number-to-treat needed to prevent one SCD in primary prevention.
A patient-level meta-analysis of the three early ICD trials349–351
comparing ICD to medical therapy for secondary prevention of
SCD demonstrated a 28% mortality reduction (HR 0.72; 95% CI
0.6–0.87; P = 0.0006) almost entirely due to reduction of arrhythmic death (HR 0.5; 95% CI 0.37–0.67; P , 0.0001) in the ICD group.352
Therefore, the use of an ICD for secondary prevention of SCD
that occurred in the absence of reversible causes is widely accepted.
Several randomized controlled trials353–356 have established the role of the ICD for primary prevention of SCD in heart failure patients with an LVEF ≤35%. The reported mortality reduction has recently been supported by two large contemporary prospective registries enrolling more than
5000
patients.357,358
In the
EU-CERT-ICD trial, primary prevention ICD implantation was associated with a 27% lower mortality with similar results in CAD and
DCM.357 Results of the DANISH trial, however, indicate that the mortality beneﬁt may be less clear in contemporary patients with non-ischaemic heart failure (see Section 7.1.3.1).359
In the work-up for ICD therapy, it is of paramount importance to consider the patient’s life expectancy, quality of life, and comorbidities,
and to reassess and discuss these issues with the patient at the time of generator change. There is evidence that patients with end-stage renal disease, with diabetes, and elderly patients beneﬁt less or not at all from
Patient requiring sodium channel blocking agents
Assessment of patient risk proﬁle before initiation
ECG 1–2 weeks after initiation or increase in dosagee
Initiate treatmentc
Initiate treatment on individual decision (risk/beneﬁt)d
Known cardiac disease or
ECG abnormalities 
or 
Abnormal echocardiogram
ΔQRS > 25%f or
Abnormal exercise test?
(new BBB, ΔQRS >25%
or QRS >130 ms)
Contraindications:
N
N
Brugada syndrome a
Prior MI (ﬂecainide)b
Severe LV dysfunction
Severe valvular heart disease
Severe bradycardia, BBB, > ﬁrst degree AV block
Precaution:
Any degree of LV dysfunction
LV hypertrophy
Any signiﬁcant valvular heart disease
First degree AV block
Prolonged QT interval (disopyramide, quinidine)
Consider to change to dffierent drug
Consider to reduce dose
Consider to measure drug serum level
Y
Y
Continue treatment
Inform patient about warning symptoms (syncope)
Periodic ECG for QRS width evaluation
Control changes in renal and hepatic function
Be aware of potential drug interactions
Figure 12 Algorithm for evaluation before initiation and follow-up of patients requiring sodium channel blocking agents. AV, atrioventricular; BBB, bundle branch block; ECG, electrocardiogram; LV, left ventricular; MI, myocardial infarction; N, No; Y, Yes. ahttp://www.brugadadrugs.org. bFlecainide, encainide.
cCo-administration of drugs with AV nodal blocking effect in patients with atrial ﬁbrillation or atrial ﬂutter. dIn implantable cardioverter deﬁbrillator carriers, a higher risk of drug-induced pro-arrhythmia might be accepted. eAccording to the 2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation.348
fA ΔQRS .25% is not an absolute cut-off value but dependent on QRS width before drug initiation and individualized patient risk–beneﬁt considerations.


<!-- PAGE 43 -->

### Page 43

a primary prevention ICD.357,360–362 Women have been underrepresented in all primary prevention trials and data suggest that they may beneﬁt less.361 In general, the SCD risk needs to be weighed against the individual’s competing risk of a non-arrhythmic death.363,364
In the context of patient-centred medicine, physicians and healthcare professionals should engage ICD candidates and recipients in a joint decision process. Communication of relevant information, ensuring a good understanding of the beneﬁts, risks, and potential consequences of different options, to enable the patient to partake in decision-making is mandatory. This shared decision-making process should discuss the different scenarios including primary prevention
ICD implantation, consideration of ICD generator replacement,
and end-of-life care. Importantly, the perception of ‘good quality of life’ depends on numerous factors that are weighed differently by people with different cultural, religious, and socioeconomic backgrounds.
Although clinical prediction scores,
such as the
MADIT-ICD beneﬁt score,365 may provide helpful additional information, clinical decision-making should not only rely on such scores.
Complications of ICD therapy include inappropriate therapies,
lead fractures, and device-related infections. A subcutaneous implantable cardioverter deﬁbrillator (S-ICD) has been introduced to address problems related to transvenous leads. S-ICD has no intravascular lead and therefore cannot deliver ATP. In the
PRAETORIAN trial, 849 patients with an ICD but no pacing indication were randomized to an S-ICD or a transvenous ICD.366 Over a mean follow-up of 49 months, non-inferiority was shown for the primary endpoint of device-related complications and inappropriate shocks. The rate of inappropriate shocks was 9.7% in the S-ICD
group and 7.3% in the ICD group (HR 1.43; 95% CI 0.89–2.30)
and the rate of device related complications was 5.9% in the S-ICD
and 9.8% in the ICD group (HR 0.69; 95% CI 0.44–1.09). There was also no difference in the secondary endpoint of death and appropriate shocks, but the trial had not been powered to show noninferiority for this secondary endpoint. Of note, more than 80% of the included patients were in NYHA class I and II and the included patients were younger than in prior ICD trials.
Patient requiring a drug associated with QT prolongationa
Assessment of patient
 risk profile befof re initiation
ECG at baseline, after 1 d
,
ay and after1–2
a weeks of initiation or increase in dosagec
Continue treatment
Inform patient about warning symptoms (syncope)
f
Control changes in renal and hepatic function
Be awa a
re of potential drug interactions
Initiate treatment
QTc >500 ms
Contraindicated: Do not initiate t
:
reatment
Start drug if strong indication with close foll f
ow-up
Long QT syndrome or baseline QTc >500 msb
Hypokalaemia/hypomagnesaemia/
Renal failure/liver failure/
LV 
L hypertrophy/
Heart failure/
Additional QT prolonging drug
N
N
N
Consider to change to difff ef rent drug
If strong indication, consider to 
,
reduce dose
Consider to assess drug serum level
Y
Y
Y
Figure 13 Algorithm for evaluation before initiation and follow-up of patients requiring drugs associated with QT prolongation. ECG, electrocardiogram; LV, left ventricular; N, No; Y, Yes. ahttp://www.crediblemeds.org. bIf strong indication and no alternative treatment, consult a specialist. cAccording to the 2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation.348
ESC Guidelines
4039


<!-- PAGE 44 -->

### Page 44

6.2.2.2. Adding cardiac resynchronization therapy2
Cardiac resynchronization therapy (CRT) does reduce mortality in heart failure,367 and careful evaluation of the potential beneﬁt of
CRT in patients with ICD indication before implantation is mandatory.2 The role of the addition of a deﬁbrillator is less well established.368,369 The ongoing randomized controlled RESET-CRT trial aims to determine the impact of CRT-deﬁbrillator on overall mortality and SCD in heart failure patients with a CRT indication.
6.2.2.3. Wearable cardioverter deﬁbrillator
The wearable cardioverter deﬁbrillator (WCD) is an external deﬁbrillator that has been shown to successfully detect and treat VT and
VF.370 It is therefore suitable for patients who are at risk but temporarily not candidates for an ICD owing, for example, to extraction of an infected device and subsequent antibiotic treatment.371 An unsolved problem is the protection of patients in the early phase (40
days) after an MI. The VEST trial enrolled 2302 patients with acute
MI and an LVEF ≤35% and randomized them early in a 2:1 fashion to receive a WCD or not under guideline-directed optimal medical treatment (OMT).372 After a follow-up of 90 days there was no difference in the primary endpoint of arrhythmic death (1.6 vs. 2.4%; RR
0.67; 95% CI 0.37–1.21; P = 0.18). Concern was raised regarding the low median wear time of 18 h (IQR 3.8–22.7). The median wear time was higher (23.4 h, IQR 22.2–23.8) in a recent multicentre registry after structured patient education.371 However, based on the available data, the task force does not recommend routine use of the
WCD in the early post-MI phase. Nevertheless, the use of the device may be considered in selected post-MI patients deemed to be at high risk for SCD.
Data on the beneﬁt of the WCD for primary prevention of SCD in other clinical situations (e.g. acute myocarditis, primary prevention indication during pregnancy) are sparse and no recommendations can be currently made.
Recommendation Table 12 — Recommendations for secondary prevention of sudden cardiac death*
Recommendations
Classa
Levelb
ICD implantation is recommended in patients with documented VF or haemodynamically not-tolerated VT in the absence of reversible causes.349–352
I
A
In patients with VT/VF, an indication for ICD, and no contraindication for amiodarone, amiodarone may be considered when an ICD is not available,
contraindicated for concurrent medical reasons,
or declined by the patient.
IIb
C
In patients with SMVT or SPVT/VF triggered by a
PVC with similar morphology and an indication for ICD, catheter ablation may be considered when an ICD is not available, contraindicated for concurrent medical reasons, or declined by the patient.
IIb
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; PVC, premature ventricular complex;
SMVT, sustained monomorphic VT; SPVT, sustained polymorphic VT; VF, ventricular
ﬁbrillation; VT, ventricular tachycardia.
*For primary prevention and speciﬁc aspects of secondary prevention, go to Section 7.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 14 — Recommendations for adding cardiac resynchronization therapy to implantable cardioverter deﬁbrillator
Recommendations
Classa
Levelb
When an ICD is indicated, it is recommended to evaluate whether the patient could beneﬁt from
CRT-deﬁbrillator.367
I
C
© ESC 2022
CRT, cardiac resynchronization therapy; ICD, implantable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 11 — Recommendations for implantable cardioverter deﬁbrillator implantation
(general aspects)
Recommendations
Classa
Levelb
Implantation of a cardioverter deﬁbrillator is only recommended in patients who have an expectation of good quality survival .1 year.
I
C
It is not recommended to implant an ICD in patients with incessant VAs until the VA is controlled.
III
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; VA, ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 15 — Recommendations for wearable cardioverter deﬁbrillator
Recommendations
Classa
Levelb
The WCD should be considered for adult patients with a secondary prevention ICD indication, who are temporarily not candidates for ICD
implantation.
IIa
C
Continued
Recommendation Table 13 — Recommendations for subcutaneous implantable cardioverter deﬁbrillator
Recommendations
Classa
Levelb
Subcutaneous deﬁbrillator should be considered as an alternative to transvenous deﬁbrillator in patients with an indication for an ICD when pacing therapy for bradycardia, cardiac resynchronization, or ATP is not needed.366
IIa
B
© ESC 2022
ATP, anti-tachycardia pacing; ICD, implantable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 45 -->

### Page 45

6.2.3. Special aspects of device therapy
6.2.3.1. Optimization of device programming
Optimization of ICD programming is essential to minimize the burden of ICD therapy and to improve patient outcome.373–375 Detailed recommendations are available in expert consensus papers.376,377
Bradycardia mode should be customized to prevent unnecessary
RV pacing, thus reducing heart failure hospitalizations and all-cause mortality378–380 (
ESC CardioMed chapter 43.21).381 A tachycardia detection programming strategy incorporating prolonged settings and high rate thresholds (≥188 b.p.m. Advance III trial,382 ≥200
MADIT-RIT383) reduces ICD therapies and all-cause mortality without increasing the risk of syncope.373,382,383 The evidence is stronger for primary prevention compared to secondary prevention indications382 (
ESC CardioMed chapter 43.21).381 Consistent use of SVT/VT discriminators even in rates up to 230 b.p.m. is recommended in ICD recipients without complete heart block to reduce inappropriate therapies.383–385 Proper atrial sensing is a prerequisite for activation of dual-chamber discriminators376
(
ESC
CardioMed chapter 43.21).381 In general, a multi-zone detection programming is favoured to enable tailored use of detection and therapy settings at different tachycardia rates.383,386 A single-zone programming with a high cut-off rate may be considered in patients with a high likelihood of VF only (e.g. primary electrical diseases).387 In subcutaneous ICDs, a dual-zone conﬁguration should be adopted.
Standardized programming including a lower ‘conditional shock’
zone with activated discrimination algorithms and a higher ‘shock zone’ based on rate criteria only has been shown to reduce inappropriate shock rates without compromising patient safety.388–390
Systematic use of ATP before shock delivery, also for very fast ventricular tachyarrhythmias, has been shown to reduce shock therapy without increase in arrhythmic syncope.375,384,391 Burst ATP is preferred over ramp due to increased efﬁcacy in ﬁrst tachycardia termination.392 Incorporation of remote monitoring into follow-up practice of ICD recipients should be promoted to optimize surveillance of device integrity, to enable prompt detection and management of actionable events,
and to prevent occurrence of inappropriate shocks393–396 (
ESC CardioMed chapter 43.
21).381 The proposed recommendations for optimal device programming are applicable to the majority of ICD recipients.
Customization may be needed in individual patients.
6.2.3.2. Concomitant treatment to avoid inappropriate implantable cardioverter deﬁbrillator therapy
Apart from optimization of device programming, pharmacological and/or invasive management may prevent inappropriate ICD
therapy. Beta-blockers (carvedilol superior to metoprolol in
MADIT-CRT) should be titrated to the maximal tolerated dose in heart failure patients to reduce the risk of inappropriate therapy.400 In patients with inappropriate therapies due to recurrent
SVT, catheter ablation should be ﬁrst-line treatment, given its high success and low complication rate.302,401–403 In case of AF-related inappropriate therapies, unresponsive to optimized pharmacological rate control treatment, individualized treatment strategy
(rate vs. rhythm) dependent on patient characteristics is suggested.348 In patients with early AF, adoption of a rhythm control strategy improved patient outcome in the EAST-AFNET 4 trial.404
In CRT-deﬁbrillator patients, AV node ablation has been associated with reduced inappropriate ICD shocks and lower hospitalization rates compared to drug treatment405
(
ESC
CardioMed chapter 41.14).406
The WCD may be considered in the early phase after MI in selected patients.371,372
IIb
B
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; WCD, wearable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 16 — Recommendations for optimization of device programming
Recommendations
Classa
Levelb
Optimization of ICD programming is indicated to avoid inappropriate and unnecessary therapies and to reduce mortality.373–375
I
A
Continued
In single- or dual-chamber ICD patients without bradycardia pacing indications,
it is recommended to minimize ventricular pacing.378–380
I
A
Programming of prolonged detection settings is indicated (duration criteria of at least 6–12 s or 30
intervals).373,382,383
I
A
It is recommended to program the slowest tachycardia therapy zone limit ≥188 b.p.m. in primary prevention ICD patients.382,383
I
A
In patients with SHD, programming of at least one
ATP therapy is recommended in all tachyarrhythmias zones.375,384,391
I
A
It is recommended to program algorithms for SVT
vs. VT discrimination for tachycardias with rates up to 230 b.p.m.383–385
I
B
It is recommended to activate lead failure alerts.397–399
I
B
Remote monitoring is recommended to reduce the incidence of inappropriate shocks.395
I
B
Programming of burst ATP as ﬁrst attempt is recommended over ramp ATP.392
I
B
For S-ICDs, a dual detection zone conﬁguration is recommended with activation of discrimination algorithm in the lower conditional shock zone.388–390
I
B
For routine ICD programming, activation of more than one tachycardia detection zone should be considered.383,386
IIa
B
© ESC 2022
ATP, anti-tachycardia pacing; ICD, implantable cardioverter deﬁbrillator; SHD,
structural heart disease; S-ICD, subcutaneous ICD; SVT, supraventricular tachycardia;
VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4041


<!-- PAGE 46 -->

### Page 46

6.2.3.3. Psychosocial impact of implantable cardioverter deﬁbrillator treatment
Almost 20% of ICD recipients suffer from anxiety and depression that are associated with increased mortality.408–411 In ICD patients,
psychological distress is mainly caused by the concern of potentially receiving ICD shocks rather than by having experienced an ICD
shock.412,413 Thus, assessment of ICD concerns is recommended in all ICD patients before ICD shocks occur. Systematic screening of ICD patients for psychological distress is feasible with the use of speciﬁc questionnaires.413–416
A signiﬁcant proportion of ICD patients with clinically relevant symptoms of anxiety and depression remains undertreated.417
Communication with all ICD recipients is needed to clarify misconceptions about the device function, to discuss concerns about sexual functioning, driving restrictions, and to recommend an action plan in case of shock therapy.418,419 Referral to mental health professionals may be needed for speciﬁc interventions.418,420 Cognitive behavioural therapy intervention may also be provided by trained cardiac nurses to alleviate anxiety.421 Web-based interventions may also prove useful in improving psychosocial well-being in ICD patients with increased psychosocial distress.422
6.2.3.4. Patients with left ventricular assist devices
VAs are common among left ventricular assist device (LVAD) carriers.425–428 VAs are usually well-tolerated, as LVADs maintain adequate cardiac output and prevent circulatory collapse.429
However, sustained untreated VAs may lead to circulatory collapse even in the presence of an LVAD, especially early after device implantation and in patients with higher pulmonary vascular resistance.430 VAs pre- and post-LVAD implantation are associated with an increased risk of cardiovascular and all-cause mortality, while
ICD can signiﬁcantly reduce sustained VA.425,426,431–434 These data support ICD implantation for secondary prevention in LVAD recipients with symptomatic VA.
Observational studies in patients with previous-generation, pulsatile LVADs reported a longer survival with ICD435–437 (
ESC
CardioMed chapter 37.32).438
Recent registries enrolling continuous-ﬂow LVAD carriers have questioned ICD mortality reduction, but available data are inconsistent.425,426,428,439,440 An analysis of the INTERMACS registry, enrolling the largest continuous-ﬂow LVAD cohort, showed that ICD
presence was not associated with prolonged survival.428 The lack of documented survival beneﬁt among continuous-ﬂow LVAD carriers, in conjunction with the likelihood of VA tolerance and the associated risks of ICD placement in these patients (risk of infection,
device interaction), favours an individualized approach.
6.2.3.5. Complications of devices
Prevention of ICD complications is important to reduce associated morbidity, mortality, and ﬁnancial burden. During implantation of devices, antibiotic prophylaxis, peri-procedural patient preparation,
and appropriate surgical technique should be implemented to prevent device infections and formation of pocket haematoma.441–443
Cephalic or axillary vein access is preferred over the subclavian vein route to reduce the risk of pneumothorax and lead failure.444–446
Proper selection of
ICD
systems is important.
Single-chamber ICDs are recommended in primary prevention patients without atrial or AV sequential pacing indications. This reduces peri-procedural complications and generator replacements as compared to dual-chamber ICDs. This approach does not increase the risk of inappropriate shocks if optimal device programming is used.447–450 Routine use of single-coil deﬁbrillator leads is favoured due to reduced risk of complications during lead removal without associated differences in shock efﬁcacy.451,452 Use of dual-coil leads can be considered in clinical settings where a higher deﬁbrillator threshold is suspected, e.g. HCM, right-sided implantations.453,454
Recommendation Table 17 — Recommendations for concomitant treatment to avoid inappropriate implantable cardioverter deﬁbrillator therapy
Recommendations
Classa
Levelb
Catheter ablation is recommended for ICD
patients with recurrent SVT resulting in inappropriate ICD therapies.401,402
I
C
Pharmacological treatment or catheter ablation is recommended in patients with AF-related inappropriate ICD therapies despite optimal ICD
programming.401,405,407
I
C
© ESC 2022
AF, atrial ﬁbrillation; ICD, implantable cardioverter deﬁbrillator; SVT, supraventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 18 — Recommendations for psychosocial management after implantable cardioverter deﬁbrillator implantation
Recommendations
Classa
Levelb
Assessment of psychological status and treatment of distress is recommended in ICD
patients.421–423
I
C
Communication between patient and physician/
healthcare professional is recommended to address ICD-related concerns and to discuss quality-of-life issues before ICD implantation and during disease progression.412,424
I
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 19 — Recommendations for implantable cardioverter deﬁbrillator implantation in left ventricular assist device recipients
Recommendations
Classa
Levelb
ICD implantation should be considered in LVAD
recipients with symptomatic sustained VAs.425,431
IIa
B
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; LVAD, left ventricular assist devices; VA,
ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 47 -->

### Page 47

6.2.3.6. End-of-life issues
Patients with active ICDs experience a considerable rate of shocks in the last phase of life.455 In terminally ill patients and at the end of life,
healthcare professionals can facilitate a decision by the patient and the patient’s family by explaining in a sensitive and understandable manner the beneﬁts and burdens of continued ICD therapy.456
Patients should be informed about the options of ICD deactivation.
In general, deactivation of anti-bradycardia therapy is discouraged to avoid quality-of-life impairment, and in some countries deactivation in pacemaker-dependent patients may be prohibited by law.457
Deactivation should be discussed before device implantation and when there is signiﬁcant deterioration of the patient’s health status.
Despite an increasing trend to address and perform device deactivation after careful consideration, current rates are still low and improved patient care is needed.458,459
6.2.4. Interventional therapy
6.2.4.1. Catheter ablation
6.2.4.1.1. Patients with structural heart disease. In patients with
SHD, SMVTs are primarily due to a scar-related re-entrant mechanism.460–465
Because of a higher risk of SCD, an ICD implantation is usually recommended in patients with sustained VAs associated with
SHD.466–468 However, ICDs do not prevent VA, and many of these patients will experience symptomatic VT/VF recurrences resulting in syncope or ICD shocks and may require additional treatment.330,383,419,469–471
In patients with SHD, the choice of anti-arrhythmic agents is mostly limited to beta-blockers, sotalol, and amiodarone to help control
VT/VF recurrences, and this treatment is frequently hampered by side effects.318,472
Owing to advances made over the last three decades, catheter ablation has become increasingly important for the management of scar-related VTs.473 Since the early 1990s, catheter ablation of
BBR-VT has been very successful474–477 and is considered as ﬁrstline therapy466,467 (Figure 5). Subsequently, catheter ablation has been shown to be very effective in controlling incessant VTs or electrical storms330,331 and in reducing subsequent VT burden.
Many observational studies have shown a positive effect of VT ablation on clinical outcome in terms of VT recurrences.478–483 In patients with CAD, three randomized trials471,484,485 have reported that catheter ablation, compared to conventional treatment, decreases the likelihood of subsequent ICD shocks and prevents recurrent VT episodes.
The critical part of re-entrant VT circuits, referred to as the ‘protected VT isthmus’, is the primary target for ablation,460,486 but it is very challenging to unmask in haemodynamically not-tolerated
VT.487,488 Due to the high likelihood of multiple re-entry circuits in a scar and difﬁculties in identifying critical isthmuses, the ablation strategy has gradually evolved over the years towards more extended ablation of the arrhythmogenic substrate.489–492 Special attention should be paid to cases of PVT/VF initiated by similar
PVCs, where the triggering PVC (often related to the Purkinje network) should be targeted for ablation.221,332,333,493
The electrophysiological characteristics of VT circuits depend on the underlying SHD. Thus, post-infarct VTs are mainly related to an endocardial VT circuit (amenable to endocardial ablation), while the location of re-entrant VT circuits is more variable in patients with cardiomyopathies.494–496 Here, intramural and/or epicardial involvement are more common. This signiﬁcantly contributes to the difference in the clinical outcomes of VT ablation in relation to the underlying heart disease with a better outcome in CAD as compared to non-ischaemic aetiologies.497–499
Effective ablation requires durable ablation lesions to arrhythmogenic tissue. In some cases, such as intramural VTs, difﬁculties remain in achieving this objective with current catheters, regardless of the approach (endocardial/epicardial).500 To improve the formation of myocardial lesions, new catheter-based techniques are being evaluated (e.g. bipolar/needle ablation, transcoronary alcohol ablation),501–506 as well as radiotherapy ablation507,508 or surgical ablation,509 which are currently bailout treatments.
When planning VT ablation, it is important to collect all available information about the arrhythmogenic substrate, especially to identify scars (using CMR or CT scan),510–514 and to help determine the exit site of VAs with the 12-lead ECG documentation of clinical VTs or PVCs that induce PVT/VF.
The mean long-term success rate of VT ablation varies from
30%
to
70%,
depending on the underlying
SHD.481,515–518
Peri-procedural complications, in particular stroke, cardiac tamponade, or death, may occur.519–522
Recommendation Table 21 — Recommendations for end-of-life issues in implantable cardioverter deﬁbrillator carriers
Recommendations
Classa
Levelb
Informed discussion with patient and family about
ICD deactivation options and shared decision-making is indicated prior to implantation and in case of signiﬁcant health status deterioration.458
I
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 20 — Recommendations for prevention of implantable cardioverter deﬁbrillator complications
Recommendations
Classa
Levelb
Single-chamber ICD is recommended over dual-chamber ICD in primary prevention patients without current or expected indication for atrial or AV sequential pacing due to a lower risk of device-related complications.447,448,450
I
A
The use of single-coil leads over dual-coil ICD
leads should be considered due to lower complication rate during transvenous lead extraction.451
IIa
C
© ESC 2022
AV, atrioventricular; ICD, implantable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4043


<!-- PAGE 48 -->

### Page 48

6.2.4.1.2. Patients without apparent structural heart disease.
‘Idiopathic VTs’ is the term for VTs that are not associated with
SHD or a genetic arrhythmic syndrome. Most idiopathic VTs are mediated by triggered activity, but a re-entrant mechanism (involving the LV Purkinje network) explains verapamil-sensitive fascicular
VTs.523 Three important key features distinguish idiopathic VTs from VTs associated with SHD. First, idiopathic VTs mostly originate from a single site and speciﬁc region of the heart (namely the right or left ventricular outﬂow tracts,524,525 along the valve annuli,526–528
papillary muscle,529 or the LV Purkinje network).523 Second, no detectable scar is found in idiopathic VTs.530 Finally, idiopathic VTs have a benign prognosis so that ICD implantation is generally not recommended.466
The earliest site of activation during VT is the ablation target for focal sources, while abnormal Purkinje tissue (with diastolic activity during VT) is the ablation target of left fascicular VTs.531,532
Catheter ablation is curative in most idiopathic VT patients and peri-procedural complications are rare.533–537
6.2.4.2. Autonomic modulation
The role of the autonomic nervous system in promoting arrhythmias has long been recognized, leading to the concept of Coumel’s triangle of arrhythmogenesis.538
Sympathetic activation has been demonstrated as playing a key role in inducing VAs in some entities, such as congenital LQTS and
CPVT,539,540 and left cardiac sympathetic denervation was shown to be associated with a decrease in the frequency of arrhythmogenic syncope in congenital LQTS.541,542 The efﬁcacy of cardiac sympathetic blockade by different approaches (thoracic epidural anaesthesia, percutaneous stellate ganglion anaesthesia, or surgical stellate ganglion resection) in reducing the arrhythmia burden in refractory VT/VF has been recognized in several small observational studies.326,328,340 Further studies are needed to assess which patients may beneﬁt from a modulation of the autonomic nervous system to better control VT/VF.
7. Diagnostic evaluation,
management, and risk stratiﬁcation according to clinical presentation and known (likely)
disease
7.1. Speciﬁc structural heart diseases
7.1.1. Coronary artery disease
7.1.1.1. Acute coronary syndromes and vasospasm
7.1.1.1.1. Acute coronary syndromes. SCD is a major cause of mortality in ACS, mostly caused by sustained VAs, in particular
VF. The majority of studies have reported on patients with
STEMI. Of patients with STEMI, 4–12% develop VA within the
ﬁrst 48 h after the onset of symptoms.69,543,544 Pre-reperfusion
VAs are more common than reperfusion-induced or postreperfusion arrhythmias in STEMI.545 Haemodynamic instability,
cardiogenic shock, LVEF , 40%, and the sum of ST-segment deviations in all leads are independent predictors of VA both in
STEMI and non-STEMI.69,546 In addition, an early repolarization pattern has been associated with increased risk of VAs and
SCD in ACS.547
Prevention of ventricular arrhythmias in ST elevation myocardial infarction
Urgent reperfusion is the most important therapy,292,548 as acute ischaemia triggers arrhythmias. Beta-blocker treatment is also recommended to prevent VA.3,549 In a recent randomized trial of patients with STEMI, early intravenous metoprolol before percutaneous coronary intervention reduced the incidence of arrhythmias in the acute phase and was not associated with an increase in adverse events.550 Prophylactic treatment with AADs has not proven beneﬁcial, and may even be harmful.322 Correction of electrolyte imbalances is strongly recommended.289
Management of sustained ventricular tachycardia and ventricular
ﬁbrillation in acute coronary syndrome
Electrical cardioversion or deﬁbrillation is the intervention of choice to acutely terminate VAs in ACS patients (Figure 14).205,339
Recurrent sustained VT, especially when polymorphic, or recurrent
VF can indicate incomplete reperfusion or recurrence of acute ischaemia. In this case, immediate coronary angiography is indicated.3
For recurrent PVT degenerating into VF, beta-blockers are recommended.551,552 In addition, deep sedation may be helpful to reduce episodes of VT or VF.553 Intravenous amiodarone should be considered to acutely suppress recurrent haemodynamically relevant VAs,
although there is a paucity of controlled studies for amiodarone during STEMI554 and the evidence in this setting is mainly extrapolated from studies of OHCA.555 If treatment with beta-blockers and amiodarone is not effective, lidocaine may be considered.322 The use of other AADs in ACS is not recommended.549,556 In haemodynamically unstable patients with refractory VA, mechanical circulatory support may be considered.336,557 For VA in the context of relative bradycardia or pause-related, pacing may be effective to prevent re-initiation.
The prognostic signiﬁcance of early ventricular arrhythmias
Early VAs are deﬁned as VT/VF occurring within 48 h after a
STEMI. In the contemporary percutaneous coronary intervention
(PCI)-based revascularization era, almost all VA occur within the ﬁrst
24 h.558 Early VA have been associated with an up to six-fold increase in in-hospital mortality, whereas long-term prognosis seems not to be signiﬁcantly affected.543,559,560 In a prospective cohort study, patients with VF during the acute STEMI phase had low and very similar incidence of late SCD as compared with VF-free patients during
5-year observation.560 Of note, early monomorphic VT was associated with signiﬁcantly higher incidence of adequate ICD interventions compared with early VF, and was an independent predictor of death during long-term follow-up.561 Thus, the prognostic signiﬁcance of VT and VF occurring in the acute phase of MI may be different. The impact of VA occurring late after reperfusion (.48 h) on late SCD is less clear.
Podolecki et al.559 recently demonstrated that long-term all-cause mortality after STEMI was predicted by VA occurring late after reperfusion (.48 h after reperfusion), while early reperfusion VAs did not affect 5-year outcome. Further studies are required to clarify


<!-- PAGE 49 -->

### Page 49

the impact of VA occurring .48 h after STEMI on late SCD in contemporary patients undergoing acute PCI.
7.1.1.1.2. Vasospasm. Coronary artery spasms might have an important role in the pathogenesis of VA. The long-term prognosis
Prevention and treatment of  VAs in the acute phase of STEMI
Beta-blocker i.v. prior to PCI, if not contraindicateda,b
(Class IIa)
Urgent CAG and revascularizationa
(Class I)
Further revascularization if appropriatea
(Class I)
Repletion of K+, Mg2+ a
(Class I)
Beta-blocker i.v.b
(Class I)
Amiodarone i.v.
(Class IIa)
Lidocaine i.v.
(Class IIb)
Deep sedation/intubation c
(Class IIb)
Sedation (for comfort)c
(Class I)
VA
Recurrent VA
Autonomic modulationc
(Class IIb)
Catheter ablationd
(Class IIa)
Mechanical circulatory support c
(Class IIb)
Overdrive pacinga
(Class IIa)
Recurrent VA
Figure 14 Algorithm for the prevention and management of ventricular arrhythmias in ST-elevation myocardial infarction. CAG, coronary angiogram; PCI,
percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; VA, ventricular arrhythmias. aThe 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.3 bIntravenous beta-blockers must be avoided in patients with hypotension, acute heart failure, AV block or severe bradycardia. cFlowchart for the management of electrical storm. dIf similar PVC triggers recurrent polymorphic VA.
ESC Guidelines
4045


<!-- PAGE 50 -->

### Page 50

of patients with variant angina who survive a CA is worse than in other patients with variant angina.562,563 In a recent multicentre
European survey,564 patients with life-threatening VAs secondary to coronary vasospasm were at high risk for recurrence, especially when insufﬁcient medical therapy was administered. While calcium channel blockers (CCB) are capable of suppressing episodes, betablockers may trigger VAs. As medical intervention and multiple vasodilator drugs may not be sufﬁciently protective, placement of an ICD
should still be considered in SCA survivors with variant angina.
7.1.1.2. Early after myocardial infarction
The ﬁrst weeks after a STEMI carry the highest risk both for allcause death and for SCD, particularly in patients with reduced
LVEF.565,566 For this reason, early assessment of LVEF, i.e. before discharge, is recommended.567,568 Early routine prophylactic ICD
implantation in the ﬁrst 40 days after MI did not reduce mortality in post-MI patients with reduced LVEF in two randomized trials
(DINAMIT and IRIS),569,570 and is therefore not recommended.
Early assessment by further non-invasive tests, apart from LVEF
measurement, has also not proven to be useful for risk stratiﬁcation with regard to SCD.571 Limited evidence suggests that invasive risk stratiﬁcation by PES in the early post-MI phase may be helpful for identiﬁcation of high-risk patients with reduced LVEF.572
However, the utility of this approach has not been conﬁrmed so far in randomized studies. The PROTECT-ICD randomized trial
(NCT03588286) is currently examining whether PES may guide the decision on ICD implantation in patients with reduced EF in the early phase after STEMI.
Reverse remodelling following an MI is associated with signiﬁcantly lower rates of death, SCA, and other adverse clinical outcomes.573,574
Therefore,
assessment of the indication for prophylactic ICD implantation, usually performed by repeat echocardiography, should take place in the post-remodelling phase of the MI after the ﬁrst 6 weeks in patients with a pre-discharge
LVEF ≤40%. Reassessment of the LVEF before 6 weeks following
MI may not discriminate between myocardial stunning and remodelling.
In the early post-MI phase, electrical storm and/or recurrent episodes of PVT or VF are immediately life-threatening conditions. In this setting, it is important to exclude ischaemia as the triggering factor for the arrhythmias. If medical treatment is not sufﬁcient to suppress the arrhythmic episodes, catheter ablation is potentially effective particularly if the episodes are focally triggered by similar PVCs.332,575 If PVT recurs despite betablocker and amiodarone treatment, suppression by quinidine therapy has been reported.323
7.1.1.3. Chronic coronary artery disease
7.1.1.3.1. Primary prevention of sudden cardiac death in patients with reduced ejection fraction. Forty days after STEMI, approximately 5% of patients will have an LVEF ≤35%.576 These patients are at risk for SCD. Therefore, in patients with LVEF ≤35% and
Recommendation Table 22 — Recommendations for treatment of ventricular arrhythmias in acute coronary syndrome and vasospasm
Recommendations
Classa
Levelb
Treatment of VAs in ACS
Intravenous beta-blocker treatment is indicated for patients with recurrent PVT/VF during STEMI
unless contraindicated.551,552
I
B
Intravenous amiodarone treatment should be considered for patients with recurrent PVT/VF
during the acute phase of ACS.552,554,555
IIa
C
Intravenous lidocaine may be considered for the treatment of recurrent PVT/VF not responding to beta-blockers or amiodarone, or if amiodarone is contraindicated during the acute phase of ACS.554
IIb
C
Prophylactic treatment with AADs (other than beta-blockers) is not recommended in ACS.322
III
B
Vasospasm
In SCA survivors with coronary artery spasm, implantation of an ICD should be considered.562–564
IIa
C
© ESC 2022
AAD, anti-arrhythmic drug; ACS, acute coronary syndrome; ICD, implantable cardioverter deﬁbrillator; PVT, polymorphic ventricular tachycardia; SCA, sudden cardiac arrest;
STEMI, ST elevation myocardial infarction; VA, ventricular arrhythmia; VF,
ventricular ﬁbrillation.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 23 — Recommendations for risk stratiﬁcation and treatment of ventricular arrhythmias early after myocardial infarction
Recommendations
Classa
Levelb
Risk stratiﬁcation
Early (before discharge) assessment of LVEF is recommended in all patients with acute MI.567,568
I
B
In patients with pre-discharge LVEF ≤40%,
re-evaluation of LVEF 6–12 weeks after MI is recommended to assess the potential need for primary prevention ICD implantation.568,573,574
I
C
Treatment of VAs
Catheter ablation should be considered in patients with recurrent episodes of PVT/VF triggered by a similar PVC non-responsive to medical treatment or coronary revascularization in the subacute phase of MI.332
IIa
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; LVEF, left ventricular ejection fraction; MI,
myocardial infarction; PVC, premature ventricular complex; PVT, polymorphic ventricular tachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 51 -->

### Page 51

heart failure symptoms NYHA class II and III, primary preventive
ICD implantation is recommended.356 ICD implantation should also be considered for asymptomatic patients with an EF ≤30%.354
In this population, mortality reduction by an ICD has been demonstrated in four RCTs.353–356 In patients with CAD, a reduced LVEF (≤40%), and asymptomatic NSVT, inducibility by
PES identiﬁes patients who beneﬁt from an ICD, independent from NYHA class.355
Since the publication of the aforementioned trials, early revascularization strategies and modern heart failure medication have reduced the overall risk of SCD in heart failure patients.577 Although total mortality has been reduced, the relative reduction by the
ICD is a consistent 27%, which has been corroborated in two recent large prospective registry studies enrolling 2327 European patients between 2014 and 2018 (EU-CERT-ICD)357 and 2610
Swedish patients enrolled between 2000 and 2016 (SwedeHF
registry).358
7.1.1.3.2. Primary prevention of sudden cardiac death in patients with preserved or mildly reduced ejection fraction. There are no data supporting primary prophylactic ICD implantation in post-infarct patients with preserved or mildly reduced LVEF. These patients are heterogeneous with regard to their potential arrhythmic substrate,
and efforts are under way to identify those with the highest risk for SCD. PES is recommended in post-infarct patients in whom syncope remains unexplained after non-invasive evaluation to guide patient management (Figure 15).146
In the PRESERVE-EF study, 41 of 575 post-infarct patients with an
LVEF ≥40% and one non-invasive ECG risk factor more than 40 days post-MI were inducible for VT/VF during PES and received an ICD.151
During the 32-month follow-up period, no SCD occurred and 9 of
37 ICD patients received an appropriate ICD therapy. However,
the role of appropriate ICD treatment as surrogate for SCD in patients with preserved LVEF is unknown, and randomized trials are needed. Prophylactic treatment with AADs other than beta-blockers is not indicated regardless of the LVEF.556,578,579
7.1.1.3.3. Secondary prevention of sudden cardiac death. The three pivotal secondary prevention ICD trials enrolled 1866 patients between
1990
and
1997.349–351
A
patient-level
Recommendation Table 24 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention,
and treatment of ventricular arrhythmias in chronic coronary artery disease
Recommendations
Classa
Levelb
Risk stratiﬁcation and primary prevention of SCD
In patients with syncope and previous STEMI, PES
is indicated when syncope remains unexplained after non-invasive evaluation.146,584
I
C
ICD therapy is recommended in patients with CAD, symptomatic heart failure (NYHA
class II–III), and LVEF ≤35% despite ≥3 months of OMT.354,356
I
A
ICD therapy should be considered in patients with
CAD, NYHA class I, and LVEF ≤30% despite ≥3
months of OMT.354
IIa
B
ICD implantation should be considered in patients with CAD, LVEF ≤40% despite ≥3 months of
OMT, and NSVT, if they are inducible for SMVT by
PES.355
IIa
B
In patients with CAD, prophylactic treatment with AADs other than beta-blockers is not recommended.556,578,579
III
A
Secondary prevention of SCD and treatment of VAs
ICD implantation is recommended in patients without ongoing ischaemia with documented VF
or haemodynamically not-tolerated VT occurring later than 48 h after MI.349–351
I
A
In patients with CAD and recurrent, symptomatic
SMVT, or ICD shocks for SMVT despite chronic amiodarone therapy, catheter ablation is recommended in preference to escalating AAD
therapy.471
I
B
Continued
The addition of oral amiodarone or beta-blocker replacement by sotalol should be considered in patients with CAD with recurrent, symptomatic SMVT, or ICD shocks for SMVT while on beta-blocker treatment.318,581
IIa
B
In patients with CAD and haemodynamically well-tolerated SMVT and LVEF ≥40%, catheter ablationinexperiencedcentresshouldbeconsidered as an alternative to ICD therapy, provided that established endpoints have been reached.c,480,580
IIa
C
ICD implantation should be considered in patients with a haemodynamically tolerated SMVT and an
LVEF ≥40% if VT ablation fails, is not available, or is not desired.
IIa
C
Catheter ablation should be considered in patients with CAD and recurrent, symptomatic SMVT, or
ICD shocks for SMVT despite beta-blockers or sotalol treatment.471
IIa
C
In patients with CAD eligible for ICD implantation,
catheter ablation may be considered just before (or immediately after) ICD implantation to decrease subsequent VT burden and ICD shocks.484,485,582,583
IIb
B
© ESC 2022
AAD, anti-arrhythmic drug; CAD, coronary artery disease; ICD, implantable cardioverter deﬁbrillator; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart
Association; OMT, optimal medical therapy; PES, programmed electrical stimulation;
SCD, sudden cardiac death; SMVT, sustained monomorphic ventricular tachycardia;
STEMI, ST elevation myocardial infarction; VA, ventricular arrhythmia; VF, ventricular
ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cVT non-inducibility and elimination of electrograms consistent with conduction delay.
ESC Guidelines
4047


<!-- PAGE 52 -->

### Page 52

meta-analysis demonstrated a 28% mortality reduction (HR 0.72;
95% CI 0.60–0.87; P = 0.0006) almost entirely due to reduction of arrhythmic death (HR 0.50; 95% CI 0.37–0.67; P , 0.0001) in the ICD group.352 This translates to an extension of survival of
4.4 months over a mean follow-up of 6 years by the ICD.
Around 80% of the study population suffered from CAD.
Patients with well-tolerated SMVT were excluded from secondary prevention trials (Figure 16).
7.1.1.3.4. Management of patients with haemodynamically tolerated ventricular tachycardia and preserved and mildly reduced ejection fraction. With the better understanding of the mechanisms of VT after MI, as well as improved ablation and imaging technologies,
catheter ablation has become an option for the treatment of haemodynamically well-tolerated VT in selected post-MI patients with preserved or mildly reduced EF, even without ICD back-up. One small monocentric retrospective trial studied patients with CAD, LVEF
.40%, and haemodynamically tolerated VT who underwent catheter ablation as ﬁrst-line therapy.580 The investigators could abolish
90% of the clinical and 58% of all inducible VTs. Subsequently, 42% of the patients received an ICD. After a mean follow-up of 3.8 years,
42% of the patients died irrespective of the presence or absence of an ICD (P = 0.47).
A larger multicentre retrospective study looked at 166 patients with an LVEF .30% presenting with well-tolerated SMVT, which were treated by catheter ablation only, and compared the outcome to a control group of 378 patients implanted with an
ICD.480 Of the 166 patients undergoing ablation as ﬁrst therapy,
55% suffered from CAD. The mean LVEF was 50%, and after a mean follow-up of 32 months, overall mortality did not differ between the groups (12%).
These data suggest that either ICD implantation or ablation in experienced centres should be considered in patients with a preserved or mildly reduced EF presenting with haemodynamically tolerated
SMVT. Of note, although ICDs have been commonly implanted in this population, the secondary preventive ICD trials failed to show a survival beneﬁt in patients with an LVEF ≥35%.352 Although
SMVT is rarely caused by ischaemia and revascularization alone
NSVT or unexplained syncope
NYHA class ≥II
LVEF
L
≤30%
LVEF 
L
≤35%
LVEF 36–40%
L
N
N
N
Patient with chronic CAD
LVEF
L
evaluation 6–12 weeks after acute MI
in patients with LVEF
L
≤40% at discharge
(Class I) 
ILR implantationa
(Class I)
PES
(Class I)
ICD
(Class I)
No SMVT inducible and unexplained syncope
SMVT inducible
ICD implantation
(Class IIa)
Follow-up
ICD implantation
(Class IIa)
Y
Y
Y
Figure 15 Algorithm for risk stratiﬁcation and primary prevention of sudden cardiac death in patients with chronic coronary artery disease and reduced ejection fraction. CAD, coronary artery disease; ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; LVEF, left ventricular ejection fraction; MI, myocardial infarction; N, No; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; PES, programmed electrical stimulation; SMVT, sustained monomorphic ventricular tachycardia; Y, Yes. aThe 2018 ESC Guidelines for the diagnosis and management of syncope.1


<!-- PAGE 53 -->

### Page 53

does not prevent VT recurrence, exclusion or treatment of signiﬁcant CAD before catheter ablation is reasonable.
7.1.1.3.5. Management of recurrent ventricular tachycardia in implantable cardioverter deﬁbrillator carriers. Frequent, symptomatic VT in ICD recipients should be treated medically with either amiodarone or sotalol.318,581 In patients with CAD in whom SMVT
recurs while on amiodarone treatment, catheter ablation is recommended over escalation of AAD therapy. In the VANISH trial, the composite endpoint of death, VT storm, and appropriate ICD therapy was reached signiﬁcantly less often in the ablation group as compared to the escalated amiodarone-therapy group over a mean follow-up of 28 months (59% vs. 68.5%; HR 0.72; 95% CI 0.53–
0.98; P = 0.04).471 The ongoing VANISH2 trial (ClinicalTrials.gov
Identiﬁer: NCT02830360) addresses the question of whether catheter ablation as ﬁrst-line treatment is superior to AAD therapy in post-MI patients with SMVT.
Preventive VT ablation after a ﬁrst documented SMVT, which was followed by ICD implantation, reduced neither mortality nor hospitalizations for arrhythmia or worsening heart failure when compared to a deferred ablation strategy only after the third ICD shock.582
However, in patients who present with a ﬁrst VT episode and in whom an ICD is indicated, catheter ablation performed immediately before or shortly after ICD implantation may be considered to decrease subsequent VT and ICD shocks.484,485,583
7.1.1.4. Coronary anomalies
Anomalous aortic origin of a coronary artery, either the left or the right, arising from the opposite sinus of Valsalva, is associated with an increased risk of SCD, especially in individuals ,35 years during or following vigorous exercise.585 Anomalous aortic origin of the left coronary artery is less common but more malignant than anomalous aortic origin of the right coronary artery. Other risk factors for SCD are interarterial course between the aorta and pulmonary artery, slit-like shaped oriﬁce, high oriﬁce, acuteangle take-off, and intramural course and its length.585,586
Indications for surgical intervention, especially in asymptomatic patients, are based on the evaluation of high-risk anatomy by CTA and the assessment of exercise-induced ischaemia using advanced imaging modalities.586–588 Cardiac stress imaging is also indicated to evaluate exercise-induced ischaemia after surgical intervention, especially in patients with an aborted CA.588
SMVT in a patient with chronic CAD
ICD implantation
(Class I)
Catheter ablation
(Class IIb)
Catheter ablation
(Class IIa)
Amiodaroneb
(Class IIa)
Catheter ablation
(Class IIa)
Amiodarone
(Class IIa)
Catheter ablation
(Class I)
Y
Y
N
N
Haemodynamically tolerated
On amiodarone
Go to flowchart electrical storm
(Figure 11)
Symptomatic SMVT
SMVT in ICD carriersa
First presentation
Electrical storm
LVE
L
F
<40%
≥40%
Sotalolc
(Class IIa)
ICD implantationb
(Class IIa)
Figure 16 Algorithm for the management of sustained monomorphic ventricular tachycardia in patients with chronic coronary artery disease. CAD,
coronary artery disease; ICD, implantable cardioverter deﬁbrillator; LVEF, left ventricular ejection fraction; N, No; SMVT, sustained monomorphic ventricular tachycardia; Y, Yes. aIncessant ventricular tachycardia in monitor zone: consider catheter ablation. bIf catheter ablation is not available, not successful or not desired by the patient. cTo reduce ICD shocks.
ESC Guidelines
4049


<!-- PAGE 54 -->

### Page 54

7.1.2. Idiopathic premature ventricular complexes/
ventricular tachycardia and premature ventricular complex-induced cardiomyopathy
7.1.2.1. Idiopathic premature ventricular complexes/ventricular tachycardia
PVCs/VT in patients without SHD are deﬁned as idiopathic
(Figure 17). In patients with presumed idiopathic PVCs/VT based on a negative history and normal physical examination, 12-lead
ECG and transthoracic echocardiography are important ﬁrst diagnostic steps to exclude underlying SHD. Twenty-four-hour ECG
Holter monitoring is usually performed to determine the PVC burden.
Multiform PVCs at prolonged ECG monitoring and subtle changes on
ECG or echocardiography need to be recognized.589 CMR should be performed whenever ECG and echocardiography are inconclusive to rule out SHD, or the clinical presentation raises suspicion for SHD.590,591
Patients need to be treated when PVCs/VT are symptomatic or associated with deterioration of cardiac function. The clinical course and responses to different treatments have been mostly studied in those originating from the RVOT or the left fascicles.
Several drugs have been used to treat idiopathic PVCs/VT.
Recommendations are based on small or non-controlled series.
Beta-blockers and CCBs are the most-studied drugs and both have been shown to be effective at arrhythmia suppression.304 The evidence for ﬂecainide is scarce.592 In case of a higher burden of
PVCs with higher heart rate or during exercise, beta-blockers should be preferred.593 If there is not such a correlation, the use of ﬂecainide or CCB drugs have been associated with more effective PVC suppression. Beta-blockers should also be selected when a focal triggered activity mechanism is suspected. CCB should be the drug of choice for fascicular PVC/VT. Although data are lacking, betablockers or CCBs are considered ﬁrst choice for PVCs with an origin outside the RVOT or the left fascicles because ﬂecainide may have proarrhythmic side effects. Amiodarone is associated with severe systemic toxicity and should be used only if ablation or other drugs fail or cannot be used.594 A summary of the recommendations for the treatment of idiopathic PVCs/VT and PVC-induced or aggravated cardiomyopathy with AADs is provided in Table 9.
A high success rate of catheter ablation of idiopathic PVCs/VT has been reported with rare complications, particularly for the RVOT
and fascicular types.535 In a randomized study including patients with RVOT PVCs, ablation was superior to AAD therapy for arrhythmia suppression with no differences in complications.595
Ablation is therefore recommended as the ﬁrst-line therapy for
RVOT and fascicular PVCs/VT. The available information for other forms of idiopathic PVCs/VT is limited and mostly restricted to the acute success of ablation, which, in general, is lower and associated with more recurrences than for RVOT and fascicular PVCs/VT.540
In addition, access to and ablation at speciﬁc locations (e.g. sinus of
Valsalva, LV summit) may increase the risk for procedural complications. Therefore, when the 12-lead ECG is highly suspicious of a
PVC/VT source outside the RVOT or left fascicles, the level of recommendation for ablation is lower.
In general, treatment of children should be similar to that of adults.
However, ablation should be deferred in young and small children due to the risk of complications and the relatively larger size of the ablation lesion as compared to the child’s heart.596,597 Verapamil is not recommended as the ﬁrst-line therapy in children ,1 year old because it has been associated with hypotension in some case reports.542 Of note, all reported patients had either heart failure, overdosing of verapamil, or other concurrent AADs at the time verapamil was given.598
Patients may present with asymptomatic frequent PVCs/VTs.
Only a minority of patients with .1000 PVCs per day will develop ventricular dysfunction after 5 years follow-up.599 A PVC burden of 10% seems to be the minimal threshold for development of LV
dysfunction,
with higher risk when the
PVC
burden is
.20%.535,600,601 Regular assessment of LVEF in this setting is therefore indicated. To date, there are no data supporting the beneﬁt of arrhythmia treatment for asymptomatic patients with preserved ventricular function. In addition, PVC burden often decreases spontaneously over time, particularly in children.599,602 In selected patients, e.g. patients who do not want to be followed, catheter ablation may be considered. In patients with PVC burden , 10%, reevaluation may be appropriate in case of development of new symptoms or change in patient condition.
Recommendation Table 25 — Recommendations for sudden cardiac death prevention in patients with coronary anomalies
Recommendations
Classa
Levelb
Diagnostic evaluation
Cardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test in patients with anomalous aortic origin of a coronary artery with an interarterial course to conﬁrm/exclude myocardial ischaemia.587
I
C
Cardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test after surgery in patients with anomalous aortic origin of a coronary artery with a history of aborted CA.
I
C
Treatment
Surgery is recommended in patients with anomalous aortic origin of a coronary artery with
CA, syncope suspected to be due to VAs, or angina when other causes have been excluded.585,586,588
I
C
Surgery should be considered in asymptomatic patients with anomalous aortic origin of a coronary artery and evidence of myocardial ischaemia or abnormal aortic origin of the left coronary artery with high-risk anatomy.c,585,586,588
IIa
C
© ESC 2022
CA, cardiac arrest; VA, ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
cHigh-risk anatomy is deﬁned as interarterial course, slit-like shaped oriﬁce, high oriﬁce,
acute-angle take-off, and intramural course and its length.


<!-- PAGE 55 -->

### Page 55

Patient with PVCs / MonomorphicVT and non-apparent SHDa
ECG, Holte
,
r, and echoca
,
rdiogram
Assessment
Assessment
>20% PVCs
RV
R OT / Fascicular PVC/VT
O
d
Symptomsc
>10% PVCs
Dischargee
Go to flowchart
PVC-induced cardio r
myopathy
(Figure 18)
SHD or PVC-induced cardiomyopathy
CMR (Class IIa)
Inconclusive or atypical presentationb
Catheter ablation
(Class I)
Beta-blockers,
k
CCB or 
Flecainide
(Class IIa)
Beta-blocker k  o r r CCB
(Class I)
Flecainide
(Class IIa)
Catheter ablation
(Class IIa)
Regular foll f
ow-up LVEF
L
(Class I)
Structural abnormal heart
Idiopathic PVC/VT
Structural normal heart
Regular foll f
ow-up LVEF
L
(Class I)
Catheter ablation
(Class IIb)
Y
Y
Y
Y
N
N
N
N
Figure 17 Algorithm for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia and non-apparent structural heart disease. CCB, calcium channel blocker; CMR, cardiac magnetic resonance; ECG, electrocardiogram; LVEF, left ventricular ejection fraction; N, No;
PVC, premature ventricular complex; RVOT, right ventricular outﬂow tract; SHD, structural heart disease; VT, ventricular tachycardia; Y, Yes. aNon-apparent
SHD is deﬁned by lack of signiﬁcant abnormalities in physical examination, basal ECG, and echocardiogram. bAtypical presentation: e.g. older age, right bundle branch block morphology, sustained monomorphic VT consistent with re-entry. cSymptoms should be relevant and related to PVC/VT. dOrigin suspected by
ECG or conﬁrmed during electrophysiological evaluation. eConsider re-evaluation in case of new symptoms or changes in patient clinical condition.
Table 9
Summary of the recommendations for the treatment of patients with frequent idiopathic premature ventricular complexes/ventricular tachycardia or premature ventricular complex-induced cardiomyopathy
Ablation
Beta-blocker
CCB
Flecainide
Amiodarone
RVOT/fascicular PVC/VT:
Symptomatic, normal LV function
Class I
Class IIa
Class IIa
Class IIa
Class III
PVC/VT other than RVOT/fascicular:
Symptomatic, normal LV function
Class IIa
Class I
Class I
Class IIa
Class III
RVOT/fascicular PVC/VT:
LV dysfunction
Class I
Class IIa
Class IIIa
Class IIab
Class IIa
PVC/VT other than RVOT/fascicular:
LV dysfunction
Class I
Class IIa
Class IIIa
Class IIab
Class IIa
PVC:
Burden .20%, asymptomatic, normal LV function
Class IIb
Class III
© ESC 2022
CCB, calcium channel blocker; LV, left ventricular; PVC, premature ventricular complex; RVOT, right ventricular outﬂow tract; VT, ventricular tachycardia.
aIntravenous calcium channel blockers.
bIn selected patients (only moderate LV dysfunction).
ESC Guidelines
4051


<!-- PAGE 56 -->

### Page 56

7.1.2.2. Premature ventricular complex-induced/-aggravated cardiomyopathy
The importance of PVC-induced cardiomyopathy as a secondary and reversible cause of LV dysfunction in patients without
SHD has been recognized.607,608 The patient’s medical and family history, 12-lead ECG, Holter-ECG, and echocardiography form the cornerstones of the evaluation of patients with suspected
PVC-induced cardiomyopathy
(Figure
18).
PVC burden has been shown to be the strongest independent predictor of PVC-induced cardiomyopathy in several studies.600,609–611 Day-by-day ﬂuctuations of PVC burden have been reported in patients undergoing 14-day monitoring, but most data are based on 24-h registrations.611 A PVC burden of at least 10% appears to be the minimal threshold for development of PVC-induced cardiomyopathy, and the risk increases further with a PVC burden .20%.600,611 In patients with a PVC
burden ,10%, other cardiomyopathy aetiologies should be suspected and further diagnostic work-up undertaken. In such patients, Holter-ECG should be repeated to assess ﬂuctuations in
PVC burden. Factors predicting adverse LV remodelling in patients with frequent PVCs include superior PVC axis, epicardial origin,
NSVT,
shorter coupling interval,
and male gender.535,611–613
Frequent PVCs can also aggravate LV dysfunction in patients with
SHD. In such cases, LV dysfunction can either be a direct consequence of PVCs as in PVC-induced cardiomyopathy, or due to the limiting effect of PVCs on optimal biventricular pacing in CRT patients. Parameters such as smaller LV end diastolic diameter and shorter intrinsic
QRS
duration might help to distinguish
PVC-induced cardiomyopathy from PVC-aggravated cardiomyopathy.614 CMR should be considered for patients suspected to have
PVC-induced cardiomyopathy to exclude subtle forms of SHD.590,615
In a patient with frequent PVCs, the presence of LGE suggests SHD
with frequent PVCs rather than PVC-induced cardiomyopathy, in which LGE is mostly absent. Given that PVCs with a RBBB morphology have been reported to show a stronger association with LGE,616 those patients should be particularly considered for CMR.
The diagnosis of PVC-induced cardiomyopathy vs. PVC-aggravated cardiomyopathy can be conﬁrmed only after LVEF improvement/normalization (reverse remodelling) following suppression of the PVCs.
Catheter ablation of the PVCs is very efﬁcient, with reported success rates of 75–90%, and is considered ﬁrst-line treatment for
PVC-induced cardiomyopathy.535,600,609,610,612,617–620 Factors affecting acute ablation success and clinical outcome include the site of origin of PVCs (highest for outﬂow tract PVCs), the number of
PVC morphologies, and the absence of LGE on CMR.535,610,614 In patients with SHD, catheter ablation of frequent monomorphic PVCs has also been shown to improve LVEF in patients with both CAD and cardiomyopathies with and without CRT.609,617,621–623 Similarly, the use of anti-arrhythmic medications for PVC suppression has been shown to improve LVEF. In one RCT, amiodarone resulted in a better PVC suppression and a higher LVEF improvement compared to placebo.624 Sodium channel blockers can also effectively suppress
PVCs.625 In one study, ﬂecainide reduced the PVC burden from
36% to 10% and resulted in LVEF increase from 37% to 49%.626
Recommendation Table 26 — Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia
Recommendations
Classa
Levelb
General recommendations
Regular assessment of ventricular function of patients with PVC burden .10% and normal ventricular function is indicated.602,603
I
C
In patients with PVCs/VT and a presentation not typical for an idiopathic origin,c CMR should be considered,
despite a normal echocardiogram.195
IIa
C
Treatment
Catheter ablation as ﬁrst-line treatment is recommended for symptomatic idiopathic VT/
PVCs from the RVOT or the left fascicles.d,535,595,596,604
I
B
Beta-blockers or non-dihydropyridine CCBs are indicated in symptomatic patients with idiopathic
VT/PVCs from an origin other than the RVOT or the left fascicles.304,593
I
C
Beta-blockers, non-dihydropyridine CCBs, or
ﬂecainide should be considered when catheter ablation is not available, desired, or is particularly risky in symptomatic patients with idiopathic VT/
PVCs from the RVOT or the left fascicles.304,592,593
IIa
B
Catheter ablation or ﬂecainide should be considered in symptomatic patients with idiopathic VT/PVCs from an origin other than the
RVOT or the left fascicles.535,604,605
IIa
C
Catheter ablation may be considered for idiopathic VT/PVCs in asymptomatic patients with repeatedly more than 20% of PVCs per day at follow-up.535,600,601
IIb
B
Catheter ablation of idiopathic VT/PVCs is not recommended in children ,5 years of age or
,10 kg weight except when previous medical therapy fails or when VT is not haemodynamically tolerated.597
III
C
Amiodarone as a ﬁrst-line treatment is not recommended in patients with idiopathic VTs/
PVCs.594
III
C
Verapamil is not recommended in children ,1 year of age with PVC/VT, particularly if they have signs of heart failure or concurrent use of other AADs.606
III
C
© ESC 2022
AAD, anti-arrhythmic drug; CCB, calcium channel blocker; CMR, cardiac magnetic resonance; PVC, premature ventricular complex; RVOT, right ventricular outﬂow tract;
SMVT, sustained monomorphic ventricular tachycardia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cIncluding but not limited to older age, right bundle branch block (RBBB) morphology,
SMVT consistent with re-entry.
dLevel of evidence C for VT/PVCs from left fascicles.


<!-- PAGE 57 -->

### Page 57

While ﬂecainide have a more favourable adverse effect proﬁle regarding organ toxicity, increased mortality has previously been shown in patients with MI.556 For selected patients with suspected
PVC-induced cardiomyopathy and PVC-aggravated cardiomyopathy,
ﬂecainide can still be considered, particularly if an ICD is in place
(Table 9).
A rare monogenetic cause of PVC-induced cardiomyopathy, referred to as multifocal ectopic Purkinje-related premature contractions, has been reported. It is characterized by a DCM phenotype and the presence of numerous PVCs with RBBB and/or left bundle branch block (LBBB) morphologies and an increased risk of SCD.627
Pathogenic mutations in the SCN5A gene lead to a gain of function of the sodium channel responsible for hyperexcitability of the fascicular Purkinje system.627,628 Limited data suggest that patients with multifocal ectopic Purkinje-related premature contractions do not respond to beta-blockers but might beneﬁt from therapy with ﬂecainide, quinidine, or amiodarone.627–631
N
N
N
N
Patient with PVC-Burden >10% and mildly reduced or reduced LVEF
L
CMR
(Class IIa)
Suspected PVC induced cardiomyopathy
SHD aggravated a
by frequent PVC’s
Further evaluation according to most like k ly diagnosis
(suspicious) CAD,
valvular heart disease or inflammatory heart disease
LV dysfunction
L
explained by underlying heart disease
Known SHD
LGE
Follow-up
Y
Y
Y
Y
Amiodarone
(Class IIa)
Catheter ablation
(Class IIa)
Catheter ablation
(Class I)
AAD
(Class IIa)
Figure 18 Algorithm for the management of patients with premature ventricular complex-induced/-aggravated cardiomyopathy. AAD, anti-arrhythmic drug; CAD, coronary artery disease; CMR, cardiac magnetic resonance; LGE, late gadolinium enhancement; LV, left ventricular; LVEF, left ventricular ejection fraction; N, No; PVC, premature ventricular complex; SHD, structural heart disease; Y, Yes.
Recommendation Table 27 — Recommendations for the management of patients with premature ventricular complex-induced or premature ventricular complexaggravated cardiomyopathy
Recommendation
Classa
Levelb
Diagnostic evaluation
In patients with an unexplained reduced EF and a
PVC burden of at least 10%, PVC-induced cardiomyopathy should be considered.600,609,610
IIa
C
In patients with suspected PVC-induced cardiomyopathy, CMR should be considered.590,615
IIa
B
Treatment
In patients with a cardiomyopathy suspected to be caused by frequent and predominately monomorphic PVCs, catheter ablation is recommended.535,600,609,612,617,618,620
I
C
Continued
ESC Guidelines
4053


<!-- PAGE 58 -->

### Page 58

7.1.3. Cardiomyopathies
7.1.3.1. Dilated cardiomyopathy and hypokinetic non-dilated cardiomyopathy
DCM is characterized by LV dilatation and systolic dysfunction unexplained by CAD or abnormal loading conditions.632 The true prevalence is difﬁcult to estimate. Older studies reported a prevalence of 1
in 2700 individuals.633
Historic data in adults with DCM showed a 1-year mortality of
20–25% and a 50% survival at 5 years.634 Recent trials of DCM patients with systolic heart failure and OMT report 5-year mortality rates in the range of 21–28%.356,359 SCD occurs in up to 12% of patients with DCM and still accounts for 25–35% of all deaths.359,634,635
In children, the annual incidence of DCM is 0.57 cases per
100 000.636 The prognosis in children is poor, with a 5-year incidence of heart transplantation or heart failure-related death of 40%.
However, in contrast to adults, the incidence of SCD in paediatric
DCM patients is much lower, with a 5-year incidence of 2.4–3% as reported in two large paediatric cardiomyopathy registries from the United States and Australia.637,638
Causes of DCM can be genetic or acquired.639 Genetic predisposition may also interact with extrinsic factors such as in peri-partum, alcoholic,
or chemotherapy-related cardiomyopathies.639 The phenotype, particularly of genetic aetiologies, can change over time and/or may not meet standard disease criteria at the time of disease manifestation. As a consequence, a new category of a hypokinetic non-dilated cardiomyopathy (HNDCM) has been proposed.639
7.1.3.1.1. Diagnostic evaluation and risk stratiﬁcation. An algorithm for risk stratiﬁcation and primary prevention of SCD in patients with DCM/HNDCM is presented in Figure 19.
Careful diagnostic work-up, including genetic testing and CMR,
should be considered to identify the underlying cause for aetiology-oriented risk stratiﬁcation and treatment.341,639
Pathogenic mutations are identiﬁed in 25–55% of DCM patients,634,639,640 most often with autosomal dominant inheritance. Truncated mutations in the titin gene (TTN) are most frequently found, followed by LMNA, sarcomeric, and desmosomal mutations. Mutations in genes such as LMNA, PLN,
RBM20, and FLNC are associated with a higher risk of VA and
SCD.641–645 Carriers of desmosomal and LMNA variants experienced the highest rate of VA/SCD, which was independent of the
LVEF in one series.645
The yield of genetic testing is particularly high in DCM patients with familial forms of DCM or SCD in a ﬁrst-degree relative at younger age.
An inherited DCM is also more likely in patients who present at young age or with signs suspicious for a speciﬁc aetiology (e.g. prolonged AV
conduction for LMNA) (Figure 20).634,639,640,646 First-degree relatives of DCM/HNDCM patients should undergo clinical diagnostic evaluation, especially if an inherited cause is suspected.
Discrimination between high- and low-risk patients for SCD
remains challenging. Beyond LVEF and NYHA class,357,359,635,647–650
recent data suggest that both genetic and CMR ﬁndings can contribute to risk stratiﬁcation. A meta-analysis of 29 studies combining
2948 patients studied the role of CMR in patients with DCM.129
LGE was signiﬁcantly associated with the arrhythmic endpoint,
even when including only studies that performed multivariate analysis
(HR 6.7; P , 0.001). Interestingly, the association between LGE and the arrhythmic endpoint remained signiﬁcant among patients with mean LVEF .35%. Similarly, a recent study of 1020 consecutive patients with DCM and CMR observed that LGE and LVEF were both risk markers for all-cause mortality and cardiac death, but only LGE
was signiﬁcantly associated with SCD risk.651
SCD risk stratiﬁcation has been reﬁned in the subgroup of patients with LMNA mutations, which represent 5–10% of all DCM patients.
LMNA mutations are associated with early atrial and ventricular arrhythmias, premature conduction disease, a high risk of SCD, and progression to end-stage heart failure.80,642,652,653 In a multicentre registry of 269 LMNA mutation carriers, NSVT, LVEF ,45% at ﬁrst evaluation, male sex, and non-missense mutations were identiﬁed as independent risk factors for VA.652 VA occurred only in persons with at least two of these risk factors. The risk stratiﬁcation was subsequently externally validated.653 Another study, which involved 589
LMNA mutation carriers, identiﬁed AV block as an additional predictor. Recently a risk calculator has been developed (https://lmna-riskvta.fr/) to predict the risk of life-threatening VA (C-index of 0.776
[95% CI: 0.711–0.842]).80 In patients with a 5-year estimated risk
≥10% and a manifest cardiac phenotype (NSVT, LVEF , 50%, or
AV conduction delay), a primary prevention ICD implantation should be considered to avoid potential over-implantation in mutation carriers without a cardiac phenotype. In LMNA mutation carriers with a DCM
phenotype, high-intensity exercise has been associated with a high risk of SCD and impaired LVEF and is therefore not recommended.654,655
A risk score for VA prediction has been recently proposed for patients with DCM or ARVC related to the p.Arg14del mutation in the
PLN gene.656 Validation studies are needed before it can be recommended for clinical use.
Beyond genetics and CMR, additional SCD predictors have been suggested, often derived from small cohorts with no or few replication studies. An unexplained syncope requires further evaluation and
PES may determine the underlying cause. The risk for arrhythmic
In patients with a cardiomyopathy suspected to be caused by frequent and predominately monomorphic PVCs, treatment with AADsc should be considered if catheter ablation is not desired,
suspected to be high-risk, or unsuccessful.624,626
IIa
C
In patients with SHD in whom predominately monomorphic frequent PVCs are suspected to be contributing to the cardiomyopathy, AAD
(amiodarone) treatment or catheter ablation should be considered. 617,621,622,624
IIa
B
In non-responders to CRT with frequent,
predominately monomorphic PVCs limiting optimal biventricular pacing despite pharmacological therapy, catheter ablation or
AADs should be considered.623
IIa
C
© ESC 2022
AAD, anti-arrhythmic drug; CMR, cardiac magnetic resonance; CRT, cardiac resynchronization therapy; EF, ejection fraction; ICD, implantable cardioverter deﬁbrillator; LV, left ventricular; PVC, premature ventricular complex; SHD,
structural heart disease.
aClass of recommendation.
bLevel of evidence.
cFlecainide only in selected patients (ICD recipients, only moderate LV dysfunction).


<!-- PAGE 59 -->

### Page 59

events in DCM patients with a low LVEF and an unexplained syncope was similar to those with prior CA657 and high, independent from the outcome of PES.148 However, data in DCM patients with a mildly reduced EF suggest an incremental value of PES. Among DCM patients with an EF ≥40% and an unexplained syncope, who underwent
ICD implantation after a positive PES, 80% had appropriate ICD
therapy during follow-up. No SCD or symptomatic VA occurred in non-inducible patients.146
7.1.3.1.2. Primary prevention of sudden cardiac death. In patients with DCM/HNDCM, OMT according to current 2021 ESC
Guidelines for the diagnosis and treatment of acute and chronic heart failure is mandatory.342 Re-evaluation of cardiac function and clinical status after 3 months’ OMT is required before primary prevention ICD implantation. LV function is more likely to improve in
DCM caused by myocarditis or TTN mutations.
The efﬁcacy of primary prevention ICDs in DCM patients with
HFrEF has been addressed in six RCTs.635
Five studies were published between 2002 and 2005 (CAT,
AMIOVIRT, DEFINITE, COMPANION, and SCD-HeFT). The
ﬁrst three were smaller studies enrolling only DCM patients,
whereas
SCD-HeFT
and
COMPANION
were larger and
Patient with DCM/HNDCM
Suspicious of cause requiring specific treatment
Family history of DCM/HNDCM or 
family history of SCD (<50 y, first-degree relative) or 
AV block <50 y
5-year risk ofVA ≥10% 
and LVEF <50%
or NSVT
or AV conduction delay
Pathogenic 
mutation LMNA
ICD implantation
(Class IIa)
ICD implantation
(Class IIa)
ICD implantation
(Class IIa)
ICD implantation
(Class IIa)
Genetic testing
(Class IIa)
(Class I)
Go to specific sections for specific aetiology-directed management,
especially for inflammatory diseases
CMR (Class IIa)
Annual reevaluation
LVEF
≥2 risk factorsa
SMVT inducible
PES (Class IIa)
ILRb (Class I)
Follow-up
Unexplained syncope
Y
Y
Y
Y
Y
Y
N
N
N
N
N
N
≤35%
36–50%
Figure 19 Algorithm for risk stratiﬁcation and primary prevention of sudden cardiac death in patients with dilated cardiomyopathy/hypokinetic nondilated cardiomyopathy. AV, atrioventricular; CMR, cardiac magnetic resonance; DCM, dilated cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; LMNA: lamin A/C gene; LVEF, left ventricular ejection fraction;
N, No; NSVT, non-sustained ventricular tachycardia; PES, programmed electrical stimulation; SCD, sudden cardiac death; SMVT, sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmias; Y, Yes. aRisk factors: unexplained syncope, pathogenic variants in PLN, FLNC, or RBM20, LGE on
CMR, inducible SMVT at PES. bThe 2018 ESC Guidelines for the diagnosis and management of syncope.1
ESC Guidelines
4055


<!-- PAGE 60 -->

### Page 60

included patients with CAD and DCM. The COMPANION study differed from the others as it compared CRT-deﬁbrillator,
CRT-pacemaker, and OMT. A meta-analysis of the ﬁve trials
(1854 patients with DCM) demonstrated a 31% reduction in allcause mortality with ICD relative to medical therapy (RR 0.69
[95% CI 0.55, 0.87], P , 0.002).658 This effect persisted when
COMPANION was excluded.
More recently, the DANISH trial enrolled 1116 symptomatic patients
(NYHA class II or III) with non-ischaemic systolic heart failure (LVEF ≤
35%). Patients were randomized to ICD or no ICD after OMT.359 No reduction in the primary endpoint of all-cause death for patients randomized to ICD therapy (HR 0.87; 95% CI 0.68–1.12; P = 0.28)
was observed, despite a signiﬁcant reduction in SCD in the ICD group
(HR 0.50; 95% CI 0.31–0.82; P = 0.005). Potential explanations are the low SCD rate in the trial (4.3% in the ICD group and 8.2% in the control group), the excellent medical treatment (.90% of patients on ACE inhibitors and beta-blockers, .50% on MRA), and the high prevalence
(58%) of CRT. A meta-analysis of all six primary prevention trials still demonstrated a reduction, although lower, in overall mortality with ICD
therapy (RR 0.76; 95% CI 0.65–0.91; P= 0.002).635 In a sensitivity analysis, the beneﬁt of ICD therapy was maintained after the removal of any single study from the pooled analysis.
ECG sinus rhythm – Small amplitude P waves and first degree AV block
ECG VT – RBBB-like, inferior axis (LV summit origin)
CMR – Mid-wall septal LGE
4-chamber
Short axis
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
Figure 20 Typical features of dilated cardiomyopathy associated with lamin A/C gene mutation with ventricular arrhythmias. AV, atrioventricular; CMR,
cardiac magnetic resonance; ECG, electrocardiogram; LGE, late gadolinium enhancement; LV, left ventricle; RBBB, right bundle branch block; VT, ventricular tachycardia.


<!-- PAGE 61 -->

### Page 61

The results of the DANISH trial emphasize the need for further reﬁning the indication for primary prevention ICDs in contemporary DCM patients. Age and comorbidity need to be considered.635
In the DANISH trial, ICD implantation was associated with a signiﬁcantly lower rate of death in younger patients.359 A further analysis of the DANISH data647 showed an association between reduced all-cause mortality and ICDs in patients ≤70 years of age (HR,
0.70; 95% CI 0.51–0.96; P = 0.03), but not in patients .70 years of age.
Prospective studies evaluating the beneﬁt of ICDs in DCM/
HNDCM patients with intermediate LV dysfunction, but with risk factors that have been associated with VA and SCD (including
LGE on CMR, pathogenic mutations in PLN, FLNC, RBM20, unexplained syncope,
and inducibility of
SMVT),
are lacking.129,641,643,644,659–662 Given the limitation of LVEF as the only risk marker in DCM/HNDCM, this panel of experts shares the opinion that in the presence of a combination of risk markers an
ICD should be considered.
7.1.3.1.3. Secondary prevention of sudden cardiac death and management of ventricular arrhythmias. Three randomized trials
(AVID, CASH, and CIDS) have compared ICD therapy and medical treatment for secondary prevention in patients after aborted CA or not-tolerated VT.349,351,352 The three trials enrolled a total of 1963
patients, of whom only 292 (14.8%) had non-ischaemic aetiologies. A
signiﬁcant reduction in death from any cause in patients with ICDs was demonstrated, which was almost entirely due to a 50% reduction in arrhythmic death.352 In the subgroup of patients with cardiomyopathies there was a similar but non-signiﬁcant trend in the reduction of death.352 RCTs have excluded patients with haemodynamically tolerated VT. In DCM patients the VT substrate is less well deﬁned, and disease progression needs to be considered.
Therefore, despite the lack of data, this panel of experts shares the opinion that an ICD should also be considered in DCM patients with haemodynamically tolerated VT.
Optimization of ICD programming (see Section 6.2.3.1) can reduce ICD shocks delivered in response to VT, but additional therapy to reduce symptomatic VA episodes is often required. In the OPTIC
trial, 412 patients with ICD implantation within 21 days of VT/VF
were randomized to amiodarone plus beta-blockers, sotalol alone,
or beta-blocker alone. ICD shock rates after one year were 10.3%,
24.3%, and 38.5%, respectively. The higher efﬁcacy of amiodarone plus beta-blockers compared to sotalol needs to be weighed against the higher rate of medication-related adverse events on an individual basis.318 Although only limited data are available, sodium channel blockers may control VT in SHD and may be beneﬁcial in ICD recipients without advanced heart failure. The majority of SMVT is due to scar-related re-entry, which can be targeted by catheter ablation.
Acute ablation outcome has been reported to be similar for CAD
and DCM.497,663 However, VT recurrence rates are usually higher in DCM patients (VT-free survival 40.5% in DCM vs. 57% in CAD
at 1 year).497 After multiple procedures in 36% of the patients, longterm freedom of VT could be achieved in 69% of cases in a retrospective, single-centre cohort of 282 patients treated between
1999 and 2014.664
Epicardial ablation is needed in 27–30% of the procedures.497,664
Outcome is particularly poor, and bailout strategies (transcoronary ethanol ablation, bipolar ablation, surgical ablation) may be required in patients with pathogenic mutations (LMNA gene) and in those with deep intramural, anteroseptal substrate locations.499,665,666 Considering the complexity of the ablation procedure, DCM patients should therefore be treated only in specialized centres.
Recommendation Table 28 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy
Recommendation
Classa
Levelb
Diagnostic evaluation and general recommendations
Genetic testing (including at least LMNA, PLN,
RBM20, and FLNC genes) is recommended in patients with DCM/HNDCM and AV conduction delay at ,50 years, or who have a family history of
DCM/HNDCM or SCD in a ﬁrst-degree relative
(at age ,50 years).641–645
I
B
CMR with LGE should be considered in DCM/
HNDCM patients for assessing the aetiology and the risk of VA/SCD.129,651,667
IIa
B
Genetic testing (including at least LMNA, PLN,
RBM20, and FLNC genes) should be considered for risk stratiﬁcation in patients with apparently sporadic DCM/HNDCM, who present at young age, or with signs suspicious for an inherited aetiology.641–645
IIa
C
Participation in high-intensity exercise including competitive sports is not recommended for individuals with DCM/HNDCM and a LMNA
mutation.655
III
C
Risk stratiﬁcation and primary prevention of SCD
ICD implantation should be considered in patients with DCM/HNDCM, symptomatic heart failure
(NYHA class II–III), and LVEF ≤35% after ≥3
months of OMT.357,359,635,650
IIa
A
ICD implantation should be considered in DCM/
HNDCM patients with a pathogenic mutation in
LMNA gene, if the estimated 5-year risk of life-threatening VA is ≥10%c and in the presence of NSVT or LVEF , 50% or AV conduction delay.80,652,653
IIa
B
ICD implantation should be considered in DCM/
HNDCM patients with a LVEF ,50% and ≥2 risk factors (syncope, LGE on CMR, inducible SMVT at
PES, pathogenic mutations in LMNA,d PLN, FLNC,
and RBM20 genes).
IIa
C
In DCM/HNDM patients, electrophysiological evaluation should be considered when syncope remains unexplained after non-invasive evaluation.661,668
IIa
C
Continued
ESC Guidelines
4057


<!-- PAGE 62 -->

### Page 62

7.1.3.2. Arrhythmogenic right ventricular cardiomyopathy
ARVC is an inherited disease characterized by ﬁbrofatty myocardial replacement.670 The prevalence ranges from 1:1000 to 1:5000 individuals, with male predominance among probands.671 Patients with
SCD/VF at ﬁrst presentation are typically younger (median age 23
[range 13–57]) compared to those who present with a SMVT
(median age 36 years [range 14–78]).672
ARVC is caused by pathogenic mutations in desmosomal genes and less commonly in non-desmosomal genes. Genetic testing is indicated and identiﬁcation of a mutation (in up to 73% of probands) is a major criterion for the diagnosis.116,671 In 4–16% compound/
digenic mutations are found, which have been associated with an increased risk of VA at younger age.672,673 The disease penetrance in
ﬁrst-degree relatives is 28–58%,674,675 supporting regular clinical evaluation of relatives.
ARVC is characterized by a predominant RV involvement. The
2010 revised international diagnostic task force criteria are based on a multiparametric strategy116 (Figure 21). Tissue characterization by CMR was not included. However, RV fatty inﬁltration and LV LGE
are frequently observed (in 29–53% and 35.5–45% of probands, respectively) and may be present before patients meet major task force imaging criteria.676–678 Both wall motion alterations and pre-/
post-contrast signal abnormalities have been suggested to enhance the diagnostic accuracy of CMR for ARVC.679 The identiﬁcation of biventricular and left-dominant involvement in ARVC
patients680,681 has recently led to the proposed term ‘arrhythmogenic cardiomyopathy’.682
Restriction from high-intensity exercise is regarded as a preventive tool in clinically affected ARVC patients to reduce the risk of VAs and disease progression.683–685 Whether sport restriction is beneﬁcial in all mutation carriers without disease expression has not been evaluated in prospective cohorts, but avoidance of competitive, highintensity exercise seems to be reasonable.686,687 SCD and VA occur disproportionately during exercise in affected patients,
and high-dose isoproterenol infusion may provoke PVT in .90% of
ARVC patients, supporting the role of sympathetic stimulation for arrhythmogeneity.152,688,689 Whether beta-blockers can prevent spontaneous VA is, however, unclear. Limited data suggest a potential beneﬁcial role of atenolol.690
7.1.3.2.1. Risk stratiﬁcation. In ARVC patients not implanted with
ICDs, CA occurs in 4.6–6.1%, while 23% of patients experience a non-fatal SMVT during an average follow-up of 8–11 years.691–694
Whether a SMVT is acutely life-threatening depends on the VT cycle length, cardiac function, and the circumstances under which VT occurs. Among deﬁnite/probable ARVC patients considered at high risk for VA, 23–48% will experience appropriate ICD intervention during a mean follow-up of 4.7 years. In 16–19% of cases, ICD intervention is triggered by fast VT ≥250 b.p.m. or VF, which is considered as surrogate for a life-threatening event.695–698 In a large cohort of 864
ARVC patients (38.8% with a prior VA), 43% had VT/VF during a median follow-up of 5.75 years, but only 10.8% a potentially lifethreatening event. Thus, in 3 out of 4 ARVC patients, ICD therapy is appropriate but may not be considered acutely life-saving. This is relevant because risk prediction algorithms and models are based on combined arrhythmic endpoints, which are often equated with
ICD indications to prevent SCD. This is particularly important for the young ARVC patients with a lifetime risk of ICD-related complications.695,699
Randomized studies of ICD therapy for secondary prevention are lacking, but the high rates of appropriate ICD therapy triggered by fast VT/VF episodes in patients implanted after CA or haemodynamically poorly tolerated VT strongly suggest a survival beneﬁt from
ICD.700 In patients who present with a haemodynamically tolerated
VT, the survival beneﬁt from ICD is less clear.691,700–702 Identiﬁcation of ARVC patients at risk for SCD is difﬁcult, and the evidence supporting risk factors for life-threatening VAs is limited. Arrhythmic syncope was a predictor for subsequent events in most series of patients with deﬁnitive
ARVC
(pooled
HR
3.67;
CI
2.75–
4.9)81,696,701,703 and, in these patients, an ICD should be considered.
RV and LV dysfunction have been associated with a higher arrhythmic risk.675,704 Cut-off values are difﬁcult to determine but, in
Secondary prevention of SCD and treatment of VAs
ICD implantation is recommended in patients with DCM/HNDCM, who survive SCA due to VT/
VF or experience haemodynamically not-tolerated SMVT.349,351,352
I
B
Catheter ablation in specialized centres should be considered in patients with DCM/HNDCM and recurrent, symptomatic SMVT or ICD shocks for
SMVT, in whom AADs are ineffective,
contraindicated, or not tolerated.481,497,664,669
IIa
C
The addition of oral amiodarone or replacement of beta-blockers by sotalol should be considered in patients with DCM/HNDCM and an ICD who experience recurrent, symptomatic VA despite optimal device programming and beta-blocker treatment.318
IIa
B
ICD implantation should be considered in patients with DCM/HNDCM and haemodynamically tolerated SMVT.
IIa
C
Management of relatives of a patient or SCD victim with
DCM/HNDCM
In a ﬁrst-degree relative of a DCM/HNDCM
patient, an ECG and an echocardiogram are recommended if:
•theindexpatientwasdiagnosed,50yearsofageor hasclinicalfeaturessuggestiveofaninheritedcause,or
• there is family history of DCM/HNDCM, or premature unexpected SD.646
I
C
In a ﬁrst-degree relative of a patient with apparently sporadic DCM/HNDCM, an ECG and an echocardiogram may be considered.646
IIb
C
© ESC 2022
AAD, anti-arrhythmic drug; AV, atrioventricular; CMR, cardiac magnetic resonance; DCM,
dilated cardiomyopathy; ECG, electrocardiogram; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OMT, optimal medical therapy; PES,
programmed electrical stimulation; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SMVT, sustained monomorphic ventricular tachycardia; VA,
ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cBased on the risk calculator https://lmna-risk-vta.fr/
dSee speciﬁc recommendations for LMNA.


<!-- PAGE 63 -->

### Page 63

patients with severe RV dysfunction (RV fractional area change ≤17%
or RV ejection fraction ≤35%), an ICD should be considered.
Likewise, ARVC patients with signiﬁcant LV involvement (LVEF
≤35%) should be treated according to the current DCM recommendation regarding ICD implantation. There are conﬂicting data on the independent predictive value of NSVT for subsequent sustained arrhythmic events.695,696,701 Likewise, the role of PES in risk stratiﬁcation, particularly in asymptomatic patients, is not well deﬁned.695,696,705 In one series including mainly symptomatic patients,
both NSVT and a positive PES independently predicted arrhythmic events, while others report a low diagnostic accuracy.696 Risk prediction based on a single parameter does not consider the potential combined effect and interactions between factors. Therefore,
although supporting data are lacking, this panel of experts supports that an ICD should be considered706 in symptomatic ARVC patients with moderate RV (,40%) and/or LV dysfunction (,45%) and who have either NSVT or have SMVT inducible at PES. An internally validated risk model has recently been developed from 528 patients with deﬁnite ARVC and no prior VA, including age, sex, arrhythmic syncope, NSVT, PVC burden, leads with T-wave inversion and RV
ejection fraction, to predict any sustained VA (c-index 0.77).81 In addition, a prediction model for speciﬁcally life-threatening VA has been promoted based on 864 ARVC patients, with predictors including male sex, age, 24 h PVC count, and leads with T-wave inversion
(c-index 0.74).702 However, validation studies are needed before these risk models can be recommended for clinical use.
ECG sinus rhythm – Negative T wavesV1-V4, terminal QRS duration >55 ms
ECG VT – LBBB-like, superior axis (basal RV origin)
CMR – Dilated RV with basal aneurysm
4-chamber
3-chamber
Short axis
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
Figure 21 Typical features of arrhythmogenic right ventricular cardiomyopathy associated with ventricular arrhythmias. CMR, cardiac magnetic resonance; ECG, electrocardiogram; LBBB, left bundle branch block; RV, right ventricle; VT, ventricular tachycardia.
ESC Guidelines
4059


<!-- PAGE 64 -->

### Page 64

7.1.3.2.2. Treatment. Up to 97.4% of all VA episodes in ARVC ICD
recipients are SMVT. The very high termination rate by ATP (92% of all episodes) independent from VT cycle length strongly supports devices with the capability for ATP.698 S-ICDs reduce lead-related complications and have been proven to effectively shock terminate
VA
in small cohorts of ARVC
patients during short-term follow-up.707
Additional treatment to supress VA is often required. Although not conﬁrmed by clinical data, beta-blockers are recommended as
ﬁrst-line therapy in symptomatic patients.
Data on AADs to prevent VT recurrence are limited to small observational studies and registries. In general, AAD therapy has limited efﬁcacy. Although sotalol was effective to prevent inducibility of
VT,708 it did not supress clinically relevant arrhythmias.690,708
Treatment with amiodarone or class 1 drugs was associated with a trend to lower VT recurrence as compared with sotalol.709 The addition of ﬂecainide to beta-blockers/sotalol was beneﬁcial in a small cohort.710 Catheter ablation provides an alternative. Endocardial and adjuvant epicardial substrate ablation, if needed, has been associated with promising VT-free survival. Potential procedural risks, drug side effects, and the patient’s preference need to be taken into consideration.482
7.1.3.3. Hypertrophic cardiomyopathy
HCM is characterized by increased LV wall thickness not explained by abnormal loading conditions (such as hypertension or valvular disease).128,715 Because the natural history and management differs according to the underlying aetiology of LVH, diagnostic work-up is of paramount importance (see Section 7.1.3.5) and includes CMR and genetic testing.716–725 HCM is usually caused by a mutation with autosomal dominant inheritance, supporting cardiac screening in
ﬁrst-degree relatives, in parallel with genetic testing in the index patient. A sarcomeric gene mutation is identiﬁed in 30–60%, most frequently in patients who are younger at diagnosis or with a family history of HCM.646,722
The estimated prevalence of HCM in adults is 1 in 500.726 In children, the prevalence is much lower.
Recommendation Table 29 — Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy
Recommendations
Classa
Levelb
Diagnostic evaluation and general recommendations
In patients with suspected ARVC, CMR is recommended.676–678
I
B
In patients with a suspected or deﬁnite diagnosis of ARVC, genetic counselling and testing are recommended.672,673
I
B
Avoidance of high-intensity exercise is recommended in patients with a deﬁnite diagnosis of ARVC.683–685
I
B
Avoidance of high-intensityc exercise may be considered in carriers of ARVC-related pathogenic mutations and no phenotype.683,687
IIb
C
Beta-blocker therapy may be considered in all patients with a deﬁnite diagnosis of ARVC.
IIb
C
Risk stratiﬁcation and primary prevention of SCD
ICD implantation should be considered in patients with deﬁnite ARVC and an arrhythmic syncope.696,701,711–713
IIa
B
ICD implantation should be considered in patients with deﬁnite ARVC and severe RV or LV systolic dysfunction.675,691
IIa
C
ICD implantation should be considered in symptomaticd patients with deﬁnite ARVC,
moderate right or left ventricular dysfunction, and
IIa
C
Continued either NSVT or inducibility of SMVT at
PES.695,696,701,703,705
In patients with ARVC and symptoms highly suspicious for VA, PES may be considered for risk stratiﬁcation.695,705
IIb
C
Secondary prevention of SCD and treatment of VAs
ICD implantation is recommended in ARVC
patients with haemodynamically not-tolerated VT
or VF.700
I
C
In patients with ARVC and non-sustained or sustained VAs, beta-blocker therapy is recommended.
I
C
In patients with ARVC and recurrent,
symptomatic SMVT or ICD shocks for SMVT
despite beta-blockers, catheter ablation in specialized centres should be considered.482,709,714
IIa
C
In ARVC patients with indication for ICDs, a device with the capability of ATP programming for
SMVT up to high rates should be considered.698
IIa
B
ICD implantation should be considered in ARVC
patients with a haemodynamically tolerated
SMVT.692
IIa
C
In patients with ARVC and recurrent,
symptomatic VT despite beta-blockers, AAD
treatment should be considered.709,710
IIa
C
Management of relatives of a patient with ARVC
In a ﬁrst-degree relative of a patient with ARVC,
ECG and echocardiogram are recommended.675
I
C
© ESC 2022
AAD, anti-arrhythmic drug; ARVC, arrhythmogenic right ventricular cardiomyopathy;
ATP,
anti-tachycardia pacing;
CMR,
cardiac magnetic resonance;
ECG,
electrocardiogram; ICD, implantable cardioverter deﬁbrillator; LV, left ventricle;
NSVT, non-sustained ventricular tachycardia; PES, programmed electrical stimulation;
RV, right ventricle; SCD, sudden cardiac death; SMVT, sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cThe 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease.4
dPresyncope or palpitations suggestive of VA.


<!-- PAGE 65 -->

### Page 65

Annual mortality related to HCM is 1–2% in most studies with contemporary management strategies,128,715 and may be as low as 0.5%.727 The annual rate of SCD or appropriate ICD therapy is about 0.8% but is largely dependent on age and risk proﬁle.85,728–730 HCM patients are at risk for heart failure, AF, and stroke.128,715 Most HCM-related deaths at age ≤60 years occur suddenly, while older patients die more often of stroke or heart failure.731 SCD is often related to VA, which can be a consequence of ischaemia, left ventricle outﬂow tract (LVOT) obstruction, or supraventricular arrhythmias. SCD may also be triggered by exercise, and participation in competitive sport has been discouraged.732 However, recent data suggest that even vigorous exercise in HCM patients without risk markers may not be associated with VA.733,734
7.1.3.3.1. Risk stratiﬁcation and primary prevention of sudden cardiac death. In primary prevention, the challenge remains to identify the relatively small group of patients with the highest risk of SCD.
NSVT is identiﬁed on continuous (24/48h) ambulatory ECG monitoring in 20–25% of patients.128,715 Its prevalence increases with age and correlates with LV wall thickness and LGE on CMR.716–721,735
The prognostic value of NSVT for SCD is more important in young patients (,30 years).735 The relation between the duration, frequency, or rate of NSVT and HCM prognosis remains unclear.735
ECG sinus rhythm – Negative T wavesV2-V6 and inferior leads
ECG VT – RBBB-like, superior axis (apical LV origin)
CMR – Apical aneurysm with LGE
4-chamber
2-chamber
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
Figure 22 Typical features of hypertrophic cardiomyopathy associated with sustained monomorphic ventricular tachycardia. CMR, cardiac magnetic resonance; ECG, electrocardiogram; LGE, late gadolinium enhancement; LV, left ventricular; RBBB, right bundle branch block; VT,
ventricular tachycardia.
ESC Guidelines
4061


<!-- PAGE 66 -->

### Page 66

Documented NSVT during exercise test is very rare, but was associated with a higher risk of SCD.732 Additional risk factors have been identiﬁed and a 5-year SCD risk stratiﬁcation score based on seven factors (age, LV wall thickness, LA size, LVOT gradient, NSVT, unexplained syncope, and family history of SCD) has been developed85
(HCM Risk-SCD: https://doc2do.com/hcm/webHCM.html) and externally validated.85,728,729 The calculator is not intended for use in elite athletes, or in individuals with metabolic or inﬁltrative diseases,
or after myectomy or alcohol septal ablation.85
Additional factors not captured by the Risk-SCD model should also be considered in patients with intermediate or low calculated risk, including LV systolic dysfunction, apical aneurysm, extensive
LGE on CMR, and presence of single or multiple sarcomeric mutations (Figure 22).716,717,722,736–739 Extensive LGE on CMR deﬁned as ≥15% of LV mass has been suggested as good predictor of
SCD in adults. However, thresholds may be difﬁcult to use because
LGE quantiﬁcation is dependent on CMR acquisition, type, and amount of contrast.
Periodic reassessment is mandatory as part of the longitudinal evaluation of patients. VA induced by PES is considered non-speciﬁc,
although conﬂicting results have been reported.740,741
In children few data on primary prevention were available until the recent development of scores and related risk calculators.83,84 The
HCM Risk-Kids score84 has been developed and externally validated742 speciﬁcally in children with HCM (1–16 years of age) and includes unexplained syncope, maximal LV wall thickness, large left atrial diameter, low LVOT gradient, and NSVT (https://hcmriskkids.
org). In contrast to adults, including age and family history of SCD
did not improve the performance of the paediatric model. Patients with prior VF or sustained VT, known inborn errors of metabolism,
and syndromic causes of HCM were excluded. The predictive value of LGE in children is less deﬁned, although preliminary data were reported.743
7.1.3.3.2. Treatment to prevent ventricular arrhythmia recurrence. Patients surviving a CA due to VT/VF or haemodynamically not-tolerated VT remain at high risk for future life-threatening VA,
and will beneﬁt from ICD therapy.128,744–746
There are no RCTs in HCM or cohort studies supporting a signiﬁcant role of drugs to prevent SCD.128,715,747 Amiodarone may reduce VA but with conﬂicting results regarding SCD prevention.747,748 Disopyramide and beta-blockers are efﬁcient to control symptoms and LVOT obstruction, but there is no evidence that they reduce the risk of SCD.128,715 Similarly, surgical myectomy or alcohol ablation are not recommended with the aim to reduce risk of SCD in patients with LVOT obstruction.128,715 Following ICD implantation for primary or secondary prevention, the most common documented VA subtype is SMVT, and ATP is successful in 69–76.5%
of all episodes.749–751 Although data on drug efﬁcacy are lacking,
AADs (beta-blockers, amiodarone, sotalol, sodium channel blockers)
should be considered in HCM patients with symptomatic VA.
Catheter ablation may also be considered in highly selected HCM patients with SMVT, in whom AADs are ineffective, contraindicated or not tolerated, as outcome after ablation is inferior compared to other non-ischaemic aetiologies.752–754
Recommendation Table 30 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention,
and treatment of ventricular arrhythmias in hypertropic cardiomyopathy
Recommendation
Classa
Levelb
Diagnostic evaluation and general recommendations
CMR with LGE is recommended in HCM patients for diagnostic work-up.716–718
I
B
Genetic counselling and testing are recommended in HCM patients.721–725
I
B
Participation in high-intensity exercise may be considered for asymptomatic adult HCM patients without risk markers.733
IIb
C
Risk stratiﬁcation and primary prevention of SCD
It is recommended that the 5-year risk of SCD is assessed at ﬁrst evaluation and at 1–3-year intervals, or when there is a change in clinical status.
I
C
ICD implantation should be considered in patients aged 16 years or more with an estimated 5-year risk of SD ≥6%.c,85,728,729
IIa
B
ICD implantation should be considered in HCM
patients aged 16 years or more with an intermediate 5-year risk of SCD (≥4 to ,6%)c and with (a) signiﬁcant LGE at CMR (usually ≥15%
of LV mass); or (b) LVEF , 50%; or (c) abnormal blood pressure response during exercise testd; or
(d) LV apical aneurysm; or (e) presence of sarcomeric pathogenic mutation.716,717,722,736–739
IIa
B
In children less than 16 years of age with HCM and an estimated 5-year risk of SD ≥6% (based on
HCM Risk-Kids scoree), ICD implantation should be considered.84,742
IIa
B
ICD implantation may be considered in HCM
patients aged 16 years or more with an estimated
5-year risk of SCD of ≥4 to ,6%.c,85,728,729
IIb
B
ICD implantation may be considered in HCM
patients aged 16 years or more with a low estimated 5-year risk of SCD (,4%)c and with (a)
signiﬁcant LGE at CMR (usually ≥15% of LV mass);
or (b) LVEF , 50%; or (c) LV apical aneurysm.716,717,722,736–739
IIb
B
Secondary prevention of SCD and treatment of VAs
ICD implantation is recommended in HCM
patients with haemodynamically not-tolerated VT
or VF.744–746
I
B
In patients with HCM presenting with haemodynamically tolerated SMVT, ICD
implantation should be considered.
IIa
C
In patients with HCM and recurrent, symptomatic
VA, or recurrent ICD therapy, AAD treatment should be considered.
IIa
C
Continued


<!-- PAGE 67 -->

### Page 67

7.1.3.4. Left ventricular non-compaction
LVNC comprises a heterogeneous group of diseases. The diagnosis is challenging, and various diagnostic criteria have been proposed. The yield of genetic tests in index patients is low.755
The morphological phenotype of non-compaction based on imaging parameters may also appear in a healthy population.756
A meta-analysis including 2501 LVNC patients revealed a risk of cardiovascular mortality similar to that of DCM patients, with no relation to the extent of trabeculation.757 CMR-based detection of focal ﬁbrosis using LGE in LVNC with preserved ejection was associated with serious cardiac events (aborted death, ICD therapy,
heart transplantation [HTX]/LVAD) in another meta-analysis including 574 patients (OR 6.1; CI 2.1–17.5; P , 0.001).758 A combination of CMR criteria with systematic genotyping may overcome current uncertainties regarding risk stratiﬁcation.759
7.1.3.5. Restrictive cardiomyopathy
The phenotype of restrictive cardiomyopathy (RCM) is rare and can be the consequence of different aetiologies, including inﬁltrative disorders (e.g. amyloidosis) and storage disease (e.g. Andersen–Fabry disease), the identiﬁcation of which is crucial for guiding therapy.
Heart failure is one of the leading symptoms in primary and secondary RCM.760
In Fabry disease the majority of the reported cardiovascular deaths have been categorized as SCD in a recent systematic review of 13 studies including 4185 patients.761 Higher age, male gender,
LVH, LGE, and NSVT have been identiﬁed as potential risk factors associated with SCD events. However, SCD rates were reported in only 11 of the studies, including 623 patients. The retrospective,
observational nature of most of these small, single-centre studies and the low absolute number of cardiovascular deaths (36/623)
and SCD (30/623) do not currently allow guidance for primary prevention ICD implantation.761
Amyloidosis can be caused by different misfolded precursor proteins leading to deposits in tissue and organs. Cardiac amyloidosis is mainly related to light-chain amyloid or transthyretin amyloid. The latter can be subdivided into wild-type, also called senile amyloid,
more often complicated by AV conduction delay and atrial arrhythmias, and amyloid due to pathogenic mutations in the TTR gene.
Disease manifestation depends on the mutation. Despite advances in the treatment of amyloid light-chain amyloidosis, outcome is still poor in patients with manifest cardiac involvement.762 Causes of death are progressive heart failure, autonomic dysfunction, and electromechanical dissociation.762,763 The beneﬁt of primary prevention ICD implantation in patients with cardiac amyloidosis is uncertain. Currently, an ICD should be considered in patients with haemodynamically not-tolerated VT after careful discussion of the competing risks of non-arrhythmic death and non-cardiac death.
7.1.3.6. Neuromuscular disorders
An algorithm for risk stratiﬁcation, SCD prevention, and treatment of VAs in myotonic dystrophy is presented in Figure 23.
Arrhythmias are common and often the ﬁrst manifestation of neuromuscular disorders.764 Myotonic dystrophy is the most common muscular dystrophy in the adult population (prevalence 1 in 8000).
Myotonic dystrophy is the consequence of trinucleotide repeat expansion in the end of DMPK gene, which results in mis-splicing of SCN5A
and cardiac conduction system delays and arrhythmia. Duchenne dystrophy also has a high incidence (1 in 3500 male births). As most patients die before the age of 20, it is rarely seen in adulthood. Other neuromuscular disorders, such as Becker (1 in 100000 male births)
and facioscapulohumeral (1 in 100000) dystrophies, are less common.
Most of these disorders are associated with conduction and rhythm
Catheter ablation in specialized centres may be considered in selected patients with HCM and recurrent, symptomatic SMVT or ICD shocks for
SMVT, in whom AAD are ineffective,
contraindicated, or not tolerated.753,754
IIb
C
Management of relatives of a patient with HCM
In a ﬁrst-degree relative of a patient with HCM,
ECG and echocardiogram are recommended.
I
C
© ESC 2022
AAD,
anti-arrhythmic drug;
CMR,
cardiac magnetic resonance;
ECG,
electrocardiogram;
HCM,
hypertrophic cardiomyopathy;
ICD,
implantable cardioverter deﬁbrillator; LGE, late gadolinium enhancement; LV, left ventricle; LVEF,
left ventricular ejection fraction; SCD, sudden cardiac death; SD, sudden death;
SMVT, sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmia;
VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cBased on the HCM Risk-SCD: https://doc2do.com/hcm/webHCM.html dDeﬁned as a failure to increase systolic pressure by at least 20 mmHg from rest to peak exercise, or a fall of .20 mmHg from peak pressure.
eBased on the HCM kid risk score: https://hcmriskkids.org
Recommendation Table 31 — Recommendations for implantable cardioverter deﬁbrillator implantation in left ventricular non-compaction
Recommendations
Classa
Levelb
In patients with a LVNC cardiomyopathy phenotype based on CMR or echocardiography,
implantation of an ICD for primary prevention of
SCD should be considered to follow DCM/
HNDCM recommendations.
IIa
C
© ESC 2022
CMR,
cardiac magnetic resonance;
DCM,
dilated cardiomyopathy;
HNDCM,
hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator;
LVNC, left ventricular non-compaction; SCD, sudden cardiac death.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 32 — Recommendations for implantable cardioverter deﬁbrillator implantation in patients with cardiac amyloidosis
Recommendations
Classa
Levelb
An ICD should be considered in patients with light-chain amyloidosis or transthyretin-associated cardiac amyloidosis and haemodynamically not-tolerated VT.
IIa
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4063


<!-- PAGE 68 -->

### Page 68

disturbances, some life-threatening, and with mechanisms amenable to speciﬁc anti-arrhythmic therapy.17 Anti-arrhythmic therapy should be considered, as muscular function and life expectancy are often only moderately limited.765 It is generally recommended to treat patients with neuromuscular diseases who have survived a CA or have VAs or ventricular dysfunction in the same way as patients without extracardiac manifestations. However, the beneﬁt of ICD implantation should be balanced with the overall prognosis in some subtypes,
such as Duchenne dystrophy.
Symptoms may be the result of bradycardia or tachyarrhythmias and invasive electrophysiological evaluation is warranted unless a cause, such as AV block, has been clinically documented.153 Sudden increase of PR interval and QRS duration have been associated with AV block and SCD in myotonic dystrophy despite the absence of symptoms, and electrophysiological evaluation should be considered.766,767 An HV interval ≥70 ms should prompt pacemaker implantation regardless of symptoms.
Induction of BBR-VT in a symptomatic patient strongly supports
BBR-VT (
ESC CardioMed chapter 42.5)768 as an underlying cause of symptoms, and ablation of the right bundle branch is recommended.153 Following bundle branch ablation, the risk of AV
block at follow-up is considered particularly high due to
BBR-VT
Pacemaker/ICD
k c
implantation
(Class I)
Pacemaker/ICD
k c
implantation
(Class I)
Spontaneous
AV block
A
b
Spontaneous
AV block
A
b
EP evaluation
(Class I)
Catheter ablation
(Class I)
Follow-up
(Class I)
PR/QRS
sudden increase
ICD implantation
(Class I)
Follow-up
(Class I)
ICD implantation
(Class IIa)
Aborted cardiac arrest/VT and non-BBRVT or 
noVT induction
HV ≥70 ms or subnodal
AV block
A
Asymptomatic/
palpitations and negative
EP evaluation
Syncopea or palpitations and non-BBRVT
N
N
PR ≥240 ms or
QRS >120 ms or
>40 y and atrial arrhythmias or
>40 y and LGE
on CMR
N
N
Y
Y
Y
Y
Patient with myotonic dystrophy
Asymptomatic
Syncope or palpitationsa
Aborted cardiac arrest
VT
Pacemaker/ICD
k c
implantation
(Class IIb)
EP evaluationd
(Class IIa)
Figure 23 Algorithm for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in myotonic dystrophy. AV, atrioventricular; BBR-VT, bundle branch re-entrant ventricular tachycardia; CMR, cardiac magnetic resonance; EP, invasive electrophysiological evaluation; HV,
His-to-ventricle interval; ICD, implantable cardioverter deﬁbrillation; LGE, late gadolinium enhancement; N, No; VT, ventricular tachycardia, Y, Yes. aSyncope or palpitations highly suspicious of arrhythmic origin. bSpontaneous AV block: third or advanced second-degree AV block. cFactors favouring ICD implantation:
age,5,6,11 CTG expansion,6–9,13,16 sudden death (SD) orfamily history of SD,5 ECG conduction abnormalities,16 PRprolongation,13 left bundle branch block,5 atrial arrhythmias,6,16 non-sustained VT,5 LV dysfunction,17 signiﬁcant LGE in CMR.14,15,18 dFurther management according to outcome of EP evaluation.


<!-- PAGE 69 -->

### Page 69

progressive His–Purkinje disease, and a pacemaker should be implanted. Prolonged PR or QRS intervals,13,16,80 concurrent atrial arrhythmias,6,16,80 and LGE at CMR14,15,18 in patients older than
40 years have all been associated with AV block and SCD at follow-up in myotonic dystrophy. Accordingly, pacemaker implantation may be considered even in the absence of symptoms.
Although data are lacking, implantation of an ICD rather than a pacemaker may be preferred in myotonic dystrophy patients,
with additional risk factors for VA and SCD (Figure 23).
Permanent pacemaker implantation may also be considered in patients with
Kearns–Sayre syndrome,
Emery–Dreiffus,
or limb–girdle muscular dystrophy with any degree of AV block because of the substantial risk of rapid progression to total block.
In patients with limb–girdle type 1B or Emery–Dreifuss muscular dystrophies who have an indication for pacing or signiﬁcant LGE
on CMR, ICD implantation should be considered.769
Implantation of an ICD rather than a pacemaker may be also considered in patients with Duchenne/Becker, when there is signiﬁcant
LGE on CMR.770,771 However, the general prognosis of these diseases should be taken into consideration. In patients who have survived a CA due to a SMVT, implantation of an ICD is recommended when other than BBR-VTs (e.g. scar-related VTs) are inducible or if
VT is not inducible. Myotonic dystrophy patients with a syncope likely due to a VA, even if not inducible, and those with palpitations and induction of a non-BBR-VT are considered at risk for arrhythmic
SCD, and ICDs should be considered.
Due to the progressive nature, annual follow-up with an ECG is recommended, even in the concealed phase of the disease when patients are asymptomatic and the ECG is normal.6,13 Due to slow progression and the fact that signiﬁcant changes are often reﬂected on the surface ECG, serial electrophysiological evaluation to assess
AV conduction and arrhythmia induction is not recommended in patients without arrhythmia suspicion or progression of ECG conduction disorders.767,772
Recommendation Table 33 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention,
and treatment of ventricular arrhythmias in neuromuscular diseases
Recommendations
Classa
Levelb
General recommendations
Annual follow-up with at least a 12-lead ECG is recommended in patients with muscular dystrophies, even in the concealed phase of the disease.6,13
I
C
It is recommended that patients with neuromuscular disorders who have VAs or ventricular dysfunction are treated in the same way for arrhythmia as patients without neuromuscular disorders.17,765
I
C
Risk stratiﬁcation, primary and secondary prevention of SCD
Invasive electrophysiological evaluation is recommended in patients with myotonic dystrophy and palpitations or syncope suggestive of VA or surviving a CA.153
I
C
Continued
ICD implantation is recommended in patients with myotonic dystrophy and SMVT or aborted
CA not caused by BBR-VT.766
I
C
Invasive electrophysiological evaluation should be considered in patients with myotonic dystrophy and a sudden increase in the PR interval or QRS
duration.766,767
IIa
B
Invasive electrophysiological evaluation should be considered in patients with myotonic dystrophy and a PR interval ≥240 ms or QRS duration
≥120 ms or who are older than 40 years and have supraventricular arrhythmiasc or who are older than 40 years and have signiﬁcant LGE on
CMR.c,5,14,16,766
IIa
B
In myotonic dystrophy patients without AV
conduction delay and a syncope highly suspicious for VA, ICD implantation should be considered.766
IIa
C
In myotonic dystrophy patients with palpitations highly suspicious for VA and induction of a non-BBR-VT, ICD implantation should be considered.766
IIa
C
In patients with limb–girdle type 1B or Emery–
Dreifuss muscular dystrophies and indication for pacing, ICD implantation should be considered.769
IIa
C
Implantation of an ICD may be considered in patients with Duchenne/Becker muscular dystrophy and signiﬁcant LGE at CMR.770,771
IIb
C
Implantation of an ICD over a permanent pacemaker may be considered in myotonic dystrophy patients with additional risk factorsd for
VAs and SCD.
IIb
C
In myotonic dystrophy patients, serial electrophysiological evaluation of AV conduction and arrhythmia induction is not recommended without arrhythmia suspicion or progression of
ECG conduction disorders.772
III
C
Management of VA
In symptomatic patients with BBR-VT, catheter ablation is recommended.e,153,474,475,477
I
C
In patients with myotonic dystrophy undergoing ablation for BBR-VT, pacemaker/ICD
implantation is recommended.153
I
C
© ESC 2022
AV, atrioventricular; BBR-VT, bundle branch re-entrant ventricular tachycardia; CA,
cardiac arrest; CMR, cardiac magnetic resonance; ECG, electrocardiogram; ICD,
implantable cardioverter deﬁbrillator; LBBB, left bundle branch block; LGE, late gadolinium enhancement; LV, left ventricular; SCD, sudden cardiac death; SD, sudden death; SHD, structural heart disease; SMVT, sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cLevel of evidence C.
dFactors favouring ICD implantation: Age,5,6,11 CTG expansion,6–9,13,16 SD or family history of SD,5 ECG conduction abnormalities,16 PR prolongation,13 LBBB,5 atrial arrhythmias,6,16 non-sustained VT,5 LV dysfunction,17 structural abnormalities in
CMR.14,15,18
eIn other cardiac conditions (e.g. aortic valve replacement) with BBR-VT, catheter ablation is also recommended.
ESC Guidelines
4065


<!-- PAGE 70 -->

### Page 70

7.1.4. Inﬂammatory cardiac diseases
Cardiac inﬂammation has been associated with altered myocardial electrical properties and arrhythmias, and has been reported in various cardiomyopathies such as, obviously, myocarditis, but also inherited cardiomyopathies or after MI.773,774
Inﬂammatory cardiomyopathies are characterized by myocardial inﬂammation (i.e. myocarditis) as the primary cause of cardiac damage, whereas secondary myocardial inﬂammations are caused by an initial myocardial pathology.775,776
Myocarditis, sarcoidosis, and Chagas’ disease are among the major entities within inﬂammatory cardiomyopathies.
7.1.4.1. Myocarditis
The diagnosis of myocarditis can be challenging. There is no pathognomonic clinical presentation of this disease,777 with cardiac manifestations ranging from subtle symptoms to severe heart failure,
complete AV block, and SCD.778 In young people, it is estimated that 2–12% of SCD are related to myocarditis.779–781
Myocarditis is diagnosed on endomyocardial biopsy by established histological, immunological, and immunohistochemical criteria, as well as polymerase chain reaction (PCR) to detect viral genomes.782,783 This implies that endomyocardial biopsy, although not widely used, is the diagnostic gold standard for myocarditis.778,784
In current practice, the diagnosis of myocarditis relies on clinical presentation, elevated troponin level, ECG changes, evidence of LV
dysfunction, absence of signiﬁcant CAD or valvular heart disease,
and suggestive ﬁndings on CMR or PET-CT.
In the context of suspected or conﬁrmed acute myocarditis, patients with a life-threatening presentation (fulminant myocarditis,
sustained VAs, or complete AV block) are to be referred to a specialized centre.785,786 A specialized centre must have the capacity to perform cardiac catheterization, endomyocardial biopsies, use mechanical circulatory support devices, and manage complex VAs.
Sustained VAs may occur in acute myocarditis. In a large series of patients,786 in-hospital VF or CA was reported in 2.5% of cases. In another series of acute myocarditis in children,787 sustained tachyarrhythmias were reported in 11.5% of patients, with VAs accounting for most cases (79.5%). Tachyarrhythmias were associated with a
2.3-fold increased risk of death.787 Giant cell myocarditis, although rare, has a higher risk of life-threatening VAs, which are seen in
14% of giant cell myocarditis patients on initial presentation, and then develop as refractory arrhythmias in more than half of the patients during the course of the disease.788,789
The management of acute myocarditis depends on clinical presentation, viral PCR from myocardial biopsies, and histological ﬁndings.
In patients with suspected myocarditis who present with mild heart failure, it is recommended to avoid exercise and use beta-blockers and ACE inhibitors.790 Patients with VAs or AV block must be admitted to the hospital and continuously monitored.
Treatment of arrhythmias in patients with inﬂammatory heart disease does not differ from generally accepted clinical principles.
Symptomatic VAs may require AADs such as amiodarone and/or beta-blockers.791–793 Of note, in a retrospective observational study,
patients with sustained VAs during the acute phase of myocarditis
(LVEF 53 + 10%) had a high risk (45% at 3 years) of VT/VF recurrences during follow-up.794
Myocarditis may resolve without sequelae, recur, or become chronic. Thus, myocarditis is often considered a precursor of
DCM.795 Development of DCM has been observed in 21% of patients with acute myocarditis over a mean follow-up period of 3
years.796 The exact proportion of chronic DCM consecutive to the progression of acute myocarditis remains unknown, but myocarditis has been identiﬁed as the cause of DCM in up to 12% of cases in a large retrospective study.797 In patients with SMVT of unclear aetiology, myocarditis should be suspected especially when CMR reveals subepicardial and/or intramural abnormal ﬁbrotic myocardial tissue.
The presence of LGE at CMR has also been associated with the late occurrence of VAs in patients with endomyocardial biopsy-proven viral myocarditis.798–800
The management of documented VAs in chronic myocarditis is similar to that of patients with DCM, including ICD implantation and the use of AADs. Catheter ablation can be effective to treat
SMVT, the arrhythmogenic substrate of which is often found on the epicardium of the lateral/basal left ventricle.752,801–803 In one publication,802 non-inducibility of VT after catheter ablation led to avoidance of ICD implantation in one-third of patients, with subsequently no VT recurrence during follow-up.
Recommendation Table 34 — Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in myocarditis
Recommendations
Classa
Levelb
General recommendations
In conﬁrmed or clinically suspected acute myocarditis, it is recommended that patients who present with life-threatening VAs are referred to a specialized centre.786,804
I
C
Secondary prevention of SCD and treatment of VA
In patients with haemodynamically not-tolerated
SMVT occurring in the chronic phase of myocarditis, an ICD implantation is recommended.794,805
I
C
In patients with haemodynamically not-tolerated sustained VT or VF during the acute phase of myocarditis, ICD implantation before hospital discharge should be considered.788,794,806
IIa
C
AADs should be considered (preferably amiodarone and beta-blockers) in patients with symptomatic non-sustained or sustained VAs during the acute phase of myocarditis.
IIa
C
In post-myocarditis patients with recurrent,
symptomatic VT, AAD treatment should be considered.
IIa
C
Catheter ablation, performed in specialized centres, should be considered in post-myocarditis patients with recurrent, symptomatic SMVT or
ICD shocks for SMVT in whom AADs are ineffective, not tolerated, or not desired.752,801,802
IIa
C
In patients with haemodynamically tolerated
SMVT occurring in the chronic phase of myocarditis, ICD implantation should be considered.
IIa
C
Continued


<!-- PAGE 71 -->

### Page 71

7.1.4.2. Cardiac sarcoidosis
Sarcoidosis is a multisystem inﬂammatory disease of unknown cause,
with a genetic predisposition,807 characterized by the accumulation of T lymphocytes, mononuclear phagocytes, and non-caseating granulomas leading to tissue scarring.808 Although lung involvement is most frequent, any organ can be affected. It is estimated that 5% of patients with sarcoidosis have symptoms indicative of cardiac involvement. However, using advanced cardiac imaging modalities
(CMR/PET-CT), subclinical cardiac sarcoidosis is increasingly diagnosed.808–811
The diagnosis of cardiac sarcoidosis is challenging. It can mimic the
ARVC phenotype in the event of a predominant RV involvement810
or the heart is the only organ affected by sarcoidosis (so-called ‘isolated cardiac sarcoidosis’).812 Cardiac electroanatomical voltage mapping may help in the differential diagnosis between isolated cardiac sarcoidosis and ARVC.813 The three usual cardiac manifestations of cardiac sarcoidosis are LV dysfunction, AV conduction abnormalities, and VAs. Complete AV block develops primarily during the acute inﬂammatory phase as opposed to sustained VT, which frequently develops in the advanced stage of the disease (Figure 24).814
In addition to isolated cardiac sarcoidosis,812 three independent factors have been found associated with an adverse outcome and,
particularly, the risk of VAs: (i) an LVEF ,35%812; (ii) documentation of high-degree AV block815,816; and (iii) presence of RV or LV scarring at CMR (Figure 25).817–821 However, VAs and SCD may occur in patients with a mildly reduced or normal LVEF. PES,822–825 PET-CT,826
and LGE-CMR help stratify the risk of VAs in such patients.827 In a series of 120 patients with biopsy-proven extracardiac sarcoidosis and preserved LV/RV systolic function, VT inducibility at PES was low (6%) but associated with the composite endpoint of VAs and
SCD, which occurred in 3 patients, all with abnormal PET or CMR
(P = 0.009).825 In a cohort of 66 asymptomatic patients with biopsyproven extracardiac sarcoidosis and abnormal PET-CT or CMR, 8
(11%) were inducible at PES and 6 of 8 had VA or died during followup, compared to 1 of 68 non-inducible patients (P , 0.0001). Of note, inducible patients had a lower LVEF at PES, which further deteriorated at 2-year follow-up.823
The beneﬁt of ICDs, both for primary and secondary prevention, has been reported.828–832 Data support the use of ICDs for primary prevention of SCD in patients with LVEF ≤35%.812,830 In addition,
whatever the LVEF, ICD should also be considered in patients with anindication for permanent cardiacpacingor the presence of signiﬁcant scaratCMR.833,834Indeed,asshownintworecent meta-analyses,821,832
the occurrence of VA is higher in patients with complete AV block (OR
= 2.19; P , 0.01), and the presence of scar at CMR is associated with a higher risk of the composite endpoint of ventricular arrhythmic events and mortality (OR= 10.74; P , 0.00001). A widely accepted deﬁnition of signiﬁcant LGE is not available. LGE in ≥9/29 segments (17 LV and 12
RV segments) and LGE affecting ≥22% of the LV mass have been associated with arrhythmic endpoints.820,827,835
Corticosteroid therapy is a mainstay of cardiac sarcoidosis treatment, but the effect of this treatment on the occurrence of
VAs has only been ascertained from observational studies.836–838
Obviously, based upon pathophysiology of the disease, inﬂammation plays a role in the development of ventricular scar in patients with cardiac sarcoidosis. However, so far there is no evidence that
VAs are directly triggered by active inﬂammation itself. Indeed, a scar-related intramural or epicardial substrate (with a predilection in peri-valvular regions) explains most VTs in patients with cardiac sarcoidosis.839 The VT substrate was more likely located in segments with scar transmurality at CMR and a lower degree of inﬂammation on PET-scan.840 Catheter ablation may help to prevent VT,839,841,842 in particular if AAD treatment fails,837 but
VT recurrences are still frequent,752,839 in particular if catheter ablation is performed during active inﬂammation, with AADs continued in many patients.839,843
In patients with haemodynamically well-tolerated
SMVT occurring in the chronic phase of myocarditis, preserved LV function and a limited scar amenable to ablation, catheter ablation may be considered as an alternative to ICD therapy,
after discussion with the patient and provided that established endpoints have been reached.c
IIb
C
© ESC 2022
AAD, anti-arrhythmic drug; ICD, implantable cardioverter deﬁbrillator; LV, left ventricular; SCD, sudden cardiac death; SMVT, sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cVT non-inducibility and elimination of electrograms consistent with conduction delay.
Recommendation Table 35 — Recommendations for risk stratiﬁcation, sudden cardiac death prevention,
and treatment of ventricular arrhythmias in cardiac sarcoidosis
Recommendations
Classa
Levelb
Risk stratiﬁcation and primary prevention of SCD
ICD implantation is recommended in patients with cardiac sarcoidosis who have a LVEF
≤35%.812,828–830,832
I
B
In patients with cardiac sarcoidosis who have an indication for permanent cardiac pacing related to high-degree AV block, ICD implantation should be considered, regardless of LVEF.816
IIa
C
In patients with cardiac sarcoidosis who have a LVEF .35% but signiﬁcant LGE at CMR
after resolution of acute inﬂammation,
ICD implantation should be considered.817–819,821,833,834
IIa
B
In patients with cardiac sarcoidosis who have a
LVEF 35–50% and minor LGE at CMR, after resolution of acute inﬂammation, PES for risk stratiﬁcation should be considered.
IIa
C
In patients with cardiac sarcoidosis, LVEF 35–50%
and inducible SMVT at PES, ICD implantation should be considered.823–825
IIa
C
Continued
ESC Guidelines
4067


<!-- PAGE 72 -->

### Page 72

7.1.4.3. Chagas’ cardiomyopathy
Chagas’ disease, a myocardial disease caused by the parasite
Trypanosoma cruzi, is the most common cause of non-ischaemic cardiomyopathy in Latin America. After the incubation period, the vast majority of infected persons have minor or no symptoms, and very few (,1%) develop acute myocarditis.845 However, people are infected for life, and years to decades after the initial infection 20–
30% of them will develop cardiomyopathy,846 which can lead to heart failure, heart block and atrial and ventricular arrhythmias.
SCD, particularly due to VF, is the most common cause of death in patients with Chagas’ cardiomyopathy.847,848 A risk score developed by Rassi et al.849 as well as the presence of myocardial ﬁbrosis at LGE-CMR850 are useful in assessing the risk of death in Chagas’ disease patients. However, whether such risk stratiﬁcation can translate into clinical beneﬁt through ICD treatment needs to be assessed in prospective trials, also considering the high annual mortality in
Chagas patients with ICDs.851
Although ICD implantation may seem reasonable for the secondary prevention of SCD in patients with Chagas’ cardiomyopathy,
there are controversial studies851–856 about the beneﬁts and risks
N
Patients with cardiac sarcoidosis
Amiodarone
(Class IIa)
Catheter ablation
(Class IIb)
Indication for permanent f
cardiac pacing
N
Significant LGEa
N
N
N
LVEF 35-50%
L
and minor LGE
PES
(Class IIa) 
ICD implantation
(Class IIa) 
Follow-up
Aborted cardiac arrest or sustainedVT or LVEF
L
≤35%
SMVT inducible
Symptomatic recurrentVA
V
Y
Y
ICD implantation
(Class I)
Y
Y
Y
Figure 24 Algorithm for sudden cardiac death prevention and treatment of ventricular arrhythmia in patients with cardiac sarcoidosis. ICD, implantable cardioverter deﬁbrillator; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; N, No; PES, programmed electrical stimulation;
SMVT, sustained monomorphic ventricular tachycardia; VA, ventricular arrhythmia; VT, ventricular tachycardia; Y, Yes. aLGE affecting ≥9/22 segments or ≥22% of the LV mass has been associated with arrhythmic endpoints.
Secondary prevention of SCD and treatment of VAs
ICD implantation is recommended in patients with cardiac sarcoidosis who (1) have documented sustained VT, or (2) aborted
CA.812,828–830,832
I
B
In patients with cardiac sarcoidosis and recurrent,
symptomatic VA, AAD treatment should be considered.
IIa
C
Catheter ablation, in specialized centres, may be considered in cardiac sarcoidosis ICD-recipients with recurrent, symptomatic SMVT or ICD
shocks for SMVT, in whom AADs are ineffective,
contraindicated, or not tolerated.839,841,842
IIb
C
© ESC 2022
AAD, anti-arrhythmic drug; AV, atrio-ventricular; CA, cardiac arrest; CMR, cardiac magnetic resonance; ICD, implantable cardioverter deﬁbrillator; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; PES, programmed electrical stimulation; SCD, sudden cardiac death; SMVT, sustained monomorphic VT; AV,
ventricular arrhythmia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 73 -->

### Page 73

of ICD implantation in these patients. Indeed, a meta-analysis of observational studies found no beneﬁt of ICD (n = 483) vs. amiodarone
(n = 115) for the secondary prevention of SCD in patients with
Chagas’ disease as all-cause annual mortality rates were comparable in both groups
(9.7%
and
9.6%,
respectively).856
Another meta-analysis found a 4.7% annual incidence of inappropriate shocks and a high 9.0% annual mortality rate in 1041 ICD patients with
Chagas’ disease.851
Amiodarone857 and catheter ablation858–860 have been successfully used to control recurrent VAs in some patients. As with various forms of myocarditis, the arrhythmogenic substrate is often found at the epicardium in Chagas’ cardiomyopathy.
ECG sinus rhythm – Prominent R’wave inV1-V3a
ECG VT – LBBB-like, inferior axis (RVOT origin)
CMR
Basal LV and RV free wall LGE
PET-CT
Lateral and basal-septal LV increased 18FDG uptake
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
Figure 25 Typical features of cardiac sarcoidosis associated with sustained monomorphic ventricular tachycardia. CMR, cardiac magnetic resonance;
ECG, electrocardiogram; LBBB, left bundle branch block; LGE, late gadolinium enhancement; LV, left ventricle; PET-CT, positron emission tomography
CT; RV, right ventricle; RVOT, right ventricular outﬂow tract; VT, ventricular tachycardia. aNote the prominent R′ in V1 to V3, a pattern frequently found in cardiac sarcoidosis with RV involvement.844
ESC Guidelines
4069


<!-- PAGE 74 -->

### Page 74

7.1.5. Valvular heart disease
Valvular heart diseases predispose to SCD both in the preoperative period and after valvular surgery. In old cohorts of symptomatic, non-operated patients with severe aortic stenosis or severe mitral regurgitation, the incidence of SCD was 50–60%. In these studies, the rate of SCD secondary to VA was not speciﬁed.861,862
Rates of SCD in patients with prosthetic valves range from 15%
to 30%, with an estimated annual risk of 0.2–0.9%.863 In a large series of 1533 patients who underwent aortic or mitral valve replacement, 6% of deaths were caused by arrhythmias.864 A recent report of 3726 patients undergoing transcatheter aortic valve implantation (TAVI) showed 5.6% SCD during 22 months of followup,
emphasizing the remaining
SCD
risk also after valve replacement.865
Small observational studies have shown that patients with residual
LV dysfunction after valvular surgery who undergo ICD implantation have appropriate therapy and mortality rates similar to patients with ischaemic or dilated cardiomyopathy.866–868 ICD implantation in these patients should therefore follow
DCM/HNDCM
recommendations.
In patients after TAVI, SCD has been associated with the presence of new-onset conduction disturbances (LBBB, QRS .
160 ms) and reduced LVEF ≤40%.865 SCD in these patients may be the consequence of advanced AV block, and permanent pacing indication should follow the 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.2 The role of ICD implantation for prevention of SCD after TAVI is less clear. Two recent retrospective analyses including a total of 203 patients in whom the LVEF remained ≤35% did not show survival beneﬁt from
ICD implantation, probably related to the high competing risk of death from heart failure and relevant comorbidities in this population.869,870
In patients presenting with SMVT after aortic valve replacement,
PES is indicated because of the high probability of BBR-VT as the underlying mechanism—an arrhythmia that is potentially curable with catheter ablation.871,872
SCD has been reported to occur in 0.2–0.4% of patients with MVP
per year.873,874 However, the total number of patients dying suddenly with this condition is most likely underestimated, considering that it is a common valve variant with an estimated prevalence of 2–3% in the general population.875
Using rigorous criteria for morphologic diagnosis (i.e. myxomatous mitral valve) at post-mortem, MVP has been associated with
7% of all cases of juvenile SCD in the Registry of the Veneto region of Italy.228 Recent pathological and clinical studies on SCD victims with MVP or patients with MVP and major VAs have provided insights into the potential VA substrate.130,228,876–880 In particular,
myocardial ﬁbrosis affecting both the infero-basal LV free wall and the papillary muscles has been recognized in pathological and
LGE-CMR studies.228 The scarring process has been related to mechanical stretch secondary to the excessive mobility of the mitral valve apparatus due to mitral valvular disjunction and posterior systolic curling.876 This indicates a promising role of CMR for arrhythmic risk stratiﬁcation beyond traditional electrophysiological markers.
Proposed criteria for an ‘arrhythmic MVP syndrome’ that have been associated with an increased risk for SCD include: young adults (most often women), QTc prolongation and/or negative
T-wave in inferior ECG leads, mitral annular disjunction, bi-leaﬂet involvement on echocardiography, frequent PVCs, or nonsustained PVT on Holter monitoring and/or exercise testing.130,228,876–880 Reduced LVEF and/or myocardial ﬁbrosis on
CMR may add to the risk proﬁle. These data are mainly derived from small retrospective series of SCD survivors and post-mortem studies. Therefore, identiﬁcation of the small subgroup of patients at risk of SCD remains challenging.228,874 Robust data to support recommendations for risk stratiﬁcation of SCD in patients with
MVP are not available.
Recommendation Table 36 — Recommendations for the treatment of ventricular arrhythmias in
Chagas’ cardiomyopathy
Recommendations
Classa
Levelb
Amiodarone should be considered to reduce arrhythmia burden in patients with Chagas’
cardiomyopathy who present with symptomatic
PVCs or VT.857
IIa
C
In patients with Chagas’ cardiomyopathy and recurrent, symptomatic SMVT or ICD shocks for
SMVT in whom AADs are ineffective,
contraindicated, or not tolerated, catheter ablation in specialized centres should be considered.859,860
IIa
C
In patients with Chagas’ cardiomyopathy and symptomatic VT in whom AADs (amiodarone and beta-blockers) are ineffective or not tolerated, ICD implantation may be considered.851,854–856
IIb
C
© ESC 2022
AAD, anti-arrhythmic drug; ICD, implantable cardioverter deﬁbrillator; PVCs,
premature ventricular complexes;
SMVT,
sustained monomorphic ventricular tachycardia; VT, ventricular tachycardia.
Recommendation Table 37 — Recommendations for sudden cardiac death prevention and treatment of ventricular arrhythmias in valvular heart disease
Recommendations
Classa
Levelb
PES with standby catheter ablation is recommended in patients with aortic valve disease and SMVT to identify and ablate BBR-VT,
especially if it occurs following a valve intervention.871,872,881
I
C
Continued


<!-- PAGE 75 -->

### Page 75

7.1.6. Congenital heart disease
Advances in surgical repair and medical treatment have improved the long-term prognosis of children born with congenital heart disease
(CHD). More than 90% now survive to adulthood,882 and consequently the prevalence of adult CHD has steadily increased.883 With fewer patients dying from peri-operative events and early heart failure, SCD has become a leading cause of death in adults with repaired CHD.884 The combination of surgical incisions, myocardial scar and residual or new anatomical abnormalities form the substrate for VAs (Figure 26).
Risk stratiﬁcation for SCD in CHD patients and no documented sustained VA remains difﬁcult due to a mixed patient population,
the absence of RCTs, and relatively small observational studies. In patients with biventricular physiology and a systemic LV, the standard criterion of an LVEF ≤35% is used for patient selection for primary prevention ICD implantation.885,886 For patients with unexplained syncope, severe arrhythmia symptoms such as palpitations or presyncope and NSVT, PES should be considered.887 In asymptomatic patients with tetralogy of Fallot (TOF) but other indicators for a
VA substrate, electrophysiological evaluation may reﬁne risk stratiﬁcation.888 The surgical era and the techniques used affect the VA substrate and occurrence of VAs and should be considered. The use of a transannular patch repair in TOF patients, for example, was found to be associated with a lower risk for VA.889 The beneﬁt of primary prevention ICD therapy in patients with single or systemic RVs is less well established and requires consideration of disease- and patientspeciﬁc factors.890,891
Sustained VA in a patient with CHD
Simple or moderate CHD and preserved biventricular function and haemodynamically tolerated VT
Catheter or surgical intervention for correctable lesions ± ICD
Pre-operative catheter mapping and ablation before or during the interventiona
(Class IIa)
N
N
Residual or new abnormalities requiring intervention
Evaluation of residual or new anatomical abnormalities
(Class I)
N
Successful ablation
Withhold of ICD
implantationa
(Class IIb)
Recurrent symptomatic
SMVT/ICD therapy despite medical treatmentb
Catheter ablation
ICD implantation
(Class I)
Catheter ablationa
(Class I)
TOF
(Class I)
Others
(Class IIa)
Y
Y
Y
Figure 26 Algorithm for the management of sustained ventricular arrhythmia in patients with congenital heart disease. CHD, congenital heart disease;
ICD, implantable cardioverter deﬁbrillator; N, No; TOF, tetralogy of Fallot; VA, ventricular arrhythmia; VT, ventricular tachycardia; Y, Yes. aData derived from patients with TOF and related lesions. bIn TOF, anti-arrhythmic drug failure is not required.
In patients with valvular heart disease and persistent LV dysfunction after surgical correction, (if possible) it is recommended that
ICD implantation for primary prevention follows
DCM/HNDCM recommendations.868
I
C
© ESC 2022
BBR-VT,
bundle branch re-entrant ventricular tachycardia;
DCM,
dilated cardiomyopathy;
HNDCM,
hypokinetic non-dilated cardiomyopathy;
ICD,
implantable cardioverter deﬁbrillator; LV, left ventricular; PES, programmed electrical stimulation; SMVT, sustained monomorphic ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4071


<!-- PAGE 76 -->

### Page 76

In CHD patients with sustained VA or CA survivors, a comprehensive evaluation of inciting factors, including cardiac imaging (particularly CMR) and haemodynamic assessment, is important
(Figure 26).892 If pre-existing or new anatomical abnormalities requiring intervention are detected, the treatment plan should consider pre- or intra-operative mapping and transection of the VT substrate,
because accessibility might be impaired post-operatively.888,893,894
Pre-operative evaluation and intervention are especially important in TOF patients undergoing surgical pulmonary re-valving. In selected patients with CHD (including those with atrial bafﬂe repair for transposition of the great arteries, Fontan operation and Ebstein anomaly), evaluation and treatment of SVT (such as intra-atrial re-entrant tachycardias or AV re-entrant tachycardias) with rapid ventricular conduction should also be considered.890,895,896
In the absence of identiﬁable reversible factors, ICD implantation for secondary prevention of SCD is recommended.349,350 While transvenous ICD systems have been most frequently used and have the advantage of anti-tachycardia and anti-bradycardia pacing,
subcutaneous ICDs may be an alternative in selected patients with limited venous access to the ventricle or with intracardiac shunts.
In CHD patients, MVT most often arises from re-entrant tachycardias using anatomical isthmuses bounded by valves, patch material, and surgical incisions. Early mapping and ablation studies,
particularly in TOF patients, identiﬁed critical anatomical isthmuses of reproducible anatomical location.897,898 Following this concept,
those anatomical isthmuses can be reconstructed and transected in sinus rhythm during catheter ablation procedures using electroanatomical mapping systems, achieving acute success rates of
80%.888,899–901 The use of conduction block across anatomical isthmuses as a procedural endpoint, in addition to non-inducibility of VT,
has further improved long-term ablation outcomes.888,899
Accordingly, catheter ablation is recommended in particular in
TOF patients with recurrent SMVT. Due to the complexity of
CHD patients as well as the VT substrate, those procedures should be performed in centres with expertise in catheter ablation of CHD
patients. Catheter ablation may be considered in lieu of ICD implantation in selected TOF patients with SMVT and preserved biventricular function, provided the combined procedural endpoint of non-inducibility and conduction block across the anatomical isthmus can be reached.888,899
Recommendation Table 38 — Recommendations for risk stratiﬁcation and primary prevention of sudden cardiac death in congenital heart disease
Recommendations
Classa
Levelb
Risk stratiﬁcation and primary prevention of SCD
All CHD patients
In adults with CHD with biventricular physiology and a left systemic ventricle presenting with symptomatic heart failure (NYHA II/III) and EF
≤35% despite ≥3 months of OMT, ICD
implantation is indicated.885,886
I
C
Continued
In patients with CHD with presumed arrhythmic syncope and with either at least moderate ventricular dysfunction or inducible SMVT on PES,
ICD implantation should be considered.887,889,902
IIa
C
In patients with advanced single ventricle or systemic RV dysfunction with additional risk factors,c ICD implantation may be considered.890,891
IIb
C
Tetralogy of Fallot
In patients after repair of TOF with arrhythmia symptoms and NSVT, electrophysiologic evaluation including PES should be considered.889,903–905
IIa
C
In patients after repair of TOF with arrhythmia symptoms and a positive PES, or a combination of other risk factorsd and a positive PES, ICD
implantation should be considered.
IIa
C
In patients after repair of TOF without arrhythmia symptoms, but with a combination of other risk factors,d electrophysiologic evaluation, including
PES, may be considered.
IIb
C
In patients with repaired TOF undergoing surgical or transcutaneous pulmonary valve replacement,
pre-operative catheter mapping and transection of VT-related anatomical isthmuses before or during the intervention may be considered.894
IIb
C
© ESC 2022
AV, atrioventricular; CHD, congenital heart disease; CMR, cardiac magnetic resonance;
EF, ejection fraction; ICD, implantable cardioverter deﬁbrillator; LV, left valve; NSVT,
non-sustained monomorphic ventricular tachycarda; NYHA, New York Heart
Association; OMT, optimal medical treatment; PES, programmed electrical stimulation;
RV, right ventricular; SCD, sudden cardiac death; SMVT, sustained monomorphic ventricular tachycarda; TOF, tetralogy of Fallot; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cData are sparse and risk factors may be lesion-speciﬁc, including non-sustained VT,
NYHA II/III, severe AV valve regurgitation, and wide QRS ≥140 ms (transposition of the great arteries).
dOther risk factors include moderate RV or LV dysfunction, extensive RV scarring on
CMR,906,907 QRS duration ≥180 ms886,908 and severe QRS fragmentation.909,910
Recommendation Table 39 — Recommendations for secondary prevention of sudden cardiac death and treatment of ventricular arrhythmia in congenital heart disease
Recommendations
Classa
Levelb
Secondary prevention of SCD and treatment of VA
All CHD patients
In patients with CHD presenting with sustained
VAs, evaluation for residual lesions or new structural abnormalities is recommended.892,893
I
B
In patients with CHD with not tolerated VT/
aborted CA due to VF, ICD implantation is indicated after exclusion of reversible causes.349,350
I
C
Continued


<!-- PAGE 77 -->

### Page 77

7.2. Primary electrical disease
7.2.1. Idiopathic ventricular ﬁbrillation
The diagnosis of idiopathic ventricular ﬁbrillation (IVF) is made in
SCA survivors, preferably with documented VF, after exclusion of structural, channelopathic, metabolic, or toxicological aetiologies.135,222,911–913 Diagnostic tests include blood chemistry, ECG (including high lead), cardiac CT/coronary angiography, telemetry/
Holter, exercise stress test, echocardiogram, sodium-channel blocker testing and CMR (see Section 5.2.3, scenario 3).135,222,911 Genetic testing for channelopathy and cardiomyopathy genes may be considered with a mutation yield of 3–17%.249,914,915 Clinical evaluation of
ﬁrst-degree family members may be considered, but the diagnostic yield is low. In particular the signiﬁcance of detected early repolarization pattern (ERP) in asymptomatic relatives is uncertain.182,916
In IVF patients, ICD implantation reduces the risk of arrhythmic death by up to
68%
compared to amiodarone352,917–921
(Figure 27). In observational studies with a mean follow-up of 5–6
years, 21.0–29.6% of IVF patients experienced an arrhythmic recurrence, corresponding to an annual ICD shock rate of 3.6–5.7%,
whereas
4.5–17.5%
experienced inappropriate shocks.919–921
Isoproterenol, verapamil, or quinidine have been employed for acute treatment of recurrent
ICD
discharges or electrical storm.912,913,918,922–926 In several small studies, quinidine was highly effective in reducing or even preventing arrhythmia inducibility during programmed stimulation.923,924,926 Moreover, a retrospective study in 46 patients showed a reduction of mean ICD shocks from
7.5 per patient over 2.9 years to 0.9 shocks per patient over 3.7
years, with a decrease in ventricular storms from 36 to 3 after quinidine initiation.922 In patients with recurrent episodes of VF triggered by a similar PVC unresponsive to medical treatment, catheter ablation has shown success (Figure 28).186,221,333,493,927–930 PVCs most commonly originate from the Purkinje system and can be eliminated with a high acute success rate of 87–100%.186,221,333,493,927–930
Detailed electroanatomic mapping may also reveal localized structural alterations (62.5% in one study).248
In patients with CHD and recurrent, symptomatic
SMVT or ICD shocks for SMVT not manageable by medical therapy or ICD reprogramming,
catheter ablation performed in specialized centres should be considered.c 899–901
IIa
C
In selected patients with CHD (including atrial bafﬂe repair for transposition of the great arteries,
Fontan operation and Ebstein anomaly)
presenting with CA, evaluation and treatment of
SVT with rapid ventricular conduction should be considered.890,895
IIa
C
Tetralogy of Fallot
In patients with repaired TOF who present with
SMVT or recurrent, symptomatic appropriate
ICD therapy for SMVT, catheter ablation performed in specialized centres is recommended.899–901
I
C
In patients with repaired TOF with SMVT who are undergoing surgical or transcutaneous pulmonary valve replacement, pre-operative catheter mapping and transection of VT-related anatomical isthmuses before or during the intervention should be considered.888,893,894
IIa
C
In patients with repaired TOF with a preserved biventricular function and symptomatic SMVT,
catheter ablation or concomitant surgical ablation performed in specialized centres may be considered as an alternative to ICD therapy.899,901
IIb
C
© ESC 2022
CA, cardiac arrest; CHD, congenital heart disease; ICD, implantable cardioverter deﬁbrillator; SCD, sudden cardiac death; SMVT, sustained monomorphic ventricular tachycardia;
SVT,
supraventricular tachycardia; TOF,
tetralogy of
Fallot;
VA,
ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cSpeciﬁc recommendations for TOF (Class I-B).
Recommendation Table 40 — Recommendations for the management of patients with idiopathic ventricular ﬁbrillation
Recommendations
Classa
Levelb
Diagnostic evaluation
It is recommended that idiopathic VF is diagnosed in a SCA survivor, preferably with documentation of VF, after exclusion of an underlying structural,
channelopathic, metabolic, or toxicological aetiology.222,911
I
B
Clinical testing (history, ECG and high precordial lead ECG, exercise test, echocardiogram) of
ﬁrst-degree family members of idiopathic VF
patients may be considered.222,278,916
IIb
B
In idiopathic VF patients, genetic testing of genes related to channelopathy and cardiomyopathy may be considered.249,278,914,915
IIb
B
Secondary prevention of SCD and treatment of VA
ICD implantation is recommended in idiopathic
VF.352,917–919
I
B
Isoproterenol infusion, verapamil, or quinidine for acute treatment of an electrical storm or recurrent ICD discharges should be considered in idiopathic VF.912,913,918,922–924,926
IIa
C
Quinidine should be considered for chronic therapy to suppress an electrical storm or recurrent ICD discharges in idiopathic VF.923,924
IIa
B
Catheter ablation by experienced electrophysiologists should be considered in idiopathic VF patients with recurrent episodes of
VF triggered by a similar PVC non-responsive to medical treatment.927–930
IIa
C
© ESC 2022
ECG, electrocardiogram; ICD, implantable cardioverter deﬁbrillator; PVC, premature ventricular complex; SCA, sudden cardiac arrest; SCD, sudden cardiac death; VA,
ventricular arrhythmia; VF, ventricular ﬁbrillation.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4073


<!-- PAGE 78 -->

### Page 78

7.2.2. Long QT syndrome (including acquired long
QT syndrome)
LQTS is characterized by a prolonged QT interval and VAs mainly triggered by adrenergic activation. The mean age at presentation is
14 years. The annual rate of SCD in asymptomatic patients with untreated LQTS has been estimated to be less than 0.5%,82 while it increases to around 5% in those with history of syncope.931
Rare variants in 17 genes932 have been associated with LQTS.
However, the causality for several of the identiﬁed genes has been questioned.166 The undisputed genes are those causing LQT1, LQT2
and LQTS3: KCNQ1, KCNH2 and SCN5A, respectively, with genespeciﬁc triggers being exercise (LQTS1), emotional stress (LQTS2)
and sleep (LQTS3). Genetic screening identiﬁes a mutation in 75% of
LQTS cases and three main genes account for 90% of positively genotyped cases.178 The subtypes of LQTS may be grouped as follows:
(1) Autosomal-dominant LQTS (prevalence: 1 in 2500) without extra-cardiac manifestation.
(2) Autosomal-dominant LQTS with extra-cardiac manifestation,
comprising:
(a) Andersen–Tawil Syndrome (LQT7), increasingly considered its own entity.933,934
(b) Timothy Syndrome (LQT8), characterized by prolonged
QT, syndactyly, cardiac malformations, autism spectrum disorder and dysmorphism.935
(3) Autosomal-recessive
LQTS
(Jervell and
Lange–Nielsen
Syndrome), combining extreme QT prolongation with congenital deafness.936
This panel of experts has conﬁrmed the diagnostic criteria proposed in the previous version of the guidelines: a QTc ≥480 ms or a LQTS risk score .3937 (Table 10) for clinical diagnosis (Figures
29 and 30). In the presence of arrhythmic syncope or CA, a QTc
≥460 ms is sufﬁcient to consider a diagnosis of LQTS. A challenge for the clinician is establishing the duration of the QT interval in patients with broad QRS complexes (e.g. in the presence of ventricular pacing or ventricular conduction defects). In this setting, a formula has been proposed that adjusts QT by QRS duration.938 While measuring the QT, the patient moving briskly from recumbent to
Patient with idiopathic ventricular fibrillation
Catheter ablation of PVC triggers
(Class IIa)
Recurrent ICD shocks
Recurrent ICD shocks
Acute treatment:
Isoproterenol
Ver
V apamil
Quinidine
(Class IIa)
Chronic treatment:
Quinidine
(Class IIa)
Genetic counselling and testing
(Class IIb)
ICD implantation
(Class I)
Figure 27 Algorithm for the management of patients with idiopathic ventricular ﬁbrillation. ICD, implantable cardioverter deﬁbrillator; PVC, premature ventricular complex.


<!-- PAGE 79 -->

### Page 79

orthostatic position may be helpful for the diagnosis of LQTS.232,939
Epinephrine challenge is not recommended as a routine diagnostic tool, as reproducibility is modest.137 Patients with a clinical diagnosis of LQTS are recommended to undergo genetic counselling and testing in specialized centres to receive genotype-speciﬁc management and permit identiﬁcation of relatives at risk. Relatives with a mutation but without QT prolongation still receive a diagnosis of LQTS, as they are at risk of experiencing VA, although less frequently than phenotype-positive patients.940
All LQTS patients receive advice on avoidance of hypokalaemia, QT-prolonging medications and genotype-speciﬁc triggers.941–943 Beta-blockers are also recommended in all LQTS
patients. Non-selective beta-blockers nadolol and propranolol have greater efﬁcacy in reducing arrhythmic risk.940,944–946
Clinical, electrocardiographic and genetic parameters should be considered for the individual risk estimation.82 Recently, risk stratiﬁcation based on QT interval duration and genotype has been integrated in a LQTS calculator (the 1-2-3 LQTS Risk calculator).947
The utility of genetic testing is exempliﬁed by the need to avoid genotype-speciﬁc risks and by the use of mexiletine as a genotypespeciﬁc treatment for LQT3, which reduces the length of QT interval and the number of arrhythmic events.948 It should be noted that different mutations in SCN5A show different responses to mexiletine.
For example, selected mutations identiﬁed in patients not responding to mexiletine showed a distinctive electrophysiological proﬁle
Telemetry tracings – short-coupled PVC inducing VF
ECG sinus rhythm – short-coupled PVCs
Figure 28 Idiopathic ventricular ﬁbrillation triggered by short-coupled premature ventricular complexes. ECG, electrocardiogram; PVC, premature ventricular complex; VF, ventricular ﬁbrillation.
ESC Guidelines
4075


<!-- PAGE 80 -->

### Page 80

when studied in vitro.949,950 Additionally, in the case of mutations that cause overlapping syndromes, mexiletine does not induce ST segment elevation, while ﬂecainide has been reported to do so.951
Given the uncertain role of beta-blockers in LQT3, there are no indications on whether mexiletine should be administered as a stand-alone therapy or in combination with beta-blockers.
Considering that some mutations may not respond to mexiletine,
it is advisable to perform oral testing to verify that the QTc shortens
40 ms before prescribing chronic treatment.948
Survivors of a CA have a high risk of recurrences, even on betablockers (14% within 5 years on therapy), supporting the use of
ICD in CA survivors.952 Moreover, ICD implantation is indicated when a patient experiences syncope and/or VA despite optimal pharmacological therapy, as syncopal events are associated with increased risk of CA.953,954 Women with LQTS, particularly
LQT2, have an increased risk of arrhythmia both during pregnancy and especially ﬁrst year post-partum.955 Silent carriers of mutations present a low, but not negligible, risk of cardiac events, and the use of beta-blockers should be considered in this group of patients.956
Left cardiac sympathetic denervation (LCSD) is recommended for symptomatic patients despite beta-blockers when ICD is contraindicated or declined, or for an ICD carrier who experiences multiple shocks while on beta-blockers. This is supported by the evidence that LCSD, especially when performed with a video-assisted technique, is safe and effective,957 well-tolerated by patients958 and does not have a negative impact on cardiovascular performance.959
However, because complications do occur and half of the patients experience breakthrough events after the procedure, LCSD is not an alternative to ICD for high-risk patients.960 Prophylactic ICD
Table 10
Modiﬁed long QT syndrome diagnostic score243
Findings
Points
ECG
QTc
≥480 ms
3.5
=460–479 ms
2
=450–459 ms (in males)
1
≥480 ms during 4th minute of recovery from exercise stress test
1
Torsade de pointes
2
T wave alternans
1
Notched T wave in 3 leads
1
Low heart rate for age
0.5
Clinical history
Syncope
With stress
2
Without stress
1
Family history
Family member(s) with deﬁnite LQTS
1
Unexplained SCD at age ,30 years in
ﬁrst-degree family
0.5
Genetic ﬁnding
Pathogenic mutation
3.5
© ESC 2022
ECG, electrocardiogram; LQTS, long QT syndrome; SCD, sudden cardiac death.
Diagnosis of LQTS with a score .3.
LQT1
LQT2
LQT3
A
B
I
II
III
aVR
aVL
aVF
V1
V4
V5
V6
V2
V3
Figure 29 Long QT syndrome electrocardiograms and torsade-de-pointes ventricular tachycardia. (A) ECG characteristics in the three major LQTS
phenotypes. (B) Example of Torsade-de-pointes in a male patient with a SCN5A (c.1238C.A, p.A413E) mutation. LQT, Long QT.


<!-- PAGE 81 -->

### Page 81

therapy in addition to OMT may be considered in asymptomatic
LQTS patients identiﬁed with high-risk according to the 1-2-3
LQTS Risk calculator.947 PES is not useful for risk stratiﬁcation in
LQTS.961
Figure 31 illustrates the algorithm for the management of patients with long QT syndrome.
Recommendation Table 41 — Recommendations for the management of patients with long QT syndrome
Recommendations
Classa
Levelb
Diagnosis
It is recommended that LQTS is diagnosed with either QTc ≥480 ms in repeated 12-lead ECGs with or without symptoms or LQTS diagnostic score .3.
I
C
In patients with clinically diagnosed LQTS, genetic testing and genetic counselling are recommended.
I
C
It is recommended that LQTS is diagnosed in the presence of a pathogenic mutation, irrespective of the QT duration.
I
C
The LQTS diagnosis should be considered in the presence of a QTc ≥460 ms and ,480 ms in repeated 12-lead ECGs in patients with an arrhythmic syncope in the absence of secondary causes for QT prolongation.952,962,963
IIa
C
Continued
Routine diagnostic testing with epinephrine challenge is not recommended in LQTS.137
III
C
General recommendations to prevent SCD
The following is recommended in LQTS:
• Avoid QT-prolonging drugs.c
• Avoid and correct electrolyte abnormalities.
• Avoid genotype-speciﬁc triggers for arrhythmias.943
I
C
Beta-blockers, ideally non-selective beta-blockers
(nadolol or propranolol), are recommended in
LQTS patients with documented QT interval prolongation, to reduce risk of arrhythmic events.940,945,946
I
B
Mexiletine is indicated in LQT3 patients with a prolonged QT interval.948
I
C
Beta-blockers should be considered in patients with a pathogenic mutation and a normal QTc interval.82
IIa
B
Risk stratiﬁcation, prevention of SCD and treatment of VA
ICD implantation in addition to beta-blockers is recommended in LQTS patients with
CA.952,953,962,963
I
B
ICD implantation is recommended in patients with LQTS who are symptomaticd while receiving beta-blockers and genotype-speciﬁc therapies.
I
C
Continued
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
T wave alternans
Brisk Standing Test
Recumbent
Standing
A
B
Figure 30 Brisk standing electrocardiogram changes and T wave alternans in Long QT syndrome patients. (A) ECG changes during brisk standing test in a male LQTS patient with KCNH2 (p.S818L) mutation, increased heart rate is associated with less adaptation of QT interval. (B) T wave alternans in a male patient with CACNA1C (p.G406R) mutation.
ESC Guidelines
4077


<!-- PAGE 82 -->

### Page 82

LCSD is indicated in patients with symptomaticd
LQTS when: (a) ICD therapy is contraindicated or declined; (b) patient is on beta-blockers and genotype-speciﬁc drugs with an ICD and experiences multiple shocks or syncope due to VA.541,957–959
I
C
Either ICD implantation or LCSD should be considered in patients with symptomaticd LQTS,
when beta-blockers and genotype-speciﬁc therapies are not tolerated or contraindicated at the therapeutic dose.
IIa
C
In LQTS, it should be considered to calculate the arrhythmic risk before initiation of therapy based on the genotype and the duration of QTc interval.940
IIa
C
Continued
ICD implantation may be considered in asymptomatic LQTS patients with high-risk proﬁle (according to the 1-2-3 LQTS Risk calculator) in addition to genotype-speciﬁc medical therapies (mexiletine in LQT3
patients).82,940,947,948
IIb
B
Invasive electrophysiologic study is not recommended in LQTS.961
III
C
© ESC 2022
CA, cardiac arrest; ECG, electrocardiogram; ICD, implantable cardioverter deﬁbrillator;
LCSD, left cardiac sympathetic denervation; LQTS, long QT syndrome; SCD, sudden cardiac death; VA, ventricular arrhythmia.
aClass of recommendation.
bLevel of evidence.
chttp://www.crediblemeds.org dArrhythmic syncope or haemodynamically non-tolerated VA.
N
N
N
Y
Y
Y
Patient with long QT syndrome
General recommendationsa (Class I)
Beta-blockers k
b (Class I)
SCN5A mutation (LQT3): Mexiletine  (Class I)
:
Beta-blockers k
b (Class IIa)
Follow-up
Follow-up
Arrhythmic syncope or non-toleratedVA
V
under medical therapy p
ICD implantation
(Class IIb)
ICD implantation
(Class I)
LCSD
(Class I)
High risk featu f
res,
based on genotype and QTc
ICD contraindicated,
declined or recurrent ICD shocks
Medical therapy p
contraindicated,
or not tolerated
If LQT1, LQT2 or LQT3,
,
assess arrhythmic risk with genotype and QTc 
(1-2-3-LQTS-Risk riskcalculator)
(Class IIb)
Aborted cardiac arrest
Syncope prior to medical treatment
Asymptomatic patient with or without pathogenic mutation and
QT prolongation
Asymptomatic patient with pathogenic mutation without QT prolongation
LCSD
(Class IIa)
ICD implantation
(Class IIa)
Figure 31 Algorithm for the management of patients with long QT syndrome. ICD, implantable cardioverter deﬁbrillator; LCSD, left cardiac sympathetic denervation; LQT, long QT; N, No; VA, ventricular arrhythmia; Y, Yes. aGeneral recommendations: avoidance of QT-prolonging drugs (http://www.
crediblemeds.org), correction of electrolyte abnormalities (hypokalaemia, hypomagnesaemia, and hypocalcaemia), avoidance of genotype-speciﬁc triggers for arrhythmias (strenuous swimming in LQT1, exposure to loud noises in LQT2). bPreferred beta-blockers: nadolol and propranolol.


<!-- PAGE 83 -->

### Page 83

7.2.3. Andersen–Tawil syndrome Type 1
Andersen–Tawil syndrome Type 1, also classiﬁed as LQT7, is a rare disease (1:1 000000) characterized by three main symptoms: frequent VA
(e.g. bidirectional VT), dysmorphologies and periodic paralysis.964–967
The inward rectiﬁer current (IK1) decreased by KCNJ2 loss of function mutation968 causes an increase in U wave amplitude rather than QT
prolongation.964,967–970 Syncope or documented VT is associated with life-threatening VA, and a study found a 5-year probability of 7.9%
of life-threatening VA.967 In patients with sustained haemodynamically not-tolerated VT or CA, an ICD is recommended.964,967
Flecainide and/or beta-blockers seem to reduce VA,964,970,971
whereas amiodarone may be proarrhythmic and should only be used with an ICD.967 In patients with syncope despite medical therapy, an ICD or ILR should be discussed.967
7.2.4. Brugada syndrome
The type 1 Brugada ECG pattern is characterized by J point elevation of .2 mV with coved ST elevation and T wave inversion in at least one right precordial ECG lead, V1 or V2, positioned in the second,
third or fourth intercostal spaces (Figure 32). It may occur either spontaneously or be induced by exposure to sodium channelblocking drugs or fever.135,231,973–978 It is mandatory to exclude other conditions that may explain the type 1 pattern, so-called phenocopies.979
BrS is diagnosed in patients without other heart disease and a spontaneous type 1 pattern, regardless of symptoms, due to its rarity in the general population and association with risk.231,979,980 The type 1 pattern may also be induced by administration of a sodium channel-blocking drug as a diagnostic test in patients suspected to have concealed BrS but without a spontaneous type 1 ECG.135,136,231,387,973,978,981–985 However, provocation with drug or fever is less speciﬁc than previously thought,
with 2–4% prevalence in healthy subjects and higher prevalence in patients with AV nodal reentry tachycardia or an accessory pathway in one study.977,978,986 In the opinion of this panel of experts, an induced type 1 ECG pattern therefore requires other clinical features, such as documented PVT/VF, arrhythmic syncope, or relevant family history.
The yield of genetic testing in BrS patients is approximately 20%,
with the SCN5A gene the only gene with evidence of association for clinical testing purposes.164,980 Phenotype and genotype mismatch is seen in SCN5A families, which is explained by variable effects of mutation severity and a polygenic risk score derived from genome-wide association studies.170,979,987 Recent data also support a potential for prognostication.988,989
Psychotropic drugs, selected AADs, anaesthetic agents, cocaine,
excessive alcohol intake and fever are potential triggers to exacerbate the type 1 pattern and trigger VF.231,297 The risk of recurrent
VF among patients presenting with CA is 48% at 10 years. ICD implantation is therefore indicated in symptomatic BrS patients who are survivors of CA or have documented spontaneous sustained
VA (Figure 33).980,990–994 Approximately one-third of BrS patients present with syncope.995 The risk of arrhythmic events in BrS patients with unexplained syncope is 4 times higher than the risk in asymptomatic patients.155,990–992,994,996 Detailed patient history, including absence of prodrome or speciﬁc triggers, is essential for distinguishing arrhythmic from non-arrhythmic syncope. Nonetheless,
the aetiology of syncope is difﬁcult to determine in up to 30% of
BrS patients. In small studies, arrhythmia detected by ILR changed clinical management in 20–36% of the BrS patients with unexplained syncope.997–999
Asymptomatic patients represent a majority of newly diagnosed
BrS patients with an incidence of arrhythmic events of 0.5% per year.1000,1001 Their risk stratiﬁcation remains challenging. A spontaneous type 1 ECG pattern, as well as other ECG markers such as early repolarization pattern and QRS fragmentation, have been associated with higher risk.980,992,1002,1003 Some have been incorporated into risk scores, although their utility in intermediate-risk patients remains low.1004,1005 Electrophysiological studies remain controversial.
A
multicentre pooled analysis showed that
Recommendation Table 42 — Recommendations for management of patients with
Andersen–Tawil syndrome
Recommendations
Classa
Levelb
Diagnosis
Genetic testing is recommended in patients with suspected Andersen–Tawil syndrome.964,967
I
C
Andersen–Tawil syndrome should be considered in patients without SHD who present with at least two of the following:
• Prominent U waves with or without prolongation of the QT interval
• Bidirectional and/or polymorphic PVCs/VT
• Dysmorphic features
• Periodic paralysis
• KCNJ2 pathogenic loss of function mutation.964,965,967,968,972
IIa
C
Risk stratiﬁcation, prevention of SCD and treatment of VA
ICD implantation is recommended in patients with Andersen–Tawil syndrome after aborted CA
or not-tolerated sustained VT.964,967
I
C
Beta-blockers and/or ﬂecainide with or without acetazolamide should be considered in patients with Andersen–Tawil syndrome to treat
VA.964,970
IIa
C
An ILR should be considered in patients with
Andersen–Tawil syndrome and unexplained syncope.
IIa
C
ICD implantation may be considered in patients with Andersen–Tawil syndrome who have a history of unexplained syncope or suffer from tolerated sustained VT.967
IIb
C
© ESC 2022
CA, cardiac arrest; ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; PVCs, premature ventricular complexes; SCD, sudden cardiac death; SHD,
structural heart disease; VA, ventricular arrhythmia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4079


<!-- PAGE 84 -->

### Page 84

induction of sustained VA during electrophysiological studies was associated with a higher future risk of VA.155 Inducibility, however, was associated with a potentially clinically actionable result only in asymptomatic patients with a spontaneous type 1 Brugada pattern ECG.
In case of recurrent ICD shocks for VF, quinidine or catheter ablation have been successful in reducing shock frequency.922,1006,1007
Isoproterenol infusion can suppress electrical storm.1008 In several small studies, quinidine was effective in reducing or even preventing arrhythmia inducibility during programmed stimulation.922,1006,1007
However, adverse effects of quinidine can occur in up to 37% of patients, and quinidine is inaccessible in many countries. Cilostazol
(phosphodiesterase-3 inhibitor) can be an alternative to quinidine.1008 Electrophysiological mapping data linked to histopathological studies suggest that an abnormal ﬁbrotic arrhythmogenic substrate in the epicardial RVOT is responsible for the ST-segment elevation in the right precordial leads and VF occurrence in BrS patients.1009 Ablation of these abnormal areas can markedly suppress recurrent VF and normalize the ECG in .75% of patients.1009–1015
In patients with recurrent episodes of VF triggered by a similar
PVC non-responsive to medical treatment, catheter ablation may target the PVC, which most commonly originates from the RVOT
or Purkinje system.1013 However, data regarding the long-term follow-up after ablation are limited, with neither trial data nor evidence for ablation in asymptomatic patients.
Brugada type 1 pattern ECG
A
B
I
II
III
V1
V2
V3
aVR
aVL
aVF
V4
V5
V6
Early repolarization pattern ECG
II
III
Figure 32 Typical examples of (A) Brugada type 1 electrocardiogram, and (B) early repolarization pattern electrocardiogram. ECG, Electrocardiogram.
Recommendation Table 43 — Recommendations for management of patients with Brugada syndrome
Recommendations
Classa
Levelb
Diagnosis
It is recommended that BrS is diagnosed in patients with no other heart disease and a spontaneous type 1 Brugada ECG pattern.974–976
I
C
It is recommended that BrS is diagnosed in patients with no other heart disease who have survived a CA due to VF or PVT and exhibit a type
1 Brugada ECG induced by sodium channel blocker challenge or during fever.135,136,975,981,982
I
C
Genetic testing for SCN5A gene is recommended for probands with BrS.164,1016
I
C
BrS should be considered in patients with no other heart disease and induced type 1 Brugada pattern who have at least one of:
• Arrhythmic syncope or nocturnal agonal respiration
• A family history of BrS
• A family history of SD (,45 years old) with a negative autopsy and circumstance suspicious for BrS.
IIa
C
Continued


<!-- PAGE 85 -->

### Page 85

7.2.5. Early repolarization syndromes
Early repolarization syndrome (ERS) is diagnosed in a patient resuscitated from PVT or VF without any heart disease and the early repolarization pattern
(ERP);
J-point elevation
≥1 mm in ≥2 adjacent inferior and/or lateral ECG leads
(Figure 32).135,231,1017–1019 However, ERP is most often a benign
ﬁnding and the prevalence of ERP has been reported as 5.8% in adults and is more common in young males and athletes.135,231,1017–1021 Nonetheless, ERP is over-represented in relatives of SADS cases282,1022 and of CA survivors.182,916 The diagnostic yield and utility of genetic testing is low.1023–1025
High-risk ECG features have been proposed to increase likelihood of ERS: prominent J-waves ≥2 mm, dynamic changes in
J-point elevation (.0.1 mV) and J-waves associated with a horizontal or descending ST-segment (Figure 34).231,1026,1027 ERP
with a horizontal ST-segment was associated with arrhythmic risk in an elderly and IVF population.1027 Nonetheless, ERS survivors and relatives of SADS cases also exhibit a higher prevalence of the ascending/upsloping
ST
segment than controls.282,1018 At least 40% of ERS patients with VF have subsequent episodes,
with
27%
suffering multiple episodes.231,1028,1029 Isoproterenol infusion is effective in acute suppression of recurrent
ICD
discharges and electrical storm.1030–1032 AADs that block the transient outward potassium current can prevent VF.922,1030,1033 A retrospective multicentre study showed a reduction of recurrent VF after initiation of quinidine.1030 Phosphodiesterase-3 inhibitors such as cilostazol and milrinone also reduced the recurrence of VF.1032
Ablation of a PVC trigger, usually from the Purkinje system,
has an acute success rate of 87–100% and may be effective in preventing recurrence in patients with drug-refractory
VF.1010,1017 Detailed electroanatomic mapping may reveal localized structural alterations in 39% of ERS patients.1010 Ablation of these areas successfully suppressed electrical storm and may be a therapeutic option in experienced centres. Whether catheter ablation improves long-term outcomes is currently unknown.
Data for risk stratiﬁcation of patients with suspected ERS without prior CA are unavailable. In individuals with ERP and unexplained syncope, this panel has recommended that follow-up with an ILR should be considered. As the prognosis of asymptomatic subjects with ERP is good, ICD therapy is usually not indicated.1034–1036 If, however, there is a high-risk ERP and a strong family history of unexplained juvenile SD, then ICD implantation or quinidine may be considered.
BrS may be considered as a diagnosis in patients with no other heart disease who exhibit an induced type 1 Brugada
ECG.136,973,975,978,984,985
IIb
C
Sodium channel blocker test is not recommended in patients with a prior type I
Brugada pattern.
III
C
General recommendations
The following is recommended in all patients with
BrS:
(a) Avoidance of drugs that may induce
ST-segment elevation in right precordial leads (http://www.brugadadrugs.org).
(b) Avoidance of cocaine, cannabis, and excessive alcohol intake.
(c) Treatment of fever with antipyretic drugs.
I
C
Risk stratiﬁcation, prevention of SCD and treatment of VA
ICD implantation is recommended in patients with BrS who:
(a) Are survivors of an aborted CA and/or
(b) Have documented spontaneous sustained
VT.980,990–992
I
C
ICD implantation should be considered in patients with type 1 Brugada pattern and an arrhythmic syncope.990,992,996
IIa
C
Implantation of a loop recorder should be considered in BrS patients with an unexplained syncope.997,999
IIa
C
Quinidine should be considered in patients with
BrS who qualify for an ICD but have a contraindication, decline, or have recurrent ICD
shocks.922,1006,1007
IIa
C
Isoproterenol infusion should be considered in
BrS patients suffering electrical storm.1008
IIa
C
Catheter ablation of triggering PVCs and/or
RVOT epicardial substrate should be considered in BrS patients with recurrent appropriate ICD
shocks refractory to drug therapy.1010–1015
IIa
C
PES may be considered in asymptomatic patients with a spontaneous type I BrS ECG.155
IIb
B
ICD implantation may be considered in selected asymptomatic BrS patients with inducible VF
during PES using up to 2 extra stimuli.155
IIb
C
Catheter ablation in asymptomatic BrS patients is not recommended.
III
C
© ESC 2022
BrS, Brugada syndrome; CA, cardiac arrest; ECG, electrocardiogram; ICD, implantable cardioverter deﬁbrillator; PES, programmed electrical stimulation; PVCs, premature ventricular complexes; PVT, polymorphic ventricular tachycardia; RVOT, right ventricular outﬂow tract; SCD, sudden cardiac death; SD, sudden death; VA,
ventricular arrhythmia; VF, ventricular ﬁbrillation.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4081


<!-- PAGE 86 -->

### Page 86

N
N
N
Patient with ECG suspicious of Brugada Syndrome
Exclude alternative diagnosis consistent with ECGa
No documentedVA
V
Spontaneous type 1 BrS ECG
No type I BrS ECG
Discharge
Discharge
Follow-up
Follow-up
Syncope
Results
Arrhythmic syncope/
nocturnal agonical respiration
SustainedVA or
V
aborted cardiac arrest
Y
Y
Y
Y
Family history of B
f rS or SADS
ICD implantati a on
(Class IIa)
Recurrent symptomati a cVA
V
Quinidine
(Class IIa)
Recurrent symptomati a cVA
V
Cath a
eter a r blati a on
(Class IIa)
N
Arrhyth y
mic syncope
Unexplained syncope
ILR
(Class IIa)
Sodium channel blocke k r test
(Class I)
Sodium channel blocke k r test
(Class I)
General recommendationsb
(Class I)
Positive
Positive
Negative
Further evaluation according to ESC
syncope
Guidelines
Results
Negative
General recommendationsb
(Class I)
Sodium channel blocker 
k test
(Class III)
Figure 33 Part One. Algorithm for the management of patients with Brugada pattern electrocardiogram.


<!-- PAGE 87 -->

### Page 87

Exclude alternative diagnosis consistent with ECG
o a
SustainedVA or abo
V
rted cardiac arrest
N
Y
Spontaneous tyt pe 1
BrS ECG
Results
Positive
Negative
ICD implantation
(Class I)
General recommendationsb
(Class I)
Sodium channel blocker 
k test
(Class III)
ICD implantation
(Class I)
General recommendationsb
(Class I)
Sodium channel blocker 
k test
(Class I)
Recurrent sym t
ptomati a cVA
V
Quinidine
(Class IIa)
Recurrent sy t
mptomati a cVA
V
Cath a
eter ablati a on
(Class IIa)
Further evaluati a on fof r alternati a ve cause of VA/
V
CA
Recurrent sy t
mptomati a cVA
V
Figure 33 Part Two. Algorithm for the management of patients with Brugada pattern electrocardiogram. BrS, Brugada syndrome; CA, cardiac arrest;
ECG, electrocardiogram; ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; N, No; SADS, sudden arrhythmic death syndrome;
VA, ventricular arrhythmia; Y, Yes. aEcho, CMR, cardiac CT, CAG indicated according to patient clinical presentation and risk factors. bGeneral recommendations: avoidance of drugs that may induce ST-segmentation elevation in right precordial leads (http://www.brugadadrugs.org), avoidance of cocaine and excessive alcohol intake, treatment of fever with antipyretic drugs.
Recommendation Table 44 — Recommendations for the management of patients with early repolarization pattern/syndrome
Recommendations
Classa
Levelb
Diagnosis
It is recommended that the ERP is diagnosed as J-point elevation of ≥1 mm in two adjacent inferior and/or lateral ECG leads.1017,1018
I
C
It is recommended that the ERS is diagnosed in a patient resuscitated from unexplained VF/PVT in the presence of
ERP.1017,1018
I
C
In an SCD victim with a negative autopsy and medical chart review, and an ante-mortem ECG demonstrating the ERP, the diagnosis of ERS should be considered.1017,1018
IIa
C
First-degree relatives of ERS patients should be considered for clinical evaluation for ERP with additional high-risk features.c,1022,1037
IIa
B
Continued
Genetic testing in ERS patients may be considered.1023,1025
IIb
C
Clinical evaluation is not recommended routinely in asymptomatic subjects with ERP.1038,1039
III
C
Risk stratiﬁcation, prevention of SCD and treatment of VA
ICD implantation is recommended in patients with a diagnosis of ERS who have survived a CA.1017
I
B
Isoproterenol infusion should be considered for ERS
patients with electrical storm.1017,1030–1032
IIa
B
Quinidine in addition to an ICD should be considered for recurrent VF in ERS patients.922,1030,1033
IIa
B
ILR should be considered in individuals with ERP and at least one risk featured or arrhythmic syncope.1020
IIa
C
PVC ablation should be considered in ERS patients with recurrent VF episodes triggered by a similar PVC
non-responsive to medical treatment.1010
IIa
C
ICD implantation or quinidine may be considered in individuals with ERP and arrhythmic syncope and additional risk features.d,1030,1033
IIb
C
Continued
ESC Guidelines
4083


<!-- PAGE 88 -->

### Page 88

7.2.6. Catecholaminergic polymorphic ventricular tachycardia
CPVT is a heritable disorder characterized by catecholamineinduced bidirectional VT and PVT in the absence of SHD or ischaemia.
The disease has an estimated prevalence of 1 in 10000 (Figure 35).135
There are two main genetic types: a dominant disorder due to mutations in the gene encoding for the cardiac ryanodine receptor
(RYR2) and a recessive disorder caused by mutations in the cardiac calsequestrin gene
(CASQ2).135,178
Mutations in
TRDN
and
CALM1-3 have been identiﬁed in patients with atypical forms of catecholaminergic VAs.1042 At the present time, however, it is unclear whether they are distinct arrhythmic entities.1043 Patients with
KCNJ2 mutations causing Andersen–Tawil syndrome type 1 may sometimes exhibit bidirectional and PVT, but are distinguished by their syndromic associations.1044
ICD implantation or quinidine may be considered in asymptomatic individuals who demonstrate a high-risk
ERPc in the presence of a family history of unexplained juvenile SD.1030,1033
IIb
C
ICD implantation is not recommended in asymptomatic patients with an isolated ERP.1034,1035,1040
III
C
© ESC 2022
CA, cardiac arrest; ECG, electrocardiogram; ERP, early repolarization pattern; ERS,
early repolarization syndrome; ICD, implantable cardioverter deﬁbrillator; ILR,
implantable loop recorder; PVC, premature ventricular complexes; PVT, ventricular tachycardia; SCD, sudden cardiac death; SD, sudden death; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation.
aClass of recommendation.
bLevel of evidence.
cERP high-risk features: J waves .2 mm, dynamic changes in J point and ST
morphology.1020,1041
dHigh-risk ERP: family history of unexplained SD ,40 years, family history of ERS.
N
N
N
Patient with early repolarization pattern
Y
Y
Y
N
Y
Catheter ablation of PVC triggers
(Class IIa)
Quinidine
(Class IIa)
Recurrent
ICD shocks
Electrical storm
Arrhythmic syncope
Aborted cardiac arrest
ILR
(Class IIa)
ICD implantation
(Class IIb)
Quinidine
(Class IIb)
Isoproterenol
(Class IIa)
Quinidine
(Class IIa)
At least one risk factor:
ICD implantation
(Class I)
Recurrence
High risk ERPa
Family history of juvenile unexplained SD
Family history of ERS
At least one risk factor:
High risk ERPa
Family history of juvenile unexplained SD
Family history of ERS
ILR
(Class IIa)
N
Y
ILR
(Class IIa)
ICD implantation
(Class IIb)
Quinidine
(Class IIb)
ILR
(Class IIa)
No further investigation
(Class III)
High risk ERPa AND
Family history of juvenile unexplained SD
Figure 34 Management of patients with early repolarization pattern/syndrome. ERP, early repolarization pattern; ERS, early repolarization syndrome;
ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder; N, No; PVC, premature ventricular complex; SD, sudden death; Y, Yes. aERP
high risk features: J waves .2 mm, dynamic changes in ST morphology.


<!-- PAGE 89 -->

### Page 89

The clinical manifestations of CPVT usually occur in the ﬁrst decade of life prompted by physical activity or emotional stress.1045 Most CPVT patients have normal ECG and echocardiogram. Nonetheless, some patients present mild ECG abnormalities, such as sinus bradycardia and prominent U waves. Exercise stress test is the most important diagnostic test, because it elicits the distinguishing bidirectional or PVT that establish the diagnosis
(Figure 36).135 A diagnosis can also be made in the presence of a mutation in genes associated with CPVT. Epinephrine or isoproterenol challenge may be considered when exercise stress testing is not feasible.1046
Diagnosis in childhood, the lack of beta-blocker therapy, and complex arrhythmias during the exercise stress test on a full dose of betablockers are independent predictors for arrhythmic events.1047
Exercise restriction and beta-blockers without intrinsic sympathomimetic activity are the ﬁrst-line therapy for CPVT patients.135
Non-selective beta-blockers such as nadolol and propranolol are preferred.1048,1049 This panel has conﬁrmed the indication to treat genetically positive family members with beta-blockers, even in the absence of documented exercise- or stress-induced VAs.1047,1050
Data suggest that ﬂecainide signiﬁcantly reduces the VA burden in
CPVT patients and should be considered in addition to beta-blockers when control of arrhythmias is incomplete.1051–1053 In selected patients who show intolerance to beta-blocker therapy, pharmacological therapy with ﬂecainide alone is an option.1054
Maximal protection with beta-blockers, ﬂecainide and ICD is indicated in survivors of a CA. An ICD should also be considered in
CPVT patients with breakthrough VA on beta-blockers and ﬂecainide.135 The ICD should, however, be programmed with long delays and high rates before deﬁbrillation, because initiating bidirectional VT
responds less effectively to deﬁbrillation than subsequent PVT/VF,
and painful shocks can trigger further and incessant arrhythmias.1055
LCSD has been proposed as an additional therapy in patients in whom pharmacological treatment is not effective or feasible.
Although LCSD reduces the recurrence of major cardiac events in previously symptomatic patients, one-third of patients still suffer recurrences of arrhythmia.1056 Therefore, LCSD has not been considered to be a replacement for ICD therapy but a complementary therapy in symptomatic patients.
A recent systematic review of 53 studies including CPVT patients with an ICD concluded that secondary prevention patients managed with OMT, LCSD and exercise restriction could reduce ICD use.1057
This observation was supported by a subsequent multicentric investigation showing that all the three SCD observed occurred in patients with an ICD.1058 At present it seems premature, on the base of this evidence, to demote ICD implant in survivors of CA with CPVT.1057
Patient with CPVT
ICD implantation (Class I)
Flecainide (Class IIa)
LCSD (Class IIa)
Flecainide (Class IIa)
General recommendationsa (Class I)
Beta-blocker k
b (Class I)
Beta-blocker k
b (Class IIa)
Arrhythmic syncope or bidirectional or polymorphicVT
Aborted cardiac arrest
Syncope or exertional PVCs orVT
Syncope or exertional PVCs orVT
Syncope or documentedVT
Syncope or documentedVT
ICD implantation (Class IIa)
LCSD (Class IIa)
Asymptomatic, no documented
,
VA
V , but pathogenic
,
mutation
Figure 35 Management of patients with catecholaminergic polymorphic ventricular tachycardia. CPVT, catecholaminergic polymorphic ventricular tachycardia; ICD, implantable cardioverter deﬁbrillator; LCSD, left cardiac sympathetic denervation; PVC, premature ventricular complex; VA, ventricular arrhythmia; VT, ventricular tachycardia. aGeneral recommendations: avoidance of competitive sports, avoidance of strenuous exercise, avoidance of stressful environments. bPreferred beta-blockers: nadolol, propranolol.
ESC Guidelines
4085


<!-- PAGE 90 -->

### Page 90

7.2.7. Short QT syndrome
Short QT syndrome (SQTS) is a rare genetic disorder characterised by a short QT interval, premature AF and VF in the context of a structurally normal heart.1061 It has been associated with gain of function mutations in KCNH2, KCNQ1 and loss of
Recommendation Table 45 — Recommendations for the management of patients with catecholaminergic polymorphic ventricular tachycardia
Recommendations
Classa
Levelb
Diagnosis
It is recommended that CPVT is diagnosed in the presence of a structurally normal heart, normal
ECG, and exercise- or emotion-induced bidirectional, or PVT.
I
C
It is recommended that CPVT is diagnosed in patients who are carriers of a mutation in disease-causing genes.
I
C
Genetic testing and genetic counselling are indicated in patients with clinical suspicion or clinical diagnosis of CPVT.
I
C
Epinephrine or isoproterenol challenge may be considered for the diagnosis of CPVT when an exercise test is not possible.
IIb
C
General recommendations
Avoidance of competitive sports, strenuous exercise, and exposure to stressful environments is recommended in all patients with CPVT.
I
C
Therapeutic interventions
Beta-blockers, ideally non-selective (nadolol or propranolol) are recommended in all patients with a clinical diagnosis of CPVT.1045,1048,1059
I
C
ICD implantation combined with beta-blockers and ﬂecainide is recommended in CPVT patients after aborted CA.1045,1047,1060
I
C
Continued
Therapy with beta-blockers should be considered for genetically positive CPVT patients without phenotype.1047,1050
IIa
C
LCSD should be considered in patients with diagnosis of CPVT when the combination of beta-blockers and ﬂecainide at therapeutic dosage are either not effective, not tolerated, or contraindicated.1056
IIa
C
ICD implantation should be considered in patients with CPVT who experience arrhythmogenic syncope and/or documented bidirectional/PVT
while on highest tolerated beta-blocker dose and on ﬂecainide.1047,1050
IIa
C
Flecainide should be considered in patients with
CPVT who experience recurrent syncope,
polymorphic/bidirectional VT, or persistent exertional PVCs, while on beta-blockers at the highest tolerated dose.1052,1053,1060
IIa
C
PES is not recommended for stratiﬁcation of SCD
risk.
III
C
© ESC 2022
CA,
cardiac arrest;
CPVT,
catecholaminergic ventricular tachycardia;
ECG,
electrocardiogram; ICD, implantable cardioverter deﬁbrillator; LCSD, left cardiac sympathetic denervation; PVT, polymorphic ventricular tachycardia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
Bidirectional PVCs during exercise
II
III
Figure 36 Exercise test of a patient with catecholaminergic polymorphic ventricular tachycardia. PVC, premature ventricular complex.


<!-- PAGE 91 -->

### Page 91

function in SLC4A.1062,1063 This panel proposed two QTc cut-off threshold for diagnosis: A QTc ≤320 ms alone, or B a
QTc ≤360 ms combined with a family history of SQTS,
aborted CA in the absence of heart disease or pathogenic mutation1064–1067 (Figure 37). The disease has high lethality in all age groups, including the ﬁrst months of life.1063,1068,1069 The probability of a ﬁrst CA by the age of 40 years is .40%.1068 While an
ICD is used for secondary prevention,1069 primary prevention remains contentious and is based upon prior symptoms and
QTc interval.1063,1068,1069 Quinidine is currently the best supported AAD, but should be monitored for excessive QT prolongation, while isoprenaline may be considered in electrical storm.1070,1071 Drugs that shorten QT interval should be avoided, e.g. nicorandil.1072 Loop recorder implantation should be considered in children and young asymptomatic SQTS
patients.
Short QT syndrome
Figure 37 Short QT syndrome.
Recommendation Table 46 — Recommendations for the management of patients with short QT syndrome
Recommendations
Classa
Levelb
Diagnosis
It is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic mutation, (b) a family history of SQTS, (c) survival from a VT/VF
episode in the absence of heart disease.1061,1068
I
C
Genetic testing is indicated in patients diagnosed with SQTS.1063
I
C
Continued
SQTS should be considered in the presence of a
QTc ≤320 ms.1064–1067,1073,1074
IIa
C
SQTS should be considered in the presence of a
QTc ≥320 ms and ≤360 ms and arrhythmic syncope.
IIa
C
SQTS may be considered in the presence of a
QTc ≥320 ms and ≤360 ms and a family history of SD at age ,40 years.
IIb
C
Risk stratiﬁcation, SCD prevention and treatment of VA
ICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA and/or (b) have documented spontaneous sustained VT.1063
I
C
ILR should be considered in young SQTS patients.
IIa
C
ICD implantation should be considered in SQTS
patients with arrhythmic syncope.
IIa
C
Quinidine may be considered in (a) SQTS patients who qualify for an ICD but present a contraindication to the ICD or refuse it, and (b)
asymptomatic SQTS patients and a family history of SCD.1069–1071
IIb
C
Isoproterenol may be considered in SQTS
patients with an electrical storm.1075
IIb
C
PES is not recommended for SCD risk stratiﬁcation in SQTS patients.
III
C
© ESC 2022
CA, cardiac arrest; ICD, implantable cardioverter deﬁbrillator; ILR, implantable loop recorder, SCD, sudden cardiac death; SD, sudden death; SQTS, short QT syndrome;
VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4087


<!-- PAGE 92 -->

### Page 92

### 8 Special aspects in selected populations

8.1. Pregnant patients and peri-partum cardiomyopathy
Pregnancy and the post-partum period contribute a signiﬁcant risk in women with arrhythmic heart disease and is covered in the 2018
ESC Guidelines for the management of cardiovascular diseases during pregnancy.1076–1080 New-onset VT may present during pregnancy and risk of recurrent VT is higher in patients with previous VT and SHD.1081
Peri-partum cardiomyopathy (PPCM) should be ruled out in the case of new-onset VT during the last 6 weeks of pregnancy or in the early post-partum period.1082 A genetic contribution may be present in up to 20% of patients with PPCM (in particular titin-truncating variants)1083 and future studies should reveal if genetic testing plays a role in PPCM patients with a positive family history.
8.1.1. Electrocardioversion and implantable cardioverter deﬁbrillator therapy in pregnancy
Cardioversion seems safe in all phases of pregnancy and case reports show neither compromise in fetal blood ﬂow nor initiation of preterm labour.1084 Foetal heart rate should be routinely controlled after cardioversion.1085 If an ICD is indicated, ICD implantation should be performed beyond 8 weeks of gestation with radiation protection by experienced operator teams.1086 Echocardiographic guidance or a 3D mapping system may be helpful in ICD implantation to avoid radiation.1087,1088 In pregnant patients with existing ICD,
routine ICD interrogation is recommended prior to delivery. In patients with PPCM, thresholds for early ICD implantations are higher than in other conditions because of a high rate of spontaneous recovery after delivery.1089 WCD have been suggested to temporarily prevent SCD during the ﬁrst 3–6 months after diagnosis of PPCM
with LVEF ≤35%, while awaiting recovery.1090,1091
8.1.2. Pharmacological treatment
Pharmacological treatment of arrhythmias and heart failure in pregnant women should follow treatment in non-pregnant patients with avoidance of drugs contraindicated in pregnancy, such as ACE inhibitors,
ARB inhibitors/ARNI and renin inhibitors.1080,1082,1092,1093 The ﬁrst trimester is associated with the greatest teratogenic risk. Start of pharmacological therapy is advised to begin at the latest possible point in the pregnancy and with the lowest effective dose. Drug exposure in the second and third trimestera may confer adverse effects on foetal growth and development as well as increasing the risk of pro-arrhythmia.
It is recommended to check drugs and safety data before initiation of a new drug during pregnancy, according to the 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.1080 From this list, AADs can be summarized as followed:
• Well tolerated: sotalol, oral verapamil
• Use only if potential beneﬁt outweighs potential risk: bisoprolol, carvedilol, digoxin, diltiazem (possible teratogenic effects), disopyramide (uterine contractions), ﬂecainide, lidocaine,
metoprolol, nadolol, propranolol, verapamil IV, quinidine
• Inadequate data:
Ivabradine,
mexiletine,
proprafenone,
vernakalant
• Contraindicated: amiodarone, atenolol, dronedarone.
In LQTS (LQT2 in particular), risk of cardiac events increases substantially in the post-partum period (up to one year after delivery).1094 Therefore, it is important to continue beta-blocker therapy throughout pregnancy and post-partum.955,1094,1095
Continuation of beta-blocker treatment is recommended in LQTS
and CPVT1096 and should be considered in ARVC.1097–1099 No additional risk by pregnancy is known in women with BrS1100,1101
(
ESC CardioMed chapter 53.6).1102
In patients with PPCM, use of bromocriptine as disease-speciﬁc therapy in addition to standard heart failure therapy has shown promising results in two clinical trials.1103,1104
8.1.3. Catheter ablation
In planned pregnancies, symptomatic tachyarrhythmia should be treated by catheter ablation before pregnancy. If catheter ablation is indicated in a pregnant patient, one should avoid the procedure in the ﬁrst trimester, and electroanatomical mapping-guided procedures should be preferred.1105,1106
Recommendation Table 47 — Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy
Recommendations
Classa
Levelb
Acute management of VA
During pregnancy, electrical cardioversion is recommended for sustained VT.1084
I
C
For acute conversion of haemodynamically tolerated SMVT during pregnancy, a beta-blocker,
sotalol, ﬂecainide, procainamide, or overdrive ventricular pacing should be considered.
IIa
C
Long-term management of VA
If ICD implantation is indicated during pregnancy,
implantation is recommended with optimal radiation protection.1087,1107
I
C
Continuation of beta-blockers is recommended during pregnancy and post-partum in women with
LQTS or CPVT.955,1094–1096
I
C
Continuation of beta-blockers should be considered during pregnancy in women with
ARVC.1097–1099
IIa
C
Oral metoprolol, propranolol, or verapamil should be considered for long-term management of idiopathic sustained VT during pregnancy.
IIa
C
Catheter ablation using non-ﬂuoroscopic mapping systems should be considered, preferably after the
ﬁrst trimester, in women with highly symptomatic recurrent SMVT refractory or who are intolerant to AADs.1105
IIa
C
© ESC 2022
AAD, anti-arrhythmic drug; ARVC, arrhythmogenic right ventricular cardiomyopathy;
CPVT, catecholaminergic polymorphic ventricular tachycardia; ICD, implantable cardioverter deﬁbrillator; LQTS, long QT syndrome; SMVT, sustained monomorphic
VT; VA, ventricular arrhythmia; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 93 -->

### Page 93

8.2. Heart transplantation
Patients listed for HTX are exposed to an SCD risk and have a high incidence of VA. Data from large registries suggest a survival beneﬁt from ICDs.1108–1111 The only randomized study including patients listed for HTX was prematurely stopped because of low enrolment.1112 There are no data regarding the role of WCD in patients listed for HTX. The median expected time on the waiting list, 8–16
months, needs to be considered.1108,1110 However, this panel shares the opinion that a WCD may be an alternative for an ICD in selected patients waiting for HTX.371,1113
In post-HTX patients, SCD is responsible for around 10% of deaths.1114,1115 Transplant rejection and allograft vasculopathy are associated with SCD1114,1116,1117; therefore, ICD implantation may be appropriate in selected high-risk patients.1118
8.3. Sudden cardiac death in athletes
The incidence of SCD in athletes increases with age.4,1120 In apparently healthy athletes (.35 years), the estimated incidence of SCD
ranges from 2 to 6.3 per 100 000 participant-years. In comparison,
in young competitive athletes (≤35 years) the incidence of fatal events is signiﬁcantly lower, 0.4–3 per 100 000 participantyears.46,47,1120 Women athletes are at low risk of SCD; on average,
1 in 14 SCD in athletes occurs in women.1121
Pre-participation cardiovascular evaluation offers the potential to identify athletes at-risk for cardiovascular disease before onset of symptoms.1122–1126 The evaluation protocol needs to be adapted to the age of the athlete to account for age-speciﬁc cardiovascular disease.1125 Pre-participation evaluation, including medical history, physical examination, and ECG, appears effective in identifying cardiovascular disease in young athletes (≤35
years of age) by identiﬁcation of relevant symptoms (e.g. exertional syncope) or ECG abnormalities consistent with inheritable cardiomyopathies or channelopathies.1127–1130 Although echocardiography can increase the sensitivity of screening for SHD,
it is unfeasible as a routine test in mass screening. More cardiovascular diseases are identiﬁed by serial (annual) evaluations of adolescent athletes.1129,1131 The prevalence of false-positive results strongly depends on the criteria used to deﬁne an ECG
as ‘abnormal’.1132,1133 Additional tests, such as echocardiography, 24-hour Holter monitoring, stress testing, and CMR, are requested for athletes who had positive ﬁndings at the initial evaluation. Athletes diagnosed with clinically relevant cardiovascular disease are managed according to available
ESC
Guidelines.4,1134–1136
In middle-aged/senior athletes, the most common cause of
SCD is CAD.1125,1137 Before engaging in a vigorous physical activity, asymptomatic middle-aged/senior athletes should be evaluated using risk score systems such as the
ESC
SCORE2.4,65
Excellent rates of survival with favourable neurological outcome after CA has been reported in sports centres equipped with
AED.1137,1138 This justiﬁes the efforts for implementing emergency programs for SCD prevention, with distribution of AED in sports arenas and training of coaches and staff to perform CPR and deﬁbrillation.1139
Recommendation Table 48 — Recommendations for the prevention of sudden cardiac death before and after heart transplantation
Recommendations
Classa
Levelb
Prior to heart transplant
In patients awaiting heart transplantation, ICD
implantation for primary prevention should be considered.1108,1111,1112
IIa
C
In patients awaiting heart transplantation, WCD
may be considered.1109,1113,1119
IIb
C
Post heart transplant
In selected transplanted patients with cardiac allograft vasculopathy or treated rejection, ICD
implantation may be considered.1114,1116
IIb
C
© ESC 2022
ICD, implantable cardioverter deﬁbrillator; WCD, wearable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.
Recommendation Table 49 — Recommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes
Recommendations
Classa
Levelb
In athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including echocardiography and/or
CMR to conﬁrm (or exclude) an underlying disease are recommended.1123,1133,1135
I
C
It is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current guidelines for sports eligibility.
I
C
It is recommended that staff at sporting facilities are trained in CPR and in the use of AED.93,1137
I
C
Pre-participation cardiovascular evaluation of competitive athletes should be considered.46,1122,1123,1127
IIa
C
It should be considered that cardiovascular evaluation of young (,35 years) competitive athletes includes history, physical examination,
and 12-lead ECG.1123,1126,1130,1140
IIa
C
The cardiovascular risk of middle-aged and elderly individuals should be evaluated before engaging in strenuous sports through established scores such as the SCORE2 risk chart.46,1141,1142
IIa
C
© ESC 2022
AED, automated external deﬁbrillator; CMR, cardiac magnetic resonance; CPR,
cardiopulmonary resuscitation; ECG, electrocardiogram; SCD, sudden cardiac death.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
4089


<!-- PAGE 94 -->

### Page 94

8.4. Wolff–Parkinson–White syndrome
In patients with Wolff–Parkinson–White (WPW) syndrome, the most common arrhythmia is AV re-entry tachycardia (AVRT;
80%), followed by AF (20–30%). SCD secondary to pre-excited AF
resulting in VF is the most feared manifestation of WPW syndrome.
The risk of CA/VF in untreated WPW patients has been estimated at
0.9–2.4 per 1000 person-year.1143,1144 The management of WPW
patients has recently been reviewed in the 2019 ESC Guidelines for the management of patients with SVT302 and updated with a particular focus on athletes in 2020.1145 In patients with ventricular pre-excitation and symptomatic AVRT, catheter ablation is recommended (class I). In asymptomatic patients with ventricular pre-excitation, both invasive (class IIa) and non-invasive (class IIb)
assessment are options for risk stratiﬁcation for SCD. While catheter ablation is recommended for asymptomatic accessory pathways with high-risk features (class I), clinical follow-up (class IIa), or catheter ablations (class IIb) are options based on informed patient choice. This decision should take into account the location of the accessory pathway, the local ablation experience and the fact that symptomatic arrhythmias will frequently develop during followup.1146 For the paediatric population, SVT due to WPW can usually be managed pharmacologically, and accessory pathways often lose antegrade conduction in the ﬁrst years of life.1147 In children with asymptomatic accessory pathways, risk stratiﬁcation is not recommend before the age of 8 years.1148
8.5. Prevention of sudden cardiac death in the elderly
Age is a strong risk factor for death. In several studies, advanced age was one of the factors associated with a reduced expected beneﬁt from ICD treatment. In patients with ischaemic cardiomyopathy enrolled in MADIT-II trial, a risk scheme composed of 5
clinical factors including age .70 years was predictive of the absence of long-term beneﬁt conferred by the ICD.1149 In a recent analysis of ICD patients enrolled in four MADIT studies, age ,75
years was a predictor of VT/VF whereas age ≥75 years was a predictor of non-arrhythmic mortality.365 Consistently, in the recent randomized DANISH trial in patients with non-ischaemic heart failure, the association between the ICD and survival decreased linearly with increasing age, while an age cut-off at ≤70 years yielded the highest survival.647 Contemporary non-randomized data corroborate these ﬁndings. In the EU-CERT-ICD prospective cohort study in patients with CAD or cardiomyopathies with indication for primary prevention ICD implantation, no
ICD beneﬁt was observed in patients aged ≥75 years.357 In contrast, there was a signiﬁcant survival beneﬁt in patients aged
,75 years. Further retrospective data are in line with this observation.1150
Biological age may vary in part according to comorbidities.
Indeed, comorbidities signiﬁcantly inﬂuence survival of ICD recipients and a high comorbidity index is associated with less survival gain in primary or secondary prevention ICD patients.1149,1151
Therefore, a simple age cut-off cannot guide the decision on ICD
implantation adequately and the ICD indication in elderly patients should be based on a personalized assessment considering the overall condition and comorbidities.
9. Key messages
9.1. General aspects
• Increased availability of public access deﬁbrillators and community training in basic life support are key elements to improve survival of out-of-hospital cardiac arrest victims.
• Risk calculators for SCD and VA implemented in clinical practice need to meet agreed high standards for the development, external validation, and reporting of prediction models.
• Patients with genetic cardiomyopathies and arrhythmia syndromes require genetic testing as a routine part of their care.
• Genetic testing and counselling require access to an expert multidisciplinary team.
• A systematic workup of cardiac arrest survivors requires a multimodal approach.
• A comprehensive autopsy is recommended in all cases of sudden death under 50 years and is desirable in all sudden death victims.
• Clinical and genetic evaluation of SADS decedents and their families leads to a diagnosis of genetic heart disease in a substantial proportion of families.
• An electrical storm refractory to drug treatment requires the availability of advanced catheter ablation techniques, mechanical circulatory support, and autonomic modulation.
• When considering ICD therapy beneﬁt, competing risk factors for non-arrhythmic death and the patient’s wishes and quality of life need to be taken into account.
9.2. Structural heart disease
• Catheter ablation is recommended in CAD patients with recurrent symptomatic SMVT despite chronic amiodarone therapy.
• Catheter ablation is the ﬁrst-line treatment for PVC-induced cardiomyopathy.
• In HNDCM/DCM patients, indication for primary prevention
ICD implantation should not be restricted to an LVEF ≤35%.
Additional risk factors (e.g. CMR and genetics) are important to consider.
• Patients with an LMNA mutation require speciﬁc risk stratiﬁcation for SCD.
• ARVC patients have a high rate of appropriate ICD interventions which may not necessarily be classiﬁed as lifesaving.
Recommendation Table 50 — Recommendations for implantable cardioverter deﬁbrillator implantation in the elderly
Recommendations
Classa
Levelb
In elderly patients in whom a beneﬁt from the deﬁbrillator is not expected due to the patient’s age and comorbidities, omission of ICD
implantation for primary prevention may be considered.647,1150,1152
IIb
B
© ESC 2022
ICD, implantable cardioverter deﬁbrillator.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 95 -->

### Page 95

• A validated risk calculator (HCM Risk-Kids score) is useful to assess the risk for SCD in HCM patients younger than 16 years.
• Myotonic dystrophy patients with palpitations suspected of arrhythmia, syncope or aborted sudden death need to be evaluated by invasive electrophysiological study.
• In patients with repaired tetralogy of Fallot and monomorphic VT,
catheter ablation is the preferred treatment.
9.3. Primary electrical disease
• Nadolol or propranolol are the preferred beta-blockers in LQTS
and CPVT patients.
• In asymptomatic LQTS patients the arrhythmic risk (1-2-3 Risk calculator) may be useful to calculate.
• A type 1 Brugada ECG pattern provoked by sodium channel blocker test in the absence of other ﬁndings does not diagnose the BrS.
• SCD risk stratiﬁcation in asymptomatic BrS patients with a spontaneous type 1 pattern remains controversial.
• Routine catheter ablation is not recommended in asymptomatic
BrS patients.
• The diagnosis of idiopathic VF requires exclusion of an underlying structural,
channelopathic,
or metabolic aetiology.
• ERP can be a benign ﬁnding and is distinct from ERS.
• Left cardiac denervation plays an important role in the management of CPVT and LQTS patients.
10. Gaps in evidence
10.1. General aspects
• Accurate screening tests to detect heart conditions associated with SCD in asymptomatic individuals in the general population are required.
• In patients with SHD, the optimal time interval between repeated non-invasive and invasive prognostic tests, in case of a negative test, is unknown.
• Improved assessment of genetic variants of uncertain signiﬁcance and likely pathogenic variants is needed.
• The utility of polygenic risk scores in patients at risk of SCD requires investigation.
10.2. Structural heart disease—general
• The long-term safety and efﬁcacy of S-ICDs is unknown.
• The role of primary preventive ICD therapy in patients with SHD
and mildly reduced or preserved ejection fraction has not been studied systematically.
• The optimal techniques to undertake VT substrate mapping and ablation in SHD remain to be determined.
• The role of ICD implantation in end-stage heart failure patients supported by current-generation, continuous-ﬂow LVADs is unclear.
10.3. Idiopathic premature ventricular complexes/ventricular tachycardia
• The beneﬁcial role of catheter ablation or anti-arrhythmic drug treatment in patients with asymptomatic, frequent PVCs and preserved cardiac function needs to be determined.
10.4. Coronary artery disease
• It is unknown which patients with chronic CAD and severely impaired LVEF are at low risk for SCD.
• The role of LGE-CMR for risk stratiﬁcation for SCD in chronic
CAD is unclear.
• RCTs are needed to determine the role of ICDs after successful
VT ablation in chronic CAD with mildly reduced or preserved
LVEF.
10.5. Cardiomyopathies
• It is unknown if PVC-induced cardiomyopathy is a diagnosis on its own or if an underlying predisposition is needed.
• The predictive value of LGE-CMR ﬁndings (e.g. pattern and amount of LGE) for individual risk stratiﬁcation for SCD in patients with cardiac sarcoidosis, HCM, and DCM/HNDC is unclear.
• Studies are needed to determine the role of PES in patients with cardiac sarcoidosis and DCM/HNDC who have a mildly reduced or preserved cardiac function and LGE on CMR.
• Prospective data on the association between intensity and duration of exercise and manifestation and severity of the phenotype in healthy ARVC mutation carriers are lacking.
• The beneﬁcial role of ICDs after successful ablation in ARVC patients who present with haemodynamically tolerated VT needs to be studied.
• Data on clinical outcome, predictors for arrhythmic events, and indication for treatment, including ICD therapy, in patients with biventricular and left-dominant arrhythmogenic cardiomyopathy are required.
10.6. Valvular heart disease
• There is a lack of knowledge to identify patients with MVP at risk for VA and SCD.
10.7. Congenital heart disease
• There is a lack of knowledge regarding the absolute risk for VA and
SCD in CHD that have undergone repair with contemporary surgical approaches.
10.8. Primary electrical disease
• Robust evidence is required to support the prophylactic use of the
ICD on top of medical therapy with beta-blockers and genespeciﬁc therapy in LQTS patients.
• More data are required to determine the role of LCSD and ICD in high-risk LQTS patients who do not tolerate medical therapy.
ESC Guidelines
4091


<!-- PAGE 96 -->

### Page 96

• Improved diagnostic and risk stratiﬁcation tools for asymptomatic
Brugada patients and suspected early repolarization syndrome are needed.
• The role of endo-epicardial mapping to identify localized structural alterations potentially related to IVF and targeted catheter ablation needs to be further studied.
• Long-term data are required on the efﬁcacy of the ICD vs. no ICD
in CPVT survivors of cardiac arrest.
• It is poorly understood why women are at low risk of sport-related SCD.
11. ‘What to do’ and ‘what not to do’ messages from the Guidelines
Recommendations
Classa
Levelb
Recommendations for public basic life support and access to automated external deﬁbrillator
It is recommended that public access deﬁbrillation be available at sites where cardiac arrest is more likely to occur.c
I
B
Prompt CPR by bystanders is recommended at OHCA.
I
B
It is recommended to promote community training in basic life support to increase bystander CPR rate and AED use.
I
B
Recommendations for genetic testing
Genetic testing is recommended when a condition is diagnosed in a living or deceased individual with a likely genetic basis and a risk of VA
and SCD.
I
B
When a putative causative variant is ﬁrst identiﬁed, evaluation for pathogenicity is recommended using an internationally accepted framework.
I
C
When a Class IV or Class V variant has been identiﬁed in a living or deceased individual with a condition that carries a risk of VA and SCD,
genetic testing of ﬁrst-degree and symptomatic relatives and obligate carriers is recommended.
I
C
It is recommended that genetic testing and counselling on its potential consequences should be undertaken by an expert multidisciplinary team.
I
C
It is recommended that Class III variants (of uncertain signiﬁcance) and Class IV variants should be evaluated for segregation in families where possible, and the variant re-evaluated periodically.
I
C
It is not recommended to undertake genetic testing in index patients with insufﬁcient evidence of a genetic disease.
III
C
Recommendations for evaluation of patients presenting with newly documented ventricular arrhythmia
In patients with newly documented VA (frequent PVCs, NSVT, SMVT), a baseline 12-lead ECG, recording of the VA on 12-lead ECG,
whenever possible, and an echocardiogram are recommended as ﬁrst-line evaluation.
I
C
Recommendations for evaluation of sudden cardiac arrest survivors
The investigation of a SCA survivor without obvious extra-cardiac cause is recommended to be overseen by a multidisciplinary team.
I
B
In electrically unstable patients after SCA, with suspicion of ongoing myocardial ischaemia, a coronary angiogram is indicated.
I
C
In SCA survivors, collection of blood samples at presentation is recommended for potential toxicology and genetic testing.
I
B
Retrieval of recordings from CIEDs and wearable monitors is recommended for all SCA survivors.
I
B
In SCA survivors, repeated 12-lead ECGs during stable rhythm (including high precordial lead ECG) as well as continuous cardiac monitoring are recommended.
I
B
Echocardiography is recommended for evaluation of cardiac structure and function in all SCA survivors.
I
C
Coronary imaging and CMR with LGE are recommended for evaluation of cardiac structure and function in all SCA survivors without a clear underlying cause.
I
B
Sodium channel blocker test and exercise testing is recommended in SCA survivors without a clear underlying cause.
I
B
Continued


<!-- PAGE 97 -->

### Page 97

Recommendations for evaluation of sudden death victims
Investigation of unexpected SD, especially in case of suspicion of inherited disease, should be made a public health priority.
I
B
In cases of SD, it is recommended to collect a detailed description of circumstances of death, symptoms prior to death, the family history, and to review prior medical ﬁles.
I
B
A comprehensive autopsy is recommended, ideally, in all cases of unexpected SD, and always in those under 50 years of age.
I
B
In cases of SCD, it is recommended to retain samples suitable for DNA extraction and consult a cardiac pathologist when an inherited cause is suspected or the cause of death unexplained.
I
B
Toxicology screens are recommended in SD cases with uncertain cause of death.
I
B
For SCD where the cause is known or suspected to be heritable, genetic testing targeted to the cause is recommended.
I
B
Following SADS, post-mortem genetic testing targeted to primary electrical disease is recommended when the decedent is young (,50
years of age) and/or the circumstances and/or family history support a primary electrical disease.
I
B
When an autopsy diagnoses possible heritable cardiac disease, it is recommended to refer ﬁrst-degree relatives for cardiac assessment in a specialized clinic.
I
B
In non-autopsied cases of SD where inherited cardiac disease is suspected, it is recommended to refer ﬁrst-degree relatives for cardiac assessment in a specialized clinic.
I
B
Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents
Following SADS, hypothesis-free post-mortem genetic testing using exome or genome sequencing is not recommended.
III
B
Familial evaluation of SADS decedents is recommended:
• for ﬁrst-degree relatives
• for relatives who must carry a mutation based on analysis of the family history
• for relatives with suspicious symptoms
• when the decedent’s age is ,50 years or if there are other circumstantial data or family history to suggest heritable disease.
I
B
Familial evaluation of SADS decedents is recommended to include genetic testing when post-mortem genetic testing in a SADS
decedent detects a pathogenic mutation.
I
B
Baseline familial evaluation of SADS decedents is recommended to include taking a medical history and performing physical examination,
standard- and high-precordial lead ECG, echocardiography, and exercise testing.
I
B
In SADS families without a diagnosis after clinical evaluation, follow-up is recommended for children of decedents until they reach adulthood.
I
C
In SADS families without a diagnosis after clinical evaluation, follow-up is not recommended for asymptomatic adults who can be discharged with advice to return if they develop symptoms or if the family history changes.
III
C
Recommendations for treatment of reversible conditions
Withdrawal of offending agents is recommended whenever drug-induced VA are suspected.
I
B
Investigation for reversible causes (e.g. electrolyte imbalances, ischaemia, hypoxaemia, fever)d is recommended in patients with VA.
I
C
Recommendations for the acute treatment of sustained ventricular tachycardia and electrical storm
DC cardioversion is recommended as the ﬁrst-line treatment for patients with haemodynamically not-tolerated SMVT.
I
B
DC cardioversion is recommended as the ﬁrst-line treatment for patients presenting with tolerated SMVT provided that the anaesthetic/sedation risk is low.
I
C
In patients presenting with a haemodynamically tolerated idiopathic VT, treatment with intravenous beta-blocker (RVOT VT) or verapamil (fascicular VT) is recommended.
I
C
Intravenous verapamil is not recommended in broad QRS complex tachycardia of unknown mechanism.
III
B
Mild to moderate sedation is recommended in patients with electrical storm to alleviate psychological distress and reduce sympathetic tone.
I
C
Antiarrhythmic therapy with beta-blockers (non-selective preferred) in combination with intravenous amiodarone is recommended in patients with SHD and electrical storm unless contraindicated.
I
B
Continued
ESC Guidelines
4093


<!-- PAGE 98 -->

### Page 98

Intravenous magnesium with supplementation of potassium is recommended in patients with TdP.
I
C
Isoproterenol or transvenous pacing to increase heart rate is recommended in patients with acquired LQT syndrome and recurrent
TdP despite correction of precipitating conditions and magnesium.
I
C
Catheter ablation is recommended in patients presenting with incessant VT or electrical storm due to SMVT refractory to AADs.
I
B
Recommendations for treatment with heart failure medication
Optimal medical treatment including ACE-I/ARB/ARNIs, MRAs, beta-blockers, and SGLT2 inhibitors is indicated in all heart failure patients with reduced EF.
I
A
Recommendations for implantable cardioverter deﬁbrillation implantation (general aspects)
Implantation of a cardioverter deﬁbrillator is only recommended in patients who have an expectation of good quality survival .1 year.
I
C
It is not recommended to implant an ICD in patients with incessant VAs until the VA is controlled.
III
C
Recommendations for secondary prevention of sudden cardiac death
ICD implantation is recommended in patients with documented VF or haemodynamically not-tolerated VT in the absence of reversible causes.
I
A
Recommendations for adding cardiac resynchronization therapy to implantable cardioverter deﬁbrillator
When an ICD is indicated, it is recommended to evaluate whether the patient could beneﬁt from CRT-deﬁbrillator.
I
C
Recommendations for optimization of device programming
Optimization of ICD programming is indicated to avoid inappropriate and unnecessary therapies and to reduce mortality.
I
A
In single- or dual-chamber ICD patients without bradycardia pacing indications, it is recommended to minimize ventricular pacing.
I
A
Programming of prolonged detection settings is indicated (duration criteria of at least 6–12 s or 30 intervals).
I
A
It is recommended to program the slowest tachycardia therapy zone limit ≥188 b.p.m. in primary prevention ICD patients.
I
A
In patients with SHD, programming of at least one ATP therapy is recommended in all tachyarrhythmias zones.
I
A
It is recommended to program algorithms for SVT vs. VT discrimination for tachycardias with rates up to 230 b.p.m.
I
B
It is recommended to activate lead failure alerts.
I
B
Remote monitoring is recommended to reduce the incidence of inappropriate shocks.
I
B
Programming of burst ATP as a ﬁrst attempt is recommended over ramp ATP.
I
B
For S-ICDs, a dual detection zone conﬁguration is recommended with activation of discrimination algorithm in the lower conditional shock zone
I
B
Recommendations for concomitant treatment to avoid inappropriate implantable cardioverter deﬁbrillator therapy
Catheter ablation is recommended for ICD patients with recurrent SVT resulting in inappropriate ICD therapies.
I
C
Pharmacological treatment or catheter ablation is recommended in patients with AF-related inappropriate ICD therapies despite optimal ICD programming.
I
C
Recommendation for psychosocial management after implantable cardioverter deﬁbrillator implantation
Assessment of psychological status and treatment of distress is recommended in ICD patients.
I
C
Communication between patient and physician/healthcare professional is recommended to address ICD-related concerns and to discuss quality-of-life issues before ICD implantation and during disease progression.
I
C
Continued


<!-- PAGE 99 -->

### Page 99

Recommendations for prevention of implantable cardioverter deﬁbrillator complications
Single-chamber ICD is recommended over dual-chamber ICD in primary prevention patients without current or expected indication for atrial or AV sequential pacing due to a lower risk of device-related complications.
I
A
Recommendations for end-of-life issues in implantable cardioverter deﬁbrillator carriers
Informed discussion with patient and family about ICD deactivation options and shared decision-making is indicated prior to implantation and in case of signiﬁcant health status deterioration.
I
C
Recommendations for treatment of ventricular arrhythmia in acute coronary syndrome and vasospasm
Intravenous beta-blocker treatment is indicated for patients with recurrent PVT/VF during STEMI unless contraindicated.
I
B
Prophylactic treatment with AADs (other than beta-blockers) is not recommended in ACS.
III
B
Recommendations for risk stratiﬁcation and treatment of ventricular arrhythmia early after myocardial infarction
Early (before discharge) assessment of LVEF is recommended in all patients with acute MI.
I
B
In patients with pre-discharge LVEF ≤40%, re-evaluation of LVEF 6–12 weeks after MI is recommended to assess the potential need for primary prevention ICD implantation.
I
C
Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in chronic coronary artery disease
In patients with syncope and previous STEMI, PES is indicated when syncope remains unexplained after non-invasive evaluation.
I
C
ICD therapy is recommended in patients with CAD, symptomatic heart failure (NYHA class II–III), and LVEF ≤35% despite ≥3 months of OMT.
I
A
In patients with CAD, prophylactic treatment with AADs other than beta-blockers is not recommended.
III
A
ICD implantation is recommended in patients without ongoing ischaemia with documented VF or haemodynamically not-tolerated VT
occurring later than 48 h after MI.
I
A
In patients with CAD and recurrent, symptomatic SMVT or ICD shocks for SMVT despite chronic amiodarone therapy, catheter ablation is recommended in preference to escalating AAD therapy.
I
B
Recommendations for sudden cardiac death prevention in patients with coronary anomalies
Cardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test in patients with anomalous aortic origin of a coronary artery with an interarterial course to conﬁrm/exclude myocardial ischaemia.
I
C
Cardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test after surgery in patients with anomalous aortic origin of a coronary artery with a history of aborted CA.
I
C
Surgery is recommended in patients with anomalous aortic origin of a coronary artery with CA, syncope suspected to be due to VAs or angina when other causes have been excluded.
I
C
Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia
Regular assessment of ventricular function of patients with PVC burden .10% and normal ventricular function is indicated.
I
C
Catheter ablation as ﬁrst-line treatment is recommended for symptomatic idiopathic VT/PVCs from the RVOT or the left fascicles.e
I
B
Beta-blockers or non-dihydropyridine CCB are indicated in symptomatic patients with idiopathic VT/PVCs from an origin other than the RVOT or the left fascicles.
I
C
Catheter ablation is not recommended in children ,5 years of age or ,10 kg weight except when previous medical therapy fails or when VT is not haemodynamically tolerated.
III
C
Amiodarone as a ﬁrst-line treatment is not recommended in patients with idiopathic VTs/PVCs.
III
C
Verapamil is not recommended in children ,1 year of age with PVC/VT, particularly if they have signs of heart failure or concurrent use of other AADs.
III
C
Recommendations for the management of patients with premature ventricular complex-induced or aggravated cardiomyopathy
In patients with a cardiomyopathy suspected to be caused by frequent and predominately monomorphic PVCs, catheter ablation is recommended.
I
C
Continued
ESC Guidelines
4095


<!-- PAGE 100 -->

### Page 100

Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in dilated cardiomyopathy/hypokinetic non-dilated cardiomyopathy
Genetic testing (including at least LMNA, PLN, RBM20, and FLNC genes) is recommended in patients with DCM/HNDCM and AV
conduction delay at ,50 years, or who have a family history of DCM/HNDCM or SCD in a ﬁrst-degree relative (at age ,50 years).
I
B
Participation in high-intensity exercise including competitive sports is not recommended for individuals with DCM/HNDCM and a
LMNA mutation.
III
C
ICD implantation is recommended in patients with DCM/HNDCM, who survive SCA due to VT/VF or experience haemodynamically not-tolerated SMVT.
I
B
In a ﬁrst-degree relative of a DCM/HNDCM patient, an ECG, and an echocardiogram are recommended if:
• the index patient was diagnosed ,50 years of age or has clinical features suggestive of an inherited cause, or
• there is family history of DCM/HNDCM, or premature unexpected SD.
I
C
Recommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention and treatment of ventricular arrhythmia in arrhythmogenic right ventricular cardiomyopathy
In patients with suspected ARVC, CMR is recommended.
I
B
In patients with a suspected or deﬁnite diagnosis of ARVC, genetic counselling and testing are recommended.
I
B
Avoidance of high-intensity exercise is recommended in patients with a deﬁnite diagnosis of ARVC.
I
B
ICD implantation is recommended in ARVC patients with haemodynamically not-tolerated VT or VF.
I
C
In patients with ARVC and non-sustained or sustained VAs, beta-blocker therapy is recommended.
I
C
In a ﬁrst-degree relative of a patient with ARVC, ECG, and echocardiogram are recommended.
I
C
Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in hypertrophic cardiomyopathy
CMR with LGE is recommended in HCM patients for diagnostic work-up.
I
B
Genetic counselling and testing are recommended in HCM patients.
I
B
It is recommended that the 5-year risk of SCD is assessed at ﬁrst evaluation and at 1–3-year intervals or when there is a change in clinical status.
I
C
ICD implantation is recommended in HCM patients with haemodynamically not-tolerated VT or VF.
I
B
In a ﬁrst-degree relative of a patient with HCM, ECG, and echocardiogram are recommended.
I
C
Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in neuromuscular diseases
Annual follow-up with at least a 12-lead ECG is recommended in patients with muscular dystrophies, even in the concealed phase of the disease.
I
C
It is recommended that patients with neuromuscular disorders who have VAs or ventricular dysfunction are treated in the same way for arrhythmia as patients without neuromuscular disorders.
I
C
Invasive electrophysiological evaluation is recommended in patients with myotonic dystrophy and palpitations or syncope suggestive of
VA, VT, or surviving a CA.
I
C
ICD implantation is recommended in patients with myotonic dystrophy and SMVT or aborted CA not caused by BBR-VT.
I
C
In myotonic dystrophy patients, serial electrophysiological evaluation of AV conduction and arrhythmia induction is not recommended without arrhythmia suspicion or progression of ECG conduction disorders.
III
C
In symptomatic patients with BBR-VT, catheter ablation is recommended.
I
C
In patients with myotonic dystrophy undergoing ablation for BBR-VT, pacemaker/ICD implantation is recommended.
I
C
Continued


<!-- PAGE 101 -->

### Page 101

Recommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in myocarditis
In conﬁrmed or clinically suspected acute myocarditis, it is recommended that patients who present with life-threatening VA are referred to a specialized centre.
I
C
In patients with haemodynamically not-tolerated SMVT occurring in the chronic phase of myocarditis, an ICD implantation is recommended.
I
C
Recommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in cardiac sarcoidosis
ICD implantation is recommended in patients with cardiac sarcoidosis who have an LVEF ≤35%.
I
B
ICD implantation is recommended in patients with cardiac sarcoidosis who (a) have documented sustained VT, or (2) aborted CA.
I
B
Recommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in valvular heart disease
PES with standby catheter ablation is recommended in patients with aortic valve disease and SMVT to identify and ablate BBR-VT,
especially if it occurs following a valve intervention.
I
C
In patients with valvular heart disease and persistent LV dysfunction after surgical correction (if possible) it is recommended that ICD
implantation for primary prevention follows DCM/HNDCM recommendations.
I
C
Recommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in congenital heart disease
In adults with CHD with biventricular physiology and a left systemic ventricle presenting with symptomatic heart failure (NYHA II/III)
and EF ≤35% despite ≥3 months of OMT, ICD implantation is indicated.
I
C
In patients with CHD presenting with sustained VAs, evaluation for residual or new anatomical abnormalities is recommended.
I
B
In patients with CHD with not-tolerated VT/aborted CA due to VF, ICD implantation is indicated after exclusion of reversible causes.
I
C
In patients with repaired TOF who present with SMVT or recurrent, symptomatic appropriate ICD therapy for SMVT, catheter ablation performed in specialized centres is recommended.
I
C
Recommendations for management of patients with idiopathic ventricular ﬁbrillation
It is recommended that idiopathic VF is diagnosed in a SCA survivor, preferably with documentation of VF, after exclusion of an underlying structural, channelopathic, metabolic, or toxicological aetiology.
I
B
ICD implantation is recommended in idiopathic VF.
I
B
Recommendations for management of patients with long QT syndrome
It is recommended that LQTS is diagnosed with either QTc ≥480 ms in repeated 12-lead ECGs with or without symptoms or LQTS
diagnostic score .3.
I
C
In patients with clinically diagnosed long QT syndrome, genetic testing, and genetic counselling are recommended.
I
C
It is recommended that LQTS is diagnosed in the presence of a pathogenic mutation, irrespective of the QT duration.
I
C
Routine diagnostic testing with epinephrine challenge is not recommended in LQTS.
III
C
The following is recommended in LQTS:
• Avoid QT-prolonging drugs.f
• Avoid and correct electrolyte abnormalities.
• Avoid genotype-speciﬁc triggers for arrhythmias.
I
C
Beta-blockers, ideally non-selective beta-blockers (nadolol or propranolol), are recommended in LQTS patients with documented QT
interval prolongation, to reduce risk of arrhythmic events.
I
B
Mexiletine is indicated in LQT3 patients with a prolonged QT interval.
I
C
ICD implantation in addition to beta-blockers is recommended in LQTS patients with CA.
I
B
ICD implantation is recommended in patients with LQTS who are symptomaticg while receiving beta-blockers and genotype-speciﬁc therapies.
I
C
Continued
ESC Guidelines
4097


<!-- PAGE 102 -->

### Page 102

LCSD is indicated in patients with symptomaticg LQTS when: (a) ICD therapy is contraindicated or declined; (b) patient is on beta-blockers and genotype-speciﬁc therapies with an ICD and experiences multiple shocks or syncope due to VA.
I
C
Invasive electrophysiologic study is not recommended in LQTS.
III
C
Recommendations for management of patients with Andersen–Tawil syndrome
Genetic testing is recommended in patients with suspected Andersen–Tawil syndrome.
I
C
ICD implantation is recommended in patients with Andersen–Tawil syndrome after aborted CA not tolerated sustained VT.
I
C
Recommendations for management of patients with Brugada syndrome
It is recommended that BrS is diagnosed in patients with no other heart disease and a spontaneous type 1 Brugada ECG pattern.
I
C
It is recommended that BrS is diagnosed in patients with no other heart disease who have survived a CA due to VF or PVT and exhibit a type 1 Brugada ECG induced by sodium channel blocker challenge or during fever.
I
C
Genetic testing for SCN5A gene is recommended for probands with BrS.
I
C
Sodium channel blocker test is not recommended in patients with a prior type I Brugada pattern.
III
C
The following is recommended in all patients with BrS:
(a) Avoidance of drugs that may induce ST-segment elevation in right precordial leads (http://www.brugadadrugs.org).
(b) Avoidance of cocaine, cannabis, and excessive alcohol intake.
(c) Treatment of fever with antipyretic drugs.
I
C
ICD implantation is recommended in patients with BrS who:
(a) Are survivors of an aborted CA, and/or
(b) Have documented spontaneous sustained VT.
I
C
Catheter ablation in asymptomatic BrS patients is not recommended.
III
C
Recommendations for management of patients with early repolarizaton pattern/syndrome
It is recommended that the ERP is diagnosed as J-point elevation of ≥1 mm in two adjacent inferior and/or lateral ECG leads.
I
C
It is recommended that the ERS is diagnosed in a patient resuscitated from unexplained VF/PVT in the presence of ERP.
I
C
Clinical evaluation is not recommended routinely in asymptomatic subjects with ERP.
III
C
ICD implantation is recommended in patients with a diagnosis of ERS who have survived a CA.
I
B
ICD implantation is not recommended in asymptomatic patients with an isolated ERP.
III
C
Recommendations for management of patients with catecholaminergic polymorphic ventricular tachycardia
It is recommended that CPVT is diagnosed in the presence of a structurally normal heart, normal ECG, and exercise- or emotion-induced bidirectional or PVT.
I
C
It is recommended that CPVT is diagnosed in patients who are carriers of a mutation in disease-causing genes.
I
C
Genetic testing and genetic counselling are indicated in patients with clinical suspicion or clinical diagnosis of CPVT.
I
C
Avoidance of competitive sports, strenuous exercise, and exposure to stressful environments is recommended in all patients with
CPVT.
I
C
Beta-blockers, ideally non-selective (nadolol or propranolol), are recommended in all patients with a clinical diagnosis of CPVT.
I
C
ICD implantation combined with beta-blockers and ﬂecainide is recommended in CPVT patients after aborted CA.
I
C
PES is not recommended for stratiﬁcation of SCD risk.
III
C
Continued


<!-- PAGE 103 -->

### Page 103

### 12 Quality indicators

Quality indicators (QIs) are tools that may be used to evaluate care quality, including structural aspects, process, and outcomes of care.1153 They serve as a mechanism for enhancing adherence to guideline recommendations, through associated quality improvement initiatives and the benchmarking of care providers.1154,1155 As such, the role of QIs in improving care and outcomes is increasingly recognized by healthcare authorities, professional organizations, payers, and the public.1153
The ESC understands the need for measuring and reporting quality and outcomes of cardiovascular care, and has established methods for the development of the ESC QIs for the quantiﬁcation of care and outcomes for cardiovascular disease.1153 In parallel with the writing of this Clinical Practice Guideline document, a process has been initiated to develop QIs for patients with, or at risk of,
VA or SCD using the ESC methodology and through the collaboration with domain experts and the European Heart Rhythm
Association. These QIs, alongside their speciﬁcations and development process, will be published separately.
13. Supplementary data
Supplementary data is available at European Heart Journal online.
14. Data availability statement
No new data were generated or analysed in support of this research.
15. Author information
Author/task force Member Afﬁliations:
Marta de Riva, Cardiology, Leiden University Medical Centre,
Leiden,
Netherlands;
Bo
Gregers
Winkel,
Cardiology,
Recommendations for management of patients with short QT syndrome
It is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic mutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease.
I
C
Genetic testing is indicated in patients diagnosed with SQTS.
I
C
ICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have documented spontaneous sustained VT.
I
C
PES is not recommended for SCD risk stratiﬁcation in SQTS patients.
III
C
Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy
During pregnancy, electrical cardioversion is recommended for sustained VT.
I
C
If ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection.
I
C
Continuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT.
I
C
Recommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes
In athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including echocardiography and/or CMR to conﬁrm (or exclude) an underlying disease are recommended.
I
C
It is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current guidelines for sports eligibility.
I
C
It is recommended that staff at sporting facilities are trained in CPR and in the use of AED.
I
C
© ESC 2022
AAD, anti-arrhythmic drug; ACE-I, angiotensin-converting-enzyme inhibitor; AED, automated external deﬁbrillator; ARB, angiotensin receptor blockers; ARNIs, angiotensin receptor neprilysin inhibitor;
ARVC,
arrhythmogenic right ventricular cardiomyopathy;
ATP,
anti-tachycardia pacing;
AV,
atrioventricular;
BBR-VT,
bundle branch re-entry;
BrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; CIED, cardiac implantable electronic devices; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization therapy; DC, direct current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection fraction; ERP, early repolarization pattern; ERS, early repolarization syndrome;
HCM, hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; CAD, coronary artery disease; ILR, implantable loop recorder; LCSD, left cardiac sympathetic denervation; LGE, late gadolinium enhancement; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction;
MRA, mineralocorticoid receptor antagonist; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCA, out-of-hospital cardiac arrest; OMT,
optimal medical therapy; PES, programmed electrical stimulation; PVC, premature ventricular complex; PVT, polymorphic ventricular tachycardia; RVOT, right ventricular outﬂow tract; SADS, sudden arrhythmic death syndrome; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SGLT2, sodium–glucose co-transporter 2; SHD,
structural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SQT, short QT syndrome; STEMI, ST-elevation myocardial infarction; SVT, supraventricular tachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
cShopping malls, stadiums, public transport stations, casinos.
dList not exhaustive.
eLOE C for VT/PVCs from left fascicles.
fhttp://www.crediblemeds.org gArrhythmic syncope or haemodynamically non-tolerated VA
ESC Guidelines
4099


<!-- PAGE 104 -->

### Page 104

Rigshospitalet,
Copenhagen,
Denmark,
European
Reference
Networks for rare, low prevalence and complex diseases of the heart, ERN-GUARD HEART; Elijah R. Behr, Cardiovascular
Clinical
Academic
Group,
Cardiology
Section,
St
George’s,
University of London, London, United Kingdom, Department of
Cardiology, St George’s University Hospitals NHS Foundation
Trust, London, United Kingdom, and Cardiology, Mayo Clinic
Healthcare, London, United Kingdom; Nico A. Blom, Paediatric
Cardiology,
Leiden
University
Medical
Centre,
Leiden,
Netherlands, and Paediatric Cardiology, Amsterdam University
Medical Center, Amsterdam, Netherlands; Philippe Charron,
APHP, Centre de Référence des Maladies Cardiaques Héréditaires ou Rares, Hôpital Pitié-Salpêtrière, Paris, France, UMR_S 1166, and
ICAN Institute for Cardiometabolism, and Nutrition, Sorbonne
Université, Paris, France, and European Reference Networks for rare,
low prevalence and complex diseases of the heart,
ERN-Guard
HEART,
Paris,
France;
Domenico
Corrado,
Department of Cardiac, Thoracic and Vascular Sciences and Public
Health, University of Padova, Padova, Italy; Nikolaos Dagres,
Department of
Electrophysiology,
Heart
Center
Leipzig at
University of Leipzig, Leipzig, Germany; Christian de Chillou,
Department of Cardiology, CHRU-Nancy, Nancy, France, and
IADI, INSERM U1254, Université de Lorraine, Nancy, France; Lars
Eckardt,
Department of
Cardiology
II—Electrophysiology,
University Hospital Münster, Münster, Germany; Tim Friede,
Department of Medical Statistics, University Medical Center
Goettingen, Goettingen, Germany, and Partner Site Goettingen,
DZHK (German Center for Cardiovascular Research), Goettingen,
Germany; Kristina H. Haugaa, Department of Cardiology, Oslo
University Hospital, Rikshospitalet, Oslo, Norway, and Faculty of
Medicine, University of Oslo, Oslo, Norway; Mélèze Hocini,
Cardiology Department, Liryc Institute, Pessac, France, Hopital
Cardiologique du Haut Lévêque, Pessac, France, and Université de
Bordeaux, Bordeaux, France; Pier D. Lambiase, Institute of
Cardiovascular
Science,
University
College,
London,
United
Kingdom, Barts Heart Centre, St Bartholomews Hospital, London,
United Kingdom, and Heart, Vascular and Thoracic Institute,
Cleveland
Clinic,
London,
United
Kingdom;
Eloi
Marijon,
Cardiology Department, European Georges Pompidou Hospital,
Paris, France; Jose L. Merino, Arrhythmia and Electrophysiology
Robotic Unit, La Paz University Hospital, Universidad Autonoma,
IdiPaz, Madrid, Spain, Cardiology Department, Hospital Ruber Juan
Bravo, Madrid, Spain, and Cardiac Electrophysiology, Hospital
Viamed Santa Elena, Madrid, Spain; Petr Peichl, Cardiology
Department, IKEM, Prague, Czech Republic; Silvia G. Priori,
Molecular Medicine Department, University of Pavia, Pavia, Italy,
Molecular
Cardiology
Department,
Istituti
Clinici
Scientiﬁci
Maugeri
SpA
SB,
Pavia,
Italy,
and
Molecular
Cardiology
Department, Centro Nacional de Investigaciones Cardiovasculares
Carlos III (CNIC), Madrid, Spain, European Reference Networks for rare, low prevalence and complex diseases of the heart, ERNGUARD HEART; Tobias Reichlin, Department of Cardiology,
Inselspital—University Hospital Bern, University of Bern, Bern,
Switzerland;
Jeanette
Schulz-Menger,
Cardiology,
ECRC,
Charité—Universitätsmedizin Berlin, corporate member of Freie
Universität Berlin and Humboldt-Universität zu Berlin, Berlin,
Germany, Cardiology, Helios Clinics Berlin-Buch, Berlin, Germany,
and DZHK Partnersite Berlin, Charité, Berlin, Germany; Christian
Sticherling, Department of Cardiology, University Hospital Basel,
University of Basel, Basel, Switzerland; Stylianos Tzeis, Cardiology
Department, Mitera Hospital, Hygeia Group, Athens, Greece; Axel
Verstrael (Belgium), ESC Patient Forum, Sophia Antipolis, France;
and Maurizio Volterrani, Department of Cardiology, IRCCS San
Raffaele Roma, Rome, Italy, and Professor of Exercise Science and
Medicine, San Raffaele Telematic University of Rome, Rome.
16. Appendix
ESC Scientiﬁc Document Group
Includes Document Reviewers and ESC National Cardiac
Societies.
Document Reviewers: Maja Cikes (CPG Review Coordinator)
(Croatia), Paulus Kirchhof (CPG Review Coordinator) (Germany),
Magdy Abdelhamid (Egypt), Victor Aboyans (France), Elena Arbelo
(Spain), Fernando Arribas (Spain), Riccardo Asteggiano (Italy), Cristina
Basso (Italy), Axel Bauer (Austria), Emanuele Bertaglia (Italy), Tor
Biering-Sørensen (Denmark), Carina Blomström-Lundqvist (Sweden),
Michael A. Borger (Germany), Jelena Čelutkienė (Lithuania), Bernard
Cosyns
(Belgium),
Volkmar
Falk
(Germany),
Laurent
Fauchier
(France), Bulent Gorenek (Turkey), Sigrun Halvorsen (Norway),
Robert Hatala (Slovakia), Hein Heidbuchel (Belgium), Stefan Kaab
(Germany), Aleksandra Konradi (Russian Federation), Konstantinos
C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf
Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech
Republic), Maja-Lisa Løchen (Norway), Lars H. Lund (Sweden),
Andreas Metzner (Germany), Richard Mindham (United Kingdom),
Jens Cosedis Nielsen (Denmark), Tone M. Norekvål (Norway),
Monica Patten (Germany), Eva Prescott (Denmark), Amina Rakisheva
(Kazakhstan), Carol Ann Remme (Netherlands), Ivo Roca-Luque
(Spain), Andrea Sarkozy (Belgium), Daniel Scherr (Austria), Marta
Sitges (Spain), Rhian M. Touyz (Canada/United Kingdom), Nicolas Van
Mieghem (Netherlands), Vedran Velagic (Croatia), Sami Viskin (Israel),
and Paul G. A. Volders (Netherlands).
ESC National Cardiac Societies actively involved in the review process of the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.
Algeria: Algerian Society of Cardiology, Brahim Kichou; Armenia:
Armenian Cardiologists Association, Mihran Martirosyan; Austria:
Austrian
Society of
Cardiology,
Daniel
Scherr;
Azerbaijan:
Azerbaijan Society of Cardiology, Farid Aliyev; Belgium: Belgian
Society of Cardiology, Rik Willems; Bosnia and Herzegovina:
Association of Cardiologists of Bosnia and Herzegovina, Nabil Naser;
Bulgaria: Bulgarian Society of Cardiology, Tchavdar Shalganov;
Croatia: Croatian Cardiac Society, Davor Milicic; Cyprus: Cyprus
Society of Cardiology, Theodoros Christophides; Czech Republic:
Czech Society of Cardiology, Josef Kautzner; Denmark: Danish
Society of Cardiology, Jim Hansen; Egypt: Egyptian Society of
Cardiology, Lamyaa Allam; Estonia: Estonian Society of Cardiology,
Priit Kampus; Finland: Finnish Cardiac Society, Juhani Junttila;
France:
French
Society of
Cardiology,
Christophe
Leclercq;
Georgia: Georgian Society of Cardiology, Kakhaber Etsadashvili;
Germany: German Cardiac Society, Daniel Steven; Greece:
Hellenic Society of Cardiology, Konstantinos Gatzoulis; Hungary:


<!-- PAGE 105 -->

### Page 105

Hungarian Society of Cardiology, László Gellér; Iceland: Icelandic
Society of Cardiology, David O. Arnar; Ireland: Irish Cardiac Society,
Joseph Galvin, European Reference Networks for rare, low prevalence and complex diseases of the heart, ERN-GUARD HEART; Israel: Israel
Heart Society, Moti Haim; Italy: Italian Federation of Cardiology, Carlo
Pappone; Kosovo (Republic of): Kosovo Society of Cardiology,
Shpend Elezi; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina
Kerimkulova; Latvia: Latvian Society of Cardiology, Oskars Kalejs;
Lebanon: Lebanese Society of Cardiology, Ali Rabah; Lithuania:
Lithuanian Society of Cardiology, Aras Puodziukynas; Luxembourg:
Luxembourg Society of Cardiology, Carlo Dimmer; Malta: Maltese
Cardiac Society, Mark Adrian Sammut; Moldova (Republic of):
Moldavian Society of Cardiology, Lilia David; Montenegro:
Montenegro Society of Cardiology, Aneta Boskovic; Morocco:
Moroccan
Society of
Cardiology,
Abdelhamid
Moustaghﬁr;
Netherlands: Netherlands Society of Cardiology, Alexander
H. Maass; North Macedonia: North Macedonian Society of
Cardiology,
Lidija
Poposka;
Norway:
Norwegian
Society of
Cardiology, Ole Christian Mjolstad; Poland: Polish Cardiac Society,
Przemysław Mitkowski; Portugal: Portuguese Society of Cardiology,
Leonor Parreira; Romania: Romanian Society of Cardiology, Dragos
Cozma; Russian Federation: Russian Society of Cardiology, Elena
Golukhova; San Marino: San Marino Society of Cardiology,
Roberto Bini; Serbia: Cardiology Society of Serbia, Sinisa Stojkovic;
Slovakia: Slovak Society of Cardiology, Peter Hlivak; Slovenia:
Slovenian Society of Cardiology, Andrej Pernat; Spain: Spanish
Society of Cardiology, Nicasio Perez Castellano; Sweden: Swedish
Society of Cardiology, Pyotr G. Platonov; Switzerland: Swiss
Society of Cardiology, Firat Duru; Syrian Arab Republic: Syrian
Cardiovascular Association, Ahmad Rasheed Al Saadi; Tunisia:
Tunisian Society of Cardiology and Cardio-Vascular Surgery, Sana
Ouali; Turkey: Turkish Society of Cardiology, Sabri Demircan;
Ukraine: Ukrainian Association of Cardiology, Oleg Sychov; and
United Kingdom of Great Britain and Northern Ireland:
British Cardiovascular Society, Alistair Slade.
ESC Clinical Practice Guidelines (CPG) Committee:
Colin Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid
(Egypt),
Victor
Aboyans
(France),
Sotiris
Antoniou
(United
Kingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas
Baumbach (United Kingdom), Michael A. Borger (Germany), Jelena
Čelutkienė (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet
(France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris
P. Gale (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung
(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian
Federation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha
(United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel),
Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Richard
Mindham (United Kingdom), Jens Cosedis Nielsen (Denmark),
Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark),
Amina Rakisheva (Kazakhstan), Marta Sitges (Spain), and Rhian
M. Touyz (Canada/United Kingdom).
